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Abstract 
Background 
Research has identified key symptoms of ovarian cancer, although there are gaps 
in the knowledge about the pattern of symptom onset, severity and frequency. 
Previous studies are limited by use of non-validated questionnaires, recall bias and 
under-reporting bias in medical records. 
Aim 
The aim of the research was to prospectively identify type, severity, frequency 
and  duration  of  symptoms  that  precede  ovarian  cancer  diagnosis  in 
postmenopausal women. 
Methods 
Questionnaire development methods described by the European Organisation for 
Research and Treatment of Cancer were utilised to develop a validated ovarian 
cancer  symptoms  questionnaire  (OCSq).  Interviews  with  21  gynaecological 
oncology  clinicians/nurses  and  25  women  with  ovarian  cancer  guided 
development  of  the  OCSq.  The  OCSq  was  piloted  among  1,339  women  and 
posted to 100,000. 
Results 
A  total  of  829  women  completed  a  pilot  OCSq  and  baseline  analysis  of  the 
finalised OCSq included 51,007. Symptoms were ubiquitous, with 89% of women 
reporting any symptoms, 55-56% symptoms at level 2-3 severity and 42-49% at 
≥12 days frequency and <12 months duration. Abdominal/pelvic pain, increased 
abdominal size/bloating or feeling full at ≥12 days and <12 months was reported 
by  11-16%.  There  were  263  women  who  had  an  abnormal  ovarian  cancer 
screening result in the pilot and two women were diagnosed with ovarian cancer. 
No symptoms were consistently associated with abnormal results when severity, 
frequency  and  duration  criteria  were  added  to  analyses.  Multivariate  analyses 
found age, pelvic pressure, tiredness/fatigue, pelvic bloating/fullness, shortness of 
breath, leg ache/pain and abdominal pressure independently predicted abnormal 
ovarian  cancer  screening  results  at  various  levels  of  analysis.  However,  odds 4 
ratios were low and confidence limits were wide. Symptom reporting was strongly 
correlated with  previous awareness of the possibility  of an ovarian  lesion and 
depression screening status. 
Conclusion 
The research is currently ongoing with follow-up analyses planned to commence 
in  late  2010.  Preliminary  findings  indicate  that  there  is  currently  insufficient 
evidence  to  justify  symptoms  awareness  campaigns  based  upon  the  results  of 
previous  retrospective  research,  and  that  such  campaigns  risk  overwhelming 
primary  care  services  with  ‘worried-well’  women,  increasing  psychological 
morbidity,  service  costs,  unnecessary  investigations  and  potentially  harmful 
surgery. 
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Chapter One – Background and Study Design 
1.0  Introduction 
Each  year in the UK approximately 6,600 women are diagnosed with ovarian 
cancer and 4,300 women die of the disease.
1 Five-year survival is approximately 
38%,
2 although only 16% among women diagnosed with stage III ovarian cancer.
3 
While ten-year survival rates have remained relatively static, these are expected to 
improve once data become available for the past decade.
2 Low survival rates are a 
result of a continuation of the trend for a majority of women to be diagnosed with 
advanced stage disease.
3 Progress has been slow in identifying new biomarkers 
and treatments resulting in a significant mortality impact. Attempts to detect the 
disease earlier through better understanding of the symptoms of ovarian cancer 
have advanced rapidly over the past nine years. However, there are concerns that 
this  knowledge  is  based  upon  largely  retrospective  research.  Many  questions 
remain, including issues of the ways in which the diagnosis of ovarian cancer 
itself, and interactions with clinical teams, shape symptom reporting. There are 
also  concerns  that  the  symptoms  of  ovarian  cancer  are  ubiquitous  among 
postmenopausal women, therefore awareness campaigns may have the perverse 
effect  of  increasing  morbidity  and  mortality  among  those  most  at  risk  of  the 
disease. 
1.1  Brief overview of ovarian cancer symptoms research 
Despite very early evidence to the contrary, ovarian cancer was regarded as a 
‘silent killer’ throughout much of the 20
th century.
4 From the late 1970s onwards a 
small number of studies began to challenge this perception. In 1979 Ranney & 
Ahmad
5 published a US study which found ‘most women’ with ovarian cancer 
experience  symptoms.  This  was  soon  followed  by  UK-based  research  which 
described abdominal distension, abnormal vaginal bleeding and change in bowel 
habit  as  important  symptoms  of  ovarian  cancer,  alongside  the  clinical  sign  of 
abdominal  mass.
6  A  steady  trickle  of  symptoms  studies  were  published 
throughout  the  1980s  and  1990s,  including  questionnaire  studies,
7  studies 21 
describing  symptoms  which  prompt  women  to  seek  medical  attention,
8-9  and 
medical records reviews describing symptoms by stage of diagnosis.
10-12 
In 2000 Goff et al.
13 published findings from their survey of symptoms among 
1,725 women with ovarian cancer. This research found 89% of women with stage 
I or II ovarian cancer reported symptoms, firmly refuting the historical perception 
of ovarian cancer as a silent disease in the early stages. This paper pushed forward 
the  research  agenda,  and  was  quickly  followed  by  a  plethora  of  other  large 
studies, including several case-control studies utilising questionnaire methods, and 
reviews of medical or insurance records. This volume of literature consistently 
identified increased abdominal size, bloating, abdominal or pelvic pain, urinary 
frequency or urgency, change in appetite or feeling full, fatigue, change in bowel 
habit and gastrointestinal symptoms, such as indigestion, as symptoms of ovarian 
cancer.
14-22 
In 2007 the Goff group published an ovarian cancer symptoms index.
23 The index 
included:  pelvic  or  abdominal  pain,  increased  abdominal  size  or  bloating  and 
difficulty eating or feeling full, when experienced more than 12 days per month 
and for less than 12 months. Since this paper was published research has focussed 
on  identifying  and  validating  symptoms  indices  which  could  be  used 
prospectively  to  identify  women  who  may  benefit  from  CA125  testing  or 
ultrasound.
24-26 
While the existing literature has contributed significantly  to knowledge of the 
spectrum  of  symptoms  associated  with  ovarian  cancer,  there  is  a  paucity  of 
research explicating symptom severity, frequency and patterns of onset. There is 
also a dearth of information about ovarian cancer symptom complexes in women 
living outside the US. 
1.2  From ‘silent killer’ to ‘symptom index’, a condensed history 
of ovarian cancer patient advocacy 
It is not clear why ovarian cancer was historically perceived as a disease with few 
or very subtle symptoms. Social scientists who have critiqued biomedicine more 
generally have suggested that, as the influence of biomedicine increased, there 22 
was shift in focus, away from ‘subjective’ symptoms reported by patients, towards 
‘objective’  signs  of  illness.
27-29  No  theorists  to-date  have  specifically  explored 
these issues in relation to ovarian cancer, although perhaps it could be suggested 
that increasing recognition of ovarian cancer as a symptomatic disease is a result 
of patient empowerment movements over the last two decades. 
In January 2007 patient advocacy groups in the US succeeded in their efforts to 
have ovarian cancer symptoms awareness campaigns signed into law (‘Johanna’s 
Law’).  This  law  set  aside  $16.5  million  to  educate  health  professionals  and 
women about the signs and symptoms of ovarian cancer. Later in the same year 
the US Gynecologic Cancer Foundation (GCF) released a symptoms ‘consensus 
statement’ which was endorsed by the American Cancer Society and the Society 
of  Gynecologic  Oncologists.
30  This  stated,  ‘women  with  bloating,  pelvic  or 
abdominal pain, difficulty eating or feeling full quickly, or a frequent or urgent 
need to urinate, for more than a few weeks should see their doctor, preferably a 
gynecologist.  Prompt  medical  evaluation  may  lead  to  detection  at  the  earliest 
possible stage of ovarian cancer’. 
In their endorsement of the US consensus statement, the American Cancer Society 
and the US Society of Gynecologic Oncologists acknowledged, ‘proof that earlier 
recognition of symptoms improves outcomes does not yet exist’. However they 
also suggested, ‘there is little to be lost and much to be potentially gained by 
increasing awareness of ovarian cancer symptoms’.
30  
After publication of the US consensus statement, the UK charity Ovarian Cancer 
Action embarked upon a symptoms awareness campaign to improve referrals and 
conversion rates of ovarian cancer, and help GPs’ monitor women who present 
with  symptoms  associated  with  ovarian  cancer.  The  campaign  included  a 
symptom  diary  (available  online  and  listing  the  same  symptoms  as  the  GCF 
consensus statement) which the group encouraged GPs to give to women to fill-in 
for  one  month.
31  The  diary  advised  that  if  bloating/increased  abdominal  size, 
pelvic/abdominal  pain,  difficulty  eating/feeling  full  quickly,  or  frequent/urgent 
urination are experienced  more than  12  times during  four weeks  then  ovarian 
cancer should be considered as part of the differential diagnosis. 23 
The UK Department of Health has responded to concerns raised by ovarian cancer 
patient  advocacy  groups  about  the  sometimes  lengthy  time  span  from  first 
presentation in primary care to diagnosis. In April 2008 a meeting attended by 
clinicians,  researchers,  policy-makers  and  ovarian  cancer  support  group 
representatives  was  held  in  London  to  discuss  symptoms  of  ovarian  cancer. 
Members of the group worked together after the initial meeting to produce a UK 
consensus statement and a key messages document for health professionals.
32-33 
The UK consensus statement noted that cancer charities, scientists and doctors 
agreed  that  three  symptoms  (persistent  pelvic  and  abdominal  pain,  increased 
abdominal  size/persistent  bloating,  but  not  bloating  that  comes  and  goes,  and 
difficulty eating/feeling full quickly) are more frequent in women with ovarian 
cancer.
32  
1.3  Risks and benefits of ovarian cancer symptoms awareness 
efforts 
Ovarian  cancer  advocacy  groups  have  argued  that  increasing  women’s  and 
clinicians’ awareness of the early warning signs of the disease may lead to earlier 
stage diagnosis, although there is no evidence to substantiate this at the current 
time. There are benefits to patient empowerment, including encouraging women 
to assert themselves in their interactions with health professionals if they do not 
feel  that  their  concerns  are  being  taken  seriously.  This  may  lead  to  prompt 
referrals and shorter diagnostic timelines. The knowledge that they have acted 
upon their awareness of symptoms, and achieved a prompt diagnosis, may also 
confer psychological benefits to women diagnosed with ovarian cancer. 
Clinicians  have  approached  ovarian  cancer  symptoms  awareness  with  caution, 
asserting  that  current  evidence  is  insufficient  to  warrant  large-scale  education 
campaigns. They have argued that raising women’s awareness of the symptoms of 
ovarian cancer could result in unnecessary and expensive investigations, anxiety 
and distress.  
There are also concerns that earlier diagnosis may not necessarily reduce the stage 
of disease. Thus women will have to live longer with the psychological, social, 24 
quality  of  life  and  financial  repercussions  of  a  cancer  diagnosis,  without  the 
benefit  of  improved  survival.  Encouraging  women  to  consult  their  GPs  based 
upon as yet unproven symptom indices also runs the risk of swamping primary 
care with the worried-well. Inevitably, this would result in escalating health care 
costs without necessarily improving the health of the target population. Indeed, 
additional investigations are likely to identify more harmless or benign conditions 
than  would  have  been  otherwise  diagnosed.  This  may  result  in  increased 
unnecessary surgery which has the potential for serious complications. 
1.4  Justification for the research 
Prospective research into the symptoms of ovarian cancer is needed as current 
screening  methodologies  have  yet  to  demonstrate  efficacy  in  the  general 
population of women. Previous studies have identified symptom complexes with 
sensitivities  approximating  CA125  screening  for  the  detection  of  ovarian 
cancer.
23-24 However, these are limited by poor design, the use of non-validated 
questionnaires,  selection  bias  and  retrospective  data  collection.  To-date  no 
research has prospectively collected symptoms data in non-clinical populations, 
then correlated symptoms with the development of ovarian cancer on follow-up. 
With  the  exception  of  a  recent  PhD  study,
34  only  one  questionnaire  study  of 
ovarian cancer diagnosis has been conducted in the UK.
35 However, symptoms 
findings from this research have not been published. 
The research presented in this thesis attempts to address these deficiencies by 
developing  an  ovarian  cancer  symptoms  questionnaire  according  to  rigorous 
methodology, then using the questionnaire in a large prospective study recruiting 
women from 13 regions throughout the UK. 
1.5  Study aims 
●  To prospectively identify type, severity, frequency and duration of 
symptoms that precede ovarian cancer diagnosis in a pilot study using 
a cohort of apparently healthy volunteers participating in a screening 
trial (UKCTOCS) 25 
●  To set up a prospective study to assess performance characteristics 
(sensitivity, specificity and positive predictive value) of a variety of 
symptoms and symptom complexes for diagnosis of ovarian cancer 
1.6  Study design 
The research described in this thesis comprised three components: 1) analysis of 
symptoms data from the Ovacome survey; 2) development of an ovarian cancer 
symptoms questionnaire (OCSq) including analysis of pilot data; and 3) analysis 
of baseline data from the OCSq study among 100,000 women (Figure 1.1). 26 
Figure 1.1  Study design 
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1.7  Ethical approval 
Ethical  approval  for  the  research  was  granted  by  the  Joint  UCL/UCLH 
Committees on the Ethics of Human Research (Committee A) on 7 March 2007 
(REC reference number 06/Q0505/103). A substantial amendment consisting of 
the  finalised  OCSq  and  associated  documentation  was  submitted  to  the  Joint 
UCL/UCLH Committees on the Ethics of Human Research (Committee A) on 17 
November  2008.  The  Sub-Committee  of  the  REC  provided  favourable  ethical 
opinion of the amendment on 2 December 2008. 27 
1.8  Overview of UKCTOCS 
The  United  Kingdom  Collaborative  Trial  of  Ovarian  Cancer  Screening 
(UKCTOCS)  is  a  randomised  controlled  trial  designed  to  provide  data  for 
clinicians  and  health  authorities  to  make  an  informed  decision  about  the 
introduction of population screening for ovarian cancer.  
Figure 1.2 summarises the trial design. The study has several objectives. Firstly, it 
aims  to  establish  the  impact  of  screening  for  ovarian  cancer  on  mortality. 
Secondly, the study set out to determine the physical and psychological morbidity 
of ovarian cancer screening. Other trial objectives include an assessment of cost 
and  resource  implications  of  screening  and  resulting  clinical  interventions, 
assessment  of  the feasibility of population screening  as reflected  by volunteer 
compliance, comparison of the performance of multimodal screening (CA125 and 
ultrasound)  versus  transvaginal  ultrasound  screening  alone  and,  finally,  to 
establish a serum bank for future biomarker studies. 
Inclusion  criteria  were  women  aged  50-74  years  and  postmenopausal  status 
(defined as amenorrhoea for 12 or more months). Exclusion criteria were previous 
bilateral  oophorectomy,  active  non-ovarian  malignancy,  previous  ovarian 
malignancy, increased risk of ovarian cancer due to familial predisposition and 
participation in other ovarian cancer screening trials. 
Invitations to participate in UKCTOCS were posted to women in 27 Primary Care 
Trusts.  These  women  were  identified  from  Primary  Care  Trust  records,  with 
invitation  letters  being  sent  between  April  2001  and  September  2005.  The 
invitation  letters  were  written  in  English  and  were  not  translated  into  other 
languages. A total of 205,090 women (74% of those sent appointments) attended 
for  recruitment  and  202,638  were  randomised  to  one  of  the  three  study  arms 
(multimodal, ultrasound or control) using a 1:1:2 ratio.
36 The trial was designed to 
screen volunteers for seven years, although this was recently extended by two 
years due to a healthy volunteer effect. UKCTOCS operates in 13 regional centres 
within  NHS  secondary  care  trusts  in  England,  Wales  and  Northern  Ireland 
(Belfast, Liverpool, Llandudno, Cardiff, Bristol, Portsmouth, Royal Free London, 
St. Bartholomew’s London, Notttingham, Derby, Manchester, Middlesbrough and 28 
Gateshead).  The  trial  coordinating  centre  is  based  within  the  Gynaecological 
Cancer  Research  Centre,  Institute  for  Women’s  Health,  University  College 
London. 
Figure 1.2.  UKCTOCS trial design 
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1.8.1  UKCTOCS data collection 
All  UKCTOCS  volunteers  completed  a  baseline  questionnaire  at  initial 
recruitment. This elicited information on demographic, lifestyle and reproductive 
variables. Approximately 3.5 and 7 years after recruitment volunteers are asked to 
complete a follow-up questionnaire which collects information on education level, 
co-morbidities and pelvic surgery. 
The psycho-social impact of ovarian cancer screening is assessed by a battery of 
questionnaires.  At  recruitment  to  UKCTOCS  women  completed  the  General 
Health Questionnaire (GHQ12), the Speilberger Trait Anxiety Inventory (STAIT) 
and a Sexual Activity Questionnaire (SAQ). Volunteers who have an abnormality 
detected at  any point during the trial are invited to complete follow-up GHQ, 
STAIT, SAQ questionnaires, and a tool to measure acceptability of screening. 
Women  who  have  surgery  for  a  pelvic  mass  are  invited  to  complete  these 
questionnaires six weeks and six months post-surgery. Women diagnosed with 
ovarian cancer are also asked to complete the FACT-O tool, which measures the 
psycho-social impact of ovarian cancer diagnosis. In addition to these event-based 
assessments, anxiety associated with screening is being measured on an annual 29 
basis in a cohort of 1,532 randomly selected women. These women are posted the 
GHQ, STAIT, SAQ and screening acceptability questionnaire after each annual 
screen. 
Cancer registrations and deaths are notified to the trial through a flagging system 
with the NHS  Information  Centre  for  Health and Social Care in  England and 
Wales and with the Central Services Agency and Cancer Registry in Northern 
Ireland. Hospital notes are obtained for volunteers who undergo surgery for pelvic 
masses and a final diagnosis including primary site, stage and grade of any cancer 
is made by an independent outcomes committee. 
UKCTOCS  questionnaires  are  electronically  scanned  using  computerised 
intelligent character reading and optical mark reading software (Teleform Elite 
version 8.1.1, Cardiff Software Inc, Vista, CA, USA). Information not recognised 
by  the  data-capture  software  is  verified  manually  by  data  entry  staff  at  the 
coordinating centre. All questionnaire, screening and diagnosis data is logged onto 
a custom-built SQL database which is hosted at the research coordinating centre. 
1.8.2  Summary of screening in the multimodal arm 
1.8.2.1  Annual (Level 1) screening 
Volunteers in the multimodal arm have annual venepuncture for serum CA125 
testing and calculation of Risk of Ovarian Cancer (ROC) (Figure 1.3). The ROC 
algorithm  determines  the  probability  of  ovarian  cancer  based  on  absolute 
concentration and serial change with time of the tumour marker serum CA125, in 
addition to age-specific incidence of ovarian cancer. ROC scores are calculated 
automatically by the UKCTOCS trial management system. Women who have a 
normal ROC (<1 in 1,000 risk of ovarian cancer) are returned to annual screening, 
with  their  next  screening  appointment  in  12  months.  Women  who  have  an 
intermediate ROC (1 in 2000 to 1 in 500 risk) are recalled for repeat CA125 in 12 
weeks. Women  with an elevated ROC (>1 in 500) are recalled for a  Level 2 
screen in 6-8 weeks. 30 
1.8.2.2  Repeat (Level 2) screening 
Women recalled for Level 2 screening undergo venepuncture for repeat CA125 
and  transvaginal  ultrasound.  Women  who  have  a  normal  ROC  and  normal 
ultrasound result are referred back to annual screening. Those with an abnormal 
scan result are referred to a named gynaecological oncologist for evaluation with 
regard to the need for surgery, irrespective of the ROC. Women with an elevated 
ROC  and  normal  or  unsatisfactory  scan  result  (one  or  both  ovaries  and  iliac 
vessels  not  visualised)  are  recalled  for  repeat  Level  2  in  six  weeks,  although 
earlier scans are arranged if there is a high index of suspicion of malignancy. If 
the ROC remains elevated at repeat Level 2 women are referred to the named 
gynaecological oncologist for clinical decision. 31 
Figure 1.3.  UKCTOCS multimodal arm screening algorithm 
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1.8.3  Summary of screening in the ultrasound arm 
1.8.3.1  Annual (Level 1) screening 
Women in the ultrasound group are sent annual appointments for a transvaginal 
scan.  If  transvaginal  ultrasound  is  not  acceptable  to  the  volunteer,  or  is  not 
possible for other reasons, transabdominal scan may be attempted after bladder 
filling.  The  ultrasonographer  assesses  ovarian  morphology  and  calculates  the 32 
volume of each ovary using the formula for an ovoid (d1 x d2 x d3 x 0·532). 
Ultrasounds are classified as unsatisfactory, normal or abnormal. The following 
findings are classified as normal: 1) ovaries not visualised but a good view of the 
iliac vessels was obtained, 2) both ovaries have normal morphology, or 3) a single 
simple  cyst  which  measures  less  than  5cm  in  diameter.  Women  with  normal 
findings are sent another annual appointment in approximately 12 months. 
Any of  the following findings  are categorised  as abnormal: 1)  more than one 
simple cyst, 2) more than one inclusion cyst in one ovary, 3) complex adnexal 
mass (having solid areas, papillations, septae or irregular outline), 4) a simple cyst 
measuring  over  5cms  in  diameter,  or  5)  ascites  (defined  as  a  vertical  pool 
measurement ≥ 10 mm). Women with abnormal ultrasound results are recalled for 
a Level 2 ultrasound in 6-8 weeks and those with highly suspicious findings are 
recalled earlier (Figure 1.4). 
1.8.3.2  Repeat (Level 2) screening 
Based on the same criteria used to assess annual scans, results of Level 2 screens 
are categorised as unsatisfactory, normal or abnormal. Women with normal results 
are  referred  back  to  annual  screening,  unsatisfactory  results  are  recalled  for  a 
repeat  Level  2  in  6-8  weeks  and  those  with  abnormal  scans  are  referred  for 
clinical assessment with a gynaecological oncologist. 33 
Figure 1.4.  UKCTOCS ultrasound arm screening algorithm 
 
1.9  Definition of a symptom and theoretical framework 
The term ‘symptom’ is used in medical contexts to describe subjective bodily 
experiences which may be interpreted as evidence of underlying disease. Theorists 
working in the fields of psychology, anthropology and sociology have proposed 
broader definitions of a symptom. For example, Pennebaker defines a symptom 
as, ‘a perception, feeling, or even belief about the state of our body. The sensation 
is often - but not always - based on physiological activity. Above all, a physical 
symptom or sensation represents information about internal state.’ (Pennebaker,
37 
p.1) 
While  symptoms  can  occur  as  a  result  of  normal  bodily  processes  or 
environmental factors, the term ‘symptom’ will be used in this thesis to describe 
bodily feelings or experiences which are consciously perceived by individuals and 
which arise from internal physiological changes which may be related to ovarian 
disease processes. 
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A  ‘common  sense’  model  of  symptom  perception  provides  a  theoretical 
framework for this definition. This model has two basic assumptions. Firstly, it 
assumes that measurable  and  verifiable bodily  signs of illness are  reflected  in 
symptom  perceptions.  Secondly,  it  is  assumed  that  there  is  a  ‘lawful 
correspondence’  between  an  underlying  physiological  state,  signs  of  this 
physiological  state  and  the  experience  of  symptoms.  In  her  critique  of  the 
common sense symptom model, St. Claire
38 provides a useful diagram to illustrate 
how it functions (Figure 1.5). 
Figure 1.5  Common sense symptom perception model 
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38 
Psycho-social  theorists  have  critiqued  the  common  sense  symptom  model  for 
failing to take into account psychological, cultural and social factors involved in 
symptom perception. They argue that there is no simple and direct correspondence 
between physiological changes and symptom perception. For example, Kolk et 
al.
39  propose  that  perception  of  physiological  changes  is  mediated  by  limited 
attention capacity. Under this model, an individual’s attention to bodily changes, 
and the detection and interpretation of symptoms, is shaped by complex internal 
factors, such as mood states and personality, and external stimuli such as family 
relationships and work (Figure 1.6). 
One  questionnaire-based  study  of  ovarian  cancer  symptoms  investigated 
psychological factors associated with symptom reporting by asking participants to 
complete depression and anxiety measures.
23 However, quantitative methods are 
generally  not  appropriate  for  the  exploration  of  nuanced  social,  cultural  and 
psychological influences on symptom perception and reporting. Thus, a common 
sense  symptom  perception  model  provides  the  theoretical  framework  for  the 
quantitative research described in this thesis.  
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Figure 1.6.  Psychological symptom perception model 
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Source: Kolk et al.
39 
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1.10  Thesis chapter plan 
This thesis begins with a description of ovarian cancer trends in Chapter Two, 
then continues with a review of previous research into the symptoms of ovarian 
cancer.  Chapter  Three  describes  analysis  of  symptoms  data  from  the  2006 
Ovacome patient survey. Chapter Four provides an overview of questionnaire 
development  theory  and  describes  the  findings  of  a  review  of  ovarian  cancer 
symptoms questionnaires used in previous studies. This chapter also details each 
stage  of  development  of  the  OCSq.  Chapter  Five  describes  findings  from 
analysis of symptoms data obtained from the questionnaire pilot. The final results 
chapter, Chapter Six, details findings from analyses of baseline data from the 
OCSq study involving 100,000 women. Chapter Seven provides an overarching 
discussion of the research findings and a summary of future plans.  
37 
Chapter Two – Literature Review 
2.0  Introduction 
This chapter  begins  with an overview of ovarian cancer trends and  diagnosis. 
These sections describe the problem of increasing ovarian cancer incidence rates 
over the past 30 years, with limited progress in improving survival rates. The 
diagnostic  pathway  is  described  and  time  spans  in  the  care  trajectory  are 
discussed, including the problem of sometimes lengthy time periods between the 
onset  of  symptoms  and  eventual  diagnosis.  The  second  part  of  the  chapter 
critically  reviews  the  literature  on  symptoms  of  ovarian  cancer  in  order  to 
understand what is already known on this topic, to identify gaps in knowledge and 
to  explore  the  limitations  of  published  research.  The  findings  of  this  critique 
provide a rationale for the research described in subsequent chapters of this thesis. 
2.1  Ovarian cancer trends, investigations and diagnosis 
2.1.1  Incidence 
Based on the latest available data from 2005, the UK has an age-standardised 
ovarian cancer incidence rate of 16.9 per 100,000.
40 This makes it one of the 
highest  rates  in  Europe,  with  only  Lithuania,  Denmark,  the  Czech  Republic, 
Estonia, Ireland and Latvia having higher incidence of the disease. Table 2.1 lists 
the  number  of  new  cases  of  ovarian  cancer  and  the  age-standardised  rate  for 
regions of the UK for 2001 to 2005. As can be seen in the table, Northern Ireland 
has the highest incidence of ovarian cancer at 19.1 per 100,000, while Scotland 
has the lowest at 14.0 per 100,000. 
Table 2.1.  New cases and age-standardised incidence of ovarian cancer 
Cases  England  Wales  Scotland  N.Ireland  UK 
Females  5,528  380  500  188  6,596 
Age-standardised rate  17.1  18.6  14.0  19.1  16.9 
Source: CRUK ovarian cancer incidence statistics 2006
40  
38 
Ovarian cancer incidence rates increase with age, tripling from approximately 10 
per  100,000  in  women  aged  40-44  years  to  approximately  37  per  100,000  in 
women aged 55-59 years (Figure 2.1).
40 Incidence peaks at around 68 per 100,000 
in women aged 80-84 years, then begins to decline. 
Figure 2.1.  Age-specific incidence rates for ovarian cancer in UK 
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Source: CRUK ovarian cancer incidence statistics
40 
Over the past 30 years incidence of ovarian cancer in the UK has increased, from 
approximately 15 per 100,000 in 1975 to a peak of 19.3 per 100,000 in 2001, 
although incidence has been falling in recent years.
1 This trend is explained by 
large increases in the incidence rate among women aged over 65 years but not 
other age groups (Figure 2.2). It has been hypothesised that this may be due to the 
widespread use of oral contraceptives, which have a protective effect for ovarian 
cancer. This trend may also have arisen from increased longevity and improved 
diagnosis and disease reporting.  
39 
Figure 2.2.  Age-specific incidence rates for ovarian cancer, UK 1975-2006 
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2.1.2  Diagnosis 
In  the  UK,  Department  of  Health  Guidance  provides  a  framework  for  the 
diagnosis of cancer. In 2000 The NHS Cancer Plan was published. This document 
stated, ‘the ultimate goal is that no one should wait longer than one month from an 
urgent referral for suspected cancer to the beginning of treatment except for a 
good clinical reason or through patient choice’ (Department of Health,
42 p.6). The 
directive established a number of targets relating to referral and treatment waiting 
times, including implementation by 2005 of maximum two week waits for urgent 
GP referrals for suspected cancer. Referral Guidelines for Suspected Cancer, also 
published in 2000,  described suspicious  pelvic  masses  detected on ultrasound, 
postmenopausal bleeding and post-coital bleeding as criteria for urgent referrals.
43 
The National Centre for Health and Clinical Excellence (NICE) issued similar 
guidance in 2005, advising that abdominal palpation should be carried out on any 
woman presenting with unexplained abdominal or urinary symptoms.
44 As in the 
earlier  guidance,  the  document  advised  that  women  with  unexplained  pelvic  
40 
masses  detected  on  examination,  persistent  inter-menstrual  bleeding  or 
unexplained postmenopausal bleeding should be urgently referred. However, the 
document noted that women with ovarian cancer may present ‘with vague, non-
specific abdominal symptoms … bloating, constipation, abdominal or back pain, 
urinary symptoms’ (NICE,
44 p.26). 
Despite  implementation  of  various  guidelines  for  suspected  cancer  referrals,  a 
2006 study found 39% of women diagnosed with ovarian cancer are not urgently 
referred.
45 Reasons for  this are unclear,  although recent research  suggests that 
symptoms included in earlier criteria for urgent referrals may not have the highest 
positive predictive values for identifying ovarian cancer.
23 46-47 This situation may 
improve following new Department of Health guidance for health professionals, 
which described persistent pelvic/abdominal pain, increased abdominal size and 
difficulty eating/feeling full as key symptoms of ovarian cancer.
33 
Women with suspected ovarian cancer are referred to specialist gynaecological 
cancer teams based in Cancer Units or regional Cancer Centres.
43 Cancer Units 
are located within district hospitals and are responsible for providing diagnostic 
procedures  for  all  suspected  gynaecological  cancers.  Where  ovarian  cancer  is 
strongly  suspected,  women  are  immediately  referred  to  the  specialist 
gynaecological oncology team at the nearest regional Cancer Centre. Members of 
these multi-professional teams have a special interest in gynaecological cancer 
and are responsible for the diagnosis, treatment and management of all women 
with ovarian cancer. 
Work-up  at  specialist  gynaecological  cancer  centres  includes  family  history 
assessment, abdominal and pelvic examination, assessment of CA125 and other 
tumour markers, transvaginal ultrasound and other cross-sectional imaging. These 
investigations  may  identify  a  mass  as  highly  suspicious  of  ovarian  cancer, 
although  a definitive diagnosis is not made until confirmed  by histopathology 
from samples obtained during surgery. 
2.1.3  Presenting symptoms 
Since the early 1990s several studies have reported that symptoms of increased 
abdominal size or bloating, abdominal or pelvic discomfort, loss of appetite or  
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early satiety, fatigue, indigestion, urinary symptoms and change in bowel habit are 
common among women with ovarian cancer, including women with early stage 
disease.
10-11 13 15-16 19 22 48-51 However, women and clinicians often attribute these 
symptoms to menopause, ageing, stress, existing conditions or changes in lifestyle 
or diet.
8 13 46 51 This mistaken attribution delays women seeking medical advice, 
and once they visit their doctor, may delay prompt referral to a specialist. By the 
time women are seen in specialist gynaecological oncology clinics, many have 
symptoms of advanced disease including increased abdominal size, abdominal or 
pelvic pain, abdominal mass and ascites. A detailed discussion of pre-diagnostic 
symptomatology continues in the second part of this chapter. 
2.1.4  Key investigations 
Transvaginal  (TVS)  or  transabdominal  ultrasounds  are  provided  by  specialist 
gynaecological cancer teams. Ultrasounds assess the morphological features of 
adnexal masses, the presence of neovascularisation and resistance to flow using 
colour and pulsed Doppler. Morphological characteristics associated with ovarian 
cancer  include  large  cyst  volume,  presence  of  papillary  projections  and  cyst 
complexities such as solid areas, loculations, wall structures, septal thickness and 
echogenicity  of  fluid.
52  In  addition  to  ultrasound,  specialist  centres  may  offer 
computerised  tomography,  magnetic  resonance  imaging  and  radio-nucleotide 
imaging.
53 
While  ultrasounds  are  useful  for  characterisation  of  adnexal  masses,  they  are 
difficult  to  interpret  and  ultrasound  alone  is  not  specific  enough  to  provide  a 
diagnosis of malignancy. To overcome this lack of specificity, various scoring 
systems  to  predict  ovarian  cancer  have  been  proposed.  Among  these  is  the 
commonly  used  system  developed  by  Sassone  et  al.
54  which  adds  individual 
scores for four ultrasound characteristics (inner wall structure, wall characteristics, 
septa and echogenicity) to give an overall risk of malignancy. For example, the 
inner wall structure is assessed as either: smooth = 1 point, irregularities ≤3mm = 
2 points, papillarities >3mm = 3 points, or mostly solid = 4 points. A total score of 
≥9 indicates a positive finding under the system.  
42 
CA125 is a tumour biomarker that is elevated in ovarian cancer. CA125 blood 
tests are routinely used in clinical investigations to diagnose ovarian cancer and 
post-treatment disease recurrence. A cut-off value of 35 U/mL is widely accepted 
for  healthy  postmenopausal  women.
55  Levels  of  ≥35  U/mL  are  found  in 
approximately 83% of patients with ovarian cancer and approximately 90% with 
advanced disease.
56 However, it has poor sensitivity for detection of early stage 
ovarian cancer as only 50-60% of patients with stage I have CA125 levels ≥35 
U/mL.
57-58 CA125 also has a lack of specificity as it is raised in a number of other 
conditions, including diverticulitis and cirrhosis, benign gynaecological disease 
such  as  endometriosis,  and  also  in  breast,  pancreatic,  bladder,  liver  and  lung 
cancers.
59 
A number of other ovarian cancer serum biomarkers have been investigated in 
recent  years,  including  HE4,  mesothelin,  M-CSF,  osteopontin,  kallikreins  and 
soluble  EGF.
60  Some  of  these  novel  biomarkers  have  shown  promising  early 
results,  although  further  research  is  needed  to  determine  their  specificity  and 
sensitivity  in  large  populations  of  women.  At  the  present  time,  CA125  and 
ultrasound remain the clinical modalities of choice for the detection of ovarian 
cancer. 
2.1.4.1  Risk of malignancy index 
Researchers have sought to overcome the limitations of CA125 and ultrasound 
investigations alone by developing scoring systems to predict ovarian cancer. It is 
now almost 20 years since Jacobs et al.
61 first described their risk of malignancy 
index  (RMI).  This  study  found  three  variables:  1)  menopausal  status,  2) 
ultrasound score and 3) serum CA125, to be independently associated with the 
likelihood of malignancy. The risk of malignancy index was defined as: RMI = U 
x M x serum CA125. Where U = ultrasound score and M = 1 if premenopausal 
and M = 3 if postmenopausal. Ultrasound reports were scored one point each for 
the presence of multilocular cyst, evidence of solid areas, evidence of metastases, 
presence of ascites and bilateral lesions. The study found an RMI score of 200 had 
a sensitivity of 85% and specificity of 97% for predicting malignancy. Moreover, 
the  combination  of  these  three  criteria  provided  a  greater  level  of  distinction  
43 
between  benign  and  malignant  masses  than  by  any  of  the  individual  criterion 
alone. This research was innovative in the way it combined CA125, ultrasound 
data  and menopausal  status data to determine  an  overall risk  score.  Since the 
initial study of 143 participants diagnosed at a single hospital research site, the 
RMI  has  been  validated by  numerous independent researchers. RMI scores  of 
>200  have  been  reported  to  have  sensitivities  ranging  from  71-90%,  with 
specificities from 77-92% and positive predictive values ranging from 75-96%.
62-
67 Furthermore, a recent systematic review of ovarian cancer prediction models 
recommended  the  RMI  as  the  scoring  system  of  choice  for  preoperative 
assessment of adnexal masses.
68 
The RMI is simple to use in clinical practice and is a useful tool for triaging 
patients with adnexal masses to either: 1) standard surveillance, 2) repeat testing 
or  3)  immediate  referral.  The  scoring  system  also  helps  clinicians  to  identify 
patients who should be urgently referred to specialist gynaecological oncology 
surgeons. The usefulness of the tool is reflected in the recommendation by the 
Royal College of Obstetricians and Gynaecologists for clinicians to use the RMI 
for triaging postmenopausal women as at either: 1) low, 2) moderate or 3) high 
risk of malignancy.
69 
2.1.5  Time spans in the care trajectory 
Researchers investigating the cancer care trajectory often divide the diagnostic 
pathway into two stages. The first of these is the patient or self-care phase and the 
second is the health care provider phase, which is composed of a primary care and 
secondary care component. A focus of much of the research in this field is the 
identification of delays, whether these are related to delays in patients presenting 
to  their  GP,  delays  in  primary  care  referrals  to  secondary  care,  or  delays  in 
investigations and treatment. 
The term ‘delay’ is problematic as it carries negative connotations of blame. It 
ignores the often complex reasons why patients do not readily attend their GP 
surgery  after  the  onset  of  symptoms,  and  why  GPs  do  not  refer  women  to 
secondary care earlier. The term also fails to take into account unavoidable lapses 
of  time  required  for  diagnostic  procedures  to  be  carried  out  and  appropriate  
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referrals made. Unfortunately, the semantic complexities of the term are often 
overlooked  in  the  literature,  where  it  is  applied  arbitrarily  to  both  quantified 
durations  of  time  in  the  care  trajectory  and  to  preventable  delays.  For  these 
reasons,  I  will  endeavour  to  avoid  using  the  term  delay  in  the  following 
discussion, although its ubiquity within the literature makes it difficult to avoid 
entirely. 
2.1.5.1  Total duration of time from symptom onset to diagnosis 
Papers  that report the duration of time  between  symptom onset and diagnosis 
suggest that  women experience symptoms for  a median  of 2-4 months before 
being diagnosed with ovarian cancer.
12 14-15 20 48 70-72 However, there is variation 
within  the  literature,  with  two  month  durations  reported  by  medical  records 
studies,
20 71-72 compared to 4-12 months in patient surveys and qualitative studies.
5 
46 
There  is  also  variation  between  studies  which  used  similar  methods.  A  US 
qualitative study described average symptom durations of 3-12 weeks,
70 while a 
UK qualitative study reported a median duration of 12 months.
46 This difference 
may be explained by the fact that the US study interviewed family members and 
women with ovarian cancer together, while women were interviewed on a one-to-
one  basis  in  the  UK  study.  Perhaps  the  women  in  the  US  study  did  have 
symptoms for much longer but were reluctant to discuss them with their family 
members for a number of reasons. Another possible explanation may be recall 
bias in the US study, although this is difficult to estimate as the authors do not 
provide  information  on  the  time  interval  between  diagnosis  and  interview. 
Alternately, as 60% of the women in the UK study were interviewed prior to 
diagnosis, perhaps they were particularly anxious about their impending surgery 
and had enhanced recollection of the timing of symptom onset. 
Similar differences may be observed in the findings of two studies conducted by 
the same group in the eastern states of America. The first study found a median 
duration of four months between symptom onset and diagnosis for women with 
invasive ovarian cancer,
15 while the second found a median duration of 12 months 
for  women  with  early  stage  invasive  cancer.
16  This  disparity  may  be  due  to  
45 
differences in the stage distribution of women included in each study, although 
this is unclear as the authors do not report stage information for the first study. 
2.1.5.2  Duration of time from symptom recognition to GP visit 
A  1970s  study  of  the  medical  records  of  250  women  with  ovarian  tumours 
reported an average interval of 13 months between symptom onset and women 
seeking medical advice.
5 Unfortunately, due to the age of this paper, I was only 
able to obtain the abstract. Therefore I was unable to ascertain how the methods 
may  have  influenced  this  finding.  However,  other  research  has  found 
comparatively  shorter  intervals  between  symptom  onset  and  medical 
consultations. Goff et al.
13 found women experienced symptoms for a median of 
2-3 months before seeking medical advice. Questionnaire studies conducted in 
Australia,
73  and  in  Iowa  in  the  US  reported  medians  of  four  weeks  between 
symptom  onset  and  medical  consultations,
8  as  did  a  Swedish  medical  records 
study,
72 although a recent Japanese study found a slightly longer median duration 
of 5.5 weeks.
74 
A pertinent issue in relation to these relatively short time spans is that the fact that 
the medians conceal a wide range of durations. For example, 25% of women in 
Thulesius et al.
72 delayed seeking medical care for nine weeks or longer and 23% 
in  Smith  and  Anderson
8  delayed  for  three  months  or  longer.  Webb  et  al.
73 
similarly found 29% of women with borderline tumours, 19% with early and 13% 
with advanced disease delayed consulting their doctor for three months or more. 
As  these  studies  utilised  survey  and  medical  records  reviews  in  countries  as 
diverse as Sweden, the US and Australia, variations in patient delays are unlikely 
to be the result country-specific variables. This indicates that 13-29% of women 
later diagnosed with ovarian cancer wait approximately three months after the 
onset of symptoms before seeking medical care. The reasons for this delay are 
often complex. These are discussed in the second section of this chapter under the 
sub-heading ‘symptom perception and interpretation’.  
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2.1.5.3  Duration of time from GP visit to diagnosis 
Research indicates that women wait an average of 2-8 weeks between initially 
consulting their doctor and receiving a diagnosis of ovarian cancer. However, the 
Goff  et  al.
13  survey  of  recipients  of  an  ovarian  cancer  patient  support  group 
newsletter found 26% waited longer than six months before receiving a correct 
diagnosis. 
A UK study of general practice records by Kirwan et al.
14 found 60% of women 
with ovarian cancer were referred to a secondary care gynaecological oncologist 
within two weeks of their first GP visit and 73% were referred within one month. 
However, by the time patients were seen in secondary care, a median of 95 days 
had elapsed since symptom onset. Similarly, a postal survey of 306 women with 
ovarian cancer, conducted by a patient support and advocacy group in the UK 
(Ovacome), reported an average clinical delay of 11.5 weeks.
35 While the findings 
of  the  US  and  UK  advocacy  group  surveys  are  likely  to  be  limited  by  self-
selection bias and recall bias, the research by Kirwan et al.
14 collected data from 
existing  primary  care  records  and  included  all  women  with  ovarian  cancer 
identified through a regional audit. It is pertinent to consider that the findings of 
Kirwan et al.
14 may not be representative of the rest of the UK. However, this 
study,  qualitative  research  by  Bankhead  et  al.
46  and  the  Ovacome  survey,  all 
established that delays in diagnosis are a problem in the UK. 
With  the  exception  of  two  studies,
13  15  longer  delays  in  diagnosis  have  been 
described  among  women  with  advanced  disease  compared  to  women  with 
borderline or early stage ovarian cancer. Flam et al.
9 and Webb et al.
73 described 
delays of three months or more occurring in approximately double the number of 
women with advanced disease, compared to women with early stage tumours. 
Another study found patients with stage I tumours waited a mean of 35 days from 
first consultation to operation, while patients with stage III tumours waited 64 
days.
48 These findings may stem from difficulties identifying the cause of disease 
due  to  the  systemic  nature  of  symptoms  in  advanced  ovarian  cancer.  The 
divergent finding  of  longer delays among women with early stage tumours in 
Vine et al.
15 is unlikely to be due to selection bias related to better survival among  
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women  with  early  stage  disease,  as  the  study  excluded  women  who  were 
diagnosed for longer than six months. However, the difference may be explained 
by country-specific factors. 
Research  has  also  found  that  many  women  endure  convoluted  and  erroneous 
referral pathways before eventually receiving a diagnosis of ovarian cancer. A 
large  study  of  the  health  insurance  records  of  women  with  ovarian  cancer  in 
California  reported  that  abdominal  imaging  (rather  than  pelvic)  and 
gastrointestinal investigations were the most common diagnostic procedures in 
women  4-36  months  prior  to  diagnosis.
21  Goff  et  al.
13  found  30%  of  women 
initially received a wrong diagnosis, while the Ovacome study reported that it 
took an average of three clinical appointments to achieve a correct referral to a 
specialist gynaecological oncologist.
35 The most common misdiagnoses reported 
by women in the Goff  et al.
13 research were irritable bowel syndrome (15%), 
stress  (12%),  being  told  nothing  was  wrong  (13%),  gastritis  (9%),  depression 
(6%) and constipation (6%). Medical records and qualitative research reported 
similar  misdiagnoses  in  addition  to  menopause,  indigestion,  thyroid  disease, 
cholecystitis, diverticulitis and depression.
50 75-77 
Incorrect initial diagnoses are not necessarily due to clinician errors. It is likely 
that the often subtle and non-specific nature of ovarian cancer symptoms, or their 
similarity to symptoms of more common gastrointestinal diseases or pre-existing 
conditions,  also  plays  a  role  in  misdiagnosis.  Poor  communication  between 
patients  and  health  professionals  has  also  been  identified  as  a  factor  which 
contributes to delays.
13 50 75  Nearly one-fifth of the women in the Goff et al.
13 
study  described  unhelpful clinician attitude as  a factor which contributed to a 
delayed  diagnosis,  while  women  in  a  small  qualitative  study  by  Fitch  et  al.
75 
described clinicians treating them in an insensitive manner or not listening to their 
intuitive concerns. However, these two studies are likely to have an element of 
self-selection bias. As described previously, the Goff questionnaire was posted to 
women who received an ovarian cancer patient support newsletter, while Fitch et 
al.
75  recruited  a  convenience  sample.  Women  who  had  lengthy  delays  or 
particularly  poor care  may have had  greater  motivation to participate in these 
studies compared to women who experienced minimal delays. Another possible  
48 
explanation  may  be  after-the-event  wisdom,  where  a  relationship  between 
symptoms and a diagnosis of ovarian cancer seems obvious on retrospect. 
Bankhead
78 also found  that the number  of symptoms reported  to  GPs, patient 
personality  and  frequency  of  previous  consultations  influence  referrals  to 
secondary care. Administrative and referral errors, problems with ordering tests 
and  lack  of  follow-up  after  initial  investigations  also  result  in  health  system 
delays.
50 77 79  
Delays in diagnosis are a cause for concern as studies involving patients with 
other types of cancers have found an association between delays and advanced 
stage at diagnosis.
80-81 A review of time spans in the diagnosis of breast cancer 
reported  that  delays  of  three  months  are  associated  with  12%  lower  five-year 
survival.
82  Among  ovarian  cancer  patients,  two  studies  have  reported  an 
association between delay in diagnosis and advanced stage,
5 13 and one of these 
studies also found an association between patient delays and reduced survival.
5 
However, other research has not found an association between delays in diagnosis 
and stage or survival.
8 14 51 72-73  
2.1.6  Pathology 
2.1.6.1  Histology 
More than two-thirds of malignant ovarian tumours arise from the ovarian surface 
epithelium.
83  These  are  grouped  into  sub-types  based  upon  the  World  Health 
Organisation’s  histomorphologic  classification  of  tumours  (Jaffe  2003  in 
Soslow
84). The main histological sub-types of ovarian cancer described by this 
system  are  serous,  mucinous,  endometrioid,  clear  cell,  transitional  cell,  and 
squamous ovarian neoplasms. These sub-types are described as benign, borderline 
or malignant depending on the cytologic and architectural features of the tumour. 
Serous carcinomas are the most common sub-type of ovarian cancer in Western 
industrialised  countries.
83  Research  indicates  that  they  comprise  approximately 
80-85%  of  ovarian  carcinomas,  followed  by  clear  cell  carcinomas  (13%)  and 
endometrioid  tumours  (9%).
85  Only  3%  are  mucinous,  while  transitional  and 
squamous ovarian carcinomas are rare at less than 1%.  
49 
In recent  years it has been increasingly accepted that ovarian cancer does not 
constitute a single disease  entity, but  rather  a heterogeneous  group of  distinct 
diseases. Each histological sub-type has its own risk factors, underlying molecular 
events,  behaviour,  natural  history  and  treatment-response.
86-87  While  stage 
distribution  is  more  commonly  reported,  six  symptoms  studies  have  described 
tumour class distribution among women in their research.
6 10 15 20 25 48 However, 
comparison  of  symptoms  findings  according  to  histological  classification  is 
difficult due to changes in tumour classification over the last 20 years. 
2.1.6.2  Stage 
Ovarian  cancer  is  staged  during  laparotomy.  Full  staging  is  defined  by  the 
EORTC as including infracolic omentectomy, sampling of iliac and para-aortic 
lymph nodes, biopsies of the right hemidiaphragm, samples of the right and left 
paracolic gutter, pelvic sidewalls, ovarian fossa, bladder peritoneum and cul-de-
sac, in  addition to sampling  of all suspicious areas and  peritoneal washings.
88 
Stage  is  then  determined  according  to  guidance  issued  by  the  International 
Federation of Gynecology and Obstetrics
89 (FIGO) (Table 2.2).  
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Table 2.2.  FIGO ovarian cancer stage 
Stage I  Tumour confined to one or both ovaries 
IA  Tumour limited to one ovary; no tumour on ovarian surface; capsule intact; no 
malignant cells in ascites or peritoneal washings. 
IB  As above with tumour involving both ovaries. 
IC 
Tumour limited to one or both ovaries with any of the following: capsule 
ruptured, tumour on ovarian surface, malignant cells in ascites or peritoneal 
washings. 
Stage II  Tumour involving one or both ovaries with pelvic extension 
IIA  Extension and/or implants in uterus and/or fallopian tubes; negative washings. No 
malignant cells in ascites or peritoneal washings. 
IIB  Extension to other pelvic organs. No malignant cells in ascites or peritoneal 
washings. 
IIC  Tumour staged 2A or 2B with malignant cells in ascites or peritoneal washings. 
Stage III 
Tumour involving one or both ovaries with microscopically confirmed 
peritoneal metastasis outside of the pelvis and/or regional lymph node 
metastases 
IIIA  Microscopic peritoneal metastases beyond the pelvis. 
IIIB  Macroscopic peritoneal metastases beyond pelvis, none exceeding 2cm in 
diameter. 
IIIC  Peritoneal metastases beyond pelvis greater than 2cm in diameter and/or regional 
lymph node metastasis. 
Stage IV  Distant metastases 
 
Source: FIGO
89 
More  than  two-thirds  of  serous  carcinomas  are  diagnosed  as  stage  III  or  IV, 
compared  to  approximately  25%  of  clear  cell  and  endometrioid  tumours.
83  86 
Stage I serous tumours are uncommon and account for less than 10% of serous 
carcinomas.  By contrast, 63% of clear cell, 48% of endometrioid and  71% of 
mucinous tumours are diagnosed as stage I disease.
86 90   
51 
2.1.7  Treatment 
The primary treatment approach for ovarian cancer is maximum cytoreductive 
surgery with full staging. The objective of surgery is to reduce residual tumour 
volume to <1cm in diameter.
91 Laparoscopy is the preferred approach in women 
with  suspected  early  stage  tumours  while  laparotomy  is  usually  conducted  in 
women  with  advanced  disease.
92  Patients  typically  have  bilateral  salpingo-
oophorectomy with tumour debulking, hysterectomy, infracolic omentectomy and 
node  sampling  during  surgery.  Surgery  is  usually  followed  by  six  cycles  of 
platinum  (carboplatin  or  cisplatin)  and  paclitaxel-based  chemotherapy  as 
recommended by NICE guidelines.
93 
A recent meta-analysis concluded that intraperitoneal administration of platinum 
and  taxane-based  chemotherapy  has  survival  advantages  over  systemic 
administration.
94 However, both routes of administration yield impressive results, 
almost doubling survival by adding a median of three years to an expected median 
survival of 2.5 years with no treatment. 
Patients  diagnosed  with  well  differentiated  stage  Ia  or  Ib  disease  who  have 
undergone removal of the tumour and optimal staging have low risk of recurrence. 
Research has found that it is safe to withhold adjuvant chemotherapy from these 
patients and that it does not improve disease-free survival.
88 95 Unfortunately, risk 
of recurrence is high in patients diseased with stage Ic or more advanced disease. 
Approximately 70% of women with stage III disease will experience recurrence 
within a median of two years.
96 For these women, cytoreductive surgery may be 
repeated and second-line treatment initiated. Patients who have no macroscopic 
residual  tumour  after  secondary  debulking  surgery  have  been  found  to  have 
significantly  longer  post-recurrence  survival  compared  to  patients  left  with 
macroscopic residual tumour.
97 
2.1.8  Prognosis 
A number of pathological, clinical and patient variables have been described as 
prognostic factors in ovarian cancer. Stage at diagnosis has been found to be the 
strongest  predictor  of  outcome,  with  a  powerful  inverse  relationship  between 
stage and survival.
98-99 (Table 2.3 in survival section
53)  
52 
Volume of residual disease after initial and secondary cytoreductive surgery has 
also been found to be an important prognostic factor. Bristow et al.
97 describe a 
‘less is more’ relationship between residual disease and survival outcome. Patients 
with microscopic residual disease up to 1cm have been found to have the longest 
progression-free  and  overall  survival.
100-103  This  association  has  been 
demonstrated both in women undergoing primary cytoreductive surgery and in 
those who have secondary surgery for recurrence.
97  
Other  clinical  factors  associated  with  better  prognosis  include  patients  being 
operated on by experienced gynaecological oncology surgeons rather than general 
surgeons, the absence of ascites, complete staging, absence of surface capsule 
involvement and management of treatment within a multidisciplinary team.
100 104-
106  
Several studies have investigated CA125 serum levels as a prognostic variable. 
This  research  has  reported  mixed  findings.  One  study  reported  pre-operative 
CA125 levels of <65 U/mL are associated with longer survival in patients with 
early stage disease,
107 while another study reported CA125 levels of ≤30 U/mL 
are most important for survival.
108 Low pre-operative CA125 has also been found 
to be an important predictor of progression-free survival in patients with advanced 
stage disease.
109 Other research suggests that lower CA125 level at the end of 
primary therapy is more important as a predictor of overall, and progression-free, 
survival than preoperative CA125 level.
110-111 
Symptom  severity  at  presentation  has  been  identified  as  an  unfavourable 
prognostic factor, independent of stage.
72 98 DiSilvestro et al.
98 reported that a one 
stage increase in symptom severity (e.g. systemic rather than localised) increased 
the hazard of death by 2.28, even after controlling for stage. 
Advanced age at diagnosis, poor performance status and malnourishment have 
also been identified as factors associated with poor prognosis.
99  112-116 Chan et 
al.
112 reported that overall survival was significantly better in younger women, 
even after stratification by stage and result of cytoreductive surgery. The same 
study also reported that women with poor performance status had a 90% increased 
risk of cancer-specific death relative to healthier patients.  
53 
2.1.9  Mortality 
In contrast to dramatic improvements in survival trends for breast cancer over the 
last two decades, mortality rates for women with ovarian cancer have only slightly 
decreased. In the UK, approximately 4,300 women die per annum as a result of 
ovarian  cancer.
117  Ovarian  cancer  mortality  rates  follow  the  same  trend  as 
incidence, increasing from approximately 12 per 100,000 in women aged 50-54 
years to approximately 55 per 100,000 in women aged 75-79 years and peaking at 
approximately 67 per 100,000 in women over 85 years (Figure 2.3).
118 
Figure 2.3.  Age-specific mortality rates for ovarian cancer in UK 
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2.1.10  Survival 
Stage of  disease at diagnosis is considered the  most  important determinant  of 
survival  for  women  with  ovarian  cancer.  Cancer  Registry  statistics  from  one 
region of the UK for the period 1992-1996 show 73% five-year relative survival 
rates for women diagnosed with stage I compared to 16% for stage III disease.
119 
Wider research indicates more dramatic survival differences based on stage at 
diagnosis (Table 2.3).
53   
54 
Table 2.3.  Median and five-year survival for FIGO stage 
Sub-stage  Median survival (months)  Five-year survival (%) 
IA  96+  92.1 ± 0.9 
IB  96+  84.9 ± 3.4 
IC  96+  82.4 ± 2.0 
IIA  85+  67.0 ± 4.3 
IIB  92.3  56.4 ± 3.6 
IIC  86.1  51.4 ± 4.5 
IIIA  41.1  39.3 ± 2.8 
IIIB  26.4  25.5 ± 2.6 
IIIC  20.7  17.1 ± 1.4 
IV  14.7  11.6 ± 0.9 
 
Source: Byrom & Davies
53 
Statistics for England for the period 1991-1993 reveal the importance of age as a 
determinant of survival. Among women aged 15-39 years, five-year survival is 
relatively high at 69%, however this figure is halved for women aged 50-59 years 
(34%).
3 Five year survival drops to 25% in women aged 60-69 years and to 18% 
for women aged 70-79 years at diagnosis. 
One-year survival rates for ovarian cancer increased from approximately 46% to 
58% during the period 1971-1993.
3 Over the same period there was a modest 
improvement in five-year survival from 23% to 29% (Figure 2.4). This trend has 
continued with recent statistics indicating 66% one-year survival for the period 
1996-1999.
2  Five-year  survival  rates  have  improved  largely  as  a  result  of 
treatment advances which have added three years to the expected median survival 
of 2.5 years in ovarian cancer patients.
94 Ten-year survival rates have remained 
low as there has been little change in stage at presentation, although these are 
expected to improve to 33% by 2013.
2  
55 
Figure 2.4.  One, five and ten year ovarian cancer survival, England and Wales 
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2.2  Symptoms of ovarian cancer 
2.2.1  Introduction 
Ovarian cancer has been historically perceived as a ‘silent killer’, with medical 
textbooks published throughout the 20
th century typically describing the disease as 
asymptomatic until the advanced stages. However, as far back as 1936 there was 
evidence to suggest one-third of patients experience pain for more than six months 
before being diagnosed with ovarian cancer (Lynch 1936 in Smith
4). 
This literature review provides an overview of ovarian cancer symptoms research 
published  over  the  past  30  years.  As  described  in  Chapter  One,  the  term 
‘symptom’ will be used throughout this and all chapters to refer to bodily feelings 
or experiences which are consciously perceived by individuals and which may be 
interpreted as evidence of underlying ovarian lesions.  
56 
2.2.2  Prevalence of symptoms 
A systematic review of ovarian cancer symptoms studies by Bankhead et al.
120 
found the proportion of asymptomatic patients ranges from 5-26%. Questionnaire 
and medical records research published after this study reported similar findings.
51 
121-122  
2.2.3  Types of symptoms associated with ovarian cancer 
The systematic review by Bankhead et al.
120 included 21 papers on symptoms of 
ovarian cancer. A meta-analysis was conducted to identify the most frequently 
reported types of symptoms. This included quantitative papers where symptoms 
were elicited directly from participants and studies utilising medical records data. 
The  analysis  found  abdominal  pain  or  discomfort,  abdominal  bloating  and 
abdominal  swelling  were  the  most  common  symptoms  in  the  literature.  Other 
symptoms  frequently  described  in  the  literature  included  fatigue,  urinary 
symptoms, early satiety, weight gain or loss and gastrointestinal symptoms such 
as indigestion, constipation or diarrhoea, while gynaecological symptoms such as 
abnormal vaginal bleeding or pain during intercourse are less commonly reported. 
Questionnaire and medical records research published after the review reported 
analogous findings.
13 47 51 71 121 
122 
There is considerable variation in the ways in which authors have chosen to report 
symptoms. Some studies combined abdominal and pelvic pain,
12  15-16  123 while 
others considered these distinct symptoms.
7 13 18 124 Abdominal pain only, and not 
pelvic pain, is reported by another group of studies,
8 14 19 22 51 while two papers 
combined  abdominal  and  back  pain  together.
11  17  All  of  these  studies  found 
abdominal or pelvic pain, or abdominal and lower back pain, were among the 
most frequently  reported  symptoms by  women  with ovarian cancer. However, 
none of the authors explained how their research participants understood the terms 
abdominal  and  pelvic.  It  is  likely  that  women  participating  in  questionnaire 
research had variable levels of understanding in relation to the term pelvic, yet no 
paper  discusses  this  possibility.  Indeed,  wider  research  has  found  poor 
understanding  of  anatomy  among  the  general  public,  with  only  40%  of 
participants in a recent study being able to locate the ovaries on a diagram.
125 This  
57 
emphasises the need to clearly define anatomical terms, or use diagrams clearly 
labelling the parts of the body these terms refer to. 
Studies  which  combine  abdominal  and  pelvic  pain  symptoms  into  one 
questionnaire item may be also be criticised for failing to distinguish between 
these different parts of the body. Both Vine et al.
15-16 studies combined a number 
of different abdominal and pelvic symptoms into one item ‘pelvic or abdominal 
discomfort such as heaviness, fullness, pressure or pain’. This is problematic as 
sensations of fullness and heaviness are very different to pain. 
Similarly, Olson et al.
17 asked participants about ‘unusual abdominal or lower 
back pain’. This terminology would have reduced the specificity of the data due to 
the high prevalence of chronic lower back pain in the general population.
126 The 
shortcomings  of  these  studies  emphasise  the  need  to  ask  research  participants 
about  specific  symptoms,  or  if  symptoms  are  combined,  to  have  very  robust 
reasons for doing so. 
The symptoms abdominal swelling (also referred to as increased abdominal size) 
and  abdominal  bloating  are  sometimes  combined  as  one  symptom  in  the 
literature,
51 77 127 although several studies report information on one or the other, 
but  not  both.  Goff  et  al.
13  differentiated  between  bloating  and  increased 
abdominal size, finding increased abdominal size was the most common symptom 
(reported by 61%) followed by abdominal bloating (57%). Another study by the 
same  group  reported  a  reversal  of  these  rankings,  with  bloating  being  more 
common  than  increased  abdominal  size  among  the  44  women  with  malignant 
tumours.
18  
Similarly  to  the  way  in  which  they  combined  pain  symptoms,  Olson  et  al.
17 
grouped together ‘bloating, fullness and pressure in the abdomen or pelvis’. The 
authors found this was reported by 71% of the 168 women with ovarian cancer in 
their  study,  making  it  the  most  common  symptom.  Paulsen  et  al.
20  reported 
‘distended or tense abdomen’ was the second most common symptom, with 44% 
of women with invasive tumours and 32% with borderline tumours having this 
symptom in their medical records. However, the authors do not define the term 
‘tense’. They explain that free-text symptoms were first extracted from medical  
58 
records, then grouped into 10 symptom categories. However, no information is 
given on the types of free text symptoms that formed the category ‘distended or 
tense abdomen’, or any of the other symptoms in their study, including the rather 
obscure symptom ‘pain outside the abdominal cavity’. 
Bankhead
78  investigated  women’s  understandings  of  the  terms  bloating  and 
abdominal distension in her qualitative research. This research was the first to 
elucidate this information, finding that persistent abdominal distension but not 
transient bloating was associated with ovarian cancer.
46 78 This study emphasises 
the value of in-depth interviews in exploratory research. The findings clarified 
how women in the UK undergoing investigations for ovarian masses understand 
symptoms terms. Apparently healthy women in the general population may have 
different interpretations of these symptoms compared to women in the study, who 
were undergoing clinical investigations. Nevertheless, this research confirmed the 
need to specifically ask women about both increased abdominal size and bloating 
in my own research, rather than combining these symptoms into one item. 
A number of qualitative, questionnaire and medical records-based studies have 
identified fatigue as one of the three most common symptoms of ovarian cancer.
7-
8 13 17-18 20 124 127 Urinary frequency or urgency is also commonly reported,
8 17-18 22 47 
50 123-124 as are gastrointestinal symptoms such as nausea, indigestion or heartburn 
and changes in bowel habit.
6 14 20 22 Abnormal vaginal bleeding has been described 
as a less common symptom of ovarian cancer.
9 12 120 124 However, recent research 
has  found  a  large  odds  ratio  for  the  symptom  in  the  medical  notes  of  cases 
compared to controls,
47 and it was one of four symptoms included in a recent 
ovarian cancer symptoms index.
25 Abnormal vaginal bleeding has also been found 
to be a symptom which is most likely to prompt women to seek medical advice.
8 
51 
2.2.4  Symptom complexes and indices 
Six studies investigated the prevalence of different combinations of symptoms, or 
symptom complexes, in women with ovarian cancer, although one of these is a 
PhD study where the findings have yet to be published. The first of these studies 
was  conducted  by  Smith  &  Anderson
8,  who  reported  on  combinations  of  
59 
symptoms in 83 women with ovarian cancer. The authors found 72% of women 
had  symptom  combinations  consisting  of  two  symptoms.  A  double  symptom 
complex  of  abdominal  swelling  and  fatigue  identified  24%  of  women,  while 
abdominal swelling and urinary symptoms, or abdominal swelling and abdominal 
pain,  identified  18%.  A  triple  symptom  complex  consisting  of  abdominal 
swelling, abdominal pain and fatigue identified 29% of women. 
Three case-control studies have investigated symptom complexes. Vine et al.
16 
investigated symptom complexes in a study of 267 women with ovarian cancer 
and 287 population-based controls. The authors calculated the number of women 
in each group who had combinations of three symptoms. The ten most common 
combinations included bloating or feeling of fullness, distended or hard abdomen, 
pelvic  or  abdominal  discomfort,  fatigue,  gas/nausea/indigestion,  and  weight 
gain/loss. Women with ovarian cancer were significantly more likely to report 
each of the top ten three symptom combinations compared to controls (26-39% 
vs. 2%). 
Goff  et  al.
18  found  the  combination  of  three  symptoms  (bloating,  increased 
abdominal  size  and  urinary  urgency)  gave  the  highest  odds  ratio  (9.4)  of  any 
symptom  complex.  This  was  reported  by  43%  of  women  who  were  later 
diagnosed with ovarian cancer compared to 8% of women attending primary care. 
Lurie  et  al.
25  investigated  symptom  complexes  in  a  population-based  study 
conducted in Hawaii. Combinations of symptoms were investigated among 432 
women with ovarian cancer compared to 491 controls, and the sensitivity and 
specificity of different complexes was assessed. The study found a four symptom 
index that included abdominal pain, distended and hard abdomen, abdominal mass 
and abnormal vaginal bleeding had the best predictive ability, with a sensitivity of 
74% and specificity of 77%. However, the findings of this study are limited by 
possible  recall  bias  as  there  was  a  median  interval  of  8.9  months  between 
diagnosis and participation in the research. 
Despite Vine et al.
16 and Lurie et al.
25 conducting research at a population level, 
22%  of  women  with  ovarian  cancer  in  the  latter  study  declined  participation, 
indicating that selection bias may have been introduced into the study. Goff et  
60 
al.
18 only reported the number of women with a pelvic mass who completed their 
survey,  but not  the  number  who refused. The authors contend that it was not 
possible to calculate the response rate in controls due to repeat primary care visits. 
While the prospective method of this study may have reduced recall bias, the 
researchers did not even attempt to estimate the effect of selection bias on the 
results. 
A later study by the Goff group developed an ovarian cancer symptom index by 
assessing symptoms in 149 women later diagnosed with ovarian cancer compared 
to 255 women participating in an ovarian cancer screening study and 233 women 
attending pelvic ultrasound appointments.
23 Symptoms included in the exploratory 
model  were  those  with  large  odds  ratios  between  the  groups.  Confirmatory 
analyses identified pelvic/abdominal pain, increased abdominal size/bloating and 
feeling  full/difficulty  eating,  when  present  for  less  than  12  months  and 
experienced more than 12 days per month, as having the greatest sensitivity for 
detecting  ovarian  cancer.  However,  feeling  full/difficulty  eating  was  not 
significant  in  exploratory  analyses.  This  combination  of  symptoms  had  a 
sensitivity of 56.7% for identifying women with early stage ovarian cancer and 
79.5% for advanced disease. In women over 50 years of age, the symptom index 
had a sensitivity of 66.7% and specificity of 90%. The authors note that these 
levels of sensitivity and specificity are similar to CA125 and have the advantage 
of minimal cost. 
While  the  Goff  et  al.
23  results  are  impressive,  the  study  had  several 
methodological weaknesses which are not addressed by the authors. Chief among 
these was the decision to include symptoms data from 55 women with ovarian 
cancer who participated in their 2004 study. These women represent over a third 
of the total 149 ovarian cancer cases. While other participants were randomly 
assigned  to  either  exploratory  or  confirmatory  analyses,  all  55  ovarian  cancer 
cases from the earlier study were allocated to the exploratory group. The authors 
state that these women filled in the same questionnaire as the rest of the women in 
the  research.  However,  this  is  not  the  case,  as  my  own  review  of  their 
questionnaires  (detailed  in  Chapter  Four)  found  the  earlier  study  presented 
participants with a 20 item symptom checklist, and the latter study used a 23 item  
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checklist. The authors fail to address how potential bias arising from the original 
study’s recruitment or data collection methods may have affected the results of the 
symptom index. The study is also limited by the recruitment of women who had 
heightened awareness of ovarian cancer (either through their participation in a 
familial ovarian cancer screening study, current pelvic ultrasound investigations 
or impending surgery for a pelvic mass) with no comparative population-based 
group. This may have resulted in over-reporting bias in each group. 
Shortly  after  publication  of  the  Goff  symptom  index  the  United  States 
Gynecologic Cancer Foundation (GCF) released their Ovarian Cancer Symptoms 
Consensus  Statement.
30  This  statement  is  based  upon  symptom  index  yet  it 
includes urinary urgency/frequency. The decision to include urinary symptoms 
was  possibly  based  upon  the  findings  of  the  earlier  Goff  group  study  which 
identified  a  three  symptom  complex  that  included  urinary  urgency,  or  other 
research which has found urinary urgency or frequency to be a common symptom 
among women with early stage ovarian cancer.
11 15 49 51 73  
A  recent  study  by  the  Goff  group  investigated  the  stability  of  the  six  item 
symptom  index  over  time.
26  Volunteers  in  an  ovarian  cancer  screening  trial 
completed the symptom index at two time periods, approximately 100 days apart. 
This research found the symptom index was negative at both points in time for 
86% of women and positive at both time points for 2%. The authors suggest that 
high correlation between symptom index results for the two time periods provides 
evidence of the reliability of the index as a clinical tool. However, it may also be 
argued that it is premature to test the reliability of the index given that its validity 
has not yet been established in populations of women living outside the state of 
Washington on the west coast of America. 
2.2.5  Number of symptoms, onset, frequency and severity 
Symptoms associated with ovarian cancer are also frequently reported by healthy 
women  and  women  with  benign  gynaecological  disease.  However,  research 
indicates women with ovarian cancer are more likely to report multiple, recently 
onset  symptoms,  which  are  more  frequent  and  persistent  compared  to  healthy 
women, or women with benign disease.  
62 
Qualitative  and  questionnaire  research  has  found  women  with  ovarian  cancer 
report an average of 3-8 symptoms during the time leading up to their diagnosis.
 
Case-control  studies  have  found  population-based  controls  report  fewer 
symptoms.
7  16-18  25  51  77 Lurie et al.
25 found controls participating in an annual 
government  health  survey  reported  a  mean  of  2.6  symptoms  compared  to  3.6 
among women  with ovarian cancer, while  an  earlier  study in New York  with 
population-based controls identified through random-digit dialling found a median 
1.3  symptoms  in  this  group  compared  to  3.0  among  in  women  with  ovarian 
cancer.
17  A  case-control  study  with  commensurate  methodology  conducted  in 
North  Carolina  found  women  with  ovarian  cancer  reported  a  median  of  5-6 
symptoms compared to just one symptom among controls.
16  
While all of these studies found women with ovarian cancer reported significantly 
more symptoms compared to controls, the findings are limited by retrospective 
research designs and possible selection bias. Recall bias is an inherent problem in 
retrospective designs and is likely to have changed the way women with ovarian 
cancer in these studies remembered symptoms. Following diagnosis women may 
have thought a lot more carefully about possible symptoms of their disease and 
may have recalled symptoms that healthy women would not recall. Selection bias 
is a possibility as other research has demonstrated that individuals who participate 
in research tend to have better health than the general population.
128 This ‘healthy 
volunteer  effect’  may  have  resulted  in  the  recruitment  of  particularly  healthy 
controls not representative of women in the general population. 
Research suggests controls recruited through primary care clinics report a greater 
number of symptoms compared to population controls, but still significantly fewer 
than women with ovarian cancer. Goff et al.
18 argue that a primary care control 
group  is  necessary  to  detect  differences  in  the  symptoms  reported  by  women 
attending  for  care  due  to  other  conditions  and  women  likely  to  have  ovarian 
cancer. The study found controls attending primary care reported a median of four 
symptoms compared to eight among women with ovarian cancer. A shortcoming 
of the study which may explain this finding is the fact that controls were 10 years 
younger than cases. Wider research has shown the number of symptoms reported 
by  individuals  increases  with  age.
37  Perhaps  the  greater  number  of  symptoms  
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among the cases simply reflects their advanced age compared to controls, rather 
than an association with ovarian cancer. 
Questionnaire-based  research  suggests  women  diagnosed  with  ovarian  cancer 
have more recent onset of symptoms compared to population-based controls and 
women  with  other  conditions.
16-18  As  their  earlier  research  suggested  some 
women with ovarian cancer are initially misdiagnosed with IBS,
13 Goff et al.
18 
investigated the onset of symptoms in women with ovarian cancer compared to 
IBS. They found that women with ovarian cancer experienced symptoms for a 
median of six months or less, while women with IBS and primary care controls 
had symptoms for a median of 12 to 24 months. 
An association has also been described between recent onset of symptoms and 
advanced  stage  disease.
12  15-17  20  Vine  et  al.
15  found  women  diagnosed  with 
borderline tumours had symptoms for six months compared to four months in 
women with invasive tumours. Similarly, Eltabbakh et al.
12 reported women with 
borderline disease had symptoms for eight months compared to 3.4 months in 
women with invasive tumours. These differences are most likely due to the rapid 
progression of invasive cancers in comparison to borderline tumours which are 
slow growing, indolent and have a good prognosis. In addition, there may have 
been  some  form  of  selection  bias  as  women  with  invasive  tumours  who 
experienced symptoms for lengthy periods may have died before researchers had 
an opportunity to interview them. Recall bias may also have contributed to these 
findings in the questionnaire studies as women were interviewed after surgery.
15 17  
Evidence  from  three  studies  suggests  that  symptoms  are  more  frequent  and 
persistent in women with ovarian cancer compared to controls. Goff et al.
18 found 
women  with ovarian cancer  typically  reported  symptoms occurring  on a daily 
basis, whereas controls experienced symptoms 2-3 times per month. The findings 
of Olson et al.
17 concur as they reported women with ovarian cancer are more 
likely to report ‘constant’ bloating, fullness and pressure in the abdomen, while 
controls experienced these symptoms intermittently. 
The symptom index published by Goff et al.
23 in 2007 confirmed the importance 
of symptom duration and frequency as predictive factors for ovarian cancer. The  
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six  symptom  index  with  the  greatest  sensitivity  specified  that  symptoms  must 
have onset within the past 12 months and have a frequency of greater than 12 days 
per month. However, these findings must be interpreted with caution as no other 
research  group  has  described  specific  symptom  frequencies  associated  with 
ovarian cancer. Also, frequency is largely irrelevant for increased abdominal size 
as this should be relatively constant. 
The questionnaires used by the Goff group for their 2004 and 2007 studies asked 
women to report symptom frequency over the past month on a seven-point Likert 
scale. Women were asked to tick the number of days they experienced symptoms, 
either: 1 day, 1-2 days, 3-6 days, 7-12 days, 13-19 days or more than 20 days. 
Questionnaire design theorists have argued that Likert scales consisting of 7-10 
points are most reliable.
129-130 However, other research has cast doubt on whether 
an  individual, particularly if  they older or unwell, can accurately recall minor 
symptoms experienced during the past month. Thus, the quality of the Goff et al.
23 
symptom frequency data is questionable. For example, it would be difficult to 
remember whether a symptom was experienced five days or seven days over the 
past month. The authors did not validate their questionnaires so the reliability is 
unknown. Perhaps a shorter time frame (e.g. one week), or fewer Likert scale 
categories, would collect more accurate data.  
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Only two published studies, both by the Goff group,
18  23 investigated symptom 
severity, although this has also been assessed in a recent PhD study.
34 The Goff 
studies asked women to rank the severity of symptoms on a five point Likert scale 
where 1 equalled minimal and 5 equalled severe. The first study found that a 
greater proportion of women with malignant masses ranked symptoms as 4 or 
higher compared  to  IBS  patients and women attending  primary care for other 
reasons.  Among  women  later  diagnosed  with  malignant  ovarian  cancer,  36% 
experienced pelvic pain ranked 4 or higher on severity, compared to 9% of IBS 
patients and 10% of primary care patients.
18 This pattern was also observed for 
abdominal  pain,  bloating,  increased  abdominal  size,  urinary  symptoms, 
constipation  and  fatigue.  These  findings  clearly  merit  further  investigation  to 
determine whether they are replicated in ovarian cancer patients living in other 
countries. However, the later Goff group study reported divergent results, finding 
that the addition of severity to a symptom index did not change odds ratios in 
exploratory analyses.
23 Therefore the final symptom index only included duration 
and frequency. 
It is important to note that symptom frequency and severity are not necessarily 
independent variables. A woman who experiences frequent abdominal pain may 
be  more  likely  to  report  it  as  having  a  higher  severity  than  a  woman  who 
experiences a similar intensity of pain infrequently. Similarly, a single episode of 
abnormal vaginal bleeding may be considered more serious than daily bouts of 
indigestion. Prospective assessment of symptom severity and frequency is crucial 
as wider research has demonstrated an association between symptom severity and 
symptom  reporting,
131-132  and  a  tendency  for  patients  to  retrospectively 
‘recompose’  frequently  experienced  symptoms  into  a  single  episode,
133  which 
may alter the perception of severity at different time periods.  
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2.2.6  Symptoms reported by studies of medical and insurance records 
One  of  the  earliest  medical  records  studies  of  ovarian  cancer  symptoms  was 
conducted by Kennedy & Gordon
6 and included 97 patients diagnosed at a UK 
hospital.  This  research  identified  abdominal  pain,  abdominal  distension, 
abdominal mass, postmenopausal bleeding and altered bowel habit as the most 
common presenting symptoms of ovarian cancer. 
Since  the  late  1990s  a  number  of  other  medical  records  studies  have  been 
conducted  in  the  UK,
14  34  47  the  US,
21  49-50  121-122  Norway,
20  Sweden,
11 
Switzerland,
134  Japan,
135  Greece,
136  Israel
137  and  Australia.
19  Many  of  these 
reviewed  hospital  and  primary  care  records,  although  two  of  the  UK  studies 
investigated  symptoms  in  general  practice  records  only,
14  47    while  the  third 
utilised questionnaires in addition to GP records.
34  
Medical and insurance records research has consistently identified abdominal or 
pelvic  pain,  increased  abdominal  size,  bloating,  urinary  symptoms, 
gastrointestinal  symptoms,  fatigue,  abnormal  vaginal  bleeding,  palpable 
abdominal mass and change in weight as symptoms most frequently recorded in 
the  medical notes of women with ovarian  cancer. However, the  proportion of 
women  with  these  symptoms  varies  considerably  from  study  to  study.  For 
example, the proportion of women with abdominal or pelvic pain recorded in their 
medical  notes  ranges  from  33-80%  in  the  literature,
6  135  while  increased 
abdominal size or bloating is recorded in 13-59% of women’s medical notes.
10 50  
It is unclear why 59% of women in the Wikborn et al.
10 study in Sweden had 
abdominal swelling in their medical records yet only 13% in a Minnesota study by 
Yawn et al.
50. Perhaps this difference stems from women in the US study being 
more willing to consult their doctor earlier, before swelling often related to the 
presence of ascites had become a significant symptom, compared to women in 
Sweden. A UK study also found fewer women had abdominal swelling in their 
hospital notes compared to the Swedish study. The difference between the 59% 
with abdominal swelling in Wikborn et al.
10 and 21% in Kennedy & Gordon
6 is 
probably  explained  by  the  different  methods  used.  The  Swedish  study  also 
collected data from referring doctors and clinics while the UK study collected data  
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only  from  secondary  care  records.  This  demonstrates  how  medical  records 
research using single-source patient notes can underestimate symptom prevalence. 
Some of the most recent records-based research included large numbers of women 
with ovarian cancer. For example, Ryerson et al.
121 investigated symptoms in the 
medical insurance records of 3,250 women aged 65 years and older with ovarian 
cancer and Wynn et al.
122 compared symptoms in the insurance records of 920 
women  with  ovarian  cancer  and  2,760  matched  controls  for  the  270-31  days 
before diagnosis. Ryerson et al.
121 found abdominal pain was the most common 
symptom (43%), followed by abdominal or pelvic swelling (43%), constipation, 
diarrhoea or other digestive disorders (18%), ascites (17%), urinary symptoms 
(13%), malaise or fatigue (12%) and menopausal disorders (12%). Hamilton et 
al.
47 also reported that abdominal pain was the most common symptom (53%), 
followed by abdominal distension (36%). Somewhat paradoxically to Ryerson et 
al.
121 who found early satiety recorded in the notes of only 2% of women with 
cancer, 21% of the women with ovarian cancer in the Hamilton et al.
47 study had 
loss of appetite in their GP notes. 
Absence of recall bias is an advantage of medical records research. However, 
these study designs are prone to misclassification bias. This may occur due to 
missed diagnoses, or cases being diagnosed shortly after the research. Another 
source  of  bias  is  under-reporting  of  symptoms.  This  can  be  observed  by 
comparing symptom prevalences reported in medical records and questionnaire 
studies. For example, Hamilton et al.
47 found abdominal distension in 36% of GP 
records,  while  Bankhead  et  al.
46  found  86%  of  women  with  ovarian  cancer 
reported the symptom in a pre-surgery questionnaire, although it must be noted 
that these differences may also stem from the progressive nature of ovarian cancer 
symptoms.  Wider  research  corroborates  these  findings.  One  study  found  the 
proportion of cervical cancer patients who reported symptoms on a questionnaire 
was seven times that recorded in medical notes.
138 While another study among 
hysterectomy  patients  found  only  fair  (k  =  0.29)  agreement  between  medical 
records and patient-reported pre-surgery pain.
139 Questionnaires have also been 
found to elicit up to twice the number of symptoms found in medical records 
(Young 1972 in Harlow & Linet
140). This is often due to time limited medical  
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consultations,  patient  personality,  physician  communication  skills,  clinical 
interests  and  a  propensity  for  clinicians  to  focus  upon  a  single  symptom.
141 
Normative social interactions explain the tendency for patients to present a single 
‘current’  symptom  and  for  physicians  to  ‘interrupt’  presentation  of  adjacent 
symptoms.
142  Under-reporting  can  also  arise  when  women  forget  to  disclose 
symptoms  during  consultations,  or  when  they  are  too  embarrassed  to  discuss 
certain  symptoms.  Researchers  investigating  symptoms  in  primary  care 
populations more generally have argued that symptoms studies should not rely 
exclusively on medical records for these reasons. 
2.2.7  Symptoms reported by questionnaire studies 
While not as common as reviews of medical records, questionnaires have been 
widely  utilised  in  ovarian  cancer  symptoms  research.  These  studies  typically 
report 90-95% of women experience symptoms leading up to diagnosis.
7 9 13 15-16 18 
123  While  questionnaire  studies  have  reported  a  wider  spectrum  of  symptoms 
compared to medical records research, the most commonly described symptoms 
are  equivalent.  Abdominal  or  pelvic  pain,  increased  abdominal  size,  fatigue, 
gastrointestinal  symptoms  such  as  indigestion,  urinary  frequency/urgency  and 
bowel symptoms are the most common symptoms reported by retrospective and 
prospective surveys.
7 13 15-18 22 25 51 73 Unfortunately, the largest questionnaire study 
conducted  in  the  UK  (by  Ovacome)  did  not  publish  detailed  findings  on 
symptoms, although the group did present a poster on diagnosis experiences,
35 
and  they  also  provided  symptoms  data  for  the  analyses  described  in  Chapter 
Three. 
The  average  number  of  symptoms  reported  by  women  varies  considerably. 
However, this may be explained differences in the number of symptoms included 
in checklists. As can be seen in Figure 2.5, the average number of symptoms 
reported appears to correlate with the number of symptoms in questionnaires. This 
graph includes seven papers which described the average number of symptoms 
reported by women and also the number of symptoms in the questionnaire (or 
provided to me directly when I requested this information, as detailed in Chapter 
Four).  
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Studies which used the longest symptom checklists, such as those by Goff et al.
23 
(23  items)  and  Igoe
7  (21  items),  also  reported  the  highest  median  number  of 
symptoms (8.3 and 8.6 respectively). Alternately, studies which presented women 
with shorter checklists, such as Olson et al.
17 (8 items) and Olsen et al.
51 (11 
items), found the lowest average number of symptoms (3.0 and 3.1 respectively). 
Olson et al.
17 and Igoe
7 state that their symptom checklists were constructed from 
reviews  of  relevant  literature,  yet  it  is  unclear  why  Olson  et  al.
17  used  a 
questionnaire with approximately half the number of symptoms used by Igoe
7. 
Figure 2.5.  Number of symptoms in checklists and number of symptoms 
reported 
Symptoms in checklists vs. average number of 
symptoms reported
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The correlation between the number of symptoms included in questionnaires and 
the  number  of  symptoms  reported  by  women  is  probably  due  to  a  stimulus-
response  or  memory-cueing  effect,  where  respondents  have  enhanced  recall  if 
they specifically asked about a symptom.
129 An acquiescent effect, described by 
Kroenke
141 as ‘over-endorsement bias’, is also likely. This refers to the tendency 
of  respondents  to  positively  endorse  a  symptom  when  asked  about  it.  These 
findings underscore the need for researchers to use validated questionnaires in 
order to avoid over or under-reporting bias. The validation process should result  
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in  the  omission  of  superfluous  items  while  ensuring  the  overall 
comprehensiveness of the symptom checklist. 
Only three studies described the use of a validated questionnaire. Igoe
7 used a 
questionnaire  that  had  undergone  face  and  content  validation,  and  reliability 
testing, while Koldjeski et al.
70 reported use of a symptoms checklist which had 
undergone  congruent  validation.  Rather  disappointingly,  these  authors  did  not 
publish findings from their validation analyses, so the validity and reliability of 
their  tools  is  unknown.  Portenoy  et  al.
143  used  an  independently  validated 
questionnaire,  although  this  was  a  generic  pain  measure  not  specifically 
developed for ovarian cancer. 
Poorly  defined  inclusion  and  exclusion  criteria  are  another  limitation of  some 
questionnaire studies. This results in selection bias and the recruitment of study 
populations not representative of the wider population of women with ovarian 
cancer. The recruitment of non-random samples is potentially a large source of 
bias in three studies. Igoe
7 recruited women through the internet and snowball 
sampling,  while  the  Goff  et  al.
13  and  Bayne  &  Gilbert
35  mailed  surveys  to 
members of ovarian cancer support groups. The women who participated in these 
studies  are  likely  to  have  been  better  educated,  more  affluent,  younger  and 
healthier than the general population of women with ovarian cancer. 
2.2.7.1  Retrospective questionnaire studies 
Most  questionnaire  studies  have  been  conducted  after  women  have  been 
diagnosed  with  ovarian  cancer.  This  is  a  source  of  considerable  bias  as 
experimental  research  has  found  participants  over-report  symptoms  associated 
with  a  disease  when  informed  of  a  positive  diagnosis.
144  While  it  would  be 
unethical to test this theory in relation to ovarian cancer, this may be one possible 
explanation  for  the  larger  median  number  of  symptoms  reported  by  cases 
compared to controls in retrospective questionnaires.  
71 
Given poor survival rates in ovarian cancer, the potential for selection bias is a 
pertinent concern in retrospective studies. Selection bias probably plays a much 
larger role in the Goff et al.
13 study, where nearly half the respondents completed 
a  questionnaire  more  than  two  years  after  diagnosis,  compared  to  Smith  & 
Anderson’s
8 research which reported an average interval of 10 weeks. 
Lengthy time intervals between diagnosis and participation result in recall bias. 
This is a source of concern as wider research has demonstrated both exponential 
memory decay over time,
129 145-147 and a tendency for respondents to overestimate 
symptoms in retrospect.
148-151 The types of symptoms reported are also likely to 
change over time. Minor, transient symptoms will often be remembered in the 
short-term.  However,  only  those  symptoms  with  particular  salience,  or  those 
which had personal implications (such as prompting medical consultations) are 
likely to be remembered after 30 days.
129 Poor recollection of symptom onset can 
also occur due to the propensity for individuals to remember salient events but 
forget  the  date  of  their  occurrence.  This  can  lead  to  ‘telescoping’  where 
respondents misplace symptoms in time.
129 133  
Only one study described a strict exclusion criterion of not interviewing women 
who had been diagnosed with ovarian cancer for longer than six months.
15 Other 
studies appear to have had more flexible recruitment criteria, including Vine et 
al.
16 who reported a median time from diagnosis to interview of 4.6 months but a 
range of up to 22 months, and Olson et al.
17 who reported a mean interval of 4.7 
months but more than a quarter of the participants were interviewed nine months 
after diagnosis. 
While most authors report the time delay between diagnosis and interview, some 
studies do not report this information while others fail to provide sufficient detail. 
For example, Chan et al.
22 and Webb et al.
73 state that ‘newly diagnosed’ patients 
were interviewed, yet the authors do not define the term ‘newly diagnosed’, or 
provide information on potential exclusions due to long delays between diagnosis 
and women being invited to participate in the research.  
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Although  it  is  rarely  discussed  in  the  literature,  it  is  also  possible  that  some 
questionnaire studies were biased by differential recall bias between cases and 
controls with benign disease. One paper that did consider this possibility noted 
that the interval between diagnosis and interview was slightly longer for women 
with borderline disease than for women with early or late stage disease.
73 The 
study  found  larger  proportions  of  women  with  borderline  disease  were 
asymptomatic, which may reflect poorer symptom recall among this group. 
2.2.7.2  Prospective questionnaire studies 
The  only  way  to  avoid  recall  bias  in  questionnaire  studies  is  to  conduct  the 
research prospectively, yet just three questionnaire studies, two by the Goff group 
in the US,
18 23 and the as yet unpublished PhD research by Anita Lim in the UK,
34 
asked women to complete symptoms checklists prior to surgery for a suspected 
ovarian mass. An earlier Swedish study described women being asked specific 
questions about symptoms prior to hospital admission.
9 However, it is unlikely 
that this took the form of a symptoms questionnaire. 
Goff et al.
18 argue their prospective design excluded the possibility of differential 
symptom reporting due to recall bias. However, they do not discuss how pre-
surgery  anxiety  may  have  led  to  over-reporting  of  symptoms  in  women  with 
ovarian cancer compared to controls attending primary care. The more recent Goff 
study interviewed three groups: women who were scheduled to have surgery for 
pelvic masses, women presenting for pelvic ultrasound and high-risk women who 
were  enrolled  in  the  Ovarian  Cancer  Early  Detection  Study  (OCEDS).
23  The 
authors  found  high  odds  ratios  between  the  three  groups  for  the  symptoms 
pelvic/abdominal  pain,  increased  abdominal  size/bloating,  and  difficulty 
eating/feeling full. It is important to note that women who were about to have 
surgery  for  an  ovarian  mass  were  probably  more  likely  to  have  heightened 
awareness of symptoms compared to women who had several normal screens in 
the  OCEDS  study.  This  limitation  of  the study  indicates  the  need  for  further, 
genuinely  prospective  questionnaire-based  research to  confirm  whether  the six 
symptoms have similar sensitivity for predicting ovarian cancer when women are  
73 
asked  about  these  symptoms  prior  to  being  informed  of  the  possibility  of 
malignancy. 
2.2.8  Qualitative studies of ovarian cancer symptoms 
A small number of studies have utilised qualitative methodological frameworks to 
investigate symptoms of ovarian cancer. Of the five published papers, the study 
by Ferrell et al.
127 was the largest, including 21,896 letters, cards and emails sent 
to  an  ovarian  cancer  support  group  newsletter.  This  large  volume  of  data  is 
unusual, and many theorists would argue unnecessary, for a qualitative study. The 
researchers  identified  677  comments  pertaining  to  symptoms  and  analyses 
revealed  bloating  or  abdominal  swelling,  fatigue,  abdominal/pelvic  pain  and 
urinary frequency as the most commonly experienced symptoms. 
Fitch et al.
75 explored experiences of being diagnosed with ovarian cancer in a 
group of 18 women. Thirteen stated that they experienced changes in their bodies 
prior to diagnosis, including bloating, weight gain around the middle of the body, 
indigestion,  bowel  changes,  abdominal  pain,  fatigue  and  urinary  problems. 
Koldjeski  et  al.
70  investigated  symptoms  of  ovarian  cancer  using  qualitative 
interviews in addition to a symptoms checklist. The study unusually interviewed 
19 women with ovarian cancer together with their family members. This may 
have resulted in under-reporting of symptoms which women were reluctant to 
discuss in front of their children, such as pain during sexual intercourse. However, 
the findings were very similar to other studies, with the most frequently reported 
symptoms being bloating, abdominal pain, indigestion, fatigue, abdominal mass 
or lumps and urinary problems. 
A fourth study, by Evans et al.
77 did not set out to specifically describe symptoms 
of ovarian cancer but did ask women about symptoms as part of an investigation 
into  delays  in  diagnosis.  Thirty-eight  of  the  43  women  interviewed  reported 
experiencing symptoms prior to diagnosis. The most common symptoms were 
abdominal  distension  or  bloating,  reported  by  27  women,  abdominal  pain, 
reported by 26 women and urinary frequency/urgency which was reported by 10 
women.  
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Each of these studies was conducted after women were diagnosed with ovarian 
cancer. In one study the mean length of time between diagnosis and participation 
in the research was 4.5 years. As stated earlier, long durations of time between 
diagnosis and interviews increase the likelihood of recall and selection bias. One 
recent qualitative study sought to avoid this bias by interviewing women prior to 
definitive diagnosis.
46 The study included 44 women with malignant tumours and 
found  persistent  abdominal  distension  (but  not  fluctuating  bloating), 
postmenopausal bleeding, loss of appetite, early satiety and progressive symptoms 
were associated with ovarian cancer. Unfortunately, the researcher was unable to 
interview 49% of the participants (61 out of 124) prior to surgery, so the findings 
of this study are also limited by recall bias. 
2.2.9  Symptoms by histology and stage 
Several  studies  have  reported  that  the  prevalence  of  symptoms  increases  with 
stage  of  ovarian  cancer.
13  15-16  19-20  51  73  Three  studies  observed  a  trend  of 
increasing  proportions  of  symptomatic  women  by  stage,  but  did  not  detect 
statistically significant differences.
12  22  49 However, this may be due to smaller 
study populations. For example, the Chan et al.
22 study included 43 women with 
early stage ovarian cancer and 37 with late stage, while the Eltabbakh et al.
12 
study included 22 women with borderline ovarian tumours and 50 with malignant 
disease. 
Research has also found women diagnosed with benign ovarian tumours report 
fewer symptoms compared to women with invasive disease. Goff et al.
18 reported 
an average of four symptoms among women with benign tumours compared to 
eight in women with malignant tumours. Olsen et al.
51 also found women with 
benign  tumours  reported  fewer  symptoms.  However,  differences  between  the 
groups were not as dramatic. Women with benign disease reported an average of 
2.2  symptoms compared to  2.8 in  women with borderline tumours and  3.6 in 
women with advanced invasive tumours. 
These studies also suggest women with benign tumours report key symptoms of 
ovarian cancer less frequently than women with malignant tumours. Goff et al.
18 
found women with malignant tumours were significantly more likely than those  
75 
with benign tumours to report bloating (70% vs. 49%), increased abdominal size 
(64%  vs.  45%),  urinary  symptoms  (55%  vs.  31%)  and  constipation  (50%  vs. 
21%).  The  study  also  identified  a  high  odds  ratio  between  the  benign  and 
malignant groups for difficulty  eating. The retrospective case-control study by 
Olsen et al.
51 included 151 women with benign tumours and 244 women with 
invasive  ovarian  cancer  and  found  similar  results.  Approximately  double  the 
number of women with advanced ovarian cancer, compared to those with benign 
masses, reported abdominal swelling (60% vs. 31%), bowel symptoms (32% vs. 
14%) and gas, nausea or indigestion (44% vs. 24%), compared to women with 
benign tumours, and differences were even more striking for weight loss (14% vs. 
2%) and malaise (22% vs. 5%). 
Women with borderline ovarian cancer have been found to report similar types of 
symptoms  to  those  with  invasive  disease,  although  the  prevalence  of  specific 
symptoms is often lower. Vine et al.
15 found those with borderline tumours were 
significantly  less  likely  to  report  bowel  irregularity  and  pelvic  discomfort 
compared to women with invasive tumours. A review of the medical records of 
486  women  diagnosed  with  invasive  ovarian  cancer  and  137  with  borderline 
ovarian tumours in Norway confirmed these findings, as smaller proportions of 
women with borderline disease reported abdominal pain (34% vs. 53%), bowel 
irregularity (10% vs. 26%) and persisting fatigue or weight loss (7% vs. 26%).
20 
However, another large study conducted in Australia involving 146 women with 
borderline tumours and 665 women with malignant tumours found women with 
borderline  disease  were  more  likely  to  report  gynaecological  symptoms, 
abdominal  swelling  and  an  abdominal  mass.
73  These  findings  require  further 
investigation  in  prospective  research  to  determine  whether  they  reflect  real 
differences in the types of symptoms experienced by women due to the differing 
natural history of borderline and invasive cancers, or  whether they are  due to 
recall  or  reporting  bias  associated  with  women’s  awareness  of  the  degree  of 
malignancy. 
There is also evidence that the type of symptoms reported by women with ovarian 
cancer vary according to stage. In their meta-analysis, Bankhead et al.
120 found 
gynaecological symptoms and symptoms of pelvic mass were more frequently  
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reported  by  women  with  early  stage  disease.  Several  other  studies  have  also 
described  an  association  between  urinary  symptoms  and  early  disease,  while 
systemic symptoms, such as malaise, fatigue and weight loss are associated with 
advanced ovarian cancer.
9 11 16 20 73  
2.2.10  Symptom perception and interpretation 
Psycho-social  research  into  symptom  perception,  interpretation  and 
communication has found that these are influenced by a number of complex and 
inter-related  variables,  including  an  individual’s  gender,  cultural  and  socio-
economic  background,  social  group,  personality,  life  experiences,  health 
knowledge, previous illness experiences and health beliefs.
152-158 Research among 
other  groups  of  cancer  patients  has  also  confirmed  that  a  person’s  symptom 
perception  and  health-seeking  behaviours  are  fundamentally  shaped  by  their 
existing knowledge of the warning signs of cancer and their fears of the disease. 
A small number of studies have explored symptom interpretation among women 
with ovarian cancer. Unfortunately, only one of these studies, by Bankhead
46 78 
included  prospective  interviews.  It  is  therefore  difficult  to  disentangle 
recollections  of  symptom  perception  and  interpretation  from  the  effects  of 
knowledge of an ovarian cancer diagnosis. 
Qualitative  and  quantitative  studies  have  identified  symptoms  not  being 
recognised as precursors of cancer as a primary reason for women not visiting 
their doctor sooner after symptom onset.
8 13 51 75 77 127 This research has also found 
symptoms being mild, intermittent or being misattributed stress, menopause or 
previous benign conditions such as pelvic inflammatory disease or IBS, are also 
common reasons for delay. For example, Smith & Andersen
8 reported that 47% of 
women in their study initially regarded their symptoms as ‘not serious’ due to 
mistaken  attribution  of  symptoms  to  normal  body  changes  (such  as  ageing  or 
menopause), lifestyle, diet, weight changes and emotional or work-related stress. 
After  women  recognise  bodily  changes  as  symptoms  of  something  potentially 
serious, fear of cancer may lead them to further delay seeking medical care.
8 51 78 
However, the role of fear is unclear as one study found 2% of women delayed due 
to fear,
51 while another found fear was a factor in the delay of 23%.
8 Hope that  
77 
symptoms  would  resolve,  not  wanting  to  bother  GPs  and  care  obligations  to 
family members are also factors which delay women seeking medical advice.
78  
Other research has suggested that the main symptom which prompts women to 
seek  medical  advice  is  not  necessarily  the  symptom  of  the  longest  duration.
9 
Abdominal or pelvic pain, increased abdominal size, abnormal vaginal bleeding or 
discharge, back pain and gastrointestinal symptoms such as heartburn have been 
described as symptoms most likely to prompt women with ovarian cancer to seek 
medical advice.
8-9 51 73 123 Olsen et al.
51 also reported that chest or respiratory pain, 
abnormal bleeding followed by abdominal pain were the symptoms most likely to 
prompt women to seek medical care within one week of onset. 
2.2.11  Depression as a symptom of ovarian cancer 
There  is  limited  data  on  depression  as  a  symptom  of  ovarian  cancer.  Two 
qualitative studies reported depression as symptom of ovarian cancer among a 
small number of women prior to diagnosis.
7 127 One of these studies utilised the 
same CONVERSATIONS! patient support group newsletter data as Goff et al.
13 
The authors found diagnostic delay was associated with patients being labelled as 
suffering from stress or depression.
127  
The recent Goff group study asked participants to complete a depression scale and 
an  instrument  to  measure  positive  and  negative  affect.
23  The  research  found 
depression was significantly more common among women with ovarian cancer 
compared  to  controls.  However,  the  authors  may  be  criticised  for  failing  to 
properly  scrutinise  this  finding.  It  is  likely  that  the  higher  prevalence  of 
depression  among  women  with  ovarian  cancer  was  associated  with  their 
impending surgery and perhaps an awareness of the possibility of malignancy, yet 
the  authors  fail  to  discuss  this  explanation.  While  the  association  between 
depression and ovarian cancer may be spurious, these findings warrant further 
investigation in other populations, particularly as depression screening measures 
can be easily integrated into existing questionnaires.  
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2.3  Summary 
In this review I have presented data on ovarian cancer trends and described time 
spans in the care trajectory. This data reveals increasing ovarian cancer incidence 
rates up until recent years, yet minimal improvements in five-year survival. UK 
research suggests that it is not uncommon for women to wait 3-4 months before 
receiving a diagnosis of ovarian cancer, and one study described a total interval of 
12  months  from  symptom  onset  to  diagnosis.
46  While  there  is  no  conclusive 
evidence that delays lead to poorer survival outcomes, this seems counter intuitive 
considering evidence from research into other types of malignancies. 
Over the last quarter of a century numerous international groups have investigated 
symptoms of ovarian cancer with the hope that furthering knowledge in this area 
may lead to earlier detection of the disease and improvements in survival. While 
this  research  has  succeeded  in  identifying  symptoms  associated  with  ovarian 
cancer, there is still a great deal to learn about the exact pattern of symptom onset, 
severity and frequency, particularly among women outside the US. 
I  have  discussed  the  methodological  weaknesses  of  previous  studies  and 
demonstrated  the  correlation  between  the  number  of  symptoms  included  in 
questionnaires and the median number of symptoms reported by women. I also 
described  the  inconsistent  and  non-validated  ways  in  which  researchers  have 
combined groups of symptoms originating in different parts of the body, such as 
abdominal  pain  and  back  pain,  or  grouped  together  different  types  of  bodily 
sensations  into  one  questionnaire  item,  such  as  abdominal  heaviness,  fullness, 
pressure and pain. These methodological weaknesses emphasise the importance of 
researchers  using  validated  symptoms  tools.  Yet  I  found  only  descriptions  of 
limited attempts at validation, and no published evidence of the results of these 
analyses in the literature. This urgently needs to be addressed as the use of non-
validated tools casts doubt on the quality of published survey data. These findings 
underscore  the  need  for  new  research  using  a  rigorously  developed  and 
thoroughly validated symptoms questionnaire. 
Four previous studies, two of which were conducted in the UK, have collected 
symptoms data directly from women prior to definitive diagnosis. However, in all  
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of  these  studies,  women  were  already  undergoing  clinical  investigations  for 
suspected malignancy. This raises questions about the ways in which an enhanced 
awareness of the possibility of ovarian cancer may have biased the results. 
A particular issue of concern associated with ovarian cancer symptom indices is 
the very limited evidence surrounding their use. The Goff et al.
23 symptom index 
was developed among women living in one state on the west coast of America. 
There is currently no evidence that the symptom index would yield equivalent 
sensitivity  or  specificity  in  other  populations  of  women.  Moreover,  the  Goff 
symptom  index  did  not  include  urinary  frequency/urgency,  yet  this  has  been 
added to the GCF symptom index and the Ovarian Cancer Action symptoms diary 
in the UK. Only two other studies have developed and evaluated the sensitivity 
and specificity of symptom indices, although the results of one study are not yet 
published,
34 and the other study was conducted retrospectively.
25 The symptom 
index developed by Lurie et al.
25 did not include difficulty eating/feeling full but 
did include vaginal bleeding. This reveals the need for further research to identify 
particular  combinations  of  symptoms which may  have superior sensitivity  and 
specificity for detecting ovarian cancer among women in other parts of the world. 
In the review I described findings on delays in diagnosis among ovarian cancer 
patients in the UK from the Ovacome survey. I noted that symptoms data from 
this survey had not been published, despite it being the largest symptoms study 
conducted  in  the  UK  to-date.  This  is  an  obvious  gap  in  the  literature  as 
questionnaire studies from several countries have been published, but not yet in 
the  UK.  In  the  next  chapter  I  describe  analysis  of  symptoms  data  from  the 
Ovacome  survey  in  order  to  establish  whether  UK-based  questionnaire 
respondents  report  similar  types  of  symptoms  compared  to  women  in  other 
countries.  
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Chapter Three – Analysis of Ovacome Survey Data 
3.0  Introduction 
Questionnaire-based  studies  of  ovarian  cancer  symptoms  have  mainly  been 
conducted in the US, although a small number of studies have been carried out in 
Sweden, Hong Kong, Australia and the UK. The survey conducted by Goff et al.
13 
in the US and Canada is the largest study of ovarian cancer symptoms to utilise 
questionnaire  methods.  Two  UK  questionnaire  studies  have  been  conducted, 
although one of these is a recent PhD study where the findings have not yet been 
published.
34 The first UK questionnaire study  was conducted by the Ovacome 
patient  support  and  advocacy  group  in  2006.  Results  of  the  research  were 
presented  as  a  poster  at  the  International  Gynaecological  Cancer  Society 
conference  in  2007,
35  although  detailed  symptoms  findings  have  not  been 
published. 
This chapter describes a symptom-focused analysis of data collected from women 
aged 50 years and over who participated in Ovacome survey. This age group was 
selected as the literature review in Chapter Two demonstrated that ovarian cancer 
incidence in the UK is highest among women aged 50 to 84 years. Furthermore, I 
was interested in analysing symptoms data collected from a population of women 
with  an  equivalent  age  range  to  the  UKCTOCS  cohort.  As  described  in  the 
literature review, Ovacome only published survey findings relating to women’s 
diagnostic  and  treatment  experiences.  Before  embarking  upon  my  own  data 
collection, I considered it vitally important to investigate symptoms reported by 
women in the Ovacome survey. Up to the present time the survey is still the 
largest European questionnaire-based study of ovarian cancer symptoms.  
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3.1  Aims 
●  To determine prevalence of symptoms among survey respondents 
aged 50 years or older at the time of diagnosis 
●  To identify types of symptoms experienced by these women 
●  To describe the symptom-diagnosis pathway 
3.2  Methods 
3.2.1  Setting 
Ovacome is a UK-based ovarian cancer patient advocacy and support group. The 
Director of Ovacome, also a member of the project consensus group, suggested 
the possibility of Ovacome sharing anonymised symptoms data from their 2006 
Patient Survey. The Ovacome Board of Directors approved the proposal and the 
anonymised data were received on 5 November 2007. 
3.2.2  Sample 
The Ovacome 2006 Patient Survey was promoted through the group’s newsletter 
and website. Ovacome members were posted the survey and the website had a 
downloadable  version  which  women  could  print  out.  Non-members  were  not 
excluded  from  the  research.  It  is  likely  that  many  participants  were  recruited 
through snowball sampling via the website and patient networks. Information on 
non-response of Ovacome members, and the number of women recruited through 
the website or other means was not provided by Ovacome. 
A total of 306 completed Patient Surveys were received by Ovacome. Survey data 
from women aged 49 years or younger at the time of diagnosis was excluded for 
the research described in this chapter. This gave a final data set consisting of 188 
respondents.  
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3.2.3  Data collection 
The Ovacome Patient Survey collected information on age, date of diagnosis, type 
of ovarian cancer, symptoms, diagnosis experiences, quality of care and treatment. 
Data provided by Ovacome for the research described in this chapter consisted of 
the demographic, symptoms and diagnosis sections of the questionnaire. 
The symptoms section asked the following questions: 
●  Did you have any signs or symptoms of your disease before 
diagnosis? Yes/No 
●  What was the date of your first symptom? Month/Year 
●  What was this symptom? 
●  Did you have any other symptoms? Yes/No (Please state what they 
were) 
●  Did you go and visit your GP or visit A&E at this point? 
●  Details of visits – date, where (GP, A&E, etc.), what were symptoms, 
treatments given, tests done, specialist referral, what was diagnosed? 
3.2.4  Data considerations 
Free text data for ‘other’ symptoms was manually recoded into numeric variables 
to enable calculation of frequencies.  It was not possible to investigate urinary 
frequency  and  urinary  urgency  as  separate  ‘first’  symptoms  as  the  data  set 
provided already combined these into one variable. 
As the survey only asked women for the year of diagnosis, and not the month, it 
was not possible to accurately calculate duration of time between symptom onset 
and diagnosis, or initial medical visit for symptoms and date of diagnosis. For the 
calculation of number of appointments to diagnosis, visits to health professionals 
for reasons not likely to be related to ovarian cancer were excluded. For example, 
appointments for high cholesterol were not included.  
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3.2.5  Data analysis 
Data were imported into SPSS version 12.0.1 (SPSS Inc., Chicago, USA) and 
variables were recoded where necessary. The data were scrutinised by running 
frequencies, descriptives and explore functions. 
Symptoms reported by respondents 
The prevalence of ‘first’ and ‘other’ symptoms were investigated separately, then 
these  variables  were  combined  to  calculate  the  overall  prevalence  of  each 
symptom.  ‘First’  symptoms  were  the  first  symptoms  women  remembered 
experiencing which they attributed to their later ovarian cancer diagnosis while 
‘other’ symptoms were any subsequent symptoms which they also attributed to 
their  diagnosis.  Combined  ‘first’  and  ‘other’  symptoms  were  investigated  in 
women with early compared to advanced stage ovarian cancer. 
Symptom complexes 
Combinations  of  symptoms  were  investigated  to  identify  complexes  with  the 
highest prevalence. These included various combinations of: abdominal or pelvic 
discomfort/pain, increased abdominal size, bloating, tiredness/fatigue, change in 
bowel  habit,  abnormal  vaginal  bleeding,  urinary  frequency/urgency, 
backache/pain,  change  in  appetite  or  difficulty  eating,  abdominal  mass/lump, 
heartburn  or  indigestion,  nausea,  weight  change,  UTIs  and  abnormal  vaginal 
discharge. 
Women were classified as positive for a symptom complex if they reported at 
least one of the symptoms in the complex. Symptom complexes derived from the 
data were compared to symptom indices proposed by Goff et al.
23 and Lurie et 
al.
25 (described in Chapter Two). 
Women  were  considered  positive  on  the  Goff  index  if  they  reported 
abdominal/pelvic pain, feeling full quickly, bloating or increased abdominal size. 
The Goff symptom index includes frequency (>12 days during the past month) 
and duration (<12 months since onset), however, the Ovacome survey did not 
collect this frequency information and duration data were inaccurate due to the 
survey not eliciting information on both the month and year of symptom onset and  
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diagnosis. Women were therefore classified as Goff index positive on the basis of 
symptom prevalence only. 
Women who reported either abdominal pain, increased abdominal size or hard 
abdomen, abdominal mass/lumps or abnormal vaginal bleeding were classified as 
positive on the Lurie symptom index. 
The number of women who were positive on symptom complexes derived from 
the data was compared to the number of women who were positive on the Goff 
and Lurie indices. Symptom complexes were then investigated according to stage 
at diagnosis. 
Duration of time from symptom onset to seeking medical advice 
Time  spans  from  symptom  onset  to  medical  consultations  were  explored 
according to number of symptoms, stage at diagnosis and symptom type. 
Duration of time from seeking medical advice to diagnosis 
Stage of ovarian cancer at diagnosis was investigated according to the duration of 
time  between  initial  consultation  for  symptoms  and  diagnosis.  The  median 
number of appointments required for a correct diagnosis to be made was explored 
according to stage. Symptoms which prompted women to consult a doctor were 
compared in those who were diagnosed within three appointments and those who 
required more than three appointments to receive a correct diagnosis. 
Statistical analysis 
Non-parametric  data  were  investigating  using  Mann-Whitney  U  and  Kruskal-
Wallis statistics with post-hoc tests. Categorical variables were compared using 
the Chi-square statistic, and Fisher’s exact test where appropriate, and odds ratios 
were calculated. As few symptoms were found to be significantly associated with 
ovarian cancer on univariate analyses, multivariate analyses were not conducted. 
Differences were accepted as significant at p < 0.05 for all tests.  
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3.3  Results 
Median age was 63.0 years (range 51-86, IQR 59-68) and median age at diagnosis 
was 58.0 years (range 50-82, IQR 53-63). The median length of time between 
diagnosis and participation in the survey was 4.0 years (range 0-19, IQR 2-6). The 
survey instrument did not collect any other demographic data. 
As can be seen in Table 3.1, 57.9% of women were diagnosed with stage III/IV 
disease, in keeping with expected stage distribution. Women diagnosed with stage 
III were older than other women (stage I Mdn 54.0 years, stage II Mdn 56.5, stage 
III Mdn 59.5 and stage IV Mdn 57.0, H(3) = 9.3, p = 0.03), with post-hoc tests test 
revealing a significant trend of advanced stage with increasing age (J = 6021, z = 
2.51, r = 0.77). 
Table 3.1.  Stage at diagnosis 
Stage  n  % 
Stage I  38  20.2 
Stage II  28  14.9 
Stage III  86  45.7 
Stage IV  23  12.2 
Don’t know  7  3.7 
Missing  6  3.2 
Total  188  100.0 
 
Serous  cancer  was  the  most  common  tumour  type  (21.3%)  among  those  who 
knew the type of ovarian cancer they were diagnosed with, although 113 (60.1%) 
women did not know this information (Table 3.2). Twelve women (6.4%) ticked 
the  ‘other’  box  (1  adenocarcinoma,  1  granulosa  cell,  1  mixed  mullerian,  1 
sarcoma, 1 fallopian tumour, 7 women did not specify type).  
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Table 3.2.  Type of ovarian cancer reported by women 
Type  n  % 
Don’t know  113  60.1 
Serous  40  21.3 
Other  12  6.4 
Clear cell  8  4.3 
Missing  7  3.7 
Mucinous  4  2.1 
Borderline  3  1.6 
Endometrial  1  0.5 
Total  188  100.0 
 
3.3.1  Symptoms reported by respondents 
A total of 169 (89.9%) women reported that they had signs or symptoms prior to 
diagnosis. Surprisingly, there was no difference in the proportion of symptomatic 
women  among  those  with  advanced  disease  (stage  III/IV)  compared  to  early 
disease  (stage  I/II)  (89.0%  vs.  92.4%,  ns).  Among  women  who  experienced 
symptoms, a median of 3.0 symptoms was reported (range 1-12, IQR 1-4). There 
was  no  difference  in  the  number  of  symptoms  experienced  by  women  with 
different  stages  of  disease.  There  was  also  no  difference  in  the  number  of 
symptoms according to age. 
The most common ‘first’ symptom was abdominal/pelvic pain (30.3%), followed 
by  increased  abdominal  size  (26.6%),  bloating  (22.9%)  and  tiredness/fatigue 
(19.7%)  (Table  3.3).  Many  women  reported  simultaneous  first  symptoms,  for 
example: abdominal/pelvic pain, bloating and fatigue.  
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Table 3.3.  „First‟ symptoms reported by women 
Symptom  n=188  % 
Abdominal discomfort/pain  57  30.3 
Increased abdominal size  50  26.6 
Bloating  43  22.9 
Tiredness, fatigue or lack of energy  37  19.7 
Urinary frequency or urgency  27  14.4 
Abnormal vaginal bleeding  27  14.4 
Change in bowel habit  24  12.8 
Change in weight  14  7.4 
Back ache or pain  11  5.9 
UTI  11  5.9 
 
Ninety  (47.9%)  women  reported  experiencing  ‘other’  symptoms.  The  most 
common  ‘other’  symptoms  were  increased  abdominal  size  (12.2%),  bloating 
(10.6%),  urinary  frequency/urgency  (9.6%)  and  abdominal/pelvic  pain  (9.6%) 
(Table 3.4).  
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Table 3.4.  „Other‟ symptoms reported by women 
Symptom  n=188  % 
Increased abdominal size  23  12.2 
Bloating  20  10.6 
Urinary frequency  18  9.6 
Abdominal or pelvic discomfort/pain  18  9.6 
Tiredness, fatigue or lack of energy  14  7.4 
Change in bowel habit  14  7.4 
Abnormal vaginal bleeding  9  4.8 
Heartburn or indigestion  8  4.3 
Change in weight  6  3.2 
Back ache or pain  4  2.1 
 
Table 3.5 lists the 10 most common symptoms overall (calculated by combining 
data  for  ‘first’  and  ‘other’  symptoms).  Abdominal/pelvic  pain  was  the  most 
common  symptom  overall  (34.6%),  followed  by  increased  abdominal  size 
(31.9%), bloating (25.5%) and tiredness/fatigue (21.3%). Change in appetite or 
difficulty eating was not among the ten most common symptoms. Seven women 
(3.7%) reported either a decrease or increase in their appetite, but just one woman 
reported  ‘difficulty  in  getting  food  down’  (in  addition  to  multiple  other 
symptoms).  
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Table 3.5.  Most common „first‟ and „other‟ symptoms combined 
Symptom  n=188  % 
Abdominal or pelvic discomfort/pain  65  34.6 
Increased abdominal size  60  31.9 
Bloating  48  25.5 
Tiredness, fatigue or lack of energy  40  21.3 
Urinary frequency or urgency  35  18.6 
Abnormal vaginal bleeding  32  17.0 
Change in bowel habit  29  15.4 
Change in weight  16  8.5 
Heartburn or indigestion  15  8.0 
Back ache or pain  12  6.4 
 
Symptoms were compared in the 66 women with stage I/II ovarian cancer and the 
109 with stage III/IV. Apart from abnormal vaginal bleeding and change in bowel 
habit  (Table  3.6),  there  were  no  associations  between  symptoms  and  stage  of 
disease.  Women  with  stage  I/II  were  more  likely  to  report  abnormal  vaginal 
bleeding (OR 4.30 95% CI 1.87-9.93), while change in bowel habit was more 
common among women with advanced disease. 
Table 3.6.  Symptoms in women with early vs. advanced disease 
Symptom  n 
Stage I/II 
n (%) 
Stage 
III/IV 
n (%) 
OR (95% CI)  p-value 
Abnormal vaginal 
bleeding  175  20 (30.3)  10 (9.2)  4.30 (1.87-9.93)  <0.0001 
Change in bowel habit  175  5 (7.6)  21 (19.3)  0.34 (0.12-0.96)  0.035 
  
90 
3.3.2  Symptom complexes 
A total of 139 (73.9%) women reported either abdominal/pelvic pain, increased 
abdominal size/bloating or abnormal vaginal bleeding (Complex 3A), making this 
the  most  prevalent  three-symptom  complex.  The  second  most  prevalent  three-
symptom  complex  identified  135  (71.8%)  women  and  was  comprised  of 
abdominal/pelvic  pain,  increased  abdominal  size/bloating  or  change  in  bowel 
habit (Complex 3B). The third most prevalent symptom complex identified 132 
(70.2%)  women  and  included  abdominal/pelvic  pain,  increased  abdominal 
size/bloating or tiredness/fatigue. 
A  four-symptom  complex  consisting  of  abdominal/pelvic  pain,  increased 
abdominal size/bloating, abnormal vaginal bleeding or urinary frequency/urgency 
(Complex 4A) identified the largest number of women (n = 152, 80.9%), followed 
by abdominal/pelvic pain, increased abdominal size/bloating, abnormal vaginal 
bleeding or change in bowel habit (Complex 4B), which identified 148 (78.7%) 
women. The third ranking four-symptom complex comprised abdominal/pelvic 
pain,  increased  abdominal  size/bloating,  abnormal  vaginal  bleeding  or 
tiredness/fatigue, which identified 142 (75.5%) women. 
3.3.2.1  Goff and Lurie symptom indices 
A total of 127 (67.6%) women were positive on the three-symptom Goff index 
(abdominal/pelvic  pain,  increased  abdominal  size/bloating  or  feeling  full 
quickly/difficulty  eating)  and  126  (67.0%)  women  were  positive  on  the  four-
symptom Lurie index (abdominal pain, increased abdominal size/hard abdomen, 
abdominal  mass/lumps  or  abnormal  vaginal  bleeding).  Fewer  women  were 
positive on the three-symptom Goff index compared to complex 3A (67.6% vs. 
73.9%, p < 0.0001) and the four-symptom Lurie index compared to complex 4A 
(67.0% vs. 80.9%, p < 0.0001). This is due to the lower prevalence of feeling 
full/difficulty eating and abdominal mass/lumps compared to abnormal vaginal 
bleeding, change in bowel habit and tiredness/fatigue.  
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Symptom complexes by stage 
Figure 3.1 shows the percentage of women from each stage who were identified 
by the most prevalent three-symptom complexes and the Goff index. As can be 
seen in the graph, complex 3A had superior performance for identifying women 
with stage I (78.9% vs. 65.8%, p < 0.0001) and II disease (82.1% vs. 67.9%, p = 
0.026) compared to the Goff index. The three complexes and the Goff index had 
commensurate performance for identifying women with stage III, while complex 
3B appeared most efficient at identifying women with stage IV disease. 
Figure 3.1.  Three-symptom complexes by stage 
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Figure 3.2 shows the percentage of women from each stage who were identified 
by  the  three  most  prevalent  four-symptom  complexes  and  the  Lurie  index. 
Complex 4A identified the largest percentage of women from stage I to stage III, 
while complex 4B identified the most women with stage IV. Complex 4B, which 
included  abdominal/pelvic  pain,  increased  abdominal  size/bloating,  abnormal 
vaginal bleeding or change in bowel habit, identified the most women (92.9% of 
stage II) out of any of the three or four-symptom complexes when investigated 
according to stage at diagnosis.  
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Figure 3.2.  Four-symptom complexes by stage 
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3.3.3  Duration of time from symptom onset to seeking medical advice 
A total of 161 women reported the month and year of symptom onset, and month 
and  year  they  first  visited  a  GP  or  other  health  care  professional  for  advice 
relating to symptoms. The median duration of time between symptom onset and 
seeking medical advice was two months (range 1-77, IQR 1-4). As can be seen in 
Figure 3.3, 45.3% visited a health care professional within one month of symptom 
onset, 63.3% within two months and 73.9% within three months. Thirteen women 
(6.8%) did not seek medical advice for longer than one year.  
93 
Figure 3.3.  Months between symptom onset and seeking medical advice 
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Table 3.7 lists the five women who did not seek medical care for longer than two 
years  after  symptom  onset.  All  of  these  women  experienced  either  increased 
abdominal size or bloating as a ‘first’ symptom. Respondent 1 first noticed an 
abdominal mass/lump, abdominal/pelvic pain and bloating. Respondent 2 noticed 
increased abdominal size and nausea. Respondent 3 noticed fatigue, bloating and 
abnormal  vaginal  bleeding  as  her  ‘first’  symptoms.  Respondent  4  noticed 
increased  abdominal  size,  fatigue,  bloating,  change  in  weight  and  indigestion, 
while  respondent  5  noticed  increased  abdominal  size,  abdominal/pelvic  pain, 
bloating, change in bowel habit, UTI and change in weight. Three of these women 
received  a  diagnosis  of  suspected  ovarian  cancer  at  their  first  medical 
appointment, one within two appointments and another within four appointments.  
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Table 3.7.  Women who did not seek medical advice for two years or more 
No.  Age at 
diagnosis 
Months to 
first 
appointment 
Appointments to 
diagnosis  Tumour type  Stage 
1  62  26  1  Don’t know  II 
2  56  26  4  Don’t know  III 
3  52  29  2  Borderline  I 
4  54  77  1  Serous  II 
5  63  77  1  Serous  III 
 
There was no association between the number of symptoms women experienced 
and the number of months between symptom onset and seeking medical advice. 
There  was  also  no  association  between  stage  at  diagnosis  and  the  number  of 
months  between  symptom  onset  and  medical  consultation.  Women  diagnosed 
with stage I (range 1-29, IQR 1-3), stage II (range 1-77, IQR 1-5.5) and stage III 
(range 1-77, IQR 1-4.8) all experienced symptoms for a median of two months 
before consulting a doctor. Women with stage IV experienced symptoms for a 
median  of  one  month  (range  1-4,  IQR  1-2)  before  seeking  medical  advice, 
however, this difference was not significant. 
A total of 175 (93.1%) women visited a GP first for medical advice, 3% visited an 
unspecified hospital department, 2% an A&E department and 1% initially saw a 
practice nurse. There were 103 (54.8%) women who reported that one symptom 
initially led them to seek medical advice, 55 (29.3%) reported two symptoms and 
24 (12.8%) reported three symptoms prompted them to consult their doctor. 
While  abdominal  mass/lump  and  nausea  or  vomiting  were  less  common 
symptoms overall, all of the women who reported these symptoms consulted their 
GP  about  them.  Abdominal/pelvic  pain  (87.7%)  was  the  next  most  common 
symptom which prompted women to consult their doctor, followed by heartburn 
or  indigestion  (80.0%)  (Table  3.8).  Surprisingly,  only  65.6%  of  those  with 
abnormal vaginal bleeding consulted their GP about the symptom.  
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Table 3.8.  Most common symptoms which prompted medical advice 
Symptom 
No. with 
symptom 
(n =188) 
No. 
symptom 
GP 
reported 
(n =188) 
% of all 
women 
% with 
symptom 
Abdominal or pelvic 
discomfort/pain  65  57  34.6  87.7 
Increased abdominal size  60  33  31.9  55.0 
Bloating  48  30  25.5  62.5 
Abnormal vaginal bleeding  32  21  17.0  65.6 
Change in bowel habit  29  17  15.4  58.6 
Tiredness or fatigue  40  14  21.3  35.0 
Urinary frequency or urgency  35  14  18.6  40.0 
Heartburn or indigestion  15  12  8.0  80.0 
Abdominal mass or lump  11  11  5.9  100 
Nausea or vomiting  9  9  4.8  100 
 
With the exception of bloating, there were no associations between the type of 
symptom  experienced  and  the  length  of  time  from  symptom  onset  to  seeking 
medical  advice.  Women  who  experienced  bloating  were  more  likely  to  wait 
longer than six months before seeking medical care (27.9% vs. 12.7%, χ
2(1) = 5.2, 
p = 0.02). 
Abnormal  vaginal  bleeding  was  the  fourth  most  common  symptom  which 
prompted women to consult a doctor. While there was no significant association 
between abnormal vaginal bleeding and the length of time women waited until 
they consulted their doctor, six of the 32 women who experienced this symptom 
waited  for more than  six months after symptom  onset  before seeking  medical 
advice.  
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3.3.4  Duration of time from initial medical consultation to diagnosis 
Due to the design of the survey instrument, it was not possible to calculate the 
exact duration of time  between initial  GP  visit  for symptoms  and the  date  of 
diagnosis. It was, however, possible to calculate the approximate number of years 
between women first seeking advice about symptoms and receiving a diagnosis of 
ovarian cancer. 
Among the 174 women who wrote the year of first visit for symptoms and the 
year of diagnosis, 94.3% were diagnosed within one year and 98.3% within two 
years. There was no association between stage and the duration of time between 
first GP visit and diagnosis. Women diagnosed with early (range 1-2, IQR 1-1) 
and advanced disease (range 1-7, IQR 1-1) were diagnosed within a median of 
one year. However, this may have changed if it was possible to calculate the exact 
number of months between GP consultation and diagnosis. 
Women attended  a median  of 3.5 appointments with  health care  professionals 
before receiving a diagnosis of ovarian cancer (range 1-11, IQR 1-4). There was 
no difference in the number of appointments according to age. Women diagnosed 
with  stage  I/II  attended  fewer  appointments  before  they  received  a  correct 
diagnosis compared to those with advanced disease (Mdn 2.0 vs. Mdn 3.0, U = 
2161.0, p = 0.001, r = -0.26). 
Women who reported that abnormal vaginal bleeding led them to consult their 
doctor were 4.75 (95% CI 1.37-16.48) times more likely to be diagnosed within 
three appointments (Table 3.9). All 11 women who reported abdominal mass or 
lump prompted them to seek medical advice received a diagnosis within three 
appointments.  There  were  no  other  associations  between  symptoms  women 
consulted  their  doctor  about  and  the  number  of  appointments  required  for  a 
diagnosis to be made.  
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Table 3.9.  Symptoms associated with diagnosis within three appointments 
Symptom  n 
≤ 3 appt. to 
diagnosis 
(%) 
>3 appt. to 
diagnosis 
(%) 
OR (95% CI)  p-
value 
Abnormal vaginal 
bleeding  174  25 (21.2)  3 (5.4)  4.75 (1.37-16.48)  0.008 
Abdominal mass or 
lump  172  11 (9.4)  0  ∞  0.017 
 
Among the 173 women who provided details about the outcome of their initial 
medical consultation, 98 (56.6%) reported that they were not given a diagnosis or 
did not write information about the diagnosis, 23 (13.2%) were told they had a 
suspected  ovarian  mass,  16  (9.2%)  were  told  they  had  IBS,  12  (6.9%)  were 
diagnosed with a gynaecological condition not related to the ovaries, seven (4.0%) 
were diagnosed with a UTI and five (2.9%) with gastroenteritis. Three (1.7%) 
were told their symptoms were related to ageing or menopause, two (1.2%) were 
told  they  had  gall  stones,  two  (1.2%)  were  informed  they  needed  to  diet  or 
exercise  and  another  two  (1.2%)  were  told  they  had  diverticulitis.  Other 
diagnoses, ranging from appendicitis to stress, were reported by only one woman 
each. 
Forty-five (26.0%) women were referred to a gynaecological oncology consultant 
during their initial GP visit, 17 (9.8%) were referred for an ultrasound or CT scan, 
13 (7.5%) were referred to another hospital department (e.g. gastroenterology or 
urology), 11 (6.4%) to a general surgeon and one woman was sent directly to 
A&E. 
3.4  Discussion 
The Ovacome patient  survey was the  first and largest study to-date  to collect 
symptoms data directly from British women diagnosed with ovarian cancer. The 
survey parallels research by Goff et al.
13 who posted symptoms questionnaires to 
subscribers  of  the  ‘Conversations’  support  group  newsletter  in  the  US  and 
Canada.  
98 
Among Ovacome survey respondents aged 50 years or more at disease diagnosis 
included in these analyses, 90% experienced symptoms during the period leading 
up to their diagnosis. This is to be expected in a disease for which screening is 
currently not available and diagnosis is only possible if a woman presents to a 
doctor  with  symptoms.  The  finding  is  commensurate  with  several  other 
questionnaire studies which reported approximately 90-95% of women experience 
symptoms prior to a diagnosis of ovarian cancer.
9 16-18 22 51 73 However, all but one 
of these studies found an increasing proportion of symptomatic women with more 
advanced disease. In contrast, in this data set there was no significant difference in 
the  proportion  of  women  with  early  stage  disease  who  reported  symptoms, 
compared to those with advanced disease. However, this may have arisen from 
selection bias, with symptomatic women across all stages more likely to take part 
in the survey than women who had no symptoms. 
The lengthy period between diagnosis and participation in the research may also 
explain  the  absence  of  a  difference  in  the  proportion  of  symptomatic  women 
across the stages. Research has found higher symptom levels increase the hazard 
of death in women with ovarian cancer.
98 Perhaps women with early stage disease 
with higher symptom levels had already died, and those with advanced disease 
who  had  low  symptom  levels  survived,  resulting  in  a  balancing  out  of  the 
proportion of symptomatic women across the stage categories. 
Women reported a median of 3.0 symptoms during the period leading up to their 
diagnosis, while a median of three to 8.6 symptoms is reported in the literature.
7 17 
The relatively low number of symptoms reported by Ovacome survey respondents 
most  likely  results  from  the  open-question  format  of  the  questionnaire,  which 
asked women to write down their ‘first’ and ‘other’ symptoms, but did not list 
symptoms  which  have  previously  been  found  to  be  associated  with  ovarian 
cancer. It is possible that women would have reported many more symptoms if 
they were presented with the 23 item list used by Goff et al.
23 especially as wider 
research has found open questions elicit comparatively few symptoms compared 
to checklists.
129 141 159-160 It is to be noted that the final endpoint of this research is 
to make it easier for doctors to diagnose ovarian cancer. The method currently 
adopted in consultations is open questions followed by a few directed questions  
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on specific symptoms. Using a checklist of a large number of symptoms for every 
consultation could prove difficult to implement. 
The relatively low number of symptoms reported by Ovacome respondents also 
raises important questions about women’s perception of symptoms and what they 
regard as precursors of cancer. Open questions rely on women having sufficient 
knowledge to spontaneously report symptoms of interest to the researcher and to 
remember these symptoms without the aid of memory cueing checklists, which 
can result in substantial under-reporting bias.
129 159 This is likely to have occurred 
in  the  Ovacome  survey  as  the  prevalence  of  bloating,  abdominal/pelvic  pain, 
fatigue and urinary symptoms were approximately half that reported by women in 
the Goff et al.
23 study. While a validated symptoms list in questionnaire-based 
research can correct this bias, it is itself associated with over-reporting bias.
129 141  
Despite using an open-question format, the types of symptoms reported by survey 
respondents were commensurate to those reported by women in other research. 
Several questionnaire studies and reviews of medical records have reported that 
abdominal/pelvic pain is the most common symptom of ovarian cancer.
6 12 14-16 19-
20  22-23  50-51  73  121  135 This was also the most  common symptom  among survey 
respondents, with 35% reporting that they experienced the symptom leading up to 
their diagnosis. 
Twenty-six  percent  of  Ovacome  respondents  reported  bloating,  which  is 
approximately half the number reported by Goff et al.
13 and Vine et al.
16, but 
equivalent to a Hong Kong study which used open-questions and a structured 
interview study conducted in Iran.
22  161 Perhaps this stems from differences in 
cultural interpretations of bloating, with US women being more attuned to the 
bodily sensation of bloating compared to women in other parts of the world. US 
women may also have a greater awareness of bloating as a symptom of benign 
conditions such as IBS or food intolerances. 
The  lack  of  awareness  of  bloating  as  a  symptom  of  ovarian  cancer  among 
Ovacome survey respondents is evidenced by the finding that the symptom was 
associated with women waiting longer than six months before seeking medical 
care. Perhaps, once these women perceived the symptom, they interpreted it as a  
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normal  physiological  change  associated  with  ageing  or  menopause,  which 
research has found to be a reason for women not consulting their doctor earlier 
after symptom onset.
8 13 17 51  
Seven women reported that they experienced change in appetite, although only 
one reported feeling full quickly. This finding is at odds with some research which 
has described early satiety as a symptom predictive of ovarian cancer.
18 23 46-47 124 
However, the low prevalence of the symptom  among Ovacome women is not 
exceptional.  Three  other  questionnaire  studies  did  not  describe  feeling  full  as 
common symptom of ovarian cancer,
22 51 73 while a large medical records study 
found only 2% of women with ovarian cancer had early satiety recorded in their 
medical insurance notes.
121 However, it is conceivable that a greater number of 
Ovacome respondents may have reported appetite changes or feeling full if they 
were specifically asked about the symptom. Women in the Goff et al.
13 research 
were asked if they were ‘unable to eat normally’ during the period leading up to 
their diagnosis and 16% responded positively. 
Given  the  median  of  four  years  between  diagnosis  and  participation  in  the 
research,  it is also probable that women forgot less salient symptoms  such as 
feeling full. Other research has demonstrated exponential memory decay and has 
indicated that symptoms which are severe, unusual or characterised by rapid onset 
are more likely to be remembered.
131-132 147 159 162 Perhaps this may explain why 
few  women  reported  the  relatively  subtle  symptom  of  feeling  full  but  many 
reported abdominal/pelvic pain and abnormal vaginal bleeding. 
No associations were observed between age at diagnosis and the number or type 
of symptoms reported by women. Findings in the literature are equivocal, with 
two studies reporting age is negatively,
13 18 and one positively,
73 correlated with 
the number of symptoms reported. Previous studies have also found an association 
between age and stage of ovarian cancer,
15 19 73 although this was not observed 
among Ovacome respondents. The disparate findings in the present data may have 
arisen from analyses being restricted to those aged 50 years or over at diagnosis, 
while other studies included women as young as 18 years.  
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Two symptoms were associated with stage of disease at diagnosis. Women who 
reported abnormal vaginal bleeding were more likely to be diagnosed with early 
stage ovarian cancer. Vaginal bleeding in older women is always referred to a 
gynaecologist  for  investigation  and  is  one  of  the  symptoms  requiring  urgent 
referral for suspected cancer in the 2005 NICE guidance.
44 In addition, some slow 
growing cancers such as granulosa cell tumours secrete hormones which lead to 
bleeding and diagnosis in stage I. The finding corresponds to several previous 
studies,
11-12  19  47  49  73  including  a  meta-analysis  which  found  gynaecological 
symptoms are more frequently reported among women with early stage ovarian 
cancer.
120 The association observed between change in bowel habit and advanced 
disease has also been widely reported.
15 20 22 51 It is often associated with delays in 
diagnosis due to referral to gastroenterological and surgical specialities. Despite 
being described in several studies, 
9 16-17 49 73  no association was found between 
other  non-gynaecological  symptoms,  such  as  urinary  frequency/urgency  or 
fatigue, and stage at diagnosis. 
The  Goff  and  Lurie  symptom  indices  were  used  to  interrogate  the  data  to 
determine their sensitivity in this data set which had been collected without use of 
a checklist. Goff et al.
23 found their symptom index had a sensitivity of 67% for 
identifying women with ovarian cancer aged 50 years or over, while Lurie et al.
25 
reported  their  index  had  a  sensitivity  of  74%.  Among  Ovacome  survey 
respondents,  the  Goff  index,  modified  to  exclude  symptom  frequency  and 
duration,  maintained  its  sensitivity  (68%).  The  four-symptom  Lurie  index  had 
decreased sensitivity of 67% for women with ovarian cancer diagnosed over the 
age  of  49.  Complex  4A  (abdominal/pelvic  pain,  increased  abdominal 
size/bloating, abnormal vaginal bleeding and urinary frequency/urgency) had the 
highest sensitivity (81%) but it must be noted that the latter were not tested on an 
independent  data  set,  which  is  usually  associated  with  a  fall  in  the  estimated 
sensitivity. 
The Goff and Lurie symptom indices seemed to have poor sensitivity for detecting 
early stage disease compared to the three and four-symptom complexes derived 
from  the  dataset.  As  stage  at  diagnosis  is  the  most  important  determinant  of 
survival in ovarian cancer,
53 99 119 this is a crucial factor in the evaluation of any  
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symptom  index.  This  finding  underscores  the  need  for  further  research  into 
symptom complexes among British with ovarian cancer, in a study that is not 
limited by recall bias. The wide publicity being mounted in response to the UK 
Department  of  Health  ‘Ovarian  cancer  -  Key  messages’  document,
33  and  the 
symptom diary being promoted by Ovarian Cancer Action,
31 adds urgency to this 
need  as  the  latter  does  not  include  change  in  bowel  habit.  Abnormal  vaginal 
bleeding is also not included but given that in postmenopausal women it is already 
part of the clinical guidance for urgent gynaecological cancer referral, omission of 
this symptom is of less concern for reducing delays in diagnosis. However, this 
symptom  may  need  to  be  considered  for  inclusion  in  general  ovarian  cancer 
awareness campaigns aimed at postmenopausal women as abnormal bleeding did 
not always prompt women to seek medical advice. 
The median duration of time between symptom onset and seeking medical advice 
was one month, which is similar to the findings of research conducted in the US, 
Hong Kong and Australia.
8  22  73 Unfortunately, due to the design of the survey 
instrument, it was not possible to calculate the number of weeks between these 
events. A concerning finding was that 26% of women reported three months or 
longer  between  symptom  onset  and  medical  consultation.  This  is  substantially 
higher than the 8% who delayed longer than three months in another UK study.
14 
This discrepancy may have arisen from the different methodological approaches. 
Kirwan  et  al.
14  study  utilised  primary  care  records  and  included  all  women 
diagnosed during a fixed period. The Ovacome research collected data directly 
from  women  and  was  perhaps  biased  by  self-selection  among  those  who 
experienced delays in diagnosis. Patients in the Kirwan et al.
14 study reported time 
of onset of symptoms to their GP with less recall bias and with no knowledge that 
they  had  ovarian  cancer,  unlike  women  in  the  Ovacome  survey  who  reported 
symptoms a median of four years after diagnosis. 
The  Ovacome  survey  asked  women  to  write  the  month  and  year  of  symptom 
onset, and the month and year of first seeking medical advice, but only the year of 
diagnosis.  Unfortunately,  this  meant  that  it  was  not  possible  to  calculate  the 
number of months between symptom onset and diagnosis. This may have yielded  
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some  interesting  information,  as  another  recent  UK  study  reported  a  lengthy 
median duration 12 months between symptom onset and diagnosis.
46  
Abdominal mass/lump, nausea or vomiting and abdominal/pelvic pain were most 
likely to prompt women to seek medical advice, while only two-thirds of those 
with abnormal vaginal bleeding discussed the symptom with their GP. The reason 
for  this  is  unknown,  although  it  may  be  due  to  women  interpreting  abnormal 
bleeding  as  a  symptom  of  menopause.  Despite  this,  women  who  reported 
abnormal bleeding to their GP were most likely to receive a prompt diagnosis. 
Abdominal mass/lump was also associated with fewer appointments to diagnosis. 
Two  studies  have  found  abdominal  mass/lump,  abdominal/pelvic  pain  and 
abnormal vaginal bleeding to be important symptoms which prompt women to 
consult  their  doctor,  although  nausea  or  vomiting  has  not  been  described 
previously as a symptom most likely to lead women to seek medical care.
8 51  
No association was found between the duration of time between symptom onset 
and seeking medical advice, and stage of ovarian cancer at diagnosis. This finding 
is  commensurate  with  two  other  studies,
8  51  although  the  largest  study  to 
investigate this found women who ignored symptoms were more likely to have 
advanced  disease.
13  By  contrast,  Chan  et  al.
22  found  women  with  advanced 
disease had shorter time intervals between symptom onset and seeking medical 
advice. The lack of an association among Ovacome women may have been the 
result  of  recall  bias  or  selection  bias  due  to  the  considerable  length  of  time 
between diagnosis and participation in the research among some women. 
Study strengths 
Strengths of the Ovacome survey include the fact that it was the first UK study to 
collect  ovarian  cancer  symptoms  data  directly  from  women  with  the  disease. 
Ovacome  is  run  by  women  living  with  ovarian  cancer,  which  meant  that  the 
survey collected information important to women with the disease. 
To-date, the Ovacome survey recruited the largest number of women with ovarian 
cancer of any UK study. This was achieved through the direct mailing of surveys 
to Ovacome members and encouraging them to direct other women with ovarian 
cancer  to  the  Ovacome  website  where  they  could  download  the  survey.  This  
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method  of  snowball  sampling,  also  used  by  Igoe
7,  is  a  cost  effective  way  of 
boosting recruitment. 
Study limitations 
Unfortunately, there were a number of problems with the design of the survey 
instrument, including not asking women to write down the month and year of their 
diagnosis and the use of open questions. 
A disadvantage of the snowball sampling method used in the Ovacome survey is 
the inability of researchers to calculate response rates. It is likely that women with 
ovarian  cancer  who  actually  experienced  symptoms,  or  had  lengthy  delays  in 
diagnosis,  responded  more  frequently  than  women  who  did  not  have  these 
experiences.  This  self-selection  bias  may  have  inflated  findings  on  symptom 
prevalence  and  the  number  of  appointments  required  to  make  a  diagnosis.  A 
disproportionate number of survivors is also likely. These biases are shared with 
the  Goff  survey,
13  which  used  the  same  method  of  recruitment.  In  contrast, 
medical records research avoids this bias by systematically collecting data from 
all women diagnosed with ovarian cancer over a certain time period. 
Women who participated in the survey may not have been representative of the 
wider population of British women with ovarian cancer due to the use of internet-
based recruitment of women already aligned to the Ovacome group. These women 
are likely to have been younger, healthier and better educated than the general 
population of women living with ovarian cancer. Research has found a minority 
(22%) of the over-60s use the internet,
163 although this is likely to have increased 
considerably over recent years. The data set described in this chapter excluded 
women aged younger than 50 years at the time of diagnosis, yet the median age 
was  still  relatively  low  at  64  years.  In  order  to  participate,  women  required 
moderate to good English literacy skills as the survey was not translated into other 
languages. This would have resulted in the recruitment of women with higher 
education levels and less ethnic diversity, compared to the general population of 
women with ovarian cancer in the UK. 
The findings of the research are also limited by recall bias. The four year interval 
between diagnosis and participation in the survey is considerably longer than the  
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average of 4.7 months reported by Olson et al.
17 However, half the women in 
Goff et al.
13 were recruited more than two years after diagnosis. No women were 
excluded  from  analyses  due  to  lengthy  time  intervals  between  diagnosis  and 
participation, as exclusion of women diagnosed for longer than three years would 
have  reduced  the  data  set  by  more  than  half.  Recall  bias  was  accepted  as  a 
significant  and  unavoidable  limitation  of  the  data.  This  emphasised  the 
importance of collecting prospective data in my own research. 
Women self-reported diagnosis of ovarian cancer in the Ovacome survey. This 
information was not confirmed by medical records or histopathology findings. 
The relatively long survival time among Ovacome survey respondents may have 
arisen from a disproportionate number of women diagnosed with less aggressive 
mucinous, endometrioid or borderline tumours. Unfortunately, poor knowledge of 
tumour subtype among women prevented exploration of this possibility. Another 
potential, although less likely, explanation is survey respondents did not correctly 
recall the year of their diagnosis. 
Poor recall of the year of symptom onset may have been a factor among the five 
women who reported that they delayed consulting their doctor for 26 to 77 months 
after symptom onset. These women may have simply inaccurately recalled the 
year  of  symptom  onset,  or  may  have  overestimated  duration  of  symptoms, 
particularly  if  they  felt  their  doctor  had  not  listened  to  their  concerns.  These 
women  were  considered  for  exclusion  from  the  data  analysis.  However,  it  is 
possible that women did experience symptoms for several years as a serum bank 
study found elevations in CA125 five years prior to clinical diagnosis,
56 while 
other  research  which  modelled  ovarian  serous  tumour  progression  estimated 
cancers originate, on average, nine years prior to clinical diagnosis.
164 
3.5  Summary 
In this chapter I have presented findings from analyses of the Ovacome Patient 
Survey 2006. I found approximately one in four women experienced an interval of 
more than  three  months  from symptom  perception to presentation for  medical 
care.  Abdominal/pelvic  pain,  increased  abdominal  size,  bloating,  fatigue  and  
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urinary frequency or urgency were the most commonly reported symptoms, while 
early satiety was rarely reported. Symptom complexes including abdominal/pelvic 
pain, increased abdominal size/bloating, abnormal vaginal bleeding and urinary 
frequency/urgency  identified  larger  numbers  of  women  compared  to  symptom 
indices described in the literature, and were particularly efficient for identifying 
women with early stage disease. 
Analysis of the Ovacome data helped to identify symptoms for inclusion in the 
prospective research described in subsequent chapters of this thesis. As the survey 
was  conducted  among  British  women,  similar  symptom  experiences  are 
anticipated  in  the  UKCTOCS  cohort.  Analyses  were  restricted  by  the  design 
shortcomings of the Ovcacome survey instrument, although this highlighted the 
need to develop a robust ovarian cancer symptoms questionnaire for a prospective 
study.  The  next  chapter  describes  development  and  validation  of  the 
questionnaire.  
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Chapter Four – Development of the Ovarian Cancer 
Symptoms Questionnaire (OCSq) 
4.0  Introduction 
This chapter describes development of the ovarian cancer symptoms questionnaire 
(OCSq) over a 28 month period from October 2006 to February 2009. The chapter 
begins  with  a  discussion  of  the  theoretical  framework  which  underpins  health 
questionnaire design and introduces the European Organisation for Research and 
Treatment  of  Cancer  (EORTC)  questionnaire  development  methodology. 
Components of questionnaire validation are explored, followed by presentation of 
the research findings. These are divided into the four stages of the questionnaire’s 
development. 
Stage  I  -  Generation  of  the  ovarian  cancer  symptoms  list,  explains  how  a 
comprehensive list of ovarian cancer symptoms was identified from the literature. 
Stage II - Review of ovarian cancer symptoms questionnaires, describes findings 
from a review of existing questionnaires and the reasons why we had to develop 
our own questionnaire. Stage III - Revision of the symptoms list and formatting 
the  provisional  questionnaire,  details  the  stepwise  process  of  editing  the 
symptoms  list  and  drafting  the  questionnaire.  Finally,  Stage  IV  -  Pilot  of  the 
provisional OCSq, details validation and reliability findings from the pilot of the 
draft questionnaire. The aims, methods and results of each stage are presented 
separately, followed by an overarching discussion and summary. 
4.1  Theoretical frameworks for investigating symptoms 
Symptoms studies may be broadly described as belonging to either the positivist 
biomedical model or the interpretivist tradition (although a minority of studies 
combine elements of both in mixed-methods frameworks). The biomedical model 
provides the theoretical foundation for bioscience and medicine. This framework 
bases knowledge on observable and measureable facts in the physical world. The 
paradigm  maintains  that  disease  is  caused  by  specific,  potentially  identifiable,  
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biological agents or disease entities. These etiological explanations are paramount 
within the model, whereas subjective interpretations based on social, cultural or 
psychological  factors  are  regarded  as  unreliable  or  irrelevant.
153-154  165  The 
biomedical model underpins well-known quantitative health surveys such as the 
Short Form 36 Health Status Questionnaire (SF-36) and the Health Survey for 
England. It also provides a framework for disease-specific measures, including 
ovarian cancer symptoms questionnaires. 
Critics  of  biomedicine  have  argued  that  the  primacy  of  observable  facts  has 
shifted  the  emphasis  away  from  the  symptom  experiences  of  patients  towards 
signs of illness. Aronowitz
27 suggests that prior to the dominance of biomedicine, 
symptoms  were  regarded  as  arising  from,  accompanying,  or  constituting  a 
particular illness. As the influence of biomedicine increased, symptoms came to 
be reconsidered as subjective and arising from functions. Signs, meanwhile, were 
increasingly defined as perceptible and objective alterations of the body arising 
from  altered  physiological  states.
27  Social  scientists  have  argued  that  this 
transformation was accompanied by a change in focus, away from listening to 
patients’ subjective symptoms, towards a search for signs of disease.
27-29 Patient 
advocacy groups may suggest this tendency is evident in the historical perception 
of ovarian cancer as a ‘silent’ disease and a research bias towards screening based 
on CA125 and ultrasound rather than symptoms indices. 
Interpretivist  and  constructivist  frameworks  are  alternatives  to  the  biomedical 
model.  Sociologists,  anthropologists  and  psychologists  commonly  adopt  these 
conceptual  models  in  order  to  study  symptoms.  All  interpretivist  approaches 
emphasise human experience in the social world, rather than the physical world. 
Theorists working within these traditions view knowledge and truth as constructed 
rather than objective ‘facts’.
166 Constructivists in particular are interested in the 
ways  in  which  meaning,  values,  ideas  and  cultural  concepts  are  socially 
constructed.
166-167  Researchers  working  within  these  paradigms  typically 
investigate  symptoms  using  qualitative  methodologies  such  as  ethnography, 
patient narratives or in-depth interviews. These methods are particularly useful for 
exploratory  research  into  a  particular  phenomenon.  For  example,  qualitative 
studies by Ferrell et al.
127, Fitch et al.
75, Koldjeski et al.
70 and Bankhead et al.
46  
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played a vital role in elucidating symptoms of ovarian cancer and the ways in 
which  women  interpret  and  communicate  bodily  changes  associated  with  the 
disease. 
4.2  Health questionnaire design theory 
The positivist biomedical paradigm provides a theoretical foundation for health 
questionnaires.  This  can  be  readily  observed  in  the  common  aim  to  gather 
objective data on variables of interest, then, using statistical methods, to correlate 
with clinical diagnoses or health outcomes. However, it could also be argued that 
questionnaires go beyond the narrow limits of the biomedical model in the way 
they  give  credence  to  the  subjective  experiences  of  research  participants.  For 
example,  a  number  of  questionnaires  have  been  developed  to  measure  highly 
subjective phenomena such as pain and anxiety. 
Foddy
129 notes that a stimulus-response model provides a conceptual framework 
which underpins the collection of ‘objective’ data in questionnaire research. This 
model refers to the theory that research participants will respond in comparable 
ways to a standardised stimulus (usually a single questionnaire item). Under this 
model,  the  researcher  makes  a  number  of  implicit  assumptions.  Firstly,  it  is 
assumed that questions are understood in the same way by all respondents. It is 
also  assumed  that  respondents  will  interpret  questions  in  the  way  that  the 
researcher  intended  them  to  be  understood  and  that  research  participants  will 
respond in the same way. Questionnaires typically utilise closed questions in order 
to fulfil this requirement for standardised responses. The standardised responses 
are  then  assumed  to  represent  facts  in  the  real  world,  rather  than  written 
interaction between the researcher and respondent. Perhaps the most important 
understanding required under the stimulus-response model is the assumption that 
standardised  responses  given  by  different  respondents  can  be  meaningfully 
compared with one another. All quantitative questionnaires and surveys operate 
under these assumptions, whether or not this is actually  acknowledged  by  the 
researchers.  
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Questionnaires are typically informed by at least one other theoretical perspective 
in addition to the stimulus-response model. For example, Brooks
168 discusses the 
ways  in  which  Lawton’s  (1972)  behavioural  model  informed  development  of 
Katz’s (1983) Instrumental Activities of Daily Living measure (IADL). Similarly, 
theories of well-being have informed the development of health-related quality of 
life  measures  (HRQoL).  Fayers  &  Machin
169  describe  how  Calman’s  (1984) 
expectations model, which takes into account an individual’s aims and goals in 
life, provided the conceptual basis for inclusion of personal values in the Patient 
Generated Index (PGI). 
Symptoms questionnaires are usually informed by the stimulus-response model 
and the ‘common sense symptom perception model’ (described in Chapter One), 
both of which are grounded within the positivist biomedical paradigm. Under the 
common sense symptom perception model it is hypothesised that women with 
ovarian cancer are able to perceive symptoms of the disease. Furthermore, the 
severity,  frequency  and  number  of  symptoms  perceived  by  women  should 
increase with advancing stage of ovarian cancer. 
4.2.1  EORTC questionnaire development methodology 
A number of questionnaire development textbooks and articles were consulted 
throughout the research period.
129-130 168-176 These outlined rigorous questionnaire 
development  methods  and  described  essential  components  of  the  validation 
process. Reading this literature identified the European Organisation for Research 
and  Treatment  of  Cancer  (EORTC)  Quality  of  Life  Group  questionnaire 
development  methodology  as  well  established  in  producing  valid  and  reliable 
tools  for  measuring  cancer-related  symptoms.
169-170  Furthermore,  EORTC 
questionnaire development methodology fulfils six of the seven criteria described 
by Guyatt et al. (1986, in Brooks
168) as a ‘Rolls-Royce’ model of questionnaire 
development. The one criterion not met is the requirement for questionnaires to 
contain Likert scales consisting of seven to 10 points. This number of categories is 
also  described  by  Streiner  &  Norman
130  as  ideal  for  good  reliability  of 
questionnaires. By contrast, EORTC questionnaire methods specify, ‘items should 
preferably employ four-point Likert scales’.
177 Moreover, validation of four-point  
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Likert scales by the EORTC group among diverse cancer populations has proven 
good reliability.
178-183 
The  EORTC  approach  to  questionnaire  development  was  also  adopted  on  the 
basis  of  demonstrated  success  in  producing  a  valid  and  reliable  measure  for 
assessing symptoms in ovarian cancer patients.
184-185 The EORTC ovarian cancer 
module (QLQ-OV28) was developed to assess treatment-related symptoms and 
quality of life. Unfortunately, the post-diagnosis focus of the questionnaire meant 
that the tool itself was inappropriate for our own research. 
On the basis of this information, it was decided to use an EORTC questionnaire 
development methodology. Guidelines published by the EORTC Quality of Life 
Group informed the research described in this chapter.
177  186-187 However, some 
aspects of the methodology were not appropriate as the ovarian cancer symptoms 
questionnaire  was  not  designed  as  a  psychometric  measure.  The  next  section 
describes the principal components of questionnaire validation. 
4.2.2  Questionnaire validation methods 
Questionnaire development methods describe a number of different components 
of validation. Face, content and construct validation are requisite to demonstrate 
the  acceptability  and  usefulness  of  any  health  questionnaire,  while  reliability 
analyses are essential to establish the consistency of a tool. 
Face validation is the fundamental component of questionnaire validation. This 
assesses whether a questionnaire is readable, appears to be sensible and whether 
the  items  in  a  tool  appear  to  measure  the  construct  they  claim  to  measure. 
Questionnaires should be visually appealing, with an uncluttered design. Clear 
instructions  showing  respondents  how  to  complete  items  should  always  be 
included and the basic format should be readily understandable. Face validity is 
vitally important as it promotes acceptance of the questionnaire among research 
participants. It is only after a questionnaire has demonstrated face validity that 
other aspects of validity can be investigated.  
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Content validation assesses whether the items in a questionnaire are relevant and 
whether it  is comprehensive enough to adequately  investigate the subject it is 
designed to measure. Convergent validity, also referred to as construct or trait 
validity, refers to the consistency with which individual items in a questionnaire 
measure the same theoretical construct. While there is no single experiment to 
prove construct validity, a number of different internal consistency analyses may 
be undertaken to assess convergent validity. 
Questionnaires which set out to measure a single construct, such as depression, 
should  have  high  internal  consistency.  This  is  determined  by  assessing 
correlations  between  items  in  a  questionnaire,  and  the  extent  to  which  they 
correlate  with  an  overall  score.  Cronbach’s  alpha  statistic,  sometimes  using  a 
split-half  method,  is  often  utilised  for  this  purpose.  Factor  analysis  typically 
follows  correlation  analyses  in  the  development  of  psychometric  scales.  This 
allows  simplification  of  a  large  number  of  correlated  variables  based  on 
underlying constructs or ‘factors’ in order to reduce the number of items in a 
scale. 
Concurrent validity, also referred to criterion or discriminant validity, involves 
assessment of a questionnaire against an established ‘gold standard’ to determine 
whether  the  new  questionnaire  measures  the  same  construct.  In  clinical  trials, 
discriminant  validity  refers  to  the  ability  of  a  health  measure  to  distinguish 
clinically  significant  outcomes  in  therapeutic  responses  among  cases  and 
controls.
168  For  example, the EORTC core questionnaire  (QLQ-C30) has been 
used to assess treatment-related quality of life outcomes in randomised controlled 
trials conducted in 35 countries.
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Test-retest reliability refers to the ability of a questionnaire to consistently capture 
equivalent  information  over  time,  other  things  being  equal.  Depending  on  the 
intended  use  of  the  questionnaire,  reliability  is  determined  either  by  different 
observers  using  the  same  tool  to  assess  the  same  person  (inter-observer 
reliability), or by a single observer using the questionnaire on different occasions 
(intra-observer reliability). For questionnaires completed by research participants, 
rather than the researcher, intra-observer reliability is assessed. Respondents are  
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asked to complete the same questionnaire within a time-frame when the outcome 
of interest is expected to be stable. The test-retest interval should not be too short 
or the respondent’s memory will influence responses but it should also not be too 
long,  or  the  phenomenon  being  measured  may  have  changed.  The  intraclass 
correlation  coefficient  is  commonly  used  to  assess  the  reliability  of  health 
questionnaires.  High  reliability  coefficients  indicate  that  a  measure  has  good 
stability. Questionnaires with low reliability should either be redesigned and re-
validated or excluded from use. 
4.3  Stage I - Generation of the ovarian cancer symptoms list 
4.3.1  Aim 
●  To generate an exhaustive list of symptoms described as associated 
with ovarian cancer by previous research 
4.3.2  Methods 
4.3.2.1  Literature search 
The literature search sought to identify journal papers and conference proceedings 
describing  research  into  the  symptoms  of  ovarian  cancer.  Three  electronic 
databases were searched: Cinahl, Embase and PubMed. The search was limited to 
English language articles, papers referring to human subjects and to the period 
from 1980. Databases were searched using the terms listed in Table 4.1.  
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Table 4.1.  Database search terms 
Database  Search terms 
Cinahl 
#1 cancer* OR malignan* OR tumo?r* OR neoplasm* OR carcinoma* (AB)  
#2 #1 AND ovar* (AB)  
#2 AND symptom* (AB) 
Embase 
#1 cancer* OR malignan* OR tumo?r* OR neoplasm* OR carcinoma* (TI)  
#2 #1 AND ovar* (TI)  
#2 AND symptom* (TI) 
Pubmed 
#1 cancer* OR malignan* OR tumo?r* OR neoplasm* OR carcinoma* (TI)  
#2 #1 AND ovar* (TI)  
#2 AND symptom* (TI) 
 
Search terms based on Bankhead et al.
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Reference lists of articles were read to identify other potentially relevant papers 
not  retrieved  through  the  literature  search.  Electronic  searches  were  also 
conducted  from  the  homepages  of  seven  journals:  Gynaecologic  Oncology, 
International  Journal  of  Gynaecological  Cancer,  European  Journal  of 
Gynaecological  Oncology,  British  Journal  of  Obstetrics  and  Gynaecology, 
European Journal of Obstetrics and Gynaecology,  Obstetrics  and Gynaecology 
and Current Obstetrics and Gynecology. Saved literature searches were used to set 
up  automatic  email  alerts  from  databases  and  journal  homepages.  Literature 
searches for the purpose of generating an ovarian cancer symptoms list concluded 
in January 2007. 
4.3.2.2  Generation of the symptoms list 
The titles of articles retrieved through literature searches were initially screened 
and the abstracts of potentially relevant papers were read to exclude those not 
directly related to the topic of ovarian cancer symptoms. The following inclusion 
and exclusion criteria were then applied to identify articles suitable for generation 
of the symptoms list.  
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Inclusion criteria 
●  Articles describing original research into the symptoms of ovarian 
cancer 
Exclusion criteria 
●  Articles describing symptoms post-diagnosis 
●  News articles and commentaries 
●  Reviews of previous research 
●  Case reports 
●  Research exclusively based upon International Classification of 
Disease (ICD) codes or medical insurance codes for symptom 
descriptions 
After applying these criteria the remaining papers were carefully read to extract 
all symptoms terms. The symptoms list was generated by typing each new term 
and reference source directly into an Excel spreadsheet whilst reading the article. 
All symptoms described as occurring during the period leading up to diagnosis 
were  included.  Similar  symptom  terms  were  separately  listed,  for  example: 
abdominal  bloating,  bloated,  abdominal  bloating  or  pressure,  bloatedness, 
bloating, etc. 
4.3.3  Results 
The literature search identified 157 potentially relevant papers in Cinahl, 58 in 
Embase, and 50 in Pubmed. After screening and additional searches, 45 journal 
papers, one conference poster and one conference abstract were read in full. A 
total of 37 articles fit the criteria for inclusion. One case report, by Goldberg et 
al.
189,  was  included as this provided  additional information on a  cohort of 52 
patients.  The  paper  by  Portenoy  et  al.
143  was  included  as  it  described  pain 
‘associated with disease onset’ in addition to post-diagnosis pain symptoms. 
At  the  conclusion  of  the  stage  I  a  list  of  349  ovarian  cancer  symptoms  were 
generated  from  the  literature.  These  terms  and  reference  sources  are  listed  in 
appendix 1.  
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4.4  Stage II – Review of ovarian cancer symptoms 
questionnaires 
4.4.1  Aims 
●  To critically review existing ovarian cancer symptoms questionnaires 
in order to identify design strengths and weaknesses 
●  To assess whether any existing questionnaire (or its sub-components) 
could be used in the prospective study 
4.4.2  Methods 
4.4.2.1  Questionnaire acquisition 
Articles  included  in  the  generation  of  the  symptoms  list  were  categorised  as 
either:  1)  potentially  utilising  a  symptoms  questionnaire;  2)  using  qualitative 
methods; or 3) utilising medical or insurance records. Papers published after the 
symptoms list was compiled were categorised in the same way up until May 2008 
when the draft OCSq was formatted. Authors of articles which appeared to use a 
questionnaire were contacted and  a copy of their research tool was requested. 
Using the criteria below, each questionnaire was then critically appraised to assess 
face and content validity. This process was overseen by a lecturer experienced in 
the development of health questionnaires. 
4.4.2.2  Questionnaire assessment criteria 
●  Does the questionnaire actually measure ovarian cancer symptoms? 
●  What is the length of the questionnaire? Is it too short or too long? 
●  How many symptoms are included? 
●  Symptoms question format – open or closed? 
●  Does the questionnaire include any symptoms not covered by the 
draft symptoms list? 
●  Is the layout visually appealing and user friendly?  
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●  Is the wording readily comprehensible by persons of average literacy? 
●  How are symptoms measured? Individually or in combinations? 
●  Does the questionnaire assess symptom severity? 
●  Does the questionnaire assess symptom frequency? 
●  Does the questionnaire assess symptom duration? 
●  Does the questionnaire collect information on symptoms reported to 
GPs? 
●  What are the main strengths of the questionnaire? 
●  What are the main weaknesses of the questionnaire? 
●  Could the questionnaire, or a sub-component, be used for the planned 
research? 
4.4.3  Results 
4.4.3.1  Questionnaire acquisition 
By May 2008, 52 ovarian cancer symptoms articles had been read in full. Thirteen 
of the 37 articles included in the generation of the symptoms list were identified 
as  potentially  utilising  a  questionnaire  (appendix  1).  One  additional  paper, 
published by Olsen et al.
51 in late 2007, also used a symptoms questionnaire and 
was included in the review. From a total of 14 articles, two questionnaires were 
accessed  directly  through  internet  searches.  The  remaining  12  authors  were 
contacted,  or  contact  was  attempted,  and  a  copy  of  their  research  tool  was 
requested (Figure 4.1). 
Two  author  groups  did  not  respond  to  the  request  to  provide  a  copy  of  their 
questionnaire and one group responded that the questionnaire had been lost. One 
author  replied  stating  his  study  did  not  use  a  questionnaire  but  provided 
information on the open questions participants were asked. Eight author groups 
provided either their full questionnaire or an excerpt containing the symptoms 
questions.  By  the  conclusion  of  this  process  a  total  of  ten  questionnaires,  or 
relevant symptoms sections, were reviewed.  
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Figure 4.1.  Questionnaire acquisition process 
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publications reviewed up to 
May 2008
14 studies potentially used an ovarian 
cancer symptoms tool/questionnaire
10 ovarian cancer 
symptoms questionnaires 
or relevant symptoms 
questions reviewed
2 questionnaires 
accessed via 
internet 12 questionnaires requested 
from authors
1 author clarified 
no questionnaire 
but provided 
information on 
open questions
8 
questionnaires 
(or excerpt from 
symptoms 
section) 
provided by 
authors
1 author group 
replied 
questionnaire 
was lost
2 author groups 
did not respond 
to request
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replied 
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was lost
2 author groups 
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to request
 
4.4.3.2  Questionnaire review findings 
Table 4.2 provides a summary of the main findings of the questionnaire review 
and Table 4.3 describes the strengths and weaknesses of each questionnaire. As 
discussed  in  the  literature  review,  two  previously  developed  ovarian  cancer 
symptoms questionnaires are described as having undergone a form of validation.
7 
70 However, these papers provided scant details of the validation process. Igoe
7  
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stated that the questionnaire used in her research had undergone reliability testing 
in addition to face and content validation, yet the paper fails to fully explain these 
components  of  the  research.  A  rather  restricted  validation  is  described  by 
Koldjeski  et  al.
70,  who  state  that  their  symptoms  checklist  had  undergone 
congruent validity testing, although the authors do not provide any details. Good 
practice in questionnaire design includes sharing questionnaires, and validation 
findings,  when  requested  by  other  researchers.  Unfortunately,  I  was  unable  to 
obtain copies of the questionnaires developed by these authors, or full details of 
their  validation  methods  and  results.  The  authors  either  did  not  receive,  or 
ignored, requests to provide these documents. The principal finding of the review 
was,  therefore,  the  absence  of  a  readily  available  ovarian  cancer  symptoms 
questionnaire which had been previously validated by another research group. 
The  secondary  finding  of  the  review  was  that  no  existing  questionnaire  was 
entirely suitable for our planned prospective research. As can be seen in Table 4.3, 
the 2007 Goff questionnaire was most compatible with our need for an instrument 
to  collect  information  on  a  wide  number  of  symptoms,  to  assess  severity, 
frequency and duration of symptoms, and to measure reporting of symptoms to 
GPs.  This  questionnaire  also  had  a  visually  appealing  layout  and  was  easily 
understandable. The main disadvantage of this questionnaire was the complexity 
of its  Likert scales. It  was noted that the range of six response categories for 
frequency, and seven for duration, may confuse respondents without necessarily 
improving validity or reliability. Given that the target population for the finalised 
questionnaire are women aged 50 to 80 years, it was thought that simplified Likert 
scales should be used. A further consideration in relation to the Goff questionnaire 
was  the  number  of  symptoms  included.  Their  list  of  23  symptoms  appeared 
comprehensive, however it was noted that additional symptoms identified in stage 
I may need to be included in our own questionnaire. 
Two  questionnaires,  by  Bayne  &  Gilbert  and  the  Webb  group  collected 
information about symptoms using open questions. All other questionnaires listed 
symptoms  associated  with  ovarian  cancer  and  asked  respondents  to  indicate 
whether  or  not  these  were  experienced  during  the  period  up  to  diagnosis  or 
participation in the questionnaire. It was noted that open questions could result in  
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under-reporting of symptoms as women are not prompted to remember specific 
symptoms. Other limitations of open questions are the need to provide adequate 
space for women to write in all relevant information. Unfortunately, the Webb 
questionnaire provided only three short lines for women to write down symptoms. 
A  further  concern  regarding  open  questions  is the  need  to  collect  all  relevant 
information. Without asking about specific symptoms, there is the possibility that 
respondents  may  report  multiple  irrelevant  symptoms  and  overlook  symptoms 
relevant to ovarian cancer. These issues led to the decision to include a list of 
specific symptoms in our own questionnaire. 
The questionnaire by Olsen asked women about abdominal pain or pressure but 
did  not  include  pelvic  symptoms.  Questionnaires  developed  by  Olson  and  the 
Vine groups combined abdominal and pelvic symptoms together, while all the 
Goff questionnaires asked about pelvic and abdominal symptoms separately. In 
order to collect specific information about the area of the body where women 
experience pain symptoms, it was decided to adopt the Goff group’s format and 
ask women about pelvic and abdominal symptoms separately. 
The number of symptoms listed in questionnaires ranged from three to 23. This 
variability  is  largely  explained  by  different  approaches  to  the  wording  of 
individual items, although the comprehensiveness of different questionnaires is 
also a factor. For example, the Goff questionnaires only combined very similar 
symptoms,  such  as  nausea  and  vomiting,  but  did  not  combine  symptoms  in 
different  parts  of  the  body.  By  contrast,  the  Vine  questionnaires  combined 
bloating with bowel symptoms such as diarrhoea, constipation and gas, while the 
Olson  questionnaire  combined  back  pain  with  abdominal  or  pelvic  bloating 
symptoms. None of the authors explained the reasons why they decided to group 
certain symptoms together into single items.  
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Table 4.2.  Questionnaire review, summary of findings 
Authors  OC 
symptoms 
Pages/symp
tom 
questions 
Format  No. 
symptoms 
Symptoms 
not in draft 
list 
Layout  Wording 
Individual 
or 
combinatio
ns of 
symptoms 
Severity  Frequency  Duration  GP Reported 
Bayne & 
Gilbert 
(2007) 
Symptoms 
section in a 
larger 
questionna
ire 
investigati
ng 
diagnosis, 
treatment 
and care 
15 pages, 4 
symptom 
questions 
Open 
questions 
None  N/A  Appealing 
except 
matrix 
section: 
too little 
space, 
doubtful 
whether 
women 
could 
remember 
details of 
10 GP 
visits, 
quality of 
informatio
n from 
matrix 
doubtful 
Clear and 
easily 
comprehen
sible 
except for 
treatment 
names and 
jargon 
term NICE 
N/A  No  No  Only asks 
year of 
first 
symptom 
onset then 
year of 
diagnosis. 
Not exact 
dates 
Yes. Asks if 
women visited 
GP or other 
health care 
provider after 
onset of first 
symptom or if 
not what made 
them visit their 
GP/A&E. 
Detailed 
information 
about GP visits 
in matrix 
section but 
probably too 
confusing to 
yield quality 
information  
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Authors  OC 
symptoms 
Pages/symp
tom 
questions 
Format  No. 
symptoms 
Symptoms 
not in draft 
list 
Layout  Wording 
Individual 
or 
combinatio
ns of 
symptoms 
Severity  Frequency  Duration  GP Reported 
Goff et al. 
(2000) 
Questionna
ire about 
symptoms 
and 
diagnosis 
2 pages  Mainly 
closed-
ended 
18  No  Largely 
appealing 
although 
layout is a 
little 
cramped. 
Tick boxes 
and line to 
write 
‘other’ 
symptom 
Clear and 
easily 
comprehen
sible 
Individual 
symptoms 
listed 
No  No  Yes, asks 
how long it 
took a 
doctor to 
make a 
diagnosis. 
Asks how 
long 
symptoms 
experience
d before 
surgery – 
n/a, 1 
month, 2 
months, 3-
4 months, 
5-6 
months, 7-
9 months, 
10-12 
months, 
over a year 
Women asked 
when they first 
saw a doctor 
about 
symptoms but 
not which type 
of symptoms 
they consulted 
about  
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Authors  OC 
symptoms 
Pages/symp
tom 
questions 
Format  No. 
symptoms 
Symptoms 
not in draft 
list 
Layout  Wording 
Individual 
or 
combinatio
ns of 
symptoms 
Severity  Frequency  Duration  GP Reported 
Goff et al. 
(2004) 
Questionna
ire about 
symptoms 
Symptoms 
section – 
single 
matrix 
Closed-
ended 
20  No  Appealing 
tick-box 
Likert 
scales 
Clear and 
easily 
comprehen
sible 
Individual 
symptoms 
listed 
Yes, Likert 
scale from 
0-no 
symptom, 
1-minimal, 
to 5-severe 
Yes, Likert 
scale for 
days per 
month 
symptom 
experience
d - <1 day, 
1-2 days, 
3-6 days, 
7-12 days, 
13-19 
days, ≥ 20 
days 
Yes, Likert 
scale for 
number of 
months 
symptom 
has 
persisted - 
<1 month, 
1-2 
months, 3-
4 months, 
5-6 
months, 7-
9 months, 
10-12 
months, > 
12 months 
Asked reason 
for clinic visit 
at time 
questionnaire 
was completed 
but no detailed 
information on 
separate 
symptoms 
reported to 
GP/other 
health care 
professionals  
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Authors  OC 
symptoms 
Pages/symp
tom 
questions 
Format  No. 
symptoms 
Symptoms 
not in draft 
list 
Layout  Wording 
Individual 
or 
combinatio
ns of 
symptoms 
Severity  Frequency  Duration  GP Reported 
Goff et al. 
(2007) 
Questionna
ire about 
symptoms 
5 pages  Closed-
ended 
23  No  Appealing 
tick-box 
Likert 
scales 
Clear and 
easily 
comprehen
sible 
Individual 
symptoms 
listed 
Yes, Likert 
scale from 
0-no 
symptom, 
1-minimal, 
to 5-severe 
Yes, Likert 
scale for 
days per 
month 
symptom 
experience
d - <1 day, 
1-2 days, 
3-6 days, 
7-12 days, 
13-19 
days, ≥ 20 
days 
Yes, Likert 
scale for 
number of 
months 
symptom 
has 
persisted - 
<1 month, 
1-2 
months, 3-
4 months, 
5-6 
months, 7-
9 months, 
10-12 
months, > 
12 months 
Separate tick 
boxes for 23 
symptoms – 
asks women to 
tick all that 
prompted them 
to seek 
medical advice 
in the last year  
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Authors  OC 
symptoms 
Pages/symp
tom 
questions 
Format  No. 
symptoms 
Symptoms 
not in draft 
list 
Layout  Wording 
Individual 
or 
combinatio
ns of 
symptoms 
Severity  Frequency  Duration  GP Reported 
Olsen et al. 
(2007) 
Questionna
ire about 
symptoms 
and 
diagnosis 
Full 
questionna
ire not 
provided, 
length 
unknown 
Mainly 
closed-
ended 
11  No  Layout not 
known 
Clear and 
easily 
comprehen
sible  
Mainly 
individual 
symptoms 
(e.g. 
unexplaine
d weight 
loss) Some 
combined 
symptoms 
(e.g. gas, 
nausea or 
indigestion
; 
unexplaine
d 
bleeding/di
scharge) 
No  No  Yes, for 
each 
symptom, 
asks 
month/year 
of onset 
and 
month/year 
when a 
doctor was 
first visited 
about the 
symptom  
For each 
symptom, asks 
whether a GP 
was consulted 
about the 
symptom and 
asks 
month/year 
when doctor 
was first 
visited about 
the symptom  
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Authors  OC 
symptoms 
Pages/symp
tom 
questions 
Format  No. 
symptoms 
Symptoms 
not in draft 
list 
Layout  Wording 
Individual 
or 
combinatio
ns of 
symptoms 
Severity  Frequency  Duration  GP Reported 
Olson et 
al. (2001) 
Symptoms 
section in a 
larger 
survey of 
risk factors 
for ovarian 
cancer 
47 pages in 
total, 2 
pages on 
symptoms 
Closed-
ended 
11 items 
but 3 of 
these on 
medication
s related to 
symptoms 
No  Slightly 
cramped 
and 
confusing 
Some 
terms (e.g. 
intermitten
t) could be 
difficult to 
comprehen
d 
Some 
individual 
symptoms 
(e.g. 
nausea) 
Some 
combined 
symptoms 
(e.g. 
unusual 
abdominal 
or lower 
back pain; 
unusual 
bloating, 
fullness & 
pressure in 
the 
abdomen 
and pelvis) 
No  Yes, asks 
whether 
each 
symptom 
was 
constant or 
intermitten
t, asks how 
many 
times each 
symptom 
was 
experience
d and if 
this was on 
a day, 
week or 
month 
basis 
Yes, for 
each 
symptom 
asks how 
many 
months 
experience
d 
No  
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Authors  OC 
symptoms 
Pages/symp
tom 
questions 
Format  No. 
symptoms 
Symptoms 
not in draft 
list 
Layout  Wording 
Individual 
or 
combinatio
ns of 
symptoms 
Severity  Frequency  Duration  GP Reported 
Portenoy 
et al. 
(1994) 
Set of 
questionna
ires 
reviewed 
but none 
specific to 
ovarian 
cancer so 
excluded 
from 
assessment 
N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  
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Authors  OC 
symptoms 
Pages/symp
tom 
questions 
Format  No. 
symptoms 
Symptoms 
not in draft 
list 
Layout  Wording 
Individual 
or 
combinatio
ns of 
symptoms 
Severity  Frequency  Duration  GP Reported 
Vine et al. 
(2001) 
Symptoms 
section in 
larger 
epidemiolo
gical 
survey of 
reproducti
ve health 
56 pages in 
total, 1 
page on 
symptoms 
Closed  3  No  Visually 
appealing, 
good 
spacing in 
symptoms 
section but 
then not 
enough 
space 
before 
symptoms 
and 
question 
about first 
GP visit 
Clear  Combinati
on for two 
symptoms 
(pelvic or 
abdominal 
discomfort 
such as 
heaviness, 
fullness, 
pressure or 
pain; 
bowel 
irregularity 
such as 
diarrhoea, 
constipatio
n, gas or 
bloating) 
One 
individual 
symptom 
(need to 
urinate 
more often 
than usual) 
No  No  Yes, for 
each 
symptom 
asks how 
many 
months 
symptom 
experience
d before 
diagnosis 
Asks the 
primary reason 
for the visit to 
the doctor that 
led to 
diagnosis but 
does not 
specifically 
ask which 
symptom 
prompted visit 
to doctor  
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Authors  OC 
symptoms 
Pages/symp
tom 
questions 
Format  No. 
symptoms 
Symptoms 
not in draft 
list 
Layout  Wording 
Individual 
or 
combinatio
ns of 
symptoms 
Severity  Frequency  Duration  GP Reported 
Vine et al. 
(2003) 
Questionna
ire about 
symptoms 
and 
diagnosis 
6 pages in 
total, 3 
pages on 
symptoms 
Closed  11  No  Visually 
appealing 
at first 
glance, 
table 
format and 
horizontal 
shading, 
but on 
closer 
inspection 
it becomes 
confusing 
– coding in 
boxes and 
final 
column too 
messy 
Clear  Some 
individual 
symptoms 
(e.g. 
fatigue) 
Some 
combined 
symptoms 
(e.g. gas, 
nausea or 
indigestion
; pelvic or 
abdominal 
discomfort 
such as 
heaviness, 
pressure or 
pain) 
Abdominal 
and pelvic 
symptoms 
asked 
together 
No  No  Yes, asks 
month and 
year of 
onset of 
each 
symptom 
and asks 
how long 
each 
symptom 
lasted 
Yes, asks if 
doctor seen for 
each symptom 
and asks the 
month and 
date a doctor 
was seen  
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Authors  OC 
symptoms 
Pages/symp
tom 
questions 
Format  No. 
symptoms 
Symptoms 
not in draft 
list 
Layout  Wording 
Individual 
or 
combinatio
ns of 
symptoms 
Severity  Frequency  Duration  GP Reported 
Webb et 
al. (2004) 
Symptoms 
section in 
larger 
epidemiolo
gical 
survey of 
ovarian 
cancer 
Symptoms 
section – 
two pages 
Mainly 
open 
questions 
None  N/A  Very 
confusing, 
unclear 
which 
boxes 
require 
informatio
n, unclear 
what type 
of 
informatio
n is 
required in 
each box 
Wording is 
clear but 
uses jargon 
word 
practitione
r instead of 
doctor 
N/A  No  No  No  Yes but 
confusing way 
of asking, asks 
respondent to 
code type of 
practitioner 
seen on 
multiple visits, 
asks for 
detailed 
information 
about each 
visit, 
questionable 
whether this 
information is 
reliable 
  
 
131
 
Table 4.3.  Main strengths and weaknesses of questionnaires 
Authors  Strengths  Weaknesses  Appropriate for prospective research 
Bayne & Gilbert 
(2007) 
Generally clear wording 
Open questions allow women to describe 
symptoms  using their own language 
Too long 
Some sections (e.g. matrix) too complex to 
collect reliable data 
Open question format does not remind 
women of potentially important symptoms – 
leading to underreporting 
No accurate assessment of symptom duration 
Symptom severity and frequency not 
assessed 
No 
Goff et al. (2000) 
Fairly comprehensive list of 18 symptoms of 
ovarian cancer  
Provides space for women to write an ‘other’ 
symptom not in the list 
Assesses symptom duration in months 
Focus mainly on diagnostic procedures and 
processes rather than symptoms 
Symptom severity and frequency not 
assessed 
No 
Goff et al. (2004) 
Comprehensive list of 20 symptoms of 
ovarian cancer 
Clear and concise 
Collects information on symptom severity, 
frequency and duration 
Does not collect detailed information about 
reporting of symptoms to GPs/ other health 
professionals 
No  
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Authors  Strengths  Weaknesses  Appropriate for prospective research 
Goff et al. (2007) 
Comprehensive list of 23 symptoms of 
ovarian cancer 
Good length overall, not too long 
Clear and appealing layout 
Includes section about symptoms which 
prompted women to seek medical attention in 
the last year 
Includes depression scale and measure of 
positive and negative affect 
Questionable whether Likert scales with 6 to 
7 categories (e.g. frequency and duration) on 
past events actually improve 
validity/reliability 
 
 
Maybe – although would have to investigate 
possibility of reducing the number of 
response categories on the Likert scales and 
adding symptoms from the draft issues list 
Olsen et al. 
(2007) 
Collects comprehensive information about 
symptom reporting to GPs 
Asks month and year of symptom onset and 
month and year the symptom was first 
reported to a GP for all symptoms 
Does not specifically ask about pelvic 
symptoms, only abdominal 
Symptom severity and frequency not 
assessed 
No 
Olson et al. 
(2001) 
Collects comprehensive information on 
symptom frequency 
Includes questions about medication use (e.g. 
were you taking laxatives to prevent 
constipation?) in with symptoms questions 
Does not ask any information about symptom 
reporting to GP/other health care 
professionals 
Layout is confusing 
No  
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Authors  Strengths  Weaknesses  Appropriate for prospective research 
Vine et al. (2001) 
Clear and concise 
Uncluttered layout 
Very long questionnaire but symptoms 
section too brief 
Combines different symptoms together (e.g. 
discomfort, heaviness, fullness, pressure or 
pain) 
Combines abdominal and pelvic 
discomfort/pain symptoms into one item 
Symptom severity and frequency not 
assessed 
No 
Vine et al. (2003) 
Collects comprehensive information about 
symptom reporting to a GP/other health care 
professional 
For all symptoms - asks month and year of 
symptom onset and month and year the 
symptom was first reported to a GP/other 
health professional 
Combines different symptoms together (e.g. 
abnormal bleeding and abnormal discharge) 
Combines abdominal and pelvic 
discomfort/pain symptoms into one item 
Symptom severity and frequency not 
assessed 
No 
Webb et al. 
(2004) 
Open questions allow women to describe 
symptoms  using their own language 
Very confusing format 
Symptom severity, frequency and duration 
not assessed 
Respondents not likely to remember the 
detailed information they are asked to 
provide about GP visits 
No 
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Another  finding  from  the  questionnaire  review  was  the  importance  of  an 
appealing and easy-to-understand layout. Questionnaires with good spacing and 
symmetry were much more inviting to complete than those which were cramped 
or  cluttered  with  data  coding  instructions.  It  was  noted  that  Likert  scales  are 
visually appealing and useful for capturing detailed information, although scales 
with more than five categories appeared overwhelming. The format of the Vine 
2003 questionnaire (large table with headed columns and shaded rows) was most 
appealing at first glance. For our own questionnaire, it was decided to combine 
the layout of the Vine 2003 questionnaire with Likert scales similar to those used 
in the Goff 2007 questionnaire. 
By the conclusion of stage II it was apparent that no existing questionnaire met 
the data collection or design specifications required for our prospective study of 
ovarian  cancer  symptoms.  It  was  therefore  decided  to  continue  using  EORTC 
questionnaire design methodology to develop our own questionnaire. The next 
stage  describes  the  process  of  refining  the  ovarian  cancer  symptoms  list  and 
formatting a draft questionnaire. 
4.5  Stage III – Revision of the symptoms list and formatting the 
provisional questionnaire 
4.5.1  Aims 
●  To use feedback from health professionals and patients to check the 
comprehensiveness and appropriateness of the symptoms list 
●  To revise the list for brevity without deleting important symptoms 
●  To identify and solve potential problems in the administration of the 
OCSq  
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4.5.2  Methods 
4.5.2.1  Preliminary revision of the symptoms list 
The symptoms list generated from the literature was reviewed by a consultant 
gynaecological  oncologist  with  extensive  experience  developing  questionnaires 
according to EORTC guidelines. The purpose of this preliminary review was: 1) 
to remove very similar and duplicate terms in order to reduce the size of the list; 
2)  to  remove  medical  terminology  and  replace  with  lay  language  where 
appropriate. This preliminary review took place on 25 January 2007. 
4.5.2.2  First consensus group review of the symptoms list 
A  group  of  12  clinicians,  nurses,  researchers  and  a  patient  peer  group 
representative met on 30 January 2007 to revise the symptoms list. The group 
systematically discussed each symptom, debating its relevance, changing wording 
where they felt it could be improved and making suggestions for the final draft. 
The revised list of symptoms agreed by the consensus group was used for health 
professional interviews. 
4.5.2.3  Interviews with health professionals 
Interviews  were  conducted  with  surgeons  and  nurses  with  expertise  in  the 
management of ovarian cancer in patients presenting clinically, as well as those 
identified  through  UKCTOCS.  Five  regional  gynaecological  oncology 
departments  out  of  13  potential  sites  were  purposively  selected  to  maximise 
regional  and  socio-economic  diversity.  We  sought  to  recruit  one  site  each  in 
Northern Ireland, Wales, the north of England, the south of England and London. 
The UKCTOCS lead clinician and lead nurse in each site were contacted by email 
and provided with a description of the proposed research. The leads discussed the 
proposal with local staff before indicating whether or not the team, as a whole, 
was willing to participate. None of the sites refused to participate, although some 
requested additional information before agreeing to take part. 
Interview  dates  and  times  were  arranged  through  the  lead  nurse  in  each  site. 
Verbal consent was provided by all health professionals prior to participation and  
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interviews were conducted face-to-face in consultation rooms, meeting rooms and 
office  spaces.  The  only  potentially  identifiable  information  written  on  the 
symptom  questionnaire  was  the  interview  location  and  the  participant’s 
professional role. No other personal information was recorded. Interviews lasted 
21 to 50 minutes. 
The  symptom  questionnaire  completed  by  health  professionals  (appendix  2) 
required  a  relevance  score  to  be  given  to  each  symptom.  Respondents  scored 
symptoms  based  on  their  knowledge  and  experience  working  with 
postmenopausal  women  diagnosed  with  ovarian  cancer.  The  focus  on 
postmenopausal women was due to the intention to use the finalised OCSq in the 
UKCTOCS cohort, where all volunteers are postmenopausal. A score of one on 
the Likert scale denoted a symptom as ‘not at all’ relevant, while four represented 
‘very much’ relevant. Respondents were also asked to select up to 25 symptoms 
they would prioritise from the list of 82 for inclusion in a draft questionnaire. 
They were also asked to identify additional symptoms not already listed in the list, 
but which they considered to be important for a finalised questionnaire. 
After completing the symptom questionnaire, health professionals were invited to 
participate  in  semi-structured  tape-recorded  interviews.  The  format  of  the 
interview  followed  EORTC  questionnaire  development  guidelines.  For  each 
symptom that the participant scored ‘not at all’ or ‘a little relevant’, they were 
asked to describe the reasons behind their decision. Participants were also asked 
to provide information about additional symptoms they suggested for inclusion in 
the finalised questionnaire. 
Data from the questionnaires was entered into SPSS version 12.0.1 (SPSS Inc., 
Chicago,  USA).  Following  EORTC  guidelines,  mean  relevance  scores  were 
calculated  for  each  symptom  by  averaging  scores  on  the  Likert  scale.  The 
percentage  of  health  professionals  who  prioritised  each  symptom  was  also 
calculated. 
Tape-recorded interviews were transcribed verbatim. The transcripts were then 
read  through  while  the  interviews  were  played  back  to  check  for  errors  or 
omissions.  Once  the  transcripts  were  quality-assured  they  were  imported  into  
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QSR-Nvivo  version  7  (QSR  International,  Doncaster,  Australia)  for  analysis. 
Transcripts  were  manually  coded  using  quantitative  content  analysis 
techniques.
190-192  ‘Free  nodes’  were  created  for  each  symptom  that  health 
professionals discussed. Transcripts were systematically analysed to ensure that 
all relevant text was coded. When data coding was complete the content of each 
node was read to check for accuracy. The validated nodes were then exported into 
a Word document for discussion during the second consensus meeting. 
4.5.2.4  Second consensus group review of the symptoms list 
A second consensus group meeting was held on 24 September 2007. Data from 
interviews with health professionals was presented to the group. The objective of 
the meeting was to delete low relevance items from the symptom list, in order to 
reduce patient burden when completing questionnaires and positively influence 
compliance. 
While there were no strict decision rules for eliminating items, symptoms with a 
mean relevance score of 2.40 or lower, and which were prioritised by less than 10 
percent  of  health  professionals,  were  considered  for  deletion.  The  consensus 
group  read  coded  interview  data  for  low  scoring  symptoms  before  deciding 
whether to delete them. All additional issues mentioned by health professionals 
were considered for inclusion in the revised symptoms list. 
4.5.2.5  Telephone interviews with ovarian cancer patients 
Women  who  previously  participated  in  UKCTOCS  and  were  diagnosed  with 
ovarian  cancer  were  invited  to  participate  in  a  telephone  interview  about  the 
symptoms they experienced prior to diagnosis. Women were recruited from the 
same five regional centres that participated in the health professional interviews, 
plus  one  additional  centre  (Nottingham),  to  increase  the  number  of  potential 
participants.  
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Inclusion criteria 
●  Previously participated in UKCTOCS 
●  Confirmed diagnosis of ovarian cancer registered on the UKCTOCS 
database 
●  Diagnosed with ovarian cancer within the last three years 
●  For controls only - telephone or questionnaire notification of ovarian 
cancer diagnosis to the UKCTOCS coordinating centre (to avoid 
invitation of women who may have been upset or angry about their 
allocation to the control group and who no longer wished to be 
contacted) 
Exclusion criteria 
●  Women who were having difficulties psychologically coping with 
their diagnosis 
●  Women unable to use a telephone (e.g. due to hearing impairments) 
●  Women with cognitive difficulties (e.g. dementia) 
●  Any woman who had made a complaint relating to their participation 
in UKCTOCS 
●  For screening group volunteers - those identified by their consultant 
as inappropriate for the research due to poor health 
The lead consultant in each of the regional centres was faxed a list of potential 
telephone  interview  participants.  Women  identified  by  their  consultant  as 
inappropriate  for  the  research  were  not  contacted.  As  the  consultants  treating 
controls were unknown, this was only done for screening group women. 
Women who met the inclusion criteria were sent a letter of invitation (appendix 
3), study information sheet (appendix 4) and consent form (appendix 5). Women 
were requested to complete the consent form if they wished to participate and to 
also  indicate  their  preferred  interview  date,  time  and  telephone  number,  then 
return  the  consent  forms  in  the  stamped,  return-addressed  envelope  provided.  
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Prior to interview, all participants provided written consent and for their interview 
to be audio-tape recorded. 
The symptoms list revised during the second consensus group was formatted as a 
questionnaire for telephone interviews (appendix 6) and an interview guide was 
used (appendix 7). Participants were posted the questionnaire to help them follow 
the  interview.  Women  were  asked  the  extent  to  which  they  experienced  each 
symptom during the 18 months leading up to their ovarian cancer diagnosis. The 
same Likert scale that was used for health professional interviews was used during 
telephone  interviews.  If  the  interviewee  experienced  the  symptom  they  were 
probed about its occurrence (interview guide, appendix 7). Participants were also 
asked to identify up to 10 symptoms that caused them the most trouble during the 
18 months leading up to their diagnosis, and if they experienced any additional 
symptoms  not  included  in  the  list.  Telephone  interviews  lasted  from  30-75 
minutes depending on the symptom experiences of the interviewee. 
All quantitative questionnaire data were entered into SPSS version 12.0.1 (SPSS 
Inc., Chicago, USA) and mean relevance scores were calculated for symptoms in 
the same way as for health professional data. Frequencies were run to calculate 
the percentage of women who prioritised each item as a symptom that ‘caused the 
most trouble’. Additional symptoms suggested by women were entered as a free 
text variable. 
Telephone  interviews  were  transcribed  verbatim  then  transcripts  were  read 
through while the tape was played back to check for errors or omissions. After 
quality  assurance,  transcripts  were  imported  into  QSR  Nvivo  version  7  (QSR 
International,  Doncaster,  Australia)  for  content  analysis.  ‘Free  nodes’  were 
created  for  all  symptom  issues  then  each  interview  was  systematically  coded. 
When all coding was complete the free nodes were read through to check for 
accuracy.  The  validated  nodes  were  then  exported  into  a  Word  document  for 
discussion with consensus group members.  
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4.5.2.6  Third consensus group review of the symptoms list 
Attempts to arrange a third meeting of the consensus group prior to formatting the 
draft  questionnaire  were  not  successful  due  to  group  members’  conflicting 
schedules.  Findings from the patient telephone interviews, including  relevance 
means, the percentage of women who described symptoms as troublesome and a 
summary of coded qualitative data for each symptom was circulated by email 
during February 2008. Potential changes to the list indicated by the data were also 
circulated.  Group  members  were  asked  to  forward  their  final  comments  or 
suggestions for the draft questionnaire by the end of March 2008. 
4.5.3  Results 
4.5.3.1  Results of preliminary revision of the symptoms list 
Preliminary review of the 349 symptoms generated from the literature resulted in 
a list of 82 symptoms. Appendix 8 provides details of each revision and reasons 
for deletions. There was one instance of an American term (hot flashes) being 
replaced by an English term (hot flushes). Several items were deleted due to a 
lack of specificity to ovarian cancer or use of medical terminology. Items were 
grouped into seven categories for the first consensus group meeting: 1) abdominal 
symptoms, 2) gastrointestinal symptoms, 3) pelvic symptoms, 4) gynaecological 
symptoms,  5)  urinary  symptoms,  6)  respiratory  symptoms  and  7)  general 
symptoms. 
4.5.3.2  Results of the first consensus group review of the symptoms list 
Revisions to the symptoms list suggested during the first consensus group meeting 
are summarised in tables for each group of symptoms. Table 4.4 lists abdominal 
symptoms following preliminary review and as revised by the consensus group. 
The  group  decided  to  remove  the  symptoms  swollen  abdomen,  abdominal 
swelling  and  abdominal  distension  as  it  was  felt  that  these  symptoms  were 
covered by increased abdominal size. Tense abdomen was deleted as the group 
thought this term was unclear. In order to keep the terminology consistent it was  
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decided  to  replace  stomach  cramping  with  abdominal  cramping.  All  other 
symptoms in the abdominal group remained unchanged. 
Table 4.4.  Abdominal symptoms, preliminary and consensus group revision 
As per preliminary review  As revised by first consensus group 
Abdominal bloating 
Abdominal fullness 
Abdominal swelling   
Swollen abdomen 
Abdominal tightening 
Increased abdominal size 
Abdominal distension 
Hard abdomen  
Tense abdomen 
Able to feel abdominal mass/lump 
Abdominal discomfort 
Abdominal pain 
Stomach cramping 
Abdominal pressure 
Abdominal bloating 
Abdominal fullness 
Increased abdominal size 
Abdominal tightening 
Hard abdomen 
Able to feel abdominal mass/lump 
Abdominal discomfort 
Abdominal pain 
Abdominal pressure 
Abdominal cramping 
 
 
 
 
 
Table  4.5  lists  gastrointestinal  symptoms  following  preliminary  review  and 
consensus group revision. The group decided to separate indigestion or heartburn 
into  two  items  as  it  was  considered  these  are  different  symptom  experiences. 
Feeling sick was added to nausea, and being sick was added to vomiting, as it was 
thought that these changes would improve interpretation among women with low 
literacy levels. The group changed belching/gas to burping as it was thought that 
this term is more commonly used among older women.  
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Table 4.5.  Gastrointestinal symptoms, preliminary and consensus group 
revision 
As per preliminary review  As revised by first consensus group 
Indigestion or heartburn 
Nausea 
Vomiting 
Reflux 
Belching, gas 
Taste changes 
Feeling full quickly after beginning to eat 
Loss of appetite 
Change in bowel habit 
Bowel irregularity 
Constipation 
Diarrhoea 
Passing wind/gas/flatulence 
Difficulty opening bowels 
Pain when opening bowels 
Rectal pain 
Rectal bleeding 
Abdominal discomfort 
Abdominal pain 
Stomach cramping 
Abdominal pressure 
Indigestion 
Heartburn 
Nausea/feeling sick 
Vomiting/being sick 
Reflux of food 
Burping 
Taste changes 
Feeling full quickly after beginning to eat 
Loss of appetite 
Change in bowel habit 
Constipation 
Diarrhoea 
Excessive passing of wind/flatulence 
Difficulty opening bowels 
Pain before, during or after opening bowels 
Rectal pain 
Rectal bleeding 
Urgent need to open bowel 
Bowel incontinence 
 
 
 
The  group  suggested  changing  the  wording  of  passing  wind/gas/flatulence  to 
excessive passing of wind/flatulence as it was thought that the terms wind or gas 
may be confused with upper GI wind. The word excessive was added to this item 
in recognition that passing wind is a normal bodily function. Pain when opening 
bowels  was  clarified  to  pain  before,  during  or  after  opening  bowels.  Bowel 
irregularity was removed as this was considered non-specific. It was decided to 
add urgent need to open bowel, and bowel incontinence, as some group members 
commented that women with ovarian cancer report these symptoms. 
Table 4.6 lists pelvic symptoms after preliminary review and as revised by the 
consensus group. The group discussed whether women are physically able to feel 
masses or lumps within the pelvis. It was suggested that internal examination is 
required for manual detection of masses within the pelvis. Nevertheless, the group 
decided  to leave this  item in the  list until feedback was  received  from health  
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professionals in the next phase of the research. The wording of this item was 
clarified and expanded from lump to able to feel mass or lump. All other pelvic 
symptoms remained unchanged. 
Table 4.6.  Pelvic symptoms, preliminary and consensus group revision 
As per preliminary review  As revised by first consensus group 
Lump 
Pelvic discomfort 
Pelvic pain 
Pelvic cramping 
Pelvic pressure 
Pelvic fullness 
Pelvic heaviness 
Able to feel mass or lump 
Pelvic discomfort 
Pelvic pain 
Pelvic cramping 
Pelvic pressure 
Pelvic fullness 
Pelvic heaviness 
 
There was considerable discussion among group members regarding the level of 
understanding women have about the terms abdomen and pelvis. It was suggested 
that many women may be unable to differentiate between these terms. To avoid 
confusion,  it  was  decided  to  include  a  mannequin  of  a  woman’s  body  in  the 
finalised OCSq. 
The gynaecological symptoms revised during preliminary review and by the first 
consensus group are listed in Table 4.7. Rather than asking women if they have 
abnormal vaginal bleeding the group suggested that the questionnaire should ask 
if women have vaginal bleeding. A similar recommendation was made to replace 
abnormal vaginal discharge with vaginal discharge. The group suggested that as 
the  questionnaire is being developed for postmenopausal women, this  is more 
appropriate  terminology.  It  was  also  suggested  that  the  questionnaire  should 
include a question about HRT to clarify this information. Prolapse was added to 
the gynaecological symptoms as group members cited examples of ovarian cancer 
patients presenting with this symptom. 
There was lively discussion of the terms intercourse and sexual intercourse. Some 
group  members  felt  that  the  term  intercourse  excludes  other  types  of  sexual 
behaviour that may also cause pain symptoms in women with ovarian tumours. 
However, other group members thought that changing the wording to pain during 
sexual  intercourse  or  other  sexual  activities  was  too  general.  After  much  
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discussion, it was agreed to alter the wording from painful intercourse to pain 
during or after sexual intercourse. 
Table 4.7.  Gynaecological symptoms, preliminary and consensus group 
revision 
As per preliminary review  As revised by first consensus group 
Abnormal vaginal discharge 
Abnormal vaginal bleeding 
Vaginal pain 
Painful intercourse 
Bleeding during/after intercourse 
 
Vaginal discharge 
Vaginal bleeding 
Vaginal pain 
Pain during/after sexual intercourse 
Bleeding during/after intercourse 
Prolapse 
 
Urinary symptoms as revised during preliminary review and by the first consensus 
group are listed in Table 4.8. Urinary urgency was deleted as it was considered 
urgent need to pass urine covered the same issue. Similarly, passing urine more 
often was deleted as urinary frequency covered the same issue. Urinary frequency 
was re-phrased to passing urine frequently. Pressure on the bladder was re-worded 
to  feeling  of  pressure  on  the  bladder.  Urinary  incontinence  was  re-worded  to 
leakage of urine as the group thought that this is more readily understandable. 
Urinary  burning  was  clarified  to  burning  on  passing  urine  and  soreness  was 
deleted  from  pain  or  soreness  on  passing  urine  as  the  group  considered  that 
soreness was already covered by the term burning. Urinary tract infection was 
removed as it is a medical term and the group thought burning on passing urine or 
pain on passing urine adequately captured this information.  
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Table 4.8.  Urinary symptoms, preliminary and consensus group revision 
As per preliminary review  As revised by first consensus group 
Urinary urgency 
Urgent need to pass urine  
Urinary frequency 
Passing urine more often 
Pressure on the bladder 
Urinary incontinence 
Difficulty emptying bladder 
Urinary burning 
Pain or soreness on passing urine 
Urinary tract infection 
Urgent need to pass urine 
Passing urine frequently 
Feeling of pressure on the bladder 
Leakage of urine 
Difficulty emptying bladder 
Burning on passing urine 
Pain on passing urine 
 
 
 
 
The  group  discussed  at  length  whether  any  respiratory  symptoms  should  be 
included in the OCSq. There was consensus that respiratory symptoms are only 
seen in advanced ovarian cancer, therefore it would be little use to include them in 
a questionnaire seeking to identify women with early stage disease. However, the 
group  decided  to  leave  respiratory  symptoms  in  the  list  until  feedback  was 
received  from  health  professionals.  Table  4.9  lists  respiratory  symptoms  as 
revised  by  preliminary  review  and  the  consensus  group.  Breathlessness  was 
removed as the group decided that shortness of breath covered the same symptom. 
Table 4.9.  Respiratory symptoms, preliminary and consensus group revision 
As per preliminary review  As revised by first consensus group 
Chest pain 
Breathlessness 
Difficulty breathing 
Shortness of breath 
Coughing 
Chest pain 
Difficulty breathing 
Shortness of breath 
Cough 
 
 
Table  4.10  lists  general  symptoms  associated  with  ovarian  cancer,  following 
preliminary review and consensus group revision. Pain in the hip/buttock/outside 
leg  was  added  to  the  list  as  some  group  members  commented  that  they  have 
known ovarian cancer patients to complain of pain in this area. The group decided 
to remove swollen lymph nodes, reasoning that women may not know where the 
lymph nodes are, or to be able to interpret them as swollen. The term lump in neck  
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was inserted to capture metastases in the neck, which the group considered a rare 
but serious sign of ovarian cancer. 
Malaise  was  replaced  by  generally  feeling  unwell  as  the  group  thought  this 
terminology  was  more  readily  understandable.  Fever  was  clarified  by  adding 
raised temperature. Flu-like symptoms was deleted as the group thought this was 
non-specific.  Weight  gain  and  weight  loss  were  qualified  by  adding  without 
trying, in order to exclude intentional changes in weight. Lump in breast was 
added  as  group  members  considered this an important  sign of cancer,  even if 
breast  metastases are  rare  in ovarian  cancer. Difficulty  sleeping was added  as 
group members recalled women describing being unable to sleep as a result of 
increased abdominal size and discomfort. Panic attacks was replaced with feeling 
tense  or  anxious  as  this  was  thought  to  be  more  accurate.  Finally,  one  group 
member  suggested  changing  the  depression  item  to  the  two  short  depression 
screening  questions  recommended  by  NICE  for  use  in  primary  care 
populations.
193 After discussion, the group agreed with this suggestion.  
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Table 4.10.  General symptoms, preliminary and consensus group revision 
As per preliminary review  As revised by first consensus group 
Backache 
Back pain 
Shoulder pain 
Pain in side of trunk, flank 
Aching limbs 
Leg cramps 
Leg pain 
Leg swelling 
Ankle swelling 
Swollen lymph nodes 
Fever 
Flu-like symptoms 
Tiredness 
Fatigue 
Lack of energy 
Malaise 
Weight loss 
Weight gain 
Hot flushes 
Night sweats 
Breast swelling 
Breast pain 
Panic attacks 
Depression* 
 
 
 
Backache 
Back pain 
Shoulder pain 
Pain in side of trunk, flank 
Pain in the hip/buttock/outside leg 
Aching limbs 
Leg cramps 
Pain in legs 
Leg swelling 
Ankle swelling 
Lump in neck 
Fever/raised temperature 
Tiredness 
Fatigue 
Lack of energy 
Generally feeling unwell 
Weight loss without trying 
Weight gain without trying 
Hot flushes 
Night sweats 
Breast swelling 
Breast pain 
Lump in breast 
Difficulty sleeping 
Feeling tense or anxious 
Feeling down, depressed or hopeless 
Little interest or pleasure doing things 
 
* Removed as a symptom but agreed to include in finalised questionnaire as depression screening 
questions 
By the conclusion of the first consensus group meeting, the symptoms list had 
been reduced to 80 items. The review process confirmed the validity of individual 
items and the comprehensiveness of the list. Revisions suggested by the group 
ensured  that  symptoms  were  linguistically  relevant  and  easily  understood  by 
persons with an average level of literacy. Amendments to the list were made prior 
to formatting the questionnaire for interviews with health professionals.  
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4.5.3.3  Results of interviews with health professionals 
Table 4.11 lists the number of interviews conducted with health professionals in 
the  five  regional gynaecological oncology  centres.  Seven of the 21 interviews 
were  conducted  with  consultant  gynaecological  oncologists,  six  with  research 
nurses, three with nurse consultants, three with nurse specialists and two with 
registrars. 
Table 4.11.  Number of health professional interviews in each site 
Site  n 
Belfast  6 
Gateshead  6 
London  3 
North Wales  4 
Portsmouth  2 
Total  21 
 
Appendix 9 lists mean relevance scores and the percentage of health professionals 
who prioritised each of the 80 symptoms. Table 4.12 lists the top ten symptoms 
according to relevance mean. Table 4.13 lists the top ten symptoms sorted first by 
the percentage of health professionals who prioritised the item for inclusion in a 
questionnaire,  then  by  relevance  mean.  Abdominal  bloating  and  increased 
abdominal  size  had  the  equal  highest  mean  relevance  scores  (3.57)  and  were 
prioritised  by  the  largest  number  of  health  professionals  (91%).  Abdominal 
fullness had the next highest mean relevance, (3.29) although this symptom was 
not among the ten most commonly prioritised for inclusion in a questionnaire.  
149 
Table 4.12.  Health professional interviews top ten symptoms by relevance 
means 
Symptom  Relevance Mean  Percentage 
Prioritised 
Abdominal bloating  3.57  91 
Increased abdominal size  3.57  91 
Abdominal fullness  3.29  57 
Generally feeling unwell  3.14  86 
Abdominal discomfort  3.10  81 
Passing urine frequently  3.10  76 
Fatigue  3.05  71 
Tiredness  3.00  57 
Lack of energy  2.95  48 
Change in bowel habit  2.95  81 
 
There were some differences in the types of symptoms considered most relevant 
and those prioritised for a questionnaire. For example, change in bowel habit had 
a  lower  mean  relevance  (2.95)  than  passing  urine  frequently  (3.10),  but  was 
prioritised by a larger number of health professionals. Indigestion and weight gain 
were not within the top ten symptoms according to relevance score but they were 
among the ten symptoms most frequently prioritised for a questionnaire.  
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Table 4.13.  Health professional interviews top ranking symptoms prioritised for 
questionnaire 
Symptom  Relevance Mean  Percentage 
Prioritised 
Abdominal bloating  3.57  91 
Increased abdominal size  3.57  91 
Generally feeling unwell  3.14  86 
Change in bowel habit  2.95  81 
Abdominal discomfort  3.10  81 
Passing urine frequently  3.10  76 
Indigestion  2.76  71 
Feeling of pressure on the bladder  2.76  71 
Fatigue  3.05  71 
Weight gain without trying  2.67  67 
 
The  ten  symptoms  described  by  health  professionals  as  having  the  lowest 
relevance to ovarian cancer are listed in Table 4.14. From the list of 80 symptoms 
the three breast symptoms had the lowest mean relevance scores and none of these 
were prioritised for inclusion in a questionnaire. Chest pain, leg cramps, pain in 
legs and taste changes were also regarded as having very low relevance to an 
ovarian cancer diagnosis.  
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Table 4.14.  Health professional interviews, lowest ranking symptoms 
Symptom  Relevance Mean  Percentage 
Prioritised 
Breast pain  1.10  0 
Lump in breast  1.14  0 
Breast swelling  1.14  0 
Chest pain  1.14  0 
Leg cramps  1.29  5 
Pain in legs  1.33  0 
Taste changes  1.33  0 
Hot flushes  1.38  0 
Fever/raised temperature  1.38  0 
Bowel incontinence  1.38  0 
 
As there were 152 pages of coded data from the semi-structured interviews this is 
not included as a full appendix. However, an example of the coding results is 
shown in appendix 10. This details comments made by health professionals when 
they were asked why they considered the relevance of breast pain as a symptom of 
ovarian  cancer.  The  coding  results  for  each  symptom  that  had  a  low  mean 
relevance,  and  those  prioritised  by  few  health  professionals  for  inclusion  in  a 
questionnaire, were presented during the second consensus group meeting. 
Ten interviewees discussed additional symptoms, or suggested slight changes to 
the wording of symptoms (Table 4.15). With the exception of IBS symptoms, all 
health  professionals  who  suggested  additional  symptoms  noted  that  these 
symptoms were very rare.  
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Table 4.15.  Additional symptoms described by health professionals 
Symptom  n  Comments 
Clothes feel tighter around middle, 
increased girth, trousers feeling 
tighter  
2 
Commonly mentioned by women.  
Patients often say that their trousers have felt 
tighter. 
Discharge from umbilicus; sudden, 
unprovoked DVT  1 
Discharge from umbilicus seen in one patient. 
DVT seen but very rare and only in those with 
advanced disease. 
Exhaustion  1  Term exhaustion or exhausted used rather than 
fatigue. 
Feeling 'out of sorts'  1  Patients often use this term rather than 
‘generally feeling unwell’. 
Generalised oedema  1  Only seen in a couple of patients. 
Had to purchase new wardrobe as 
clothes no longer fit  1 
Mentioned by many women, although these 
women also notice their abdomens have 
increased in size rather than just put on weight. 
Hirsutism, excess facial hair or 
baldness  1  Very rare but has been seen. 
IBS symptoms  1 
Some patients with knowledge or past 
experience of IBS have mentioned IBS-type 
symptoms. 
Rectal discharge, but only seen in 
one patient  1  Mucus discharge mentioned by only one patient 
but it was an unusual symptom. 
 
4.5.3.4  Results of the second consensus group review of the symptoms list 
The second consensus group meeting started with a discussion of the meaning of 
abdominal bloating and abdominal fullness. It was agreed that these terms are 
very  similar  and  could  be  used  interchangeably.  This  was  reflected  in  the 
comment  by  a  research  nurse,  ‘Fullness,  I‟ve  put  it  on  the  same  lines  as  the 
bloating really, I think it‟s the same feeling to the woman as bloating.’ (Research 
Nurse,  Site  5).  After  discussion,  the  group  decided  to  merge  these  to  one 
symptom,  abdominal  bloating/fullness.  Table  4.16  lists  abdominal  symptoms 
presented  to  health  professionals  and  amendments  made  during  the  second 
meeting of the consensus group.  
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Table 4.16.  Abdominal symptoms as revised by the second consensus group 
Presented to health professionals  As revised by second consensus group 
Abdominal bloating 
Abdominal fullness 
Increased abdominal size 
Abdominal tightening 
Hard abdomen 
Able to feel abdominal mass/lump 
Abdominal discomfort 
Abdominal pain 
Abdominal pressure 
Abdominal cramping 
Abdominal bloating/fullness 
Increased abdominal size/waistband feels 
tighter 
Able to feel abdominal mass/lump 
Abdominal discomfort, pain or pressure 
 
 
 
 
 
 
Increased abdominal size was re-worded, in line with suggestions made by health 
professionals,  to  increased  abdominal  size/waistband  feels  tighter.  Abdominal 
tightening  and  hard  abdomen  had  moderate  relevance  scores  but  low  priority 
scores. Comments by interview participants supported deletion of these issues. 
For example, ‘I think it‟s the general use of words from the ladies I‟ve seen. It‟s 
usually bloating followed by fullness, but tightening is not really mentioned at all’ 
(Research  Nurse,  Site  2)  and,  ‘Nobody  has  actually  said  that  they  felt  their 
abdomen was hard’ (Research Nurse, Site 3). The consensus group also noted that 
abdominal  tightening  may  be  confused  by  clothes  feeling  tighter  around  the 
abdomen. 
The group discussed how women might interpret similar types of sensations as 
abdominal discomfort, abdominal pain or pressure depending on their previous 
experiences and personal outlook. For this reason the group decided to merge 
abdominal discomfort, pain and pressure. Abdominal cramping was deleted as it 
had  a  low  relevance  score  of  1.62  and  was  not  prioritised  by  any  health 
professionals. The group noted health professionals’ comments, which suggested 
that  women  with  ovarian  cancer  do  not  use  the  term  cramping  to  describe 
abdominal discomfort. For example, ‘Nobody has ever described it as a cramping 
pain, they say it‟s more of an ache, more of a, you know, an ache or discomfort or 
pain, but nobody has ever called it a cramp as such’. (Research Nurse, Site 3).  
154 
Table 4.17 lists gastrointestinal symptoms presented to health professionals and 
revised by the second consensus group. The group discussed the unlikely event of 
a woman with ovarian cancer being sick without feeling nauseous beforehand. It 
was noted that projectile vomiting is not described as symptom of ovarian cancer 
in  any  previous  research.  The  group  also  noted  that  many  previous  studies 
combined  nausea  and  vomiting.  For  these  reasons  it  was  decided  to  merge 
nausea/feeling sick and vomiting/being sick. 
Table 4.17.  Gastrointestinal symptoms as revised by the second consensus 
group 
Presented to health professionals  As revised by second consensus group 
Indigestion 
Heartburn 
Nausea/feeling sick 
Vomiting/being sick 
Reflux of food 
Burping 
Taste changes 
Feeling full quickly after beginning to eat 
Loss of appetite 
Change in bowel habit 
Constipation 
Diarrhoea 
Excessive passing of wind/flatulence 
Difficulty opening bowels 
Pain before, during or after opening bowels 
Rectal pain 
Rectal bleeding 
Urgent need to open bowel 
Bowel incontinence 
Indigestion 
Heartburn 
Nausea/feeling sick or vomiting/being sick 
Feeling full quickly after beginning to eat 
Change in appetite 
Change in bowel habit 
Excessive passing of wind/flatulence 
Difficulty emptying bowels 
Pain before, during or after opening bowels 
 
 
 
 
 
 
 
 
 
 
 
Loss of appetite was re-worded to change in appetite as the group recalled women 
with ovarian cancer reporting both increased and decreased appetite. Reflux of 
food had a mean relevance score of 2.05 and was prioritised by only one health 
professional. Given this information, and the fact that reflux is very similar to 
vomiting, the group decided to delete the item. Similarly, burping had a low mean 
relevance  of  1.43  and  was  prioritised  by  one  health  professional.  Interview 
participants suggested that burping was unrelated to ovarian cancer, or was such a  
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rare symptom that it is of little use to collect this information. Taste changes also 
had  a  low  mean  relevance  of  1.33,  and  was  not  prioritised  by  any  health 
professional. Interview participants noted the symptom is non-specific, very rare 
and  probably  related  to  indigestion  or  vomiting  rather  than  being  a  separate 
symptom in itself. For example, ‘Taste changes, I know it does happen sometimes 
but it‟s very rare. It‟s very non-specific’ (Registrar, Site 1) and, ‘I heard of one 
lady but it was more taste changes as in a bad taste in her mouth, due to being 
nauseated and having indigestion all the time (Research Nurse, Site 1). 
Constipation and diarrhoea were deleted as the group felt that change in bowel 
habit  adequately  covered  both  symptoms.  Difficulty  opening  bowels  was  re-
worded to difficulty emptying bowels as women who participated in the Ovacome 
survey used this wording. Rectal pain was deleted as it had a low relevance mean 
of 1.76 and was prioritised by only one health professional. The group agreed 
with comments made by health professionals that patients can experience bowel 
symptoms but rectal pain is rarely reported. For example, ‘Although I see people 
with bowel symptoms they don‟t mention rectal pain to me’ (Nurse Specialist, Site 
1). 
Rectal bleeding had a low relevance mean of 1.43 and was prioritised by 10% of 
health professionals. While some interviewees commented that rectal bleeding is 
an  important  ‘flag’  symptom,  the  group  noted  that  rectal  bleeding  is  rare  in 
ovarian cancer, ‘I think an ovarian tumour is unlikely to penetrate into the bowel 
itself, it may encase the surface of the bowel but we don‟t generally see rectal 
bleeding.  The only  time  we  come across it in  gynae-oncology is  if there‟s an 
extensive tumour infiltrating the bowel’ (Consultant, Site 3). 
Urgent need to open bowel was deleted as the group thought change in bowel 
habit would adequately capture this information. Bowel incontinence had a low 
relevance mean of 1.38 and was not prioritised by any health professionals. The 
consensus group noted that health professionals described this symptom as very 
rare, and when it does occur, it only occurs in advanced ovarian cancer, ‘I haven‟t 
come across that, not in the early stages. In the later stages, yes, but not in the 
early stages’ (Research Nurse, Site 4). However, one health professional reasoned  
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that  this  may  be  due  to  women  being  too  embarrassed  to  disclose  bowel 
incontinence during gynaecological consultations, ‘Very few patients will tell you 
about incontinence, even when they are incontinent. So it‟s a symptom they tend 
to  ignore  or  suppress.  If  you  ask  colorectal  surgeons  they‟d  say  a  lot  more 
patients, 24 percent say, are incontinent with faeces but never admit it … because 
it‟s sort of a cleanliness thing‟ (Consultant, Site 2). After considerable discussion 
the group decided to delete this as it was thought change in bowel habit would 
sufficiently capture information on bowel incontinence. 
Excessive passing of wind/flatulence was considered for removal as it had a low 
mean  of  1.71  and  only  one  health  professional  prioritised  the  symptom  for  a 
questionnaire.  The  group  discussed  deleting  the  issue  but  noted  that  the  low 
relevance and priority scores may reflect patients being embarrassed about the 
symptom and therefore reluctant to tell their doctor or nurse. Additionally, it was 
noted that a small number of Ovacome survey participants reported this symptom. 
It was therefore decided to leave the issue in the list for feedback from ovarian 
cancer patients. 
Table 4.18 lists pelvic symptoms presented to health professionals and as revised 
by the second consensus group. The group noted that the word pelvic is likely to 
be poorly understood by women. It was agreed to add the term lower abdominal 
to all pelvic symptoms, and to include a mannequin in the finalised questionnaire, 
to help women understand which part of the body this refers to. 
A lengthy debate centred on the symptom able to feel a mass or lump in the 
pelvis. The group agreed with the comment of one health professional, „I don‟t 
think the patients would be able to feel or examine themselves, to that extent, so 
they can‟t actually feel something in the pelvis’ (Consultant, Site 2). Other health 
professionals suggested that a tumour in the pelvis would have to be very large for 
a woman to be able to feel. The group noted that any mass/lump a woman is able 
to feel herself is, by definition, located outside the pelvis. It was therefore decided 
to delete this as relevant information would be covered by able to feel mass or 
lump in the abdomen.  
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Table 4.18.  Pelvic symptoms as revised by the second consensus group 
Presented to health professionals  As revised by second consensus group 
Able to feel mass or lump 
Pelvic discomfort 
Pelvic pain 
Pelvic cramping 
Pelvic pressure 
Pelvic fullness 
Pelvic heaviness 
Lower abdominal or pelvic discomfort, pain 
or pressure 
Lower abdominal or pelvic fullness 
Lower abdominal or pelvic heaviness 
 
 
 
 
Paralleling the re-wording of the abdominal symptoms, the group decided that 
discomfort,  pain  and  pressure  may  describe  similar  sensations.  These  separate 
symptom  issues  were  merged  into  one  issue  and  re-worded  as  lower 
abdominal/pelvic  discomfort,  pain  or  pressure.  Pelvic  cramping  was  removed 
from the list as it had a low mean relevance score of 1.76 and was prioritised by 
only one person.  The  consensus  group agreed  with the comment,  ‘They don‟t 
really talk about cramping very much. They talk about pain, discomfort, they very 
rarely describe their pain as crampy pain … it‟s not something that they would 
describe  their  pain  as  being,  as  a  crampy  nature’  (Lead  Nurse,  Site  1). 
Furthermore, the group agreed that the sensation of pelvic cramping would be 
covered by lower abdominal/pelvic discomfort, pain or pressure. 
Table 4.19 lists gynaecological symptoms presented to health professionals during 
interviews and as revised during the second consensus group. The group discussed 
deleting vaginal discharge, although it was eventually decided to leave this in the 
list as a small number of women reported the symptom in the Ovacome survey. 
The  word  abnormal  was  added  to  vaginal  bleeding  and  vaginal  discharge  in 
consideration of the fact that women participating in finalised questionnaires may 
be taking HRT.  
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Table 4.19.  Gynaecological symptoms as revised by the second consensus group 
Presented to health professionals  As revised by second consensus group 
Vaginal discharge 
Vaginal bleeding 
Vaginal pain 
Pain during/after sexual intercourse 
Bleeding during/after intercourse 
Prolapse 
Abnormal vaginal discharge 
Abnormal vaginal bleeding 
Pain during/after sexual intercourse 
 
 
 
 
Vaginal  pain  had  a  mean  relevance  of  1.52  and  only  one  health  professional 
prioritised  it  for  a  questionnaire.  Following  discussion  of  health  professional 
comments,  the  group  agreed  to  delete  this  issue.  Bleeding  during/after  sexual 
intercourse  was  also  deleted.  This  had  a  low  relevance  mean  of  1.38  and 
interviewees frequently commented that they had not come across this symptom 
among women with ovarian cancer. For example, ‘Bleeding with intercourse is 
associated with cancer of the cervix rather than ovarian cancer’ (Consultant, Site 
5). Prolapse had a low relevance score of 1.71 but was not prioritised by any 
health professionals. Interview participants described prolapse as a rare, late-stage 
symptom usually preceded by ascites, ‘It does happen with ascites, so I do see it, 
but by the time they‟ve got prolapse they‟ve got so many other symptoms that 
they‟d mention that as part of huge bloating and pressure and all the rest of it’ 
(Consultant, Site 5). The group acknowledged that prolapse is a medical term that 
some women may not understand. After discussion, prolapse was deleted from the 
list. 
Table 4.20 lists urinary symptoms presented to health professionals and as revised 
during the second consensus group. Two urinary symptoms were deleted: burning 
on  passing urine  and  leakage of urine. While burning on passing urine  had  a 
slightly higher mean relevance score compared to pain on passing urine, the group 
agreed that pain would also cover burning sensations. Leakage of urine had a 
relevance  mean  of  2.0  and  was  prioritised  by  one  health  professional.  The 
consensus group agreed with the comments of several health professionals that 
urinary incontinence is very common among healthy postmenopausal women and 
is not specific to ovarian cancer. For example, ‘Leakage of urine I haven‟t given a  
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high score because that‟s quite common in the older age group, they‟ll have some 
sort of stress incontinence when they sneeze or something like that‟ (Research 
Nurse, Site 2). 
Table 4.20.  Urinary symptoms as revised by the second consensus group 
Presented to health professionals  As revised by second consensus group 
Urgent need to pass urine 
Passing urine frequently 
Feeling of pressure on the bladder 
Leakage of urine 
Difficulty emptying bladder 
Burning on passing urine 
Pain on passing urine 
Urgent need to pass urine 
Passing urine frequently 
Feeling of pressure on the bladder 
Difficulty emptying bladder 
Pain on passing urine 
 
 
 
Three of the four respiratory symptoms presented to health professionals were 
deleted (Table 4.21). Chest pain, cough and difficulty breathing had relevance 
means of 1.14, 1.38 and 1.71 respectively. Chest pain was not prioritised by any 
health professionals for a questionnaire, one person prioritised cough and 14% 
prioritised difficulty breathing. However, the group decided to remove these three 
symptoms as health professionals commented they are only relevant in late-stage 
ovarian  cancer.  For  example,  ‘We  don‟t  usually  see  chest  metastases  in  early 
ovarian tumours. So usually you‟ve got to be very distended with ascites to have 
difficulty breathing, etcetera.’ (Consultant, Site 2). 
Table 4.21.  Respiratory symptoms as revised by the second consensus group 
Presented to health professionals  As revised by second consensus group 
Chest pain 
Cough 
Difficulty breathing 
Shortness of breath 
Shortness of breath 
 
 
 
 
Table 4.22 lists general symptoms presented to health professionals and as revised 
during the second consensus group meeting. Several symptoms were deleted from 
the list as they had low relevance and priority scores and health professionals 
commented that they were not specific to ovarian cancer. Backache and back pain  
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were  merged  to  form  one  item  as  some  health  professionals  commented  that 
women  with  ovarian  cancer  describe  backache  while  others  commented  that 
women tend to experience back pain. Aching limbs had a relevance mean of 1.48 
and was not prioritised by any health professionals. However, the patient peer 
group representative could remember women with ovarian cancer describing this 
symptom. It was therefore decided to leave this symptom in the list for feedback 
from women with ovarian cancer. 
Table 4.22.  General symptoms as revised by the second consensus group 
Presented to health professionals  As revised by second consensus group 
Backache 
Back pain 
Shoulder pain 
Pain in side of trunk, flank 
Pain in the hip/buttock/outside leg 
Aching limbs 
Leg cramps 
Pain in legs 
Leg swelling 
Ankle swelling 
Lump in neck 
Fever/raised temperature 
Tiredness 
Fatigue 
Lack of energy 
Generally feeling unwell 
Weight loss without trying 
Weight gain without trying 
Hot flushes 
Night sweats 
Breast swelling 
Breast pain 
Lump in breast 
Difficulty sleeping 
Feeling tense or anxious 
Feeling down, depressed or hopeless 
Little interest or pleasure doing things 
Backache or pain  
Pain in side of trunk, flank 
Aching limbs 
Pain in legs 
Leg swelling 
Tiredness, fatigue or lack of energy 
Generally feeling unwell 
Weight loss without trying 
Weight gain without trying 
Feeling down, depressed or hopeless 
Little interest or pleasure doing things 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
While leg swelling was left in the list, ankle swelling was deleted as the group 
agreed  with  the  comments  of  health  professionals  who  suggested  that  ankle  
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swelling is non-specific. ‘So many people have ankle swelling, even young people 
have ankle swelling if they‟ve been sedentary for a while. I think it‟s so non-
specific, it‟s not too pertinent to ovarian tumours, but leg swelling, when you‟ve 
got generalised oedema as a result of low albumin, I think it is more important’ 
(Consultant, Site 2). 
Tiredness, fatigue and lack of energy were merged to form one symptom as the 
group  agreed  each  of  these  terms  describe  similar  experiences.  One  health 
professional  commented  that  women  with  ovarian  cancer  describe  exhaustion 
rather than fatigue. This was noted by the group, although it was not added to 
tiredness, fatigue or lack of energy as the group considered this was sufficiently 
descriptive to also capture information on exhaustion. 
By  the conclusion of the  second consensus  group,  the symptom  list had been 
reduced from 80 to 34 items. The next phase entailed formatting the 34 item list 
into a questionnaire to be used as a basis for telephone interviews with women 
with ovarian cancer. 
4.5.3.5  Results of telephone interviews with ovarian cancer patients 
Thirty-eight women were identified in the selected UKCTOCS regional centres as 
diagnosed with primary malignant ovarian cancer within the past three years. Two 
women  were  excluded  because  their  consultants  considered  them  too  ill  to 
participate and one woman had died (notification of her death had not yet been 
received by the UKCTOCS coordinating centre). These exclusions resulted in a 
total of 35 women being sent a letter inviting them to participate in a telephone 
interview.  Twenty-nine  women  responded,  and  four  subsequently  declined 
participation.  Two  of  these  women  telephoned  to  say  that  they  had  terminal 
ovarian cancer and were too ill to participate, one woman was recently bereaved 
and too upset to participate and the fourth woman wrote a letter to explain that she 
had  recovered  from  ovarian  cancer  and  no  longer  wished  to  dwell  on  her 
diagnosis. This gave a total of 25 interview participants. Table 4.23 lists the stage 
of ovarian cancer at diagnosis for women invited to participate, and those who 
took part in an interview.  
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Table 4.23.  Stage of ovarian cancer, women invited and participants 
Stage  Invited  Participated 
Stage I  19  12 
Stage II  4  3 
Stage III  9  9 
Unknown  3  1 
Total  35  25 
 
The median duration of time from date of diagnosis to participation in a telephone 
interview was 17.8 months (range 1.3-35.5, IQR 9.5-26.6) and median age was 64 
years (range 58-76, IQR 62-69). 
One participant reported she was asymptomatic leading up to her ovarian cancer 
diagnosis. Appendix 11 lists the relevance mean scores for each of the 34 items 
discussed with patients during telephone interviews. The percentage of women 
who described a symptom as ‘causing the most trouble’ is also given. Table 4.24 
lists the top nine symptoms according to mean relevance.  
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Table 4.24.  Ovarian cancer patients top ranking symptoms by relevance mean 
Symptom  Relevance 
Mean 
Caused the 
Most Trouble 
(%) 
Tiredness, fatigue or lack of energy  2.04  4 
Lower abdominal/pelvic discomfort, pain or pressure  1.96  24 
Increased abdominal size/waistband feels tighter  1.88  4 
Passing urine frequently  1.80  8 
Weight gain without trying  1.72  0 
Abdominal bloating or fullness  1.68  8 
Indigestion  1.56  4 
Urgent need to pass urine  1.48  12 
Excessive passing of wind/flatulence  1.48  0 
 
The  lowest  ranking  symptoms  based  on  relevance  score  were  abdominal 
mass/lump, pelvic heaviness, pain when passing urine, pain during/after sexual 
intercourse and pelvic fullness. 
Pelvic discomfort, pain or pressure was the second most relevant symptom and 
was  most  frequently  (24%)  described  as  a  symptom  which  caused  the  most 
trouble. By contrast, abdominal discomfort/pain or pressure had a relevance mean 
of only 1.16 and no woman prioritised it as a symptom which caused the most 
trouble. 
There were a number of discrepancies between the rankings of items based on 
mean relevance score compared to the percentage of women who described the 
symptom  as  causing  the  most  trouble.  Urinary  urgency  was  ranked  eighth  on 
mean relevance score but second in terms of the number of women who described 
it as causing the most trouble. Four symptoms shared equal third ranking as a 
symptom  that  caused  women  the  most  trouble:  urinary  frequency,  abdominal 
bloating/fullness,  feeling full and pressure on  the bladder,  yet feeling  full and 
pressure on the bladder only had moderate relevance scores. This suggests that  
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these two symptoms were fairly uncommon but, among those who experienced 
them, they were quite troublesome. 
Nineteen of the 34 symptoms were not prioritised by any woman as a symptom 
that  caused  the  most  trouble  (appendix  11).  These  included  symptoms  with 
relatively  high  relevance  scores  such  as  weight  gain,  excessive  passing  of 
wind/flatulence, difficulty emptying bowels and backache/pain. 
Five participants stated that they experienced additional symptoms (not already in 
the list) during the period leading up to their diagnosis (Table 4.25). None of the 
additional  symptoms  were  mentioned  by  more  than  one  woman.  All  of  the 
participants  who  described  additional  symptoms  also  reported  that  they 
experienced three to 14 symptoms already in the list. 
Table 4.25.  Additional symptoms reported by women 
Symptom  Interview No. 
Leakage of urine, feeling of pressure/discomfort in the rectum  4 
Hair became very unmanageable  14 
Hair and nails became thin, became very emotional  16 
Cough when trying to sing  17 
Skin became noticeably darker  23 
 
Participants were asked if any additional symptoms caused them the most trouble 
during the time leading up to their diagnosis. With the exception of leakage of 
urine and feeling of pressure/discomfort in the  rectum, none of the symptoms 
caused women particular trouble. 
4.5.3.6  Results of the third consensus group review of the symptoms list 
Three symptoms (pain in side of trunk/flank, aching limbs and generally feeling 
unwell) were deleted from the list following review of data from interviews with 
ovarian cancer patients. While these symptoms did not have the lowest rankings, 
they  did  have  relatively  low  scores  and  evidence  from  patient  interviews 
supported their deletion.  
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Pain in side of trunk/flank had a mean relevance of 1.16 and was not described as 
a  symptom  which  caused  the  most  trouble  by  any  woman.  Findings  from 
interviews suggested that women have difficulty understanding what area of the 
body the terms trunk and flank refer to. Several women sought clarification of 
these terms before they responded. Four women stated that they had a little pain in 
the side of trunk or flank prior to diagnosis but no participant had this symptom 
quite a bit or very much. For example, ‘I did occasionally have pains, I suppose in 
my side but there was never any pattern. I might just have one then not have one 
for a few months … I mean I never ever considered going to the doctors. It never 
lasted. It was very spasmodic, I might have one, one week then another the next 
week then not for a couple of months. I might have one then the next in three 
weeks. You know, sort of very hit and miss, nothing that you could actually put 
your finger on and say there was a problem’. (Patient interview 8) All of the 
women who described having pain in the side of trunk or flank also had either 
abdominal, pelvic or back pain. Taking all of these factors into consideration, the 
consensus group agreed to delete this symptom. 
Aching limbs had a mean relevance score of 1.20 and was not described as a 
symptom which caused the most trouble by any participant. The decision to delete 
this  symptom  was  supported  by  the  finding  that  all  telephone  interview 
participants who had the symptom described aches in their legs but not in their 
arms. Additionally, when participants were asked about the next item on the list, 
leg  pain,  they  described  both  leg  ache  and  pain  together,  not  as  two  separate 
symptoms, for example, ‘I used to get lots of pains in my legs, at the top of my 
legs, it would ache for hours. Then some days I would walk up the road and my 
legs would be so heavy and achy and I thought, what is wrong with me?’ (Patient 
interview 18). The group agreed to delete aching limbs and change the wording of 
the leg pain to leg ache or pain. 
The third issue that was deleted by the consensus group, generally feeling unwell, 
had  a higher relevance  score  of 1.44  and was  prioritised by  one  woman as  a 
symptom which caused the most trouble. The decision to delete this item was 
based upon the consideration that it is not specific to ovarian cancer. All seven of 
the  women  who  reported  this  symptom  also  reported  other  symptoms.  The  
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consensus group also noted that inclusion of generally feeling unwell in any list of 
symptoms  designed  for  identification  of  women  for  ovarian  cancer  screening 
would result in GP surgeries being swamped with worried-well women. 
Following email discussion on the meaning of the term pressure, the consensus 
group  decided  to  separate  abdominal  discomfort,  pain  or  pressure  into  two 
symptoms: abdominal discomfort or pain, and abdominal pressure. It was also 
decided to separate lower abdominal/pelvic discomfort, pain or pressure into two 
symptoms. The group agreed that women may feel pressure but not necessarily 
discomfort or pain. 
One other minor change was the decision to merge the symptoms indigestion and 
heartburn  into  one  item.  The  consensus  group  decided  that  keeping  these  as 
separate symptoms would not necessarily improve the sensitivity of the finalised 
questionnaire. After the proposed changes were agreed by all group members a 
questionnaire  was  formatted  for  piloting.  Wherever  possible,  symptoms  were 
phrased using the terminology of validated EORTC questionnaires. 
Decisions to delete, merge or separate certain items reduced the symptoms list 
from 34 to 32 items by the conclusion of the third consensus process. The 32 
symptom list was formatted as a pilot questionnaire (appendix 12) which was 
subsequently  field-tested  in  the  UKCTOCS  cohort.  Findings  from  the 
questionnaire pilot are presented in the next section. 
4.6  Stage IV – Pilot of the provisional ovarian cancer symptoms 
questionnaire 
4.6.1  Aims 
●  To determine the validity and reliability of the draft OCSq 
●  To identify symptoms for potential removal from the questionnaire 
●  To seek feedback from UKCTOCS volunteers on the draft 
questionnaire and revise the according to these findings 
●  To format a finalised OCSq for a prospective study  
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4.6.2  Methods 
4.6.2.1  Setting 
The OCSq was piloted in the UKCTOCS cohort from 21 May to 3 December 
2008.  Women  receiving  screening,  or  enrolled  as  a  UKCTOCS  control,  were 
invited  to  participate.  Letters  of  invitation  and  questionnaires  were  posted  to 
women from all 13 regional centres from the UKCTOCS coordinating centre in 
London. 
GPs of women invited to participate were posted a GP study information letter 
(appendix 13). This letter described the aims of the research and included the 
names of all women registered at the practice who were invited to participate. 
4.6.2.2  Sample size 
For validation of the pilot OCSq, the research group took into account the need to 
maximise participant feedback within a short timescale and restricted budget. As 
the plan was to send the finalised questionnaire to 100,000 women, recruiting 
approximately one percent of this total (n = 1,000) for the pilot was considered 
sufficient  for  validation  and  the  identification  of  potential  problems  in 
administering the OCSq. Given that the response rate for UKCTOCS follow-up 
questionnaires was 75%, it was calculated that approximately 1,333 volunteers 
should be invited to participate in the pilot. 
The sample size required for test-retest reliability was considered separately. The 
project group acknowledged that retest validation would impose a slight burden 
on women, as they would be asked to complete a second questionnaire two days 
after their first questionnaire. This process may have been confusing or irritating 
for  women.  In  order  to  reduce  participant  burden,  it  was  agreed  to  send  the 
minimum number of retest questionnaires dictated by statistical validity in order 
to assess the stability of item wording and the severity section (as women were 
instructed to only completed the frequency, duration and GP consultation sections 
if they experienced the symptom).  
168 
Within the questionnaire design literature there is debate regarding sample sizes 
required for retest validation. Streiner and Norman
130 note two previous studies 
which identified the need for 200 participants, and one study which identified a 
minimum sample of 300 for retest validation. This information, in parallel with 
sample size tables for the kappa statistic, was considered for calculation of the 
sample size required for reliability testing. For a two-tailed test assuming a null k 
value of 0.60 (as repeat test response should have a fairly high level of agreement 
with the initial test) the number of participants required at 80% power ranges from 
126  to  335  to  detect  a  kappa  of  0.80,  with  the  proportion  of  positive  ratings 
ranging from 0.10 to 0.90.
194 Given UKCTOCS response rates, approximately 168 
to 447 women should be invited to calculate test-retest kappa statistics. According 
to questionnaire design literature more generally, 267 to 400 participants should 
be invited for retest validation. 
4.6.2.3  Pilot questionnaire sample 
Two groups were invited to participate in the OCSq pilot: 1) UKCTOC controls 
and  2)  women  receiving  screening  in  the  multimodal  or  ultrasound  arms  of 
UKCTOCS.  The  second  group  was  comprised  of  two  sub-groups:  a)  women 
attending annual (Level 1) screening; and b) women recalled for repeat (Level 2) 
screening due to an abnormal finding on annual screen. Inclusion and exclusion 
criteria were as follows: 
Inclusion criteria 
●  Women participating in UKCTOCS - as a control or receiving 
screening in the multimodal or ultrasound arms 
●  For controls – return of a UKCTOCS follow-up questionnaire within 
the past 12 months, in order to reduce the number of women already 
lost to follow-up  
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Exclusion criteria 
●  Withdrawal from UKCTOCS for any reason 
●  Women who had both ovaries surgically removed since joining 
UKCTOCS 
●  Women who had made a complaint relating to their participation in 
UKCTOCS 
●  For women in the multimodal or ultrasound arms - non-attendance of 
the screening appointment prior to their current appointment letter 
UKCTOCS controls 
A list of controls who met the inclusion and exclusion criteria was exported from 
the main UKCTOCS database and imported into SPSS version 12.0.1 (SPSS Inc., 
Chicago,  USA).  The  random  sample  of  cases  function  was  used  to  select  the 
UKCTOCS  volunteer  reference  numbers  of  25  controls  from  each  of  the  13 
regional  centres.  A  mail  merge  was  conducted  in  Word  then  letters  inviting 
control group women to participate were printed out and posted. 
UKCTOCS volunteers in the multimodal and ultrasound arms 
All  UKCTOCS  screening  appointment  letters  are  printed  and  posted  from  the 
research coordinating centre in London. Screening appointment letters are printed 
every Monday, Tuesday and Wednesday. These letters are printed by order of 
appointment  type  (either  annual  screen,  repeat  annual  screen,  Level  2  screen, 
repeat  Level  2  screen  or  clinical  decision),  screening  arm  (multimodal  then 
ultrasound), year of screening (in chronological order) and sequential regional site 
number. The repeat letters are new appointments for women who failed to attend 
their original appointment. Screening letters are sorted by administration staff into 
piles for each type of appointment. Annual screen and repeat letters are placed in 
an envelope stuffing machine then letters are franked and dispatched. Level 2 and 
clinical  decision  letters  are  given  to  a  Nurse  Consultant  for  checking  prior  to 
postage.  
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All repeat appointment letters were excluded to reduce the number of volunteers 
potentially lost to follow-up since their last screening appointment. The following 
process was then used to identify 15 women from each screening arm in the 13 
regional centres sent an annual appointment and 24 women from each screening 
arm in the 13 regional centres sent a Level 2 appointment: 
●  Annual screen appointment letters were hand sorted, on a daily basis, 
into a multimodal and ultrasound group for each of the regional 
centres 
●  Every fifth annual appointment letter from each pile was selected 
until a sufficient number of women in the multimodal and ultrasound 
groups was selected for each regional centre 
●  Level 2 letters were first checked by a research nurse then, on a 
weekly basis, they were sorted in the same way as annual screen 
letters 
●  Every Level 2 letter was selected from each pile until a sufficient 
number of women in the multimodal and ultrasound groups was 
identified for each regional centre 
●  The volunteer reference numbers on all selected appointment letters 
were entered into a database, a mail merge was conducted in Word 
(daily for annual screening appointments and weekly for Level 2 
appointments), then letters inviting women to participate in the 
questionnaire pilot were printed out 
4.6.2.4  Test-retest validation sample 
Prior to each mail merge, a group of women were selected to participate in test-
retest  validation  of  the  pilot  OCSq.  Approximately  every  third  woman  was 
selected for test-retest validation. This group of women were invited to complete 
an initial (test) OCSq then complete a second (retest) OCSq two days later. As 
completion of two seven-page questionnaires was considered time-consuming and 
rather onerous, it was decided to stop selecting women for retest validation once  
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sufficient  numbers  of  test-retest  questionnaires  were  received  back  at  the 
UKCTOCS coordinating centre. 
4.6.2.5  Data collection 
The pilot OCSq included 32 symptoms  and a  section for women to write the 
details of up to three ‘other’ symptoms (appendix 12). Women identified for the 
pilot  were  sent  a  letter  of  invitation  (appendix  14),  study  information  sheet 
(appendix 15), consent form (appendix 16) and the pilot OCSq (appendix 12). 
Women  selected  for  the  test-retest  validation  were  sent  a  slightly  different 
invitation letter (appendix 17), study information sheet (appendix 18) and two 
pilot OCSqs, one labelled questionnaire A and the other questionnaire B. The first 
1,000 women across all groups were also sent a feedback form (appendix 19). 
Those  who  wished  to  take  part  in  the  research  were  asked  to  complete  these 
documents then post them back in the pre-paid envelope provided. 
The  pilot  OCSq  elicited  information  on  symptom  severity,  frequency  and 
duration, as well as GP consultations for symptoms. Respondents were asked if 
they experienced each of the 32 symptoms in the last week, using a Likert scale to 
assess severity (0 denoted not at all, 1 a little, 2 quite a bit and 3 very much). If 
women experienced the symptom during the last week they were asked about its 
frequency, whether the symptom was experienced 1-2 days, 3-5 days or 6-7 days. 
They were also asked about the duration of the symptom (less then 3 months, 3-6 
months, 7-12 months or more than 12 months), and whether they had discussed 
the symptom with a GP in the last three months (yes or no). The questionnaire 
also included a section asking respondents about co-morbidities and whether they 
were currently using HRT. The two short depression screening questions were the 
final items in the questionnaire: 1) In the past month have you often been bothered 
by feeling down, depressed or hopeless? 2) In the past month have you often been 
bothered by little interest or pleasure doing things? 
Women  selected  for  test-retest  validation  were  asked  to  complete  two 
questionnaires two days apart. This time frame was adopted as symptoms should 
be relatively stable over this time and a two day period between questionnaires 
was considered sufficient to avoid women completing items based on memory of  
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their previous responses. In order to obtain accurate test-retest data the invitation 
letter and study information sheet sent to this group clearly requested them not to 
copy information from one questionnaire to the next: ‘If you would like to take 
part in this study please complete the consent section then fill in questionnaire A. 
Two days later please complete questionnaire B. We would like to know about 
your symptom experiences on the two separate dates so please don’t copy from 
questionnaire A.’ 
The feedback form asked respondents how long it took to complete the OCSq, if 
they had any difficulties answering questions, if they were upset by any questions 
and if they had any comments or other feedback on the study. 
4.6.2.6  Data analysis 
Data  from  the  symptoms  and  feedback  questionnaires  was  entered  into  SPSS 
version  12.0.1 (SPSS  Inc.,  Chicago,  USA). Detailed feedback comments were 
typed into Word then imported into QSR-Nvivo version 7 (QSR International, 
Doncaster,  Australia)  for  coding  using  content  analysis  techniques.
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Frequencies were run in SPSS to describe variables. 
Factor analysis was described earlier in the chapter. This was not appropriate as a 
method  of  identifying  variables  for  potential  removal  from  the  draft  OCSq. 
However,  relationships  between  symptoms  were  investigated  using  correlation 
analyses, with the aim of merging or removing highly correlated symptoms in 
order to reduce the length of the questionnaire. 
Statistical analysis 
Spearman’s  correlation  coefficients  were  calculated  to  investigate  correlations 
between  ordinal  symptoms  data.  Spearman  coefficients  of  rs  >  0.30  indicate 
medium correlation and rs > 0.50 large correlation. Correlation coefficients of rs > 
0.90  were  considered  potential  candidates  for  merging  prior  to  formatting  the 
finalised questionnaire. Differences were accepted as significant at p < 0.05 for all 
statistical  analyses  and  95%  confidence  intervals  were  calculated  where 
appropriate.  
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The intra-class correlation coefficient (ICC) is the preferred statistic for test-retest 
analyses  of  continuous  data.  However,  this  statistic  was  not  appropriate  for 
reliability testing of the OCSq as all data were binary or ordinal. Cohen’s kappa 
coefficient was therefore the most appropriate  statistic for this data. Quadratic 
weightings  were  applied  to  ordinal  data  as  these  approximate  the  intraclass 
correlation coefficient.
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Cohen’s kappa statistic for binary data is represented by: 
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where  P(o)  represents  the  proportion  of  observed  agreement  and  P(c)  is  the 
proportion of agreement by chance. SPSS was utilised for the calculation of kappa 
coefficients for binary data. 
Quadratic weighted kappas were calculated as a measure of agreement between 
ordinal test-retest data. The quadratic weighting set penalises disagreement by the 
square of the number of categories and is represented by: 
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This weighting set essentially treats disagreements between close responses (e.g. 
not at all and a little) as less important than disagreements between responses 
further apart on the scale (e.g. not at all and quite a bit). STATA version 10.0 
(STATA Corp., College Station, USA) was used for the calculation of weighted 
kappas. Table 4.26 shows how quadratic weights were applied to test-retest data 
where respondents used all four Likert scale response categories.  
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Table 4.26.  Quadratic weights for ordinal data with four categories 
  Not at all  A little  Quite a Bit  Very Much 
Not at all  1.0       
A little  0.8889  1.0     
Quite a Bit  0.5556  0.8889  1.0   
Very Much  0  0.5556  0.8889  1.0 
 
Kappa coefficients from 0.21-0.40 were considered indicative of fair agreement, 
0.41-0.60 as moderate agreement, 0.61 to 0.80 as substantial agreement and 0.81 
or greater as excellent agreement.
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4.6.3  Results 
This  section  describes  the  results  of  questionnaire  validation  and  reliability 
analyses  following  the  pilot.  Results  of  symptoms  analyses  are  presented 
separately in Chapter Five. 
4.6.3.1  Validity of the questionnaire 
A total of 1,339 women were posted the pilot OCSq and 829 women returned a 
questionnaire  (61.9%  response  rate).  A  small  number  of  women  initially 
overlooked the  consent  section. These questionnaires were returned to women 
with a polite note asking them to provide written consent then return the signed 
questionnaire  to  the  coordinating  centre.  All  returned  questionnaires  were 
included in analyses. 
Table 4.27 lists the number of women who missed each question. No data is given 
for pain during or after sexual intercourse as this was preceded by an instruction 
to participants to miss this question if they had not been sexually active during the 
past  week.  The  symptoms  with  the  largest  amount  of  missing  data  were 
abdominal pressure (q8) and pelvic heaviness (q13), which were missed by 81 
(9.8%) participants each.  
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Table 4.27.  Number of participants who missed each question 
Questionnaire item  n  % 
Q1 Lower abdominal or pelvic discomfort or pain  53  6.4 
Q2 Upper abdominal discomfort or pain  65  7.8 
Q3 Indigestion or heartburn  51  6.2 
Q4 Nausea or vomiting  66  8.0 
Q5 Felt full quickly when eating  61  7.4 
Q6 Change in appetite  65  7.8 
Q7 Upper abdominal bloating or fullness  62  7.5 
Q8 Upper abdominal pressure  81  9.8 
Q9 Increased abdominal size  66  8.0 
Q10 Abdominal to feel abdominal mass or lump  80  9.7 
Q11 Lower abdominal or pelvic bloating or fullness  70  8.4 
Q12 Lower abdominal or pelvic pressure  74  8.9 
Q13 Lower abdominal or pelvic heaviness  81  9.8 
Q14 Pain before, during or after opening bowels  67  8.1 
Q15 Difficulty emptying bowels  61  7.4 
Q16 Change in bowel habit  74  8.9 
Q17 Excessive wind or flatulence  58  7.0 
Q18 Passed urine frequently  66  8.0 
Q19 Urgent need to pass urine  57  6.9 
Q20 Pressure on the bladder  68  8.2 
Q21 Difficulty emptying bladder  77  9.3 
Q22 Pain when passing urine  75  9.0 
Q23 Short of breath  77  9.3  
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Questionnaire item  n  % 
Q24 Back ache or pain  61  7.4 
Q25 Leg ache or pain  67  8.1 
Q26 Leg swelling  67  8.1 
Q27 Tiredness, fatigue or lack of energy  61  7.4 
Q28 Weight gain without trying  71  8.6 
Q29 Weight loss without trying  80  9.7 
Q30 Abnormal vaginal bleeding  78  9.4 
Q31 Abnormal vaginal discharge  76  9.2 
Q32 Pain during or after sexual intercourse  n/a  n/a 
 
The  matrix  in  appendix  20  presents  results  of  Spearman  correlations.  No  two 
symptoms  had  correlations  above  rs  =  0.90,  therefore  no  symptoms  were 
candidates for merging. Pelvic pressure (q12) and pelvic heaviness (q13) were the 
two most highly correlated symptoms (rs = 0.64, p < 0.0001), followed by urinary 
frequency (q18) and urinary urgency (q19) (rs = 0.63, p < 0.0001), then pelvic 
discomfort/pain  (q1)  and  pelvic  pressure  (q12)  (rs  =  0.59,  p  <  0.0001).  No 
symptoms were strongly negatively correlated, although there was a significant 
negative correlation between weight gain and weight loss (rs = -0.13, p < 0.0001). 
Due to very few women reporting ‘a little’, ‘quite a bit’ or ‘very much’ weight 
loss, this negative correlation is not as large as would be expected if the response 
categories were restricted to yes or no for both variables. 
From the 1,000 women posted a feedback form, 584 returned the form (58.4% 
response rate). A total of 452 (77.4%) replied that the OCSq took them 10-15 
minutes  to  complete  (Table  4.28).  Six  (1%)  replied  that  they  needed  help  to 
complete the questionnaire. Three of these women were helped by their spouse or 
partner, one by her daughter, one by her care coordinator and one by myself (over 
the telephone).  
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Table 4.28.  Time taken to complete symptoms questionnaire 
Time to complete questionnaire  n  % 
10-15 minutes  452  77.4 
16-20 minutes  93  15.9 
21-30 minutes  27  4.6 
More than 30 minutes  4  0.7 
Missing  8  1.4 
Total  584  100.0 
 
Sixty-six  respondents  (11%)  replied  that  they  had  difficulty  answering  any 
questions, four women (0.7%) found one or more questions upsetting and 24 (4%) 
found one or more questions irrelevant. Table 4.29 lists the number of women 
who found each question difficult to answer, upsetting or irrelevant. Participants 
were  also  asked  to  write  the  reasons  why  they  found  symptoms  difficult  to 
answer, upsetting or irrelevant.  
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Table 4.29.  Number of women, question difficult to answer, upsetting or 
irrelevant 
Questionnaire item 
Difficulty  Upsetting  Irrelevant 
n  n  n 
Q1 Lower abdominal or pelvic discomfort or 
pain  9  0  2 
Q2 Upper abdominal discomfort or pain  8  0  2 
Q3 Indigestion or heartburn  7  0  1 
Q4 Nausea or vomiting  1  0  2 
Q5 Felt full quickly when eating  2  0  3 
Q6 Change in appetite  6  0  3 
Q7 Upper abdominal bloating or fullness  8  0  4 
Q8 Upper abdominal pressure?  7  0  3 
Q9 Increased abdominal size  8  0  2 
Q10 Able to feel abdominal mass or lump  3  0  2 
Q11 Lower abdominal or pelvic bloating or 
fullness  10  0  2 
Q12 Lower abdominal or pelvic pressure  9  0  3 
Q13 Lower abdominal or pelvic heaviness  9  0  4 
Q14 Pain before, during or after opening 
bowels  2  0  2 
Q15 Difficulty emptying bowels  12  0  2 
Q16 Change in bowel habit  6  0  2 
Q17 Excessive wind or flatulence  15  0  1 
Q18 Passed urine frequently  10  0  1 
Q19 Urgent need to pass urine  7  0  2 
Q20 Pressure on bladder  4  0  1  
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Questionnaire item  Difficulty  Upsetting  Irrelevant 
Q21 Difficulty emptying bladder  2  0  2 
Q22 Pain when passing urine  2  0  1 
Q23 Short of breath  4  0  4 
Q24 Back ache or pain  9  0  3 
Q25 Leg ache or pain  12  0  4 
Q26 Leg swelling  5  0  2 
Q27 Tiredness, fatigue or lack of energy  9  0  2 
Q28 Weight gain without trying  3  1  2 
Q29 Weight loss without trying  2  0  1 
Q30 Abnormal vaginal bleeding  2  1  2 
Q31 Abnormal vaginal discharge  1  1  2 
Q32 Pain during or after sexual intercourse  0  0  13 
 
Participants explained that the reason they had difficulty answering questions was 
due  to  interpretation  of  their  bodily  experiences  in  terms  of  the  symptoms 
described  in  the  questionnaire.  For  example,  ‘I  couldn‟t  decide  whether  I  felt 
bloated or full or whether it was pressure I felt’. Difficulties also arose when 
respondents attempted to attribute symptoms, rather than simply reporting their 
experiences, ‘With IBS and ulcerative colitis I often get feelings of discomfort or 
pain, bloating, fullness, pressure and heaviness. I have answered these questions 
regarding  “unusual”  feelings’.  The  symptom  women  had  the  most  difficulty 
answering was excessive wind/flatulence. Table 4.30 presents coded data relating 
to this symptom for the 13 women who wrote the reason why they had difficulty.  
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Table 4.30.  Reasons why women had difficulty answering question 17 
 
Coded data – reasons why q17 (excessive wind or flatulence) difficult to answer 
 
Respondent 1, site 5 
Have no idea how to quantify, I have a high fibre diet therefore virtually every day I have 
flatulence but it‟s part of life. 
 
Respondent 1, site 6 
Unsure as to whether the fact that I have been prescribed alendronic acid and calcium may 
affect answer. 
 
Respondent 1, site 7 
Since colectomy in 1997 I have a tendency to flatulence as normal. So wasn‟t sure whether it 
would count as „excessive‟ when compared with average. The flatulence is of no anxiety. 
 
Respondent 2, site 7 
Re-phrase maybe – Have you had flatulence/wind at unusual times and excessive? 
 
Respondent 1, site 9 
Not sure how much is excessive. 
 
Respondent 2, site 9 
I have an ongoing problem with excessive wind, for which I have medication. 
 
Respondent 1, site 11 
I do not know how much flatulence is normal. 
 
Respondent 2, site 11 
Difficult to tick boxes as I had not experienced the problem over the past week, but just 
occasionally over the past year or more. 
 
Respondent 3, site 11 
Due to aspirin and other drugs, now taking omeprazole 10mg.  
 
Respondent 1, site 13 
Have for years been bothered by flatulence. Now break a lot of wind. 
 
Respondent 1, site 17 
Increased flatulence – embarrassingly due to age. 
 
Respondent 2, site 17 
I do have diverticular disease, but have not had an attack lately. 
 
Most of the women who had difficulty answering question 15 explained that this 
was due to a long history of constipation. For example, ‘I take fibre gel most 
nights. Constipation is something I have suffered with for 40 years’ (Respondent, 
site 2). Women who had difficulty responding to the leg pain question explained 
this was due to varicose veins, arthritis or injury. For example, ‘I decided not to 
answer this question as I have pain in my left leg, on a regular basis, due to a  
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broken ankle three and a half years ago. I felt that this would be irrelevant or 
misleading to the survey‟ (Respondent, site 11). 
From the list of 32 symptoms only one woman found two questions (abnormal 
vaginal  bleeding  and  abnormal  vaginal  discharge)  upsetting.  This  participant 
wrote, ‘Could be re-phrased “have you had any vaginal bleeding” and “have you 
had vaginal discharge”, then list why these might be occurring‟. This response 
suggests that the respondent was not particularly upset by these questions. 
With the exception of pain during or after sexual intercourse (q32), few women 
reported  that  any  symptom  was  irrelevant.  The  13  women  who  found  q32 
irrelevant wrote that this was because they were not sexually active. For example, 
‘Not sexually active as I am a widow’ (Respondent, site 5), and „My husband and 
I are not sexually active any longer’ (Respondent, site 13). 
Two women ticked that they were they were upset by q34, the co-morbidities 
section of the questionnaire. However their responses indicated that they were not 
particularly upset by the question. For example, the first woman wrote, ‘Very glad 
to say I haven‟t had any health problems that needed treatment’ (Respondent, site 
3) and the second, ‘I have not been diagnosed with any of the symptoms stated’ 
(Respondent, site 9). Eight women had difficulty answering the co-morbidities 
section (Table 4.31). Women explained that they had difficulties fitting what they 
had  been  told  by  their  doctor  to  a  diagnosis  listed  in  the  questionnaire.  For 
example, ‘Have had both hips replaced (no other arthritis) should I have ticked 
the arthritis box? If so, please do so on my behalf’ (Respondent, site 3) and ‘I 
have never been told I have heart failure but had a triple by-pass in May 2000’ 
(Respondent, site 9).  
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Table 4.31.  Difficulties answering other parts of the questionnaire, number of 
women 
Questionnaire item 
Difficulty  Upsetting  Irrelevant 
n  n  n 
Q34 Co-morbidities  8  0  2 
Q35 Taking HRT  1  0  2 
Q36 Feeling down, depressed or hopeless  6  2  1 
Q37 Little interest or pleasure doing things  5  3  1 
 
Two of the three women who ticked that they found q37 (little interest or pleasure 
doing things) upsetting also ticked that they found q36 upsetting (feeling down, 
depressed or hopeless). These women found the questions upsetting due to recent 
bereavement and a history of depression. ‘I just felt very sad as a much beloved 
dog had to be put to sleep’ (Respondent, Site 5). ‘I have lost my husband this year 
and am still at the tearful stage’ (Site 6) and ‘I am a very up and down person, it 
seems  to  be  my  personality.  I  am  often  low  but  fight  to  keep  up.  Talking  or 
thinking about it upsets me’ (Site 14). 
4.6.3.2  Acceptance of the study among GPs 
None of the 1,325 GPs who were posted a study information letter raised concerns 
about  the  research  with  the  study  supervisor  or  myself.  The  details  of  14 
volunteers’  GPs  were  insufficient  to  post  a  letter  about  the  research.  One  GP 
telephoned  to  inform  the  UKCTOCS  team  that  a  patient  sent  the  OCSq  had 
recently been diagnosed with ovarian cancer. This patient was participating as a 
control in UKCTOCS and was diagnosed two months before the letter was sent to 
the GP. Confirmation of the diagnosis was not yet received by the coordinating 
centre. A total of 27 GPs returned study information letters with a note stating that 
the patient named in the letter was no longer registered at the practice.  
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4.6.3.3  Reliability of the questionnaire 
A total of 409 women (135 controls, 132 multimodal, 142 ultrasound) were sent 
two  questionnaires  for  reliability  analyses,  and  220  returned  at  least  one 
questionnaire  (53.7%  response  rate).  Of  these,  214  complied  with  the  retest 
exercise  by  completing  both  questionnaires.  Compliance  among  controls  was 
50.4%,  53.0%  among  women  in  the  multimodal  group  and  54.2%  in  the 
ultrasound group. 
Of the 170 women who wrote the date on both questionnaires, 128 completed 
questionnaire  B  two  days  after  questionnaire  A  (Table  4.32).  A  total  of  42 
participants  wrote  the  date on questionnaire  A  only. Table  4.33 lists the days 
between the date questionnaire A was completed, and the date both questionnaires 
were received back at the research centre for those respondents who failed to date 
questionnaire B. Two participants did not date either questionnaire: one woman’s 
questionnaires were received back at the coordinating centre within nine days of 
being posted out and the other woman’s questionnaires within 19 days. 
Table 4.32.  Days between questionnaire A and B 
Days between QA & QB  n 
2 days  128 
3 days  32 
4 days  6 
5 days  1 
7 days  1 
10 days  1 
13 days  1 
Total  170 
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Table 4.33.  Days between questionnaire A and received 
Days between QA & received  n 
4 days  6 
5 days  4 
6 days  3 
7 days  6 
8 days  5 
9 days  6 
10 days  4 
11 days  3 
13 days  2 
18 days  1 
26 days  1 
35 days  1 
Total  42 
 
Inclusion criteria for test-retest reliability analyses 
●  Where questionnaires A and B were both dated, all participants who 
completed questionnaire B within four days of questionnaire A were 
included 
●  Where there was no date on questionnaire B, those whose 
questionnaires were received back within 10 days of the date on 
questionnaire A were included 
●  Where neither questionnaire A or B were dated, those whose 
questionnaires were received back at the research coordinating centre 
within 14 days of being sent to the participant were included  
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Exclusion  of  questionnaires  not  eligible  for  reliability  analyses  resulted  in  a 
sample of 201 participants. 
Reliability of symptom severity assessments 
Sample sizes for the calculation of individual severity kappas ranged from 189 for 
short of breath (q23) and urgent need to pass urine (q19), to 198 for abdominal 
discomfort/pain  (q2)  and  increased  abdominal  size  (q9).  A  sample  of  74 
respondents was included in the calculation of the kappa for pain during/after 
sexual intercourse (q32). Kappa coefficients for test-retest reliability of severity 
items are listed in Table 4.34, Table 4.35 and Table 4.36. 
Quadratic kappas were lowest for abdominal pressure (q8) k = 0.63 and pelvic 
pressure (q12) k = 0.67. There was almost perfect agreement between test and 
retest  questionnaires  for  pain  during  or  after  sexual  intercourse  (k  =  0.97). 
Quadratic kappa 95% confidence intervals were widest for abdominal mass/lump 
(q10), abnormal vaginal bleeding (q30) and abnormal vaginal discharge (q31). 
Alternately, confidence intervals were tightest for excessive flatulence (q17), leg 
swelling  (q26),  pelvic  discomfort/pain  (q1),  heartburn  or  indigestion  (q3), 
difficulty emptying bowels (q15), backache/pain (q24) and leg ache/pain (q25).  
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Table 4.34.  Kappa coefficients for 4x4 severity data 
Questionnaire item  n 
Agreement 
unweighted 
% 
Unweighted k  95% CI 
Agreement 
quadratic 
weighted 
% 
Quadratic 
weighted 
k 
95% CI 
Q1 Lower abdominal or pelvic discomfort or pain  196  88.3  0.74  0.65-0.84  98.7  0.87  0.81-0.92 
Q2 Upper abdominal discomfort or pain  198  92.4  0.77  0.66-0.87  98.5  0.85  0.72-0.92 
Q3 Indigestion or heartburn  197  86.8  0.76  0.69-0.85  98.4  0.88  0.82-0.93 
Q4 Nausea or vomiting  196  92.4  0.65  0.49-0.81  99.0  0.80  0.63-.091 
Q5 Felt full quickly when eating  196  93.9  0.78  0.63-0.88  99.2  0.89  0.79-0.95 
Q6 Change in appetite  193  95.9  0.74  0.53-0.89  99.5  0.83  0.66-0.95 
Q7 Upper abdominal bloating or fullness  192  83.3  0.61  0.50-0.72  97.6  0.78  0.66-0.86 
Q8 Upper abdominal pressure  192  90.1  0.54  0.36-0.72  98.4  0.63  0.39-0.80 
Q9 Increased abdominal size  198  84.9  0.68  0.57-0.77  97.5  0.81  0.69-0.88 
Q11 Lower abdominal or pelvic bloating or 
fullness  193  87.6  0.67  0.54-0.78  98.5  0.87  0.78-0.92 
Q12 Lower abdominal or pelvic pressure  195  90.8  0.65  0.47-0.77  98.3  0.67  0.49-0.82  
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Questionnaire item  n 
Agreement 
unweighted 
% 
Unweighted k  95% CI 
Agreement 
quadratic 
weighted 
% 
Quadratic 
weighted 
k 
95% CI 
Q13 Lower abdominal or pelvic heaviness  193  89.6  0.61  0.46-0.75  98.2  0.75  0.55-0.87 
Q15 Difficulty emptying bowels  196  91.8  0.79  0.68-0.88  99.1  0.89  0.82-0.94 
Q16 Change in bowel habit  194  92.8  0.71  0.55-0.83  98.9  0.83  0.67-0.92 
Q17 Excessive wind or flatulence  195  86.2  0.76  0.68-0.84  98.5  0.89  0.84-0.93 
Q18 Passed urine frequently  191  83.3  0.71  0.61-0.79  96.8  0.82  0.71-0.89 
Q19 Urgent need to pass urine  189  87.8  0.79  0.70-0.86  98.0  0.90  0.82-0.95 
Q20 Pressure on bladder  192  92.2  0.71  0.57-0.83  98.0  0.78  0.59-0.91 
Q21 Difficulty emptying bladder  191  99.0  0.92  0.76-1.00  99.7  0.90  0.61-1.00 
Q23 Short of breath  189  94.7  0.72  0.55-0.86  99.1  0.79  0.60-0.92 
Q24 Back ache or pain  195  83.6  0.72  0.63-0.81  97.5  0.86  0.80-0.91 
Q25 Leg ache or pain  194  87.1  0.75  0.65-0.84  98.4  0.89  0.82-0.93 
Q26 Leg swelling  195  96.4  0.86  0.73-0.95  99.6  0.94  0.88-0.98  
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Questionnaire item  n 
Agreement 
unweighted 
% 
Unweighted k  95% CI 
Agreement 
quadratic 
weighted 
% 
Quadratic 
weighted 
k 
95% CI 
Q27 Tiredness, fatigue or lack of energy  194  79.9  0.70  0.62-0.79  97.1  0.85  0.78-0.90 
Q28 Weight gain without trying  195  91.3  0.81  0.73-0.88  98.7  0.90  0.82-0.95 
Q31 Abnormal vaginal discharge  193  98.4  0.87  0.69-1.00  99.4  0.74  0.43-1.00 
 
Table 4.35.  Kappa coefficients for 3x3 severity data 
Questionnaire item  n  Agreementun
weighted %  Unweighted k  95% CI 
Agreement 
quadratic 
weighted  
% 
Quadratic 
weighted  
k 
95% CI 
Q10 Able to feel abdominal mass or lump  193  98.5  0.57  0.25-1.00  99.6  0.77  0.00-0.89 
Q14 Pain before, during or after opening bowels  193  90.7  0.74  0.63-0.85  97.7  0.85  0.77-0.91 
Q29 Weight loss without trying  192  99.0  0.90  0.66-1.00  99.4  0.85  0.51-1.00 
Q32 Pain during or after sexual intercourse  74  98.7  0.95  0.81-1.00  99.7  0.97  0.84-1.00 
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Table 4.36.  Kappa coefficients for binary severity data 
Questionnaire item  n  % Agreement  Unweighted k  95% CI 
Q22 Pain when passing urine  192  99.5  0.91  0.72-1.00 
Q30 Abnormal vaginal bleeding  191  99.0  0.66  0.22-1.00 
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Reliability of symptom frequency assessments 
The reliability of frequency, duration and GP data was considered secondary to 
the need for the questionnaire to collect reliable severity data. This was because 
the  severity  section,  most  importantly,  collected  data  on  the  prevalence  of 
symptoms. Women were instructed to only complete the frequency, duration and 
GP consultation components if they experienced the symptom, thus several items 
had small numbers of test-rest questionnaires included in analyses. 
Kappa coefficients for frequency items are listed in Table 4.37 and Table 4.38. 
Frequency data was not collected for three items: abdominal mass/lump (q10), 
weight  gain  (q28)  and  weight  loss  (q29),  as  these  symptoms  generally  have 
temporal stability over a one-week reference period. There was insufficient data to 
calculate kappas for pain when passing urine (q22) and abnormal vaginal bleeding 
(q30). 
Quadratic weighted kappa coefficients ranged from k = 0.62 to k = 0.94. However, 
kappa calculations for difficulty emptying the bladder (q21), abnormal vaginal 
discharge  (q31)  and  pain  during/after  sexual  intercourse  (q32)  should  be 
interpreted  with  caution  due  to  the  small  number  of  test-retest  questionnaires 
included in analyses. Items with substantial numbers of test-retest questionnaires 
and the highest kappas for frequency reliability were urinary frequency (q18) k = 
0.87, pelvic bloating/fullness (q11) k = 0.85, pelvic discomfort/pain (q2) k = 0.84 
and urinary urgency (q19) k = 0.83. 
Reliability of symptom duration assessments 
Kappa coefficients for test-retest reliability of symptom duration items are listed 
in  Table  4.39  and  Table  4.40.  There  was  insufficient  data  to  calculate  kappa 
coefficients  for  six  items:  abdominal  mass/lump  (q10),  difficulty  emptying 
bladder (q21), pain when passing urine (q22), weight loss without trying (q29), 
abnormal vaginal bleeding (q30) and abnormal vaginal discharge (q31). Quadratic 
kappas for all other symptom durations were k ≥ 0.65. Items with the highest 
reliability scores for duration, and the largest number of test-retest questionnaires 
included in analysis, were abdominal bloating/fullness (q7) k = 0.95 and pelvic 
bloating/fullness (q11) ) k = 0.94.  
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Reliability of GP symptom reporting assessments 
Table 4.41 lists kappa coefficients for test-retest reliability of the GP consultations 
component of the questionnaire. There was insufficient data to calculate kappas 
for four items: change in appetite (q6), abdominal mass/lump (q10), pain when 
passing urine (q22) and abnormal vaginal bleeding (q30). Five GP consultation 
items had perfect test-retest agreement. However, four of these were calculated 
from fewer than 20 women. One item, increased abdominal size (q9), included 47 
women and had perfect agreement k = 1.00. The item with the lowest reliability 
for GP consultation was difficulty emptying bladder (q21) k = 0.62, although only 
10 women were included in the calculation. 
Reliability of depression screening questions 
Question  36,  which  asked  women  if  they  were  bothered  by  feeling  down, 
depressed or hopeless during the past month had excellent test-retest agreement, k 
= 0.91 (95% CI 0.84-0.98), as did q37, which asked women if they were bothered 
by little interest or pleasure doing things during the past month k = 0.89 (95% CI 
0.81-0.96).  
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Table 4.37.  Kappa coefficients for 3x3 frequency data 
Questionnaire item  n 
Agreement 
unweighted 
% 
Unweighted k  95% CI 
Agreement 
quadratic 
weighted  
% 
Quadratic 
weighted  
k 
95% CI 
Q1 Lower abdominal or pelvic discomfort or pain  44  75.0  0.60  0.37-0.80  92.1  0.77  0.57-0.90 
Q2 Upper abdominal discomfort or pain  29  86.2  0.77  0.54-1.00  94.0  0.84  0.59-0.98 
Q3 Indigestion or heartburn  63  68.3  0.45  0.23-0.63  92.1  0.68  0.52-0.80 
Q4 Nausea or vomiting  18  66.7  0.39  -0.01-0.78  91.7  0.60  0.13-0.91 
Q5 Felt full quickly when eating  24  79.2  0.69  0.46-0.91  94.8  0.85  0.66-0.97 
Q6 Change in appetite  37  76.9  0.65  0.03-1.00  94.2  0.79  0.40-1.00 
Q7 Upper abdominal bloating or fullness  37  83.8  0.75  0.55-0.91  93.9  0.82  0.61-0.95 
Q8 Upper abdominal pressure  14  71.4  0.59  0.29-1.00  92.9  0.78  0.50-1.00 
Q9 Increased abdominal size  41  73.2  0.60  0.38-0.79  93.3  0.81  0.69-0.91 
Q10 Able to feel abdominal mass or lump  n/a*             
Q11 Lower abdominal or pelvic bloating or fullness  32  84.4  0.74  0.53-0.92  93.8  0.85  0.63-0.97  
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Questionnaire item  n 
Agreement 
unweighted 
% 
Unweighted k  95% CI 
Agreement 
quadratic 
weighted  
% 
Quadratic 
weighted  
k 
95% CI 
Q12 Lower abdominal or pelvic pressure  18  83.3  0.71  0.41-1.00  95.8  0.91  0.78-1.00 
Q13 Lower abdominal or pelvic heaviness  21  85.7  0.76  0.47-1.00  96.4  0.91  0.77-1.00 
Q14 Pain before, during or after opening bowels  31  67.7  0.43  0.19-0.72  91.9  0.66  0.40-0.84 
Q15 Difficulty emptying bowels  34  67.7  0.49  0.21-0.74  89.7  0.65  0.33-0.84 
Q16 Change in bowel habit  17  76.5  0.61  0.25-1.00  89.7  0.72  0.18-0.96 
Q17 Excessive wind or flatulence  64  73.4  0.58  0.40-0.74  89.8  0.65  0.44-0.83 
Q18 Passed urine frequently  56  87.5  0.80  0.66-0.93  95.5  0.87  0.74-0.96 
Q19 Urgent need to pass urine  54  79.6  0.69  0.50-0.84  93.5  0.83  0.68-0.93 
Q20 Pressure on bladder  18  77.8  0.65  0.32-1.00  94.4  0.81  0.62-0.96 
Q21 Difficulty emptying bladder  9  77.8  0.66  0.18-1.00  94.4  0.86  0.55-1.00 
Q22 Pain when passing urine  n/a
†             
Q23 Short of breath  14  85.7  0.77  0.43-1.00  96.4  0.92  0.76-1.00  
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Questionnaire item  n 
Agreement 
unweighted 
% 
Unweighted k  95% CI 
Agreement 
quadratic 
weighted  
% 
Quadratic 
weighted  
k 
95% CI 
Q24 Back ache or pain  61  78.7  0.69  0.54-0.82  93.4  0.80  0.65-0.90 
Q25 Leg ache or pain  46  71.7  0.58  0.39-0.75  91.3  0.73  0.53-0.87 
Q26 Leg swelling  19  79.0  0.68  0.43-0.91  94.7  0.85  0.67-0.97 
Q27 Tiredness, fatigue or lack of energy  84  71.4  0.57  0.43-0.71  92.9  0.80  0.72-0.87 
Q28 Weight gain without trying  n/a*             
Q29 Weight loss without trying  n/a*             
Q31 Abnormal vaginal discharge  10  90.0  0.84  0.46-1.00  97.5  0.94  0.74-1.00 
 
* Frequency data not collected 
† Insufficient data, kappa calculation not possible 
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Table 4.38.  Kappa coefficients for binary frequency data 
Questionnaire item  n  % Agreement  Unweighted k  95% CI 
Q30 Abnormal vaginal bleeding  n/a
†       
Q32 Pain during or after sexual intercourse  10  90.0  0.62  -0.05-1.00 
 
† Insufficient data, kappa calculation not possible  
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Table 4.39.  Kappa coefficients for 4x4 duration data 
Questionnaire item  n 
Agreement 
unweighted 
% 
Unweighted k  95% CI 
Agreement 
quadratic 
weighted  
% 
Quadratic 
weighted  
k 
95% CI 
Q1 Lower abdominal or pelvic discomfort or pain  43  90.7  0.86  0.72-0.97  96.1  0.89  0.68-0.99 
Q2 Upper abdominal discomfort or pain  29  89.7  0.84  0.65-1.00  95.8  0.86  0.55-1.00 
Q3 Indigestion or heartburn  57  84.2  0.74  0.55-0.89  97.1  0.92  0.81-0.97 
Q4 Nausea or vomiting  14  92.9  0.90  0.64-1.00  92.9  0.73  0.10-1.00 
Q5 Felt full quickly when eating  22  77.3  0.69  0.44-0.93  89.4  0.66  0.24-0.98 
Q6 Change in appetite  10  80.0  0.72  0.34-1.00  88.9  0.65  0.05-1.00 
Q7 Upper abdominal bloating or fullness  35  88.6  0.83  0.63-0.96  98.7  0.95  0.86-0.99 
Q8 Upper abdominal pressure  13  76.9  0.63  0.18-1.00  97.4  0.92  0.75-1.00 
Q9 Increased abdominal size  43  83.7  0.77  0.60-0.91  94.1  0.81  0.54-0.97 
Q10 Able to feel abdominal mass or lump  n/a
†             
Q11 Lower abdominal or pelvic bloating or fullness  31  83.9  0.77  0.55-0.93  98.2  0.94  0.88-0.99  
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Questionnaire item  n 
Agreement 
unweighted 
% 
Unweighted k  95% CI 
Agreement 
quadratic 
weighted  
% 
Quadratic 
weighted  
k 
95% CI 
Q12 Lower abdominal or pelvic pressure  19  89.5  0.85  0.61-1.00  98.8  0.97  0.89-1.00 
Q13 Lower abdominal or pelvic heaviness  20  85.0  0.79  0.54-1.00  98.3  0.96  0.88-1.00 
Q14 Pain before, during or after opening bowels  29  79.3  0.70  0.48-0.90  96.6  0.89  0.76-0.97 
Q15 Difficulty emptying bowels  30  80.0  0.67  0.45-0.89  96.7  0.90  0.72-0.97 
Q16 Change in bowel habit  17  64.7  0.48  0.19-0.82  94.1  0.77  0.34-0.93 
Q17 Excessive wind or flatulence  54  92.6  0.89  0.76-0.97  97.5  0.92  0.75-0.99 
Q18 Passed urine frequently  55  92.7  0.88  0.72-0.97  97.6  0.91  0.71-0.99 
Q19 Urgent need to pass urine  55  90.9  0.84  0.68-0.96  97.2  0.87  0.69-0.98 
Q20 Pressure on bladder  19  89.5  0.86  0.61-1.00  98.9  0.95  0.85-1.00 
Q21 Difficulty emptying bladder  n/a
†             
Q22 Pain when passing urine  n/a
†             
Q23 Short of breath  14  71.4  0.59  0.22-0.90  90.5  0.74  0.29-0.98  
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Questionnaire item  n 
Agreement 
unweighted 
% 
Unweighted k  95% CI 
Agreement 
quadratic 
weighted  
% 
Quadratic 
weighted  
k 
95% CI 
Q24 Back ache or pain  63  85.7  0.77  0.62-0.90  94.5  0.84  0.68-0.96 
Q25 Leg ache or pain  42  88.1  0.81  0.64-0.95  97.9  0.93  0.84-0.99 
Q26 Leg swelling  20  90.0  0.85  0.63-1.00  94.4  0.83  0.45-1.00 
Q27 Tiredness, fatigue or lack of energy  82  78.1  0.69  0.56-0.81  94.2  0.81  0.65-0.92 
Q28 Weight gain without trying  50  80.0  0.69  0.49-0.86  97.8  0.89  0.80-0.95 
Q29 Weight loss without trying  n/a
†             
Q30 Abnormal vaginal bleeding  n/a
†             
Q31 Abnormal vaginal discharge  n/a
†             
 
† Insufficient data, kappa calculation not possible 
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Table 4.40.  Kappa coefficients for 3x3 duration data 
Questionnaire item  n 
Agreement 
unweighted 
% 
Agreement 
unweighted 
% 
95% CI 
Agreement 
quadratic 
weighted  
% 
Quadratic 
weighted  
k 
95% CI 
Q32 Pain during or after sexual intercourse  10  90.0  0.80  0.0-1.00  97.5  0.89  0.00-1.00 
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Table 4.41.  Kappa coefficients for binary GP symptom reporting data 
Questionnaire item  n  % Agreement  Unweighted k  95% CI 
Q1 Lower abdominal or pelvic discomfort or pain  47  91.5  0.73  0.48-0.97 
Q2 Upper abdominal discomfort or pain  29  82.8  0.65  0.39-0.91 
Q3 Indigestion or heartburn  62  96.8  0.91  0.78-1.00 
Q4 Nausea or vomiting  18  88.9  0.77  0.48-1.00 
Q5 Felt full quickly when eating  23  95.7  0.78  0.36-1.00 
Q6 Change in appetite  n/a
†       
Q7 Upper abdominal bloating or fullness  36  94.4  0.84  0.62-1.00 
Q8 Upper abdominal pressure  14  100.0  1.00  1.00-1.00 
Q9 Increased abdominal size  47  100.0  1.00  1.00-1.00 
Q10 Able to feel abdominal mass or lump  n/a
†       
Q11 Lower abdominal or pelvic bloating or fullness  31  96.8  0.90  0.72-1.00 
Q12 Lower abdominal or pelvic pressure  19  100.0  1.00  1.00-1.00 
Q13 Lower abdominal or pelvic heaviness  20  100.0  1.00  1.00-.100  
 
201
 
Questionnaire item  n  % Agreement  Unweighted k  95% CI 
Q14 Pain before, during or after opening bowels  31  93.6  0.79  0.52-1.00 
Q15 Difficulty emptying bowels  36  94.4  0.80  0.54-1.00 
Q16 Change in bowel habit  16  87.5  0.75  0.44-1.00 
Q17 Excessive wind or flatulence  63  96.8  0.73  0.38-1.00 
Q18 Passed urine frequently  61  96.7  0.86  0.66-1.00 
Q19 Urgent need to pass urine  60  96.7  0.88  0.72-1.00 
Q20 Pressure on bladder  18  100.0  1.00  1.00-1.00 
Q21 Difficulty emptying bladder  10  90.0  0.62  -0.05-1.00 
Q22 Pain when passing urine  n/a
†       
Q23 Short of breath  15  86.7  0.71  0.34-1.00 
Q24 Back ache or pain  69  94.2  0.87  0.75-0.99 
Q25 Leg ache or pain  46  97.8  0.95  0.86-1.00 
Q26 Leg swelling  21  90.5  0.81  0.56-1.00  
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Questionnaire item  n  % Agreement  Unweighted k  95% CI 
Q27 Tiredness, fatigue or lack of energy  87  94.3  0.85  0.72-0.98 
Q28 Weight gain without trying  50  92.0  0.75  0.52-0.98 
Q29 Weight loss without trying  9  88.9  0.73  0.24-1.00 
Q30 Abnormal vaginal bleeding  n/a
†       
Q31 Abnormal vaginal discharge  9  100.0  1.00  1.00-1.00 
Q32 Pain during or after sexual intercourse  11  100.0  1.00  1.00-1.00 
 
† Insufficient data, kappa calculation not possible  
203 
4.6.4  Formatting the finalised questionnaire 
A fourth consensus group meeting was held on 2 October 2008 to agree content 
for the finalised OCSq. Pilot findings up to this date were presented to the group, 
including missing data, correlations between symptoms, retest reliability kappa 
coefficients and feedback from respondents relating to specific questions. 
The group decided to continue with the ‘past week’ timeframe for all questions, 
except weight loss and weight gain. For these two items it was agreed to ask 
women about the ‘past year’. It was also agreed to add the wording ‘during the 
past week’ or ‘during the past year’ to all individual questions rather than just 
have this information at the top of each page. 
To improve readability, it was decided to change the direction of the text in the 
severity column (e.g. not at all, a little, quite a bit and very much) to a horizontal 
direction  and  change  ‘not  at  all’  to  ‘no’.  The  group  decided  to  revise  the 
questionnaire  so  that  it  appeared  less  cluttered,  removing  the  arrows  and  the 
numbers under the boxes for not at all, a little, etc. It was agreed to experiment 
with shading the columns and to seek feedback on the questionnaire’s readability 
prior to final formatting. 
No questions were removed on the basis of correlation with another question. The 
group agreed that removal of any symptom with a correlation coefficient of less 
than rs = 0.90 with another symptom would potentially result in information being 
missed  by  the  finalised  questionnaire.  As  all  kappa  correlations  indicated 
moderate or higher reliability, no symptoms were deleted on the basis of poor 
reliability. 
The group noted that women were confused by the ordering of shortness of breath 
(q23) on the same page, and directly after, the five urinary symptoms (q18-q22). 
Several women wrote comments similar to the following on their feedback forms: 
‘I  get  short  of  breath  but  not  when  I  pass  urine’  (Respondent,  Site  3)  and 
‘Shortness  of  breath  is  not  something  I  associate  with  passing  urine,  and  its 
position in the questionnaire seemed to refer to urination. Was it included as a 
joke  perhaps?’  (Respondent,  Site  6).  The  group  therefore  decided  to  reorder  
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shortness breath, placing it before the urinary symptoms. The order of all other 
questions remained unchanged. 
The group noted that only 15 out of 829 women (2%) wrote more than one ‘other’ 
symptom in the space provided. The symptoms reported by these women were dry 
skin, headache, sore throat and other symptoms not specific to ovarian cancer. It 
was decided to remove the space where respondents could write second and third 
‘other’ symptoms in order to reduce the length of the questionnaire. 
The group decided to add diverticulitis to the co-morbidities section as several 
women wrote similar comments to, ‘I‟m not sure if diverticulitis is classed as 
inflammatory bowel disease‟ (Respondent, Site 13). It was also agreed to add a 
section  to  the  questionnaire  where  participants  can  write  relevant  information 
about their symptoms. 
The  finalised  OCSq  was  formatted  according  to  the  decisions  of  the  fourth 
consensus group. Several weeks after the meeting, a questionnaire was received 
from a participant who commented that she specifically remembered the date of 
onset of a symptom as it started whilst she was on holiday. The duration of the 
symptom was 6.5 months, which made it difficult for the respondent to decide 
whether to tick 4-6 months or 7-12 months, so both durations were ticked. After 
receiving  this  feedback  it  was  decided  to  change  the  duration  options  to:  <3 
months, 3-6 months, 6-12 months and >12 months. This improved the consistency 
of the symptom duration assessment as the pilot OCSq covered durations of 3.5 
months (e.g. <3 months and 3-6 months) but not 6.5 months. 
Four  drafts  with  different  shading  schemes  were  presented  to  a  convenience 
sample of 14 women aged over 50 years. These women were asked to select the 
questionnaire they found most visually appealing and easiest to read. A majority 
(six of the 14 women) preferred shading format B (appendix 21), thus this was 
adopted for the finalised OCSq (appendix 22). 
By the conclusion of stage IV the draft OCSq had been piloted with 829 women, 
validity  analyses  confirmed  the  questionnaire  was  acceptable  to  women  and 
reliability analyses demonstrated its stability over time. The finalised OCSq was  
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formatted  and  planning  commenced  for  the  prospective  research  described  in 
Chapter Six. 
4.7  Discussion 
The process of developing a valid and reliable questionnaire for any research topic 
is resource and time intensive. The absence of a previously validated and readily 
available  ovarian  cancer  symptoms  questionnaire  necessitated  the  research 
described in this chapter. Unfortunately, it is not possible to compare the findings 
of my own research with the two earlier studies which described the use of a 
validated questionnaire,
7 70 as they did not publish findings of their validation, or 
provide details when requested. 
Face and content validation was conducted throughout the development process. 
Each  component  of  this  process  was  guided  by  input  from  experts,  including 
women living with ovarian cancer, nurses who provide care to ovarian cancer 
patients, gynaecological oncology surgeons, questionnaire design specialists and 
UKCTOCS  volunteers.  Generation  of  the  symptoms  list  from  ovarian  cancer 
symptoms papers ensured that its contents were relevant to the intended topic. 
Consensus group review and feedback from health professionals and women with 
ovarian cancer further validated the content of the symptoms list. 
The OCSq layout was based upon a combination of the formatting used by Vine et 
al.
16  and  Goff  et  al.
18  23  for  their  respective  questionnaires.  The  questionnaire 
review in stage II identified these previously developed questionnaires as having 
as the most visually-appealing, user-friendly formats. Wider research has shown 
that user-friendly formats and the exclusion of difficult or objectionable items 
increase response rates.
199 To reduce ‘question threat’,
129 more intimate questions 
about  symptoms  of  vaginal discharge, vaginal  bleeding  and sexual intercourse 
were placed towards the end of the questionnaire, and an instruction was included 
for women to respond to the question about painful sexual intercourse only if they 
had been sexually active in the past week. 
Further content validation was achieved through the analysis of completed pilot 
questionnaires  and  feedback  forms.  This  found  less  than  10%  of  respondents  
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missed any question on the OCSq, indicating a reasonable degree of acceptability. 
Fayers  &  Machin
169  suggest  questions  with  3-4%  missing  data  should  be  re-
examined with a view to rewording. However, this proportion of missing data 
relates to questionnaires completed in the presence of the researcher. It is to be 
expected that the proportion of missing data for each question will be higher for 
postal questionnaires. Piloting of the OCSq found a maximum of 15 women had 
difficulty replying to any question. The consensus group discussed this finding but 
decided against re-wording questions due to the due to the fact that women did not 
have trouble understanding wording. Rather, their difficulty was associated with 
their indecision whether to respond positively to questions for symptoms which 
they had experienced for many years. 
No symptoms were excluded on the basis of correlation with another item, as the 
highest Spearman coefficient was rs = 0.64. All 32 symptoms in the draft OCSq 
therefore  remained  in  the  finalised  OCSq.  This  number  of  symptoms  is 
considerably more than the next largest checklists reported in the literature, such 
as  the  questionnaire  used  by  Goff  et  al.
23  which  included  23  symptoms  and 
Igoe’s
7  questionnaire  which  included  21.  However,  the  consensus  group 
considered  it  important  to  include  as  comprehensive  a  list  as  possible  in  the 
finalised  OCSq,  as  asking  about  specific  symptoms  elicits  reporting  through 
memory-cueing effects.
129 141 A comprehensive list of symptoms is also important 
as it provides a common frame of reference for all respondents. This reduces the 
arbitrariness  of  symptom  recall  associated  with  questionnaires  which  elicit 
information  using  open  questions.  As  discussed  in  chapter  three,  this  was  the 
principal flaw of the Ovacome Patient Survey. 
Construct validation was not appropriate as all women who participated in the 
questionnaire  pilot  were  apparently  healthy  at  the  time.  Construct  validation 
would only be appropriate when sufficient numbers of women who complete the 
OCSq are diagnosed with ovarian cancer. 
Factor analysis was not appropriate in the development of the OCSq as it is not a 
psychometric tool. Moreover, as the women recruited for the pilot did not yet 
have the outcome of interest (ovarian cancer), it would be impossible to determine  
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underlying symptom factors associated with ovarian cancer. Criterion validation 
was also not attempted as there is no gold standard ovarian cancer symptoms 
measure. 
Likert scales for symptom severity ranged from not at all to very much. This four-
point  scale  is  the  same  as  the  Likert  scales  used  in  EORTC  Quality  of  Life 
questionnaires. This is less than the 5-7 or 7-10 response categories described in 
the  literature  as  having  the  greatest  accuracy.
129-130  Rather  than  increase  the 
number of response categories the consensus group decided to adhere to EORTC 
questionnaire formatting for the measurement of symptom severity. Consensus 
group members noted that the four-category scale has been well-validated among 
cancers patients in several different countries.
178 181 185 200-204 Moreover, the wider 
questionnaire design literature is largely based upon psychological studies where 
nuanced information elicited by 7-10 point scales may be more relevant than in a 
symptoms study. 
The consensus group also discussed whether the symptom frequency column (e.g. 
1-2 days, 3-5 days, 6-7 days) should be broken down into seven categories for the 
seven  days  of  the  week.  It  was  debated  whether  to  increase  the  number  of 
response  categories  for  symptom  duration  into  shorter  timeframes  (e.g.  one 
month, two to three months, three to four months, etc.), or expand these to include 
durations of longer than 12 months. However, the group decided that this would 
not necessarily increase the accuracy of the data given the study population (i.e. 
women aged 50 to 80 years). Also, increased response options may create greater 
confusion  among  respondents.  It  was  therefore  decided  to  limit  the  symptom 
severity to four categories, frequency to three categories and duration to four. 
The reference period selected for assessment of symptom prevalence/severity and 
frequency  was  one  week.  This  timeframe  was  selected  after  reviewing  the 
literature on ovarian cancer symptoms, questionnaire design and the measurement 
of symptoms in diverse patient populations. The literature review in Chapter Two 
revealed the persistent nature of ovarian cancer symptoms and a recent paper by 
the Goff group demonstrated the temporal stability of key symptoms over several 
months.
26 Thus, a one-week reference period was considered sufficient to capture  
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information  on  symptom  prevalence.  A  one-week,  rather  than  one-month, 
reference  period  was  selected  as  it  is  less  susceptible  to  exponential  memory 
decay.
129  147  151  Evidence  indicates  one  to  two-week  periods  have  similar 
reliability to daily symptom diaries,
131 149 162 while one-month recall can be half as 
accurate  as  daily  reports  for  symptoms  such  as  tiredness,  indigestion  or  back 
pain.
160 The consensus group also considered that women would not be able to 
accurately  remember  detailed  information  on  symptom  severity  and  frequency 
over a one-month period. While research suggests that severe symptoms are often 
remembered  in  the  medium  to  long-term,  minor  symptoms  are  likely  to  be 
forgotten after short lapses of time.
132 205-206 Restricting the reference period to one 
week had the additional advantage of limiting telescoping, which refers to the 
tendency for patients to misplace symptom events in time.
129 133  
A daily symptoms diary was rejected as they present a considerable burden to 
research participants. Studies have also found conditioning effects associated with 
symptom diaries, where participants tend to under-report symptoms they associate 
with  long-term  disease.
149  Other  disadvantages  of  symptom  diaries  include 
reporting-fatigue  and  higher  rates  of  attrition  compared  to  one-off 
questionnaires.
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Our  aim  to  recruit  a  sufficiently  large  sample  of  participants  for  reliability 
analyses  was  balanced  by  a  consideration  to  limit  participant  burden.  After 
exclusion of ineligible questionnaires, test-retest validation was conducted using 
data from a sample of 201 respondents. Streiner & Norman
130 demonstrated that a 
sample of 200 participants yields a 95% confidence interval with a width of 0.15 
for reliability coefficients. Confidence intervals for kappa coefficients could have 
been narrower had the response rate been higher than 53% among women invited 
to  complete  a  retest  questionnaire.  However,  it  would  have  been  difficult  to 
improve this given the fact that the questionnaire was conducted via post, and that 
at  seven  pages  in length, it  was fairly onerous for  women to  complete  twice. 
Furthermore,  our  sample  size  of  201  is  greater  than  the  194  women  who 
participated  in  test-retest  validation  of  an  EORTC  questionnaire  for  assessing 
quality of life in ovarian cancer patients (QLQ-OV28
185) and approximately four 
times  the  number  of  subjects  included  in  reliability  analyses  of  the  Women’s  
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Health Questionnaire (WHQ) and a questionnaire designed to assess bowel and 
lower urinary tract symptoms.
208-209 
Test-retest reliability analyses produced an overall median quadratic weighted (or 
unweighted where quadratic weighting was not possible for binary data) kappa of 
k = 0.85 (range 0.60-1.00) for the questionnaire as a whole, indicating excellent 
stability over time. The median quadratic weighted kappa for symptom severity 
was k = 0.85 (range 0.63-0.97) and the median for symptom frequency was k = 
0.81 (range 0.60-0.94), while symptom duration had a median of k = 0.89 (range 
0.65-0.97). Kappa scores for the reliability of GP consultation data ranged from 
0.62-1.00 with a median of k = 0.85. Only one item, frequency of nausea and 
vomiting (q4) (k = 0.60), had a kappa just under the minimum score of k = 0.61 
described by Landis & Koch
198 as indicative of substantial agreement. 
The very high percentage agreement and substantially lower kappa scores of some 
questionnaire items (e.g. severity of abdominal pressure (q8) k = 0.63) are an 
example of the  ‘paradox of kappa’.
210 This arises  when  the prevalence of the 
outcome being measured is either very high or very low, resulting in an imbalance 
in the marginal or horizontal totals of a 2 x 2 table. Over 81% of women replied 
‘not at all’ to the severity section of abdominal pressure (Q8) on their test-retest 
questionnaires. Prevalence of ‘a little’, ‘quite a bit’ or ‘very much’ responses was 
very low, which produced an imbalance in the table for this item. This was also 
the case for a number of frequency, duration and GP consultation items. 
Several frequency, duration and GP consultation items had small numbers of test-
retest  questionnaires included in kappa  calculations  and some (e.g.  pain when 
passing urine (q22) had too few questionnaires to enable calculation. Items with 
both small numbers of test-retest questionnaires and imbalanced 2 x 2 tables had 
wide 95% confidence intervals. Small numbers for frequency, duration and GP 
consultation items are to be expected as women were instructed to complete these 
sections only if they experienced the symptom during the past week. The primary 
purpose  of  reliability  analyses  was  assessment  of  the  stability  of  symptom 
wording and prevalence measures (i.e. the severity component). From the outset 
we appreciated that we would not have the time or resources to collect sufficient  
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test-retest  data  to  validate  the  stability  of  all  frequency,  duration  and  GP 
consultation components of the questionnaire. 
Quadratic  kappa  coefficients  were  considerably  higher  than  the  minimum 
coefficient of 0.5 described  by Streiner  & Norman
130 as acceptable for health 
measures, although they are in a similar range to that reported for the Women’s 
Health Questionnaire.
208 It is plausible that high kappa coefficients resulted from 
some women directly copying information from questionnaire A to questionnaire 
B. However, we tried to avoid this by including an instruction in the cover letter 
specifically  requesting  women not to simply  copy  information from their first 
questionnaire. 
During the first consensus group it was agreed to remove depression from the 
symptoms list, but to add two short depression screening questions which have 
been validated and are recommended by NICE for use in primary care settings.
193 
In  the  interest  of  brevity,  the  group  decided  against  the  use  of  a  separate 
depression screening tool such as the Short Form 36, Beck Depression Inventory 
or the General Health Questionnaire (GHQ-12). 
The two depression screening questions included in the questionnaire were: 1) 
During the past month have you often been bothered by feeling down, depressed 
or hopeless? and 2) During the past month have you often been bothered by little 
interest or pleasure doing things? These questions were originally developed by 
Spitzer et al.
211 as part of the PRIME-MD tool, designed to screen for mental 
health disorders in primary care populations. Research has shown that these two 
questions have a sensitivities ranging from 68-96% and specificities of 57-84% 
for  identifying  depression  in  hospital  out-patients,  primary  and  palliative  care 
populations and pregnant women.
212-217 A recent meta-analysis concluded that a 
positive response on one of the two questions identifies eight out of 10 cases of 
depression.
218  These  questions  were  included  in  the  questionnaire  as  they  are 
short, easily comprehended by research participants and recommended to screen 
for depression in primary care.   
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Study strengths 
Strengths of the research include feedback from experts in each sequential stage 
of the questionnaire’s development and recruitment of a large sample of women 
for the OCSq pilot. The review of existing questionnaires also helped to identify 
examples of good questionnaire design for inclusion in the OCSq. 
Study limitations 
Unfortunately, the study was limited by a moderate response rate (53%) among 
women  asked  to  complete  test  and  retest  questionnaires,  which  may  have 
introduced  an  element  of  selection  bias.  The  project  group  decided  against 
sending  women  a  reminder  letter  as  we  recognised  that  two  seven  page 
questionnaires represent a  burden to  women  and we  wished to maintain good 
relations with UKCTOCS volunteers. 
Selection  bias  is  also  likely  to  have  occurred  during  the  telephone  interview 
component. We were advised by consultants that two of the 38 women initially 
identified as candidates for telephone interviews were too ill to be approached for 
invitation. Perhaps a greater proportion of those who agreed to participate had 
symptoms  compared  to  other  women  diagnosed  with  ovarian  cancer  in 
UKCTOCS.  We  attempted  to  limit  recall  bias  in  the  telephone  interview 
component by inviting women who were diagnosed with ovarian cancer within 
the past three years. However, women who were diagnosed with late stage disease 
may have already died within this time-frame, resulting in further selection bias. 
4.8  Summary 
In this chapter I have described the sequential development of the OCSq, from 
generation of the initial ovarian cancer symptoms list, up to formatting of the 
finalised questionnaire. Although this process was time-consuming, it succeeded 
in developing a robust, valid and reliable questionnaire for use in the prospective 
study. Analyses of symptoms data collected during the OCSq pilot are presented 
in the next chapter. 
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Chapter Five – Symptoms Reported by Women Who 
Participated in the OCSq Pilot 
5.0  Introduction 
The literature review  in Chapter Two  described  the absence of  any  genuinely 
prospective ovarian cancer symptoms research. Three studies assessed symptoms 
prior to women undergoing surgery for possible ovarian lesions.
18 23 46 However, 
these studies collected symptoms information from patients who were aware of 
the  presence  of  a  serious  abnormality  and,  undoubtedly,  the  possibility  of 
malignancy. The research described in this chapter attempts to address this gap in 
existing knowledge by investigating symptoms in apparently healthy women, then 
correlating symptoms with results of ovarian cancer screening. 
The data presented in this chapter were collected during the course of piloting the 
OCSq.  The  methods  are  the  same  as  those  described  for  the  pilot  of  the 
provisional OCSq in Chapter Four. However, the aims and data analysis sections 
differ. The chapter  begins with the aims  of symptoms analyses. Data  analysis 
methods are documented and results are presented. Findings are reviewed in the 
discussion and compared to the literature on ovarian cancer symptoms. Strengths 
and limitations of the research are considered, then the final section of the chapter 
summarises the main findings. 
5.1  Aims 
●  To estimate the prevalence of ‘key symptoms’ in apparently healthy 
women participating in the pilot of the OCSq 
●  To correlate symptoms data with: 1) participation in screening, 2) 
abnormal results on ovarian cancer screening, 3) diagnosis of 
ovarian/fallopian tube cancer, 4) awareness of a possible ovarian 
lesion due to the need to have repeat tests following annual screen, 
and 5) depression screening status  
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●  To develop models based on symptoms to detect ovarian 
abnormalities and to establish the performance characteristics of the 
generated and previously published indices 
●  To generate a preliminary hypothesis of symptom reporting that will 
be tested in the final phase of the research 
5.2  Methods 
The methods of the OCSq pilot are fully described in Chapter Four. A summary 
of this information is provided below. Data cleaning and analysis methods unique 
to this chapter are also described. 
5.2.1  Setting 
The OCSq was piloted in the UKCTOCS cohort. To summarise, women invited to 
participate  were:  1)  UKCTOC  controls,  2)  women  receiving  screening  in  the 
multimodal or ultrasound groups of UKCTOCS. Women in the screening groups 
were  either:  1)  attending annual (Level  1) screening, or 2) recalled for repeat 
(Level 2) screening due to an abnormal finding on annual screen. 
5.2.1.1  Summary of UKCTOCS screening 
Chapter One details the design of UKCTOCS, including screening algorithms for 
the multimodal and ultrasound groups. A summary of this information is given 
below. 
Multimodal group 
Women in the multimodal group receive an annual CA125 blood test and a risk of 
ovarian cancer (ROC) score is calculated (Chapter One, Figure 1.3). The ROC 
score  is  then  classified  as  either:  1)  normal,  2)  intermediate  or  3)  elevated 
(>0.2578%). Women with an intermediate ROC are recalled for repeat CA125 in 
12 weeks. Women with an elevated ROC are recalled for Level 2 screen in 6-8 
weeks when they have another CA125 test and a transvaginal ultrasound. They 
are then triaged according to their results to: 1) annual screening, 2) repeat Level 2 
if the scan is normal or unsatisfactory, or 3) clinical assessment.
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Ultrasound group 
Women  in  the  ultrasound  group  receive  an  annual  transvaginal  ultrasound 
(Chapter One, Figure 1.4). Results are classified as: 1) unsatisfactory, 2) normal, 
or 3) abnormal. Any of the following are abnormal: a single simple cyst over 
5cms diameter, more than one cyst including more than one inclusion cyst in one 
ovary, complex morphology (solid areas, septae or cysts with irregular outline or 
anechoic contents). Women with abnormal ultrasound results are recalled for a 
Level 2 ultrasound in 6-8 weeks and those with highly suspicious findings are 
recalled  earlier.  Level  2  screens  are  also  categorised  as:  1)  unsatisfactory,  2) 
normal, or 3) abnormal. Women with normal results are referred back to annual 
screening, unsatisfactory results are recalled for a repeat Level 2 in 6-8 weeks and 
those  with  abnormal  scans  are  referred  for  clinical  assessment  with  a 
gynaecological oncology consultant. 
5.2.2  Sample 
In  the  control  group,  only  women  who  returned  their  UKCTOCS  follow  up 
questionnaires in the last 12 months were eligible (Chapter 4). A random sample 
of 25 controls from each of the 13 regional centres was mailed the OCSq. 
In the screen group, in order to enrich the population with those with possible 
ovarian abnormalities, 60% of the women mailed were those who were being sent 
a Level 2 screen appointment. Women were identified for mailing as described in 
Chapter 4. 
5.2.3  Data collection 
The pilot OCSq is described in Chapter Four and presented in appendix 12. All 
questionnaires were date stamped on receipt. Questionnaires without the written 
consent  section  completed  were  considered  ineligible.  These  were  returned  to 
women  with  a  second  reply-stamped  envelope  and  letter  requesting  them  to 
provide consent if they wished their questionnaire to be included in the study. 
The  UKCTOCS  data  collection  instruments  are  described  in  Chapter  One. 
Participants  completed  the  UKCTOCS  baseline  questionnaire  at  initial 
recruitment  and  the  follow-up  questionnaire  approximately  3.5  years  later.  
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Demographic and reproductive history data from the questionnaires were exported 
from  the  main  UKCTOCS  Trial  Management  System  on  28  April  2009  and 
included in analyses described in this chapter. 
In addition to symptoms data, the OCSq elicited information on current HRT use 
and  co-morbidities  (including  past  non-ovarian  cancer  diagnoses)  previously 
diagnosed  by  a  doctor.  Two  depression  screening  questions,  validated  by 
international groups and recommended for use in primary care by NICE, were 
included in the final section of the OCSq. 
Screening, surgery, ovarian cancer diagnoses and outcomes data were exported 
from the main UKCTOCS Trial Management System on 26 June 2009. This data 
included an NHS Information Centre for Health and Social Care in England and 
Wales cancer registry notification update received at the UKCTOCS coordinating 
centre on 30 January 2009 and a notification received 17 February 2009 from the 
Northern Ireland Central Services Agency and Cancer Registry. 
5.2.4  Data cleaning 
●  An estimated completion date was calculated for respondents who did 
not write the date on their questionnaire. This was based upon the 
overall median number of days between the date of questionnaire 
completion and receipt date for all participants. 
●  Where respondents completed the frequency section (ticking either: 
1-2 days, 3-5 days or 6-7 days during the past week), the duration 
section (ticking either: less than 3 months, 3-6 months, 6-12 months 
or more than 12 months) or ticked yes to reported to GP section but 
did not complete the severity section (either: no, a little, quite a bit or 
very much) the symptom was coded as present during the past week 
but without a severity rating. 
●  Where respondents did not complete the severity, frequency or 
duration sections but ticked no to the discussed with GP section, the 
symptom was coded as not experienced during the past week.  
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5.2.5  Data analysis 
OCSq data were entered directly into SPSS version 12.0.1 (SPSS Inc., Chicago, 
USA)  on  a  daily  basis  until  the  final  questionnaire  was  received.  UKCTOCS 
baseline questionnaire, follow-up questionnaire and screening data were imported 
into the same SPSS database for analysis. Frequencies were run to describe the 
data and distributions of continuous variables were explored. 
Screening results 
UKCTOCS screening results concurrent with the OCSq were investigated for the 
multimodal  and  ultrasound  groups.  The  concurrent  screen  was  defined  as  the 
screening appointment given in the letter which accompanied the OCSq. If the 
respondent did not attend the scheduled appointment, the concurrent screen was 
the  first  screening  appointment  attended  after  the  date  the  questionnaire  was 
posted to the volunteer. 
Concurrent screening results were categorised as either normal or abnormal based 
on the ‘action’ generated following classification and triage on UKCTOCS (Table 
5.1). 
Table 5.1.  Criteria for categorising UKCTOCS concurrent screening results 
Screening action  Coded for analysis 
Return to annual screening  Normal 
Repeat screen (repeat Level 1, Level 2 or repeat Level 2 screen)  Abnormal 
Referred to gynaecological oncologist for assessment  Abnormal 
 
In addition to the classification of results in Table 5.1, results were also explored 
in the multimodal group by comparing: 1) those with elevated ROC scores (risk 
>0.2578%) versus those with normal and intermediate ROC scores (<0.2578%), 
and  2)  those  with  CA125  ≥30  U/mL  (traditional  cut-off  adopted  in  clinical 
practice in postmenopausal women) versus those with CA125 <30 U/mL. 
Ultrasound results were available for women in the ultrasound group and those 
attending Level 2 appointments in the multimodal group. In the UKCTOCS trial  
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ultrasonographers report whether ovaries are visualised or not. In women where 
ovaries are visualised, the morphology on ultrasound of each ovary (right and left 
separately) is described as: 1) normal, 2) simple cysts, or 3) complex morphology 
(as described in Chapter One). Left and right ovary morphology  and volumes 
were investigated for all respondents where this information was available. 
End of study outcomes 
In all participants, the UKCTOCS database was searched for further information 
with regard to annual or repeat screening, referrals to gynaecological oncologists, 
trial  surgery,  cancer  registrations,  deaths  and  reasons  for  withdrawal  from  the 
trial. Histopathology and hospital notes of women who underwent surgery were 
reviewed to ascertain any ovarian pathology and morphology, stage and grade of 
ovarian/fallopian tube cancer. GP notes were requested for women diagnosed with 
ovarian/fallopian tube cancer. 
For the purpose of this analysis, all participants were censored on the date of 
surgery during which ovaries were removed, diagnosis of ovarian cancer, death or 
withdrawal from UKCTOCS. The date of data export from the UKCTOCS Trial 
Management System was used as the censorship date for participants who were 
continuing as a control, or continuing to receive screening in the UKCTOCS trial. 
Number of days follow-up was calculated for each woman from the questionnaire 
completion date to the date of censorship and total person-years of follow-up was 
calculated for all respondents. 
Symptoms reported by OCSq respondents 
Symptoms were investigated using four different approaches to classify ‘positive’ 
symptoms: 
1  Symptoms reported at any level of severity. 
2  Symptoms  reported  at  level  2-3  severity.  This pragmatic  approach 
was adopted based on the hypothesis that it is difficult to define ‘a 
little’ in terms of symptoms and women are unlikely to consult their 
doctor about mild symptoms.  
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3  Symptoms reported at any level of severity with ≥12 days per month 
frequency and <12 months duration as described in the Goff Index 
(detailed in Chapter Two).
23 This approach was utilised as symptoms 
included in the Goff index had a similar frequency (>12 days during 
the past month) and equivalent duration criteria. 
4  Symptoms  with  a  frequency  ≥12  days  per  month,  <12  months 
duration and level 2-3 severity. 
Symptoms  reported  by  all  respondents  were  investigated  and  symptoms  were 
compared  between  women  receiving  screening  and  controls  using  the  four 
approaches. 
Symptoms and concurrent screen results 
Concurrent  screen  results  were  investigated  using  the  four  approaches  to 
symptoms analysis. 
●  Symptoms were compared in respondents with abnormal and normal 
screen results (Table 5.1) 
●  Symptoms were compared in respondents with elevated ROC scores 
versus those with normal and intermediate ROC scores 
●  Symptoms were compared in respondents with concurrent CA125 
>30 U/mL and those with CA125 <30 U/mL 
●  Symptoms were compared in respondents with complex morphology 
in one or both ovaries and those with normal morphology or non-
visualised ovaries 
●  In women with an ultrasound detected ovarian abnormality, 
symptoms were investigated according to estimated ovarian volume 
(calculated during ultrasound) 
Multivariate  analysis  of  symptoms  associated  with  abnormal  results  on 
concurrent screen 
Symptoms  associated  with  abnormal  results  on  each  of  the  four  univariate 
approaches were entered into backwards stepwise multivariate logistic regression  
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models. A backwards method was chosen as forwards regression has a higher risk 
of  Type  II  error  (acceptance of the  null hypothesis when in  reality  there is  a 
genuine effect within a population). 
Model  1  included  symptoms  associated  with  abnormal  results  at  any  level  of 
severity, model 2 at level 2-3 severity, model 3 at ≥12 days frequency and <12 
months duration and model 4 at ≥12 days, <12 months and level 2-3 severity. Co-
morbidities associated with an abnormal result on univariate analyses were also 
entered  into  models,  with  age  and  total  number  of  symptoms  entered  as 
continuous  variables  (when  associated  with  an  abnormal  result  on  univariate 
analyses). The likelihood ratio statistic p = 0.05 was the criterion for entry into 
models and p = 0.1 for removal. Variables with missing cells were excluded due 
to confidence intervals of odds ratios being inestimable. 
Performance of the models for detecting abnormal results 
Models 1-4 developed using this dataset 
Receiver  operating curves were plotted from the predicted values for  the four 
models and the area under the curve was calculated to assess the goodness-of-fit. 
Receiver  operating  curves  typically  plot  the  performance  of  diagnostic  tests, 
demonstrating the sensitivity (true positive rate) versus one-minus specificity (true 
negative rate) of a test. The sensitivity of the receiver operating curves plotted for 
the four models refers to the ability of the symptoms in the final models to predict 
an abnormal ovarian cancer screening result. One-minus specificity refers to the 
proportion of women the symptoms model predicts will have a normal screening 
result. A symptoms model which perfectly predicts an abnormal result at all levels 
of the test would have an area under the curve equal to one, and models which 
perform no better than chance would have an area equal to 0.5. 
Goff Symptom Index 
Women who had either pelvic discomfort/pain (q1), abdominal discomfort/pain 
(q2), feeling full (q5), abdominal bloating (q7) or increased abdominal size (q9) 
for 3-5 or 6-7 days during the past week and where the symptom had a duration of 
<3, 3-6 or 7-12 months, were considered positive on the Goff symptom index  
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(detailed in Chapter Two).
23 This gave an approximate frequency of ≥12 days, 
which  was similar to  the stated  frequency in the Goff index of  >12 days per 
month. It is to be noted that one item on the Goff index, difficulty eating, was not 
included in the OCSq. Reasons for exclusion are discussed in Chapter Four. 
Lurie Symptom Index 
Women  who  had  either  abdominal  pain  (q1),  increased  abdominal  size  (q9), 
abdominal  mass  or  lumps  (q10)  or  abnormal  vaginal  bleeding  (q30)  were 
considered positive on the Lurie symptom index (described in Chapter Two).
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The  Lurie  index  included  hard  abdomen  but  no  data  were  available  for  this 
symptom as the item was not included in the OCSq. 
Performance  of  the  Goff  and  Lurie  indices  for  detecting  abnormal  concurrent 
screen  results  was  assessed  by  calculating  sensitivity,  specificity,  positive 
predictive value (PPV) and negative predictive value (NPV). 
Performance of symptoms models for detecting ovarian cancer 
Performance of the four symptoms models, and the Goff and Lurie indices, for 
identifying women with ovarian/fallopian tube cancer was assessed. The number 
of women with and without malignancy who were identified by each model was 
determined and the sensitivity, specificity, PPV and NPV were calculated. 
Symptom reporting according to prior awareness of a possible ovarian lesion 
All women in the UKCTOCS control group were categorised as unaware of a 
possible ovarian lesion as they had not undergone any screening. Women in the 
multimodal  and  ultrasound  groups  were  categorised  into  unaware  or  aware 
depending  on  whether  their  OCSq  was  posted  with  their  annual  or  Level  2 
screening appointment. Where women completed the OCSq after being informed 
of the result of their concurrent screening appointment, awareness was adjusted 
based upon their concurrent screen result. 
Symptoms were analysed according to women’s awareness of a possible ovarian 
lesion prior to receipt of the OCSq. It was hypothesised that awareness of the 
possibility of an ovarian lesion, raised by the need to have repeat tests, would  
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make  women  more  aware  of  symptoms  and  perhaps  cause  a  certain  level  of 
anxiety. 
Odds  ratios  were  calculated  for  symptoms  reported  by  aware  vs.  unaware 
respondents using the four approaches: 1) any severity, 2) level 2-3 severity, 3) 
≥12 days and <12 months duration, 4) ≥12 days, <12 months duration and level 2-
3 severity. Using the same approaches, symptoms were analysed in a sub-group of 
unaware women receiving screening compared to controls. 
Symptoms reported to GPs 
Symptoms most commonly reported to GPs during the three months prior to the 
OCSq were investigated. The percentage of respondents who consulted their GP 
was calculated from the number of women who were positive for the symptom on 
each of the four approaches. Women were excluded from these analyses if they 
did not provide both symptom and GP consultation information. 
Symptoms and depression screening status 
In  accordance  with  the  literature  discussed  in  Chapter  Four,  respondents  who 
replied positively to one or both depression screening questions were categorised 
as depression screen positive. Prior awareness of a possible ovarian lesion and 
symptom reporting were investigated according to depression screening status. 
The same four approaches to classify positive symptoms were utilised for this 
analysis. 
Statistical analysis 
Chi-square  or  Fisher’s  exact  statistics  were  used  to  investigate  univariate 
relationships between categorical variables and odds ratios with 95% confidence 
intervals were calculated. Mann-Whitney U tests were used to test differences 
between  two  groups  for  non-parametric  continuous  data.  Effect  sizes  were 
calculated and interpreted according to Cohen’s criteria of r = 0.3 for a medium 
effect and r = 0.5 for a large effect. Differences were accepted as significant at p < 
0.05 for all tests.  
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Sensitivity and specificity 
Sensitivity  refers  to  the  number  of  respondents  who  had  the  defined  outcome 
(abnormal  result  or  ovarian/fallopian  tube  cancer)  who  were  positive  on  each 
symptom model (true positives) divided by the total number of respondents with 
ovarian/fallopian tube cancer (Figure 5.1 depicts sensitivity, specificity, NPV and 
PPV of symptom models or indices for detecting ovarian/fallopian tube cancer). 
Specificity refers to the number of respondents who did not have the specified 
outcome who were negative on each symptom model (true negatives) divided by 
the total number of respondents who did not have the defined outcome. The PPV 
is the number of respondents with the defined outcome identified by the model 
divided by the total number of respondents with the defined outcome. The NPV is 
the  number  of  respondents  who  did  not  have  the  defined  outcome  who  were 
negative on the model divided by the total number of respondents who did not 
have the defined outcome. 
Figure 5.1.  Sensitivity, specificity, PPV and NPV of symptom models for 
detecting ovarian/fallopian tube cancer 
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5.3  Results 
5.3.1  Response rates 
A  total  of  1,339  UKCTOCS  volunteers  (325  from  the  control  group  and  507 
women from each of the screening groups) were posted the pilot OCSq between 
21 May 2008 and 3 December 2008 (Chapter Four). This included 103 women 
from  each  of  the  13  regional  centres  (25  controls,  39  multimodal  and  39 
ultrasound group women). Completed questionnaires were received between 23 
May and 3 February 2009. No women were excluded from analysis on the basis 
of ineligible data as all provided written consent. Ten women initially overlooked 
completing the consent section. All subsequently provided written consent after 
their questionnaire was returned to them. 
A  total  of  829  women returned  the  OCSq,  giving  an  overall  response  rate  of 
61.9%. Response rates varied across the 13 regional centres (Table 5.2), with a 
significant difference between Bristol, which had the highest response rate, and 
Liverpool, which had the lowest (74.8% vs. 54.4%, χ
2(1) = 9.4, p = 0.002). A 
larger  proportion  of  women  in  the  screening  groups  responded  compared  to 
controls (65.2% vs. 51.7%, χ
2(1) = 19.0, p < 0.0001) and a larger proportion of 
women  attending  for  Level  2  appointments  responded  compared  to  those 
attending for annual screening (67.8% vs. 61.0%, χ
2(1) = 4.8, p = 0.028) (Table 
5.3).  
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Table 5.2.  OCSq response rates by regional centre 
Centre 
Invited  
(n) 
Responded 
(n) 
Response Rate 
(%) 
Belfast  103  64  62.1 
Bristol  103  77  74.8 
Cardiff  103  64  62.1 
Derby  103  59  57.3 
East London (St Bart’s)  103  59  57.3 
Gateshead  103  67  65.0 
Liverpool  103  56  54.4 
Manchester  103  69  67.0 
Middlesbrough  103  62  60.2 
North London (Royal Free)  103  57  55.3 
North Wales  103  63  61.2 
Nottingham  103  61  59.2 
Portsmouth  103  71  68.9 
Total  1,339  829  61.9 
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Table 5.3.  OCSq - Number of women invited, number who responded and 
response rates 
Group  Control  Annual Screening  Repeat Screening 
 
Responded  
(Invited) 
% 
Responded  
(Invited) 
% 
Responded  
(Invited) 
% 
Controls  168 (325)  51.7  -  -  -  - 
Multimodal  -  -  117 (195)  60.0  202 (312)  64.7 
Ultrasound  -  -  121 (195)  62.1  221 (312)  70.8 
Total  168 (325)  51.6  238 (390)  61.0  423 (624)  67.8 
 
Nineteen respondents (5 controls, 8 multimodal and 6 ultrasound) did not have a 
completion date for the OCSq. The median time from OCSq completion to receipt 
in the remaining 810 respondents was seven days (range 1-133, IQR 4-15). For 
the respondents with a missing completion date, an estimated completion date was 
calculated by subtracting seven days from the stamped receipt date. 
5.3.2  Demographics and co-morbidities 
5.3.2.1  Reported on OCSq 
Mean age was 65.6 years (range 53-80, SD = 5.6), with no difference in the age of 
controls compared to respondents receiving screening (Table 5.4). Sixty (7.2%) 
respondents were using hormone replacement therapy (HRT) at the time of the 
OCSq,  with  fewer  controls  reporting  current  HRT  use  compared  to  the  other 
groups (χ
2(2) = 6.5, p = 0.04). 
A total of 268 (32.2%) women reported they had been diagnosed with arthritis, 
124 (15.0%) with depression, 120 (14.5%) with irritable bowel syndrome (IBS), 
73  (8.8%)  with hiatus hernia and 39 (4.7%)  with  inflammatory bowel disease 
(Table 5.4). There were no significant differences in the proportion of women 
who reported each of the co-morbidities across the three groups. Excluding basal 
cell carcinomas (BCCs), 74 women (8.9%) reported having a history of cancer, of 
whom 46 were diagnosed with breast cancer, six with colon or bowel cancer, four  
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with cervical cancer, three with malignant melanoma and two with non-Hodgkin’s 
lymphoma. One woman each reported being diagnosed with lung cancer, head 
and neck cancer, multiple myeloma, oesophagus cancer, sarcoma, face cancer or 
adenocarcinoma of rectum. Six women did not specify cancer type. 
5.3.2.2  Reported on UKCTOCS baseline questionnaire 
A  majority  of  the  respondents  (98.4%)  were  of  white  ethnic  origin.  All  were 
postmenopausal, with median of 15.7 years (range 3.1-44.6, IQR 10.4-21.7) since 
last menstruation at recruitment to UKCTOCS (Table 5.5). A total of 169 (20.4%) 
were  using  HRT  at  recruitment  and  147  (17.7%)  reported  that  they  had  a 
hysterectomy. Respondents reported a median of two viable pregnancies (range 0-
8,  IQR  2-3)  and  506  (61.0%)  reported  ever  using  the  oral  contraceptive  pill 
(OCP). The groups were well balanced with regard to demographics (Table 5.5). 
While fewer women in the control group reported HRT use, and more women in 
the  ultrasound  group  reported  hysterectomy,  these  differences  were  not 
significant. 
5.3.2.3  Reported on UKCTOCS follow-up questionnaire 
Information  about  education  was  not  collected  at  baseline.  This  omission  was 
corrected  in  the  UKCTOCS  follow-up  questionnaire.  As  a  result  of  the  study 
design, only women in the control group who completed this questionnaire in the 
previous 12 months were eligible. Among the 661 women in the screen group, 
160  had  not  completed  a  follow-up  questionnaire  when  this  analysis  was 
undertaken.  In  the 669  women who  had completed a  follow-up questionnaire, 
there was no significant difference in education level between controls and the 
screen group, although controls had fewer missing data for education (Table 5.6).  
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Table 5.4.  OCSq demographic and co-morbidity data 
OCSq 
Controls 
n=168 
n (% or SD) 
Multimodal Group 
n=319 
n (% or SD) 
Ultrasound Group 
n=342 
n (% or SD) 
Overall 
n=829 
n (% or SD) 
Age at questionnaire†  64.2 (SD 5.3)  66.2 (SD 5.6)  65.7 (SD 5.7)  65.6 (SD 5.6) 
Current HRT use  5 (3.0)  24 (7.5)  31 (9.1)  60 (7.2) 
Personal history of cancer*  9 (5.4)  38 (11.9)  27 (7.9)  74 (8.9) 
Personal history of breast cancer  6 (3.6)  21 (6.6)  17 (5.0)  46 (5.5) 
Diagnosed with hiatus hernia  11 (6.5)  29 (9.1)  33 (9.6)  73 (8.8) 
Diagnosed with IBS  19 (11.3)  56 (17.6)  45 (13.2)  120 (14.5) 
Diagnosed with inflammatory bowel disease  7 (4.2)  13 (4.1)  19 (5.6)  39 (4.7) 
Diagnosed with arthritis  51 (30.4)  113 (35.4)  104 (30.4)  268 (32.2) 
Diagnosed with depression  30 (17.9)  46 (14.4)  48 (14.0)  124 (15.0) 
 
* Excluding BCCs/skin cancer 
† Mean  
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Table 5.5.  UKCTOCS baseline questionnaire demographic data and reproductive history 
UKCTOCS baseline questionnaire 
Controls 
n=168 
n (% or IQR) 
Multimodal Group 
n=319 
n (% or IQR) 
Ultrasound Group 
n=342 
n (% or IQR) 
Overall 
n=829 
n (% or IQR) 
Ethnic origin 
White 
Black 
Asian 
Other 
Missing 
 
166 (98.8) 
1 (0.1) 
0 
0 
1 
 
313 (98.1) 
2 (0.6) 
0 
3 
1 
 
337 (98.5) 
4 (1.2) 
0 
0 
1 
 
816 (98.4) 
7 (0.8) 
0 
3 
3 
Height at recruitment (cm)
†  162.6 (157.5-65.1)  162.6 (157.5-167.6)  162.6 (157.5-167.6)  162.6 (157.5-167.6) 
Weight at recruitment (kg)
†  67.8 (60.3-76.2)  66.7 (60.3-77.2)  66.7 (60.3-73.0)  66.7 (60.3-76.2) 
Median Body Mass Index (BMI) at recruitment  26.0 (23.0-30.0)  25.4 (23.0-30.0)  25.0 (23.0-28.0)  25.4 (23.0-29.0) 
BMI group
† 
Under-weight (BMI <18.5) 
Optimal weight (BMI 18.5-25.0) 
Over-weight  (BMI 25.1-30.0) 
Obese (BMI >30.0) 
Missing 
 
 
0 
73 (43.5) 
54 (32.1) 
38 (22.6) 
3 (1.8) 
 
3 (0.9) 
142 (44.5) 
98 (30.7) 
71 (22.3) 
5 (1.6) 
 
0 
170 (49.7) 
121 (35.4) 
48 (14.0) 
3 (0.9) 
 
3 (0.4) 
385 (46.4) 
273 (32.9) 
157 (18.9) 
11 (1.3)  
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UKCTOCS baseline questionnaire 
Controls 
n=168 
n (% or IQR) 
Multimodal Group 
n=319 
n (% or IQR) 
Ultrasound Group 
n=342 
n (% or IQR) 
Overall 
n=829 
n (% or IQR) 
Years since last menstruation  14.4 (9.5-20.0)  16.5 (10.5-21.7)  16.5 (10.5-22.7)  15.7 (10.4-21.7) 
Ever use oral contraceptive pill (OCP)  110 (65.5)  180 (56.4)  216 (63.2)  506 (61.0) 
Duration of OCP (years) if applicable  5.0 (2.0-10.0)  5.0 (2.0-10.0)  5.5 (2.0-10.0)  5.0 (2.0-10.0) 
Ever use hormone replacement therapy (HRT) at 
recruitment 
25 (14.9)  74 (23.2)  70 (20.5)  169 (20.4) 
Miscarriages (pregnancies < 6 months)  0 (0-1)  0 (0-1)  0 (0-1)  0 (0-1) 
Number of children (pregnancies ≥ 6 months)  2 (1-3)  2 (2-3)  2 (2-3)  2 (2-3) 
Hysterectomy  27 (16.1)  46 (14.4)  73 (21.6)  147 (17.7) 
 
† Median  
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Table 5.6.  UKCTOCS follow-up questionnaire education data 
UKCTOCS follow up questionnaire 
Controls 
n=168 
n (%) 
Multimodal Group 
n=234 
n (%) 
Ultrasound Group 
n=267 
n (%) 
Overall 
n= 669 
n (%) 
Education level 
No qualification 
O level 
A level 
Clerical qualification 
Professional qualification 
Degree level 
Missing 
 
 
41 (24.4) 
23 (13.7) 
8 (4.8) 
43 (25.6) 
15 (8.9) 
35 (20.8) 
3 (1.8) 
 
 
64 (27.4) 
24 (10.3) 
8 (3.4) 
59 (25.2) 
27 (11.5) 
41 (17.5) 
11 (4.7) 
 
 
74 (27.7) 
35 (13.1) 
21 (7.9) 
58 (21.7) 
19 (7.1) 
37 (13.9) 
23 (8.6) 
 
 
179 (26.8) 
82 (12.3) 
37 (5.5) 
160 (23.9) 
61 (9.1) 
113 (16.9) 
37 (5.5) 
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5.3.3  Screening results 
Screen results concurrent with the questionnaire were available for 643 of the 661 
respondents from the screening groups, of whom 380 (59.1%) had a normal result 
and 263 (40.9%) had an abnormal result (Table 5.7). There was an association 
between  concurrent  screen  result  and  self-reported  history  of  cancer  diagnosis 
(excluding BCCs) but there were no other associations between screening result 
and co-morbidities. Women reporting a history of cancer were significantly more 
likely to have an abnormal concurrent screen result compared to women with no 
history of cancer (54.0% vs. 39.5%, χ
2(1) = 4.9, p = 0.026). Among women with 
abnormal results, 23  from the multimodal group and 107 from  the  ultrasound 
group were referred to a gynaecological oncologist for clinical assessment. 
Table 5.7.  Concurrent screening results by group 
Group 
Normal 
n (%) 
Abnormal 
n (%) 
Multimodal  182  131 
Ultrasound  198  132 
Total  380 (59.1)  263 (40.9) 
 
Among the 313 women in the multimodal group with a concurrent screen result, 
median serum CA125 level was 16.5 U/mL (range 4.0-187.0, IQR 12.3-22.6) and 
35 women had a CA125 level >30. The median ROC score was 0.034% (range 0-
100.0, IQR 0.016-0.235) and 74 respondents had an elevated ROC. 
Table 5.8 lists the concurrent ultrasound result for women in the ultrasound group 
and women in the multimodal group who underwent a scan as part of the Level 2 
screen. Overall, 172 women had complex morphology in one or both ovaries and 
336 women had non visualised or normal ovaries, or simple ovarian cysts.  
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Table 5.8.  Ultrasound results 
Result 
Left ovary 
n 
Right ovary 
n 
Not visualised  125  97 
Normal  277  271 
Simple cyst  17  25 
Complex morphology  89  115 
Total  508  508 
 
Left ovarian volume was available for 360 women, with a median of 11.7 cm
2 
(range 0.6-7878.9, IQR 6.8-22.7) and right ovarian volume was available for 374 
women, with a median of 13.9 cm
2 (range 1.4-4487.3, IQR 8.2-27.2). 
5.3.4  End-of-study outcomes 
There was a median of 329 (range 0-400, IQR 288-353) days between the date of 
OCSq  completion  and  censorship  date,  and  a  total  of  710.4  person-years  of 
follow-up. One woman was diagnosed with ovarian cancer and one with fallopian 
tube cancer. Fifteen women had pelvic surgery during follow-up and seven were 
diagnosed with benign tumours (Table 5.9).  
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Table 5.9.  Outcomes at end of study 
Outcome  n=829  % 
Continuing as control  166  20.0 
Continuing with annual screening  539  65.0 
Level 2 screening  71  8.6 
Referred to gynaecological oncologist  17  2.1 
Surgery - ovary looked normal, no histology  1  0.1 
Surgery - oophorectomy – normal ovaries  3  0.4 
Surgery - oophorectomy - benign ovarian neoplasm  7  0.8 
Surgery - ovarian or fallopian tube cancer  2  0.2 
Non-UKCTOCS surgery - oophorectomy, awaiting details  2  0.2 
Died - other reason  1  0.1 
Withdrawn - controls  2  0.2 
Withdrawn - screening groups  18  2.2 
Total  829  100 
 
Ovarian cancer case 
The one case of ovarian cancer was diagnosed seven weeks after the volunteer 
completed the OCSq. The volunteer was in the UKCTOCS ultrasound screening 
group and had attended for an annual scan on 21 June 2008. A complex cyst (with 
papillations and an irregular wall) was detected on the left ovary. A symptoms 
questionnaire  was  posted  to  the  volunteer  on  2  July  2008  with  a  Level  2 
appointment letter. The questionnaire was completed on 14 July 2008 and the 
volunteer was assessed by a gynaecological oncology consultant on 21 August 
2008 (during the scheduled Level 2 appointment). The ultrasound conducted at 
this appointment found a 32 mm x 26 mm x 34 mm tumour with an estimated 
volume of 4.8 cm
2. The volunteer was referred for surgery, which took place on 2 
September 2008. Pre-operative CA125 was 8.18 U/mL. A tumour was removed  
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during bilateral salpingo-oophorectomy and a diagnosis of Stage IA, Grade III, 
clear cell ovarian cancer was confirmed on histopathology. The respondent was 
79 years of age, had been previously diagnosed with arthritis, inflammatory bowel 
disease and emphysema, and answered no to both depression screening questions. 
Symptoms reported by the volunteer diagnosed with ovarian cancer are listed in 
Table  5.10.  As  can  be  seen  in  the  table,  23  of  the  32  symptoms  in  the 
questionnaire were reported. The volunteer also described three ‘other’ symptoms. 
The respondent ticked that she reported 14 of the 32 standardised symptoms to her 
GP. Eleven of these were recorded in her GP notes during the three months prior 
to the date of OCSq completion. On 22 April 2008 the woman was referred by her 
GP for an abdominal and pelvic ultrasound. The scan was conducted 9 May 2008, 
finding a small area of fatty infiltration on the liver and a 26 mm cyst in the left 
adnexal  region.  There  was  no  referral  recorded  in  the  notes  to  a  specialist 
gynaecological  oncologist.  The  volunteer  was  already  receiving  specialist 
respiratory and orthopaedic care at the time of her ovarian cancer diagnosis. 
Fallopian tube cancer case 
One  woman  was  diagnosed  with  fallopian  tube  cancer  during  the  follow-up 
period. The volunteer was in the multimodal group and was posted the OCSq on 
21 June 2008 with a Level 2 appointment letter. The questionnaire was completed 
on 25 June 2008 and the volunteer attended the scheduled appointment on 21 
August 2008. At Level 2 screening the volunteer’s CA125 level was 43.9 U/mL 
and the ROC value was elevated (2.68%). No cysts were detected on ultrasound 
and the result was normal, with an ultrasound-estimated left ovary volume of 9.4 
cm
2  and  right  ovary  volume  of  6.4  cm
2.  The  volunteer  was  referred  to  a 
gynaecological  oncology  consultant  for  clinical  assessment  following  Level  2 
investigations.  Clinical  assessment  was  conducted  on  24  September  2008, 
whereupon  the  woman  was  referred  for  surgery.  The  volunteer  underwent 
laparotomy and bilateral salpingo-oophorectomy on 27 January 2009. A tumour 
measuring 40 mm x 20 mm x 10 mm was removed from the left fallopian tube. A 
diagnosis of Stage I, Grade III, poorly differentiated invasive adenocarcinoma of 
the  fallopian  tube  was  confirmed  on  histopathology.  No  malignant  cells  were  
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detected in the left ovary or right fallopian tube and ovary. On 19 March 2009 the 
volunteer underwent completion surgery (hysterectomy). Histology findings from 
the second surgery confirmed that there were no malignant cells. 
At the time of OCSq completion, the respondent was aged 74 years, was taking 
HRT,  had  been  previously  diagnosed  with  arthritis  and  answered  no  to  both 
depression screening questions. The one symptom reported by the volunteer was 
urinary frequency (Table 5.11).  
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Table 5.10.  Symptoms reported on OCSq by the respondent diagnosed with ovarian cancer 
Symptom  Severity  Frequency  Duration 
Symptom 
reported to 
GP 
GP consultation confirmed by 
notes (date if confirmed) 
Pelvic discomfort or pain  Quite a bit  3-5 days  >12 months  Yes  Yes (22/04/08) 
Abdominal discomfort or pain  Very much  6-7 days  3-6 months  Yes  Yes (22/04/08) 
Indigestion or heartburn  A little  1-2 days  3-6 months  Yes  Not recorded 
Pelvic bloating or fullness  Very much  6-7 days  3-6 months  Yes  Yes (22/04/08) 
Abdominal pressure  Very much  6-7 days  3-6 months  Yes  Not recorded 
Increased abdominal size  Very much  6-7 days  3-6 months  Yes  Yes (22/04/08) 
Pelvic bloating or fullness  Quite a bit  3-5 days  >12 months  No  - 
Pelvic pressure  Quite a bit  3-5 days  7-12 months  No  - 
Pelvic heaviness  Quite a bit  6-7 days  7-12 months  No  - 
Pain before, during or after opening bowels  Quite a bit  6-7 days  >12 months  No  - 
Change in bowel habit  Quite a bit  6-7 days  >12 months  No  - 
Excessive flatulence  Very much  3-5 days  >12 months  No  -  
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Symptom  Severity  Frequency  Duration 
Symptom 
reported to 
GP 
GP consultation confirmed by 
notes (date if confirmed) 
Urinary frequency  Quite a bit  6-7 days  >12 months  Yes  Yes (22/04/08) 
Urinary urgency  Very much  6-7 days  >12 months  Yes  Not recorded 
Pressure on the bladder  Quite a bit  1-2 days  3-6 months  No  - 
Difficulty emptying the bladder  Quite a bit  6-7 days  7-12 months  No  Yes (22/04/08) 
Pain when passing urine  A little  missing  missing  missing  Yes (22/04/08) 
Shortness of breath  Very much  6-7 days  >12 months  Yes  Yes (several 2/04/08-04/06/08) 
Back ache or pain  Very much  6-7 days  >12 months  Yes  Yes (07/07/08) 
Leg ache or pain  Very much  6-7 days  >12 months  Yes  Yes (07/07/08) 
Leg swelling  Quite a bit  3-5 days  7-12 months  Yes  Yes (07/07/08) 
Tiredness, fatigue or lack of energy  Quite a bit  6-7 days  >12 months  Yes  Not recorded 
Weight gain  Very much  -  >12 months  Yes  Not recorded 
Other – ‘pressure on lungs’  Quite a bit  6-7 days  >12 months  Yes  Yes (06/05/08) 
Other – ‘excessive bruising’  Very much  6-7 days  7-12 months  Yes  Not recorded  
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Symptom  Severity  Frequency  Duration 
Symptom 
reported to 
GP 
GP consultation confirmed by 
notes (date if confirmed) 
Other – ‘lower back pain’  Very much  6-7 days  >12 months  Yes  Yes (18/03/08) 
 
 
Table 5.11.  Symptoms reported on the OCSq by the respondent diagnosed with fallopian tube cancer 
Symptom  Severity  Frequency  Duration 
Symptom 
reported to 
GP 
GP consultation confirmed by 
notes 
Urinary frequency  Quite a bit  3-5 days  <3 months  No  N/A* 
 
* GP notes not yet received  
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5.3.5  Symptoms reported by OCSq respondents 
A total of 739 (89.1%) women reported any of the 32 symptoms during the past 
week, with a median of 5.0 (range 0-26, IQR 2.0-9.50) symptoms reported at any 
level. Ninety (10.9%) women were asymptomatic. Table 5.12 lists the ten most 
commonly reported symptoms at any level of severity, frequency or duration. Of 
note,  while  abdominal  bloating/fullness  and  increased  abdominal  size  were 
reported by approximately 28% of respondents, pelvic symptoms did not feature 
in the top ten. 
Table 5.12.  Most common symptoms reported by OCSq respondents 
Symptom at any level  n=829  % 
Tiredness, fatigue or lack of energy  443  53.4 
Back ache or pain  365  44.0 
Excessive flatulence  345  41.6 
Leg ache or pain  329  39.7 
Indigestion or heartburn  329  39.7 
Urinary urgency  326  39.3 
Urinary frequency  312  37.6 
Weight gain  242  29.2 
Abdominal bloating or fullness  233  28.1 
Increased abdominal size  232  28.0 
 
A total of 457 (55.1%) women reported at least one of the following symptoms: 
abdominal  or  pelvic  discomfort/pain,  increased  abdominal  size,  abdominal  or 
pelvic bloating/fullness, change in appetite or feeling full. Addition of urinary 
frequency or urgency increased this number to 577 (69.6%). Abdominal or pelvic 
discomfort/pain, increased abdominal size, abdominal or pelvic bloating/fullness, 
change in appetite, feeling full or abnormal vaginal bleeding was reported by 461 
(55.6%).  
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A total of 493 (50.5%) women reported symptoms at level 2-3 severity (quite a bit 
or very much) with a median of zero symptoms (range 0-17, IQR 0-1.0) at this 
level. The 10 most common symptoms experienced at level 2-3 severity were the 
same as the 10 most common symptoms overall, although the order was slightly 
different (Table 5.13). 
Table 5.13.  Most common symptoms reported by OCSq respondents at level 2-3 
severity 
Symptom at level 2-3 severity  n=829  % 
Tiredness, fatigue or lack of energy  190  22.9 
Back ache or pain  161  19.4 
Urinary frequency  161  19.4 
Leg ache or pain  157  18.9 
Excessive flatulence  154  18.6 
Urinary urgency  153  18.5 
Indigestion or heartburn  102  12.3 
Weight gain  95  12.3 
Increased abdominal size  86  10.4 
Abdominal bloating or fullness  71  8.6 
 
A total of 404 (48.7%) respondents reported symptoms at a frequency of ≥12 days 
during the past month and <12 months duration, with median of zero symptoms 
(range  0-20,  IQR  0-2.0)  reported  with  this  frequency  and  duration.  Difficulty 
emptying bowels was the most common symptom in this group, but it was not 
among the ten most common symptoms at any level of severity or at level 2-3 
severity (Table 5.14).  
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Table 5.14.  Most common symptoms reported by OCSq respondents at ≥12 days 
frequency & <12 months duration 
Symptom ≥12 days & <12 months  n=829  % 
Difficulty emptying bowels  118  14.2 
Tiredness, fatigue or lack of energy  117  14.1 
Weight gain  115  13.9 
Leg ache or pain  76  9.2 
Urinary frequency  69  8.3 
Excessive flatulence  68  8.2 
Increased abdominal size  61  7.4 
Urinary urgency  59  7.1 
Back ache or pain  57  6.9 
Abdominal bloating or fullness  46  5.5 
 
There were 237 (28.9%) respondents who reported any symptom at a frequency of 
≥12 days during the past month, <12 months duration and at level 2-3 severity, 
with a median of zero symptoms (range 0-17, IQR 0-1.0) meeting these criteria. 
Pelvic discomfort/pain was among the ten most common symptoms using this 
approach, but not the other three approaches (Table 5.15).  
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Table 5.15.  Most common symptoms reported by OCSq respondents at ≥12 days 
frequency, <12 months duration & level 2-3 severity 
Symptom ≥12 days, <12 months & level 2-3 severity  n=829  % 
Tiredness, fatigue or lack of energy  73  8.8 
Difficulty emptying bowels  56  6.8 
Leg ache or pain  48  5.8 
Excessive flatulence  47  5.7 
Weight gain  39  4.7 
Urinary frequency  38  4.6 
Urinary urgency  36  4.3 
Increased abdominal size  34  4.1 
Back ache or pain  30  3.6 
Pelvic discomfort or pain  27  3.3 
 
5.3.5.1  Symptoms reported by screening group respondents vs. controls 
There was no difference in the proportion of screened women who reported any 
symptoms  compared  to  controls  (89.9%  vs.  86.3%,  ns).  However,  a  greater 
proportion  of  screened  women  reported  any  symptoms  at  level  2-3  severity 
(63.1% vs. 50.9%, χ
2(1) = 8.2, p = 0.004), any symptoms with a frequency of ≥12 
days and <12 months duration (51.6% vs. 42.2%, χ
2(1) = 4.5, p = 0.035) and any 
symptoms with a frequency of ≥12 days, <12 months duration and severity level 
2-3 (30.9% vs. 22.4%, χ
2(1) = 4.5, p = 0.033). There was no difference in the 
median number of symptoms reported by screened women compared to controls 
on each of the four approaches.  
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Screened women were more likely to report six individual symptoms at any level 
of severity, frequency and duration (Table 5.16), although only one symptom - 
tiredness/fatigue at ≥12 days, <12 months and level 2-3 severity. None of the 
differences  in  symptom  reporting  among  screened  women  vs.  controls  were 
consistent  across  all  four  levels  of  analysis,  although  tiredness/fatigue  was 
significant at three levels. Controls were more likely to report only one symptom, 
pain  during  or  after  sexual  intercourse,  at  any  level  of  severity,  frequency  or 
duration.  
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Table 5.16.  Symptoms reported by screening group vs. controls 
Symptom reported  n 
Screening groups 
n (%) 
Controls 
n (%) 
OR (95% CI)  p-value 
At any level 
Pelvic discomfort or pain  780  199 (31.8)  32 (20.6)  1.80 (1.18-2.74)  0.006 
Feeling full quickly  771  139 (22.6)  20 (12.9)  1.97 (1.19-3.26)  0.008 
Change in appetite  766  73 (12.0)  9 (5.7)  2.24 (1.09-4.58)  0.02 
Pelvic pressure  757  97 (16.1)  14 (9.0)  1.95 (1.08-3.52)  0.02 
Pelvic heaviness  750  86 (14.5)  13 (8.3)  1.86 (1.01-3.43)  0.04 
Difficulty emptying the bladder  752  49 (8.2)  5 (3.2)  2.71 (1.06-6.91)  0.03 
Pain during or after sexual intercourse  247  17 (9.0)  11 (19.0)  0.42 (0.19-0.96)  0.04 
Level 2-3 severity 
Pelvic discomfort or pain  776  64 (10.3)  6 (3.9)  2.83 (1.20-6.66)  0.01 
Difficulty emptying bowels  768  58 (9.5)  7 (4.4)  2.30 (1.03-5.15)  0.04 
Tiredness, fatigue or lack of energy  768  164 (26.8)  26 (16.8)  1.81 (1.15-2.86)  0.01  
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Symptom reported  n 
Screening groups 
n (%) 
Controls 
n (%) 
OR (95% CI)  p-value 
≥12 days & <12 months 
Abdominal bloating or fullness  733  43 (7.4)  3 (2.0)  3.94 (1.20-12.87)  0.02 
Difficulty emptying bowels  740  103 (17.6)  15 (9.6)  2.01 (1.13-3.57)  0.02 
Change in bowel habit  730  32 (5.6)  2 (1.3)  4.47 (1.06-18.87)  0.03 
Tiredness, fatigue or lack of energy  670  101 (19.1)  16 (11.4)  1.82 (1.04-3.21)  0.03 
Weight gain*  726  103 (17.9)  12 (8.1)  2.48 (1.32-4.65)  0.004 
≥12 days, <12 months & level 2-3 severity 
Tiredness, fatigue or lack of energy  670  65 (12.3)  8 (5.7)  2.31 (1.08-4.93)  0.03 
 
* Reported at <12 months duration only as frequency data not collected  
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5.3.6  Symptoms and concurrent screen results 
5.3.6.1  Symptoms associated with abnormal screen results 
There were 263 respondents with an abnormal concurrent screen result and 380 
with a normal result. Women with abnormal results were more likely than those 
with normal results to report any symptoms across three of the four levels of 
analysis (Table 5.17), with the largest odds ratio for report of symptoms at any 
level of severity, frequency or duration (OR 2.07, 95% CI 1.15-3.75). There was 
no association between concurrent screening result and report of any symptoms at 
≥12 days frequency, <12 months duration and level 2-3 severity. 
Women with abnormal results also reported a greater number of symptoms overall 
(Mdn 6.0 vs. Mdn 5.0, U = 42687.5, p = 0.002, r = -0.12) and a greater number of 
symptoms at level 2-3 severity (Mdn 2.0 vs. Mdn 1.0, U = 44323.0, p < 0.01, r = -
0.10).  However,  there  was  no  association  between  concurrent  result  and  the 
number of symptoms at ≥12 days and <12 months or ≥12 days, <12 months and 
level 2-3 severity (Table 5.17).  
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Table 5.17.  Symptom reporting in women with abnormal vs. normal concurrent screen results 
Symptom reported  n 
Abnormal result 
n (% or IQR) 
Normal result 
n (% or IQR) 
Odds ratio 
(95% CI) 
p-value 
 
At any level 
Reported 
643 
247 (93.9)  335 (88.2)  2.07 (1.15-3.75)  0.014 
Median  6.0 (3.0-11.0)  5.0 (2.0-9.0)  - 
0.002 
Range  0-26  0-23  - 
Level 2-3 severity 
Reported 
632 
179 (69.1)  222 (59.5)  1.52 (1.09-2.13)  0.014 
Median  2.0 (0-4.0)  1.0 (1.0-3.0)  - 
0.012 
Range  0-21  0-18  - 
≥12 days & <12 months 
Reported 
631 
151 (59.0)  175 (46.7)  1.64 (1.19-2.27)  0.002 
Median  1.0 (0-3.0)  0 (0-2.0)  - 
ns 
Range  0-20  0-18  -  
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Symptom reported  n 
Abnormal result 
n (% or IQR) 
Normal result 
n (% or IQR) 
Odds ratio 
(95% CI) 
p-value 
 
≥12 days, <12 months & level 2-3 severity 
Reported 
632 
90 (35.0)  107 (28.5)  ns  ns 
Median  0 (0-1.0)  0 (0-1.0)  - 
ns 
Range  0-17  0-11  - 
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Odds ratios were significant between those with abnormal results compared to 
those with normal results for nine symptoms at any level, four symptoms at level 
2-3 severity and five at ≥12 days and <12 months and four when level 2-3 severity 
was added to this criteria (Table 5.18). Increased abdominal size and abdominal or 
pelvic pressure were significant across three of the four approaches. Abdominal 
pressure (OR 5.38, 95% CI 1.11-26.15) and shortness of breath (OR 5.29, 95% CI 
1.09-25.70) had the largest odds ratios, although small numbers resulted in wide 
confidence intervals. Women with normal results were not more likely to report 
any of the 32 symptoms in the OCSq. 
The symptoms pelvic bloating/fullness, pelvic pressure and pelvic heaviness were 
combined  into  a  single  variable  for  further  analysis  and  abdominal 
bloating/fullness,  abdominal  pressure  and  increased  abdominal  size  were  also 
combined into a single variable. Significantly more women with abnormal results 
reported pelvic symptoms at any level (34.6% vs. 26.4%, χ
2(1) = 4.6, p = 0.021) 
and at level 2-3 severity (5.0% vs. 1.7%, χ
2(1) = 5.3, p = 0.032). However, there 
was no association between concurrent screen result and pelvic symptoms at ≥12 
days frequency and <12 months duration, or when level 2-3 severity was added to 
these criteria. There was also no association between concurrent screen result and 
the combined abdominal symptoms on three of the levels of analysis. A larger 
proportion of women with abnormal concurrent screen results reported abdominal 
symptoms at ≥12 days  frequency, <12 months duration and level 2-3 severity 
compared to those with normal results (8.4% vs. 4.5%, χ
2(1) = 5.3, p = 0.042), 
although this had borderline significance.  
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Table 5.18.  Symptoms associated with abnormal results 
Symptom reported  n 
Abnormal 
n (%) 
Normal 
n (%) 
OR (95% CI)  p-value 
At any level 
Change in appetite  594  42 (17.1)  30 (8.6)  2.20 (1.33-3.63)  0.002 
Increased abdominal size  593  92 (38.0)  94 (26.8)  1.68 (1.18-2.38)  0.004 
Pelvic pressure  585  51 (21.7)  44 (12.6)  1.93 (1.24-3.00)  0.003 
Pelvic heaviness  578  45 (19.3)  39 (11.3)  1.88 (1.18-2.99)  0.007 
Excessive flatulence  601  128 (53.1)  149 (41.4)  1.60 (1.15-2.23)  0.005 
Urinary urgency  600  121 (49.4)  142 (40.0)  1.46 (1.05-2.03)  0.02 
Leg ache or pain  598  122 (50.6)  142 (39.8)  1.55 (1.12-2.16)  0.009 
Tiredness, fatigue or lack of energy  600  159 (65.7)  194 (54.2)  1.62 (1.16-2.27)  0.005 
Abnormal vaginal bleeding  583  6 (2.5)  0  ∞  0.005 
Level 2-3 severity 
Increased abdominal size  589  37 (15.4)  31 (8.9)  1.85 (1.12-3.08)  0.007  
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Symptom reported  n 
Abnormal 
n (%) 
Normal 
n (%) 
OR (95% CI)  p-value 
Level 2-3 severity 
Pelvic bloating or fullness  586  31 (13.0)  20 (5.8)  2.44 (1.35-4.39)  0.002 
Excessive flatulence  597  63 (26.1)  63 (17.7)  1.65 (1.11-2.45)  0.01 
Shortness of breath  583  22 (9.3)  16 (4.6)  2.11 (1.08-4.11)  0.03 
Symptom ≥12 days & <12 months 
Nausea or vomiting  586  10 (4.2)  4 (1.1)  3.77 (1.17-12.17)  0.02 
Abdominal pressure  567  12 (5.2)  7 (2.1)  2.61 (1.01-6.75)  0.04 
Pelvic pressure  563  15 (6.6)  7 (2.1)  3.33 (1.33-8.29)  0.007 
Pelvic heaviness  557  14 (6.3)  8 (2.4)  2.73 (1.13-6.62)  0.02 
Leg ache or pain  553  36 (16.1)  29 (8.8)  2.00 (1.19-3.37)  0.008 
≥12 days, <12 months & level 2-3 severity 
Abdominal pressure  552  7 (3.2)  2 (0.6)  5.38 (1.11-26.15)  0.03 
Increased abdominal size  550  17 (7.9)  11 (3.3)  2.51 (1.15-5.47)  0.02  
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Symptom reported  n 
Abnormal 
n (%) 
Normal 
n (%) 
OR (95% CI)  p-value 
≥12 days, <12 months & level 2-3 severity 
Shortness of breath  564  7 (3.1)  2 (0.6)  5.29 (1.09-25.70)  0.04 
Leg swelling  563  14 (6.1)  7 (2.1)  3.00 (1.19-7.54)  0.02 
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5.3.6.2  Symptoms associated with CA125 level 
Thirty-five (11.2%) of the 313 women with a concurrent CA125 result had a level 
≥30 U/mL and 273 (87.2%) had a CA125 <30 U/mL. There were no associations 
between CA125 level and report of symptoms overall across the four approaches. 
There was also no difference in the number of symptoms reported by women with 
CA125 levels ≥30 U/mL compared to those with levels <30 U/mL on any of the 
four approaches. 
When individual symptoms were analysed, odds ratios were significant between 
those with CA125 levels ≥30 U/mL compared to those with CA125 <30 U/mL for 
difficulty emptying the bladder at level 2-3 severity (OR 16.83, 95% CI 1.48-
191.36), and urinary frequency (OR 3.43, 95% CI 1.30-9.06) and shortness of 
breath (OR 4.62, 95% CI 1.30-16.44) at ≥12 days  frequency  and <12 months 
duration.  At  ≥12  days,  <12  months  and  level  2-3  severity,  odds  ratios  were 
significant  for  change  in  appetite  (OR  5.85,  95%  CI  1.25-27.41),  urinary 
frequency (OR 4.46, 95% CI 1.42-14.02), shortness of breath (OR 6.78, 95% CI 
1.44-31.96) and backache or pain (OR 4.68, 95% CI 1.32-16.65) (appendix 23). 
5.3.6.3  Symptoms associated with elevated ROC scores 
Concurrent ROC scores were available for 313 women, of whom 74 (23.6%) had 
an elevated score. There were no associations between ROC scores and report of 
symptoms overall, at level 2-3 severity or ≥12 days, <12 months and level 2-3 
severity.  However, respondents with elevated ROCs  were  1.80 (95%  CI  1.05-
3.09) times more likely to report symptoms with a frequency of ≥12 days and <12 
months  duration,  although  the  lower  confidence  limit  indicates  marginal 
significance.  There  was  no  association  between  elevated  ROCs  and  either  the 
Goff or Lurie indices. 
There was no difference in the number of symptoms reported overall, at level 2-3 
severity,  or  with  a  frequency  of  ≥12  days  and  <12  months  duration,  by 
respondents with elevated ROCs compared to others. However, a greater number 
of symptoms were reported by respondents with elevated ROCs at ≥12 days, <12 
months and level 2-3 severity (Mdn 3.0 vs. Mdn 1.0, U = 742.0, p = 0.02, r = - 
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0.23). This effect size  indicates a  small  increase in symptom  reporting  at this 
severity, frequency and duration, associated with elevated ROC scores. 
Appendix  24  lists  individual  symptoms  which  were  associated  with  elevated 
ROCs. The largest odds ratio was for increased abdominal size (OR 4.70, 95% CI 
1.67-13.18)  at  ≥12  days,  <12  months  and  level  2-3  severity,  followed  by 
indigestion  or  heartburn  (OR  4.06,  95%  CI  1.32-12.50)  at  ≥12  days  and  <12 
months.  No  single  symptom  was  significant  on  all  four  approaches,  although 
increased abdominal size was associated with elevated ROC score on three of the 
four approaches. 
5.3.6.4  Symptoms associated with complex ovarian morphology 
Symptoms were compared in 172 women with complex ovarian morphology and 
336 women with normal findings (ovaries not visualised, ovaries normal or simple 
cysts). There was no difference in the proportion of women with complex masses 
compared to those with normal findings who reported symptoms overall (91.3% 
vs. 90.2%, ns), at level 2-3 severity (63.4% vs. 64.0%, ns), at ≥12 days frequency 
and <12 months duration (50.6% vs. 52.1%, ns) or at level 2-3 severity, ≥12 days 
and  <12  months  (30.2%  vs.  31.8%,  ns).  There  was  also  no  difference  in  the 
number  of  symptoms  reported  by  women  with  complex  ovarian  morphology 
compared to others (both Mdn 6.0), at level 2-3 severity (both Mdn 1.0), at ≥12 
days and <12 months (both Mdn 2.0) or when level 2-3 severity was added to this 
frequency and duration (both Mdn 2.0). 
Pelvic pressure (OR 1.88, 95% CI 1.15-3.09) at any level and change in bowel 
habit (OR 2.34, 95% CI 1.11-4.94) at level 2-3 severity were the only symptoms 
which  women  with  complex  ovarian  morphology  were  more  likely  to  report 
(appendix 25). Surprisingly, there was no association between complex ovarian 
morphology and pelvic bloating/fullness, pressure or heaviness on any of the four 
approaches when these symptoms were combined into a single variable. 
5.3.6.5  Symptoms associated with abnormal ovarian volume 
Of the 172 women with an ovarian abnormality (complex ovarian morphology), 
ovarian volume was recorded for 55 of the 57 women who had a left-sided lesion,  
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77  of  the  83  women  with  a  right-sided  lesion  and  30  of  the  32  women  with 
bilateral ovarian abnormalities. Median ovarian volume in the 172 women with an 
ovarian abnormality was 25.26 cm
2 (range 2.6-7878.9, IQR 12.5-57.5). 
Women who reported abdominal bloating/fullness and urinary frequency at any 
level, or at level 2-3 severity, had larger median total ovarian volumes compared 
to women who did not report the symptoms (Table 5.19). Effect sizes for these 
symptoms indicate a moderate increase in reporting with increasing total ovarian 
volume. No pelvic symptoms were associated with total ovary volume, even after 
combining pelvic bloating/fullness, heaviness and pressure into a single variable. 
Interestingly, women who reported leg swelling ≥12 days during the past month 
and onset within the past 12 months had smaller median total ovarian volumes.  
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Table 5.19.  Symptoms associated with total ovary volume 
Symptom at any level  n 
Symptom reported 
Median volume cm
2 (IQR) 
Symptom not reported 
Median volume cm
2 (IQR) 
U  p-value  r 
Urinary frequency  29  129.2 (57.3-270.0)  59.5 (27.2-89.4)  53.0  0.023  -0.42 
Abdominal bloating or fullness  29  117.3 (27.5-342.4)  76.7 (41.8-139.5)  9.0  0.032  -0.40 
Level 2-3 severity 
Urinary frequency  29  143.4 (78.7-234.1)  59.7 (27.4-116.9)  40.0  0.032  -0.40 
≥12 days & <12 months 
Leg swelling  27  27.5 (18.3-43.4)  88.8 (52.9-142.8)  9.0  0.036  -0.40 
 
Note: there were no associations between total ovary volume and symptoms ≥12 days, <12 months & level 2-3 severity  
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5.3.7  Multivariate analysis of symptoms associated with abnormal 
results 
5.3.7.1  Symptoms at any level of severity predictive of an abnormal result – 
Model 1 
Eight symptoms with significant odds ratios on univariate analyses were entered 
into  the  regression  model  with  previous  cancer  diagnosis  and  the  continuous 
variables age and total number of symptoms at any level of severity, frequency or 
duration.  Symptoms  included  in  the  model  were:  1)  change  in  appetite,  2) 
increased abdominal size, 3) pelvic pressure, 4) pelvic heaviness, 5) excessive 
flatulence,  6)  urinary  urgency,  7)  leg  ache/pain,  and  8)  tiredness/fatigue. 
Abnormal vaginal bleeding was excluded from the model due to missing cells. 
The regression found age, pelvic pressure and tiredness/fatigue at any level of 
severity  independently  predicted  an  abnormal  concurrent  screening  result 
(receiver operating curve = 0.62). Adjusted odds ratios for all symptoms models 
are listed in Table 5.20 and Figure 5.2 shows the receiver operating curves. 
5.3.7.2  Symptoms at any level 2-3 severity predictive of an abnormal result – 
Model 2 
Four  symptoms  at  level  2-3  severity  associated  with  an  abnormal  result  on 
univariate analyses, 1) increased abdominal size, 2) pelvic bloating/fullness, 3) 
excessive flatulence and 4) shortness of breath, were entered into a second model 
with previous cancer diagnosis, age and total number of symptoms at level 2-3 
severity. This found that age, pelvic bloating and shortness of breath at level 2-3 
severity were independently predictive of an abnormal result (receiver operating 
curve = 0.60). 
5.3.7.3  Symptoms ≥ 12 days and <12 months predictive of an abnormal result 
- Model 3 
Five symptoms, 1) nausea or vomiting, 2) abdominal pressure, 3) pelvic pressure, 
4) pelvic heaviness, and 5) leg ache/pain, reported at ≥12 days during the past 
month and <12 months duration associated with an abnormal concurrent screen  
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result were entered into a third logistic regression model with previous cancer 
diagnosis. Age was entered as a continuous variable. Total number of symptoms 
reported ≥12 days and <12 months was not included as univariate analyses found 
this was not associated with screening result. The regression identified age, pelvic 
pressure and leg ache/pain as independent predictors of an abnormal result when 
experienced  ≥12  days  and  <12  months  (receiver  operating  curve  =  0.61). 
However, leg ache/pain had marginal significance. 
5.3.7.4  Symptoms ≥ 12 days, <12 months and level 2-3 severity predictive of 
an abnormal result – Model 4 
Four symptoms, 1) abdominal pressure, 2) increased abdominal size, 3) shortness 
of breath, and 4) leg swelling, experienced at ≥12 days, <12 months and level 2-3 
severity were entered into a fourth backwards stepwise logistic regression model 
with previous cancer diagnosis, and age as a continuous variable. Total number of 
symptoms  reported  ≥12  days,  <12  months  and  at  level  2-3  severity  was  not 
included as this was not associated with screening result on univariate analysis. 
The  regression  identified  abdominal  pressure,  shortness  of  breath  and  age  as 
independent predictors of an abnormal result (receiver operating curve = 0.59). 
However, the confidence intervals for these symptoms were wide and the area 
under the curve was slightly smaller than the model using frequency and duration 
criteria alone.  
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Table 5.20.  Results of multivariate logistic regression of symptoms and 
abnormal screening results 
 
Multivariate logistic regression models 
predictive of abnormal results  n  Exp β (95% CI)  p-value 
Symptoms at any level - model 1 
Pelvic pressure 
539 
1.93 (1.16-3.21)  0.011 
Tiredness, fatigue or lack of energy  1.58 (1.09-2.28)  0.015 
Age  1.05 (1.02-1.09)  0.001 
Symptoms at level 2-3 severity - model 2 
Pelvic bloating or fullness 
561 
2.37 (1.25-4.49)  0.008 
Shortness of breath  2.33 (1.13-4.83)  0.023 
Age  1.05 (1.02-1.08)  0.004 
Symptoms ≥12 days & <12 months - model 3 
Pelvic pressure 
495 
3.31 (1.22-8.96)  0.019 
Leg ache or pain  1.78 (1.00-3.15)  0.049 
Age  1.05 (1.01-1.08)  0.005 
Symptoms ≥12 days, <12 months & level 2-3 severity - model 4 
Abdominal pressure 
491 
9.33 (1.10-78.80)  0.04 
Shortness of breath  12.94 (1.52-109.40)  0.019 
Age  1.10 (1.02-1.09)  0.003  
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Figure 5.2.  Receiver operating curves for the models 
 
5.3.8  Performance of the Goff Symptom Index for detecting an 
abnormal screen result 
A total of 129 women (15.6%) were positive on the Goff index. Of these, 110 
were from the screening group and 57 had an abnormal concurrent result. The 
index  had  a  sensitivity  of  21.7%  and  a  specificity  of  86.1%  for  detecting  an 
abnormal result. The PPV was 51.8% and NPV was 61.4%. 
Model 1 
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5.3.9  Performance of the Lurie Symptom Index for detecting an 
abnormal screen result 
The Lurie symptom index identified 325 women (39.2%), of whom 261 were 
from  the  screening  group  and  125  had  an  abnormal  result.  The  index  had  a 
sensitivity of 46.8% and a specificity of 63.9% for detecting respondents with 
abnormal screen results. The PPV was 46.8% and NPV was 63.9%. 
5.3.10  Performance of symptom models and indices for detecting ovarian 
cancer 
As there were only two women diagnosed with ovarian/fallopian tube cancer, the 
following analyses were conducted mainly to assess the specificity of symptom 
models. Other performance characteristics are included to demonstrate how we 
intend to assess the performance of symptoms models in follow-up analyses of the 
100,000 women study (Chapter Six). 
Table  5.21  details  the  performance  of  the  four  models  which  predicted  an 
abnormal screen result, in addition to the Goff and Lurie indices, for detecting 
ovarian/fallopian  cancer.  The  respondent  diagnosed  with  fallopian  tube  cancer 
reported only one symptom, urinary frequency, and was therefore negative on all 
models.  The  respondent  diagnosed  with  ovarian  cancer  was  positive  on  all 
models. Thus all six models had a sensitivity of 50.0%. 
Model  1  identified  460  women  without  ovarian  cancer  (including  four  of  the 
seven women with benign masses), resulting in the lowest specificity (44.4%) 
among the six models. Model 4 identified 20 women without ovarian/fallopian 
cancer, resulting in the highest specificity at 97.6%. The Goff index ranked fourth 
on specificity (84.5%) while the Lurie index ranked fifth (60.8%).  
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Table 5.21.  Performance of symptoms models for predicting ovarian/fallopian tube cancer  
 
Model 
 
Ovarian/ 
fallopian 
cancer 
n=2 
Non-
cancer 
cases 
n=827 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
Model 1 
Any pelvic pressure or tiredness/fatigue 
1  460 
50.0% 
(9.5%-90.5%) 
44.4% 
(44.1%-47.8%) 
0.2% 
(0.04%-1.2%) 
99.7% 
(98.5%-99.95%) 
Model 2 
Pelvic bloating/fullness or shortness of breath at level 
2-3 severity 
1  92 
50.0% 
(9.5%-90.5%) 
88.9% 
(86.6%-90.8%) 
1.1% 
(0.2%-5.8%) 
99.9% 
(99.2%-99.98%) 
Model 3 
Pelvic pressure or leg ache/pain at ≥12 days & <12 
months  
1  88 
50.0% 
(9.5%-90.5%) 
89.4% 
(87.1%-91.3%) 
1.1% 
(0.2%-6.1%) 
99.9% 
(99.2%-99.98%) 
Model 4 
Abdominal pressure or shortness of breath at level 2-3 
severity, ≥12 days & <12 months 
1  20 
50.0% 
(9.5%-90.5%) 
97.6% 
(96.3%-98.4%) 
4.8% 
(0.8%-22.7%) 
99.9% 
(99.3%-99.98%) 
Goff index 
Pelvic discomfort/pain, abdominal discomfort/pain, 
feeling full quickly, abdominal bloating or increased 
abdominal size at ≥12 days & <12 months 
1  128 
50.0% 
(9.5%-90.5%) 
84.5% 
(81.9%-86.8%) 
0.8% 
(0.1%-4.3%) 
61.4% 
(99.2%-99.97%)  
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Model 
 
Ovarian/ 
fallopian 
cancer 
n=2 
Non-
cancer 
cases 
n=827 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
Lurie index 
Any abdominal pain, increased abdominal size, abdominal 
mass/lump or abnormal vaginal bleeding 
1  325 
50.0% 
(9.5%-90.5%) 
60.8% 
(57.3%-57.0%) 
0.3% 
(0.1%-1.7%) 
99.8% 
(98.9%-
99.96%)  
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5.3.11  Symptom reporting according to prior awareness of a possible 
ovarian abnormality 
Awareness was based on previous screen results. All 168 controls and the 238 
screen  group  women  who  were  sent  the  OCSq  with  their  annual  screen 
appointments were initially classified as unaware of any abnormality. The 423 
women  who  were  sent  the  OCSq  along  with  their  Level  2  appointment  were 
initially classified as aware of a possible ovarian lesion as they had been asked to 
attend  for  repeat  testing.  However,  34  women  from  the  screening  groups  (15 
multimodal  and  19  ultrasound)  completed  their  questionnaires  after  being 
informed  of  the  result  of  their  concurrent  screening  appointment  (defined  as 
greater than two days after the result letter was posted for the multimodal group 
and equal to or greater than the appointment date in the ultrasound group). In 
these  women,  awareness  status  was  altered  to  reflect  concurrent  results.  This 
identified 416 (50.2%) women as unaware and 413 (49.8%) who were aware of a 
possible ovarian lesion. 
5.3.11.1  Symptoms reporting in aware vs. unaware respondents 
There was no association between awareness and symptom reporting at any level 
of severity, frequency or duration (90.8% vs. 87.5%, ns). However, women who 
were aware of the possibility of an ovarian abnormality were more likely (OR 
1.81, 95% CI 1.37-2.40) to report symptoms at level 2-3 severity compared to 
unaware women. They were also more likely to report symptoms of ≥12 days 
frequency and <12 months duration (OR 1.41, 95% CI 1.07-1.85) and symptoms 
at ≥12 days, <12 months and level 2-3 severity (OR 1.61 95% CI 1.19-2.18). 
Aware women were also more likely to be positive on the Goff symptom index 
(OR 1.95, 95% CI 1.32-2.87) and the Lurie index (OR 1.48 95% CI 1.11-1.97). 
There was no difference in the median number of symptoms reported at level 2-3 
severity (Mdn 1.0 in both groups). However, the median number of symptoms 
reported at any level (Mdn 6.0 vs. Mdn 4.0, U = 72136.0, p <0.0001, r = -0.14), at 
≥12 days and <12 months (Mdn 3.0 vs. Mdn 1.0, U = 15517.5, p < 0.0001, r = -
0.15) and ≥12 days, <12 months and level 2-3 severity (Mdn 2.0 vs. Mdn 1.0, U =  
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5414.5, p = 0.004, r = -0.10) was greater among those aware of an abnormality, 
although the effect sizes indicate awareness had a minimal impact on the number 
of symptoms reported. 
Women  who  were  aware  of  an  abnormality  were  significantly  more  likely  to 
report 19 symptoms at any level of severity, frequency and duration compared to 
unaware women (Table 5.22). Eight symptoms were more likely to be reported by 
aware respondents at level 2-3 severity, 13 at ≥12 days and <12 months, and five 
when level 2-3 severity was added to this criteria. Change in bowel habit at ≥12 
days, <12 months and level 2-3 severity had the highest odds ratio (OR 6.81, 95% 
CI 1.99-23.34) across the four approaches, although the confidence limits were 
wide. Pelvic heaviness was among the two highest odds ratios on three of the four 
approaches, with odds ratios ranging from 2.61 (95% CI 1.66-4.11) to 6.00 (95% 
CI 2.04-17.67). Interestingly, women who were aware of a possible ovarian lesion 
were more likely to report both weight gain and weight loss.  
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Table 5.22.  Symptom reporting in aware vs. unaware respondents 
Symptom reported  n 
Aware of possible 
ovarian 
abnormality 
n (%) 
Unaware 
n (%) 
OR (95% CI)  p-value 
At any level 
Pelvic discomfort or pain  780  133 (34.5)  98 (24.8)  1.60 (1.17-2.18)  0.003 
Abdominal discomfort or pain  766  80 (21.1)  58 (15.0)  1.52 (1.05-2.20)  0.028 
Change in appetite  766  54 (14.4)  28 (7.2)  2.18 (1.35-3.53)  0.001 
Increased abdominal size  767  130 (34.9)  102 (25.9)  1.53 (1.12-2.09)  0.007 
Abdominal mass or lump  749  14 (3.8)  5 (1.3)  3.04 (1.08-8.52)  0.027 
Pelvic bloating or fullness  764  108 (28.9)  67 (17.2)  1.96 (1.39-2.76)  <0.0001 
Pelvic pressure  757  71 (19.3)  40 (10.3)  2.09 (1.37-3.17)  <0.0001 
Pelvic heaviness  750  68 (8.6)  31 (8.1)  2.61 (1.66-4.11)  <0.0001 
Pain before, during or after opening bowels  766  97 (26.0)  60 (15.3)  1.95 (1.36-2.79)  <0.0001 
Change in bowel habit  759  81 (22.0)  50 (12.8)  1.92 (1.31-2.83)  0.001  
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Symptom reported  n 
Aware of possible 
ovarian 
abnormality 
n (%) 
Unaware 
n (%) 
OR (95% CI)  p-value 
At any level 
Excessive flatulence  775  187 (49.5)  158 (39.8)  1.48 (1.11-1.97)  0.007 
Urinary frequency  765  175 (46.8)  137 (35.0)  1.63 (1.22-2.18)  0.001 
Urinary urgency  775  183 (47.9)  143 (36.4)  1.61 (1.21-2.14)  0.001 
Difficulty emptying the bladder  752  36 (9.9)  18 (4.7)  2.24 (1.25-4.03)  0.006 
Shortness of breath  755  85 (23.2)  52 (13.4)  1.95 (1.33-2.85)  0.001 
Leg ache or pain  769  182 (48.3)  147 (37.5)  1.56 (1.17-2.07)  0.003 
Tiredness, fatigue or lack of energy  772  234 (62.1)  209 (52.9)  1.46 (1.09-1.94)  0.01 
Weight gain  762  135 (36.4)  107 (27.4)  1.52 (1.12-2.06)  0.007 
Weight loss  749  30 (8.3)  17 (4.4)  1.97 (1.07-3.63)  0.028 
Level 2-3 severity 
Pelvic discomfort or pain  776  44 (11.5)  26 (6.6)  1.84 (1.11-3.06)  0.017  
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Symptom reported  n 
Aware of possible 
ovarian 
abnormality 
n (%) 
Unaware 
n (%) 
OR (95% CI)  p-value 
Level 2-3 severity 
Pelvic bloating or fullness  759  42 (11.4)  18 (4.6)  2.64 (1.49-4.68)  0.001 
Pelvic heaviness  748  25 (6.9)  10 (2.6)  2.77 (1.31-5.86)  0.005 
Difficulty emptying bowels  768  44 (11.9)  21 (5.3)  2.42 (1.41-4.16)  0.001 
Change in bowel habit  755  32 (8.8)  12 (3.1)  3.03 (1.53-5.97)  0.001 
Excessive flatulence  771  94 (25.1)  60 (15.1)  1.89 (1.31-2.70)  0.001 
Urinary frequency  763  94 (25.2)  67 (17.2)  1.62 (1.14-2.31)  0.007 
Urinary urgency  772  92 (24.1)  61 (15.6)  1.75 (1.22-2.50)  0.003 
≥12 days & <12 months 
Pelvic discomfort or pain  752  30 (8.1)  14 (3.7)  2.33 (1.22-4.47)  0.009 
Increased abdominal size  715  40 (11.7)  21 (5.6)  2.22 (1.28-3.85)  0.004 
Pelvic pressure  732  19 (5.4)  5 (1.3)  4.21 (1.55-11.39)  0.002  
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Symptom reported  n 
Aware of possible 
ovarian 
abnormality 
n (%) 
Unaware 
n (%) 
OR (95% CI)  p-value 
≥12 days & <12 months 
Pelvic heaviness  728  21 (6.0)  4 (1.1)  6.00 (2.04-17.67)  <0.0001 
Change in bowel habit  730  24 (6.9)  10 (2.6)  2.72 (1.28-5.78)  0.007 
Feeling of pressure on the bladder  725  22 (6.3)  11 (2.9)  2.22 (1.06-4.64)  0.03 
Pain when passing urine  740  6 (1.7)  0  ∞  0.01 
Shortness of breath  731  15 (4.3)  5 (1.3)  3.35 (1.20-9.31)  0.014 
Leg ache or pain  709  51 (14.8)  25 (6.9)  2.35 (1.42-3.89)  0.001 
Leg swelling  733  30 (8.5)  14 (3.7)  2.40 (1.25-4.61)  0.007 
Tiredness, fatigue or lack of energy  670  68 (21.3)  49 (14.0)  1.66 (1.11-2.48)  0.014 
Weight gain*  726  69 (19.7)  46 (12.2)  1.76 (1.17-2.64)  0.006 
Weight loss*  744  24 (6.7)  8 (1.9)  3.38 (1.50-7.62)  0.002 
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Symptom reported  n 
Aware of possible 
ovarian 
abnormality 
n (%) 
Unaware 
n (%) 
OR (95% CI)  p-value 
≥12 days, <12 months & level 2-3 severity 
Pelvic discomfort or pain  776  19 (5.0)  8 (2.0)  2.53 (1.09-5.84)  0.025 
Increased abdominal size  713  24 (7.0)  10 (2.7)  2.72 (1.28-5.78)  0.007 
Difficulty emptying bowels  740  38 (10.8)  18 (4.7)  2.47 (1.38-4.42)  0.002 
Change in bowel habit  730  18 (5.1)  3 (0.8)  6.81 (1.99-23.34)  <0.0001 
Excessive flatulence  711  32 (9.4)  15 (4.0)  2.48 (1.32-4.67)  0.004 
 
* Reported at <12 months duration only as frequency data not collected  
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5.3.11.2  Symptoms reported by screening group women vs. controls in the 
unaware group 
Sub-group analysis of 416 women in the unaware group found that there was no 
difference between screened women and controls for symptoms at any level of 
severity, frequency or duration (88.3% vs. 86.3%, ns), at level 2-3 severity (54.0% 
vs. 50.0%, ns), at ≥12 days frequency and <12 months duration (46.4% vs. 41.7%, 
ns), or ≥12 days, <12 months and level 2-3 severity (25.0% vs. 22.0%, ns). 
When individual symptoms were analysed, larger proportions of screened women 
reported  feeling  full  at  any  level  (21.9%  vs.  12.9%,  χ
2(1)  =  5.1,  p  =  0.024) 
compared to controls. However, greater proportions of controls reported nausea or 
vomiting at any level (7.2% vs. 14.2%, χ
2(1) = 5.1, p = 0.024) and backache or 
pain at level 2-3 severity, ≥12 days and <12 months (1.3% vs. 6.0%, χ
2(1) = 6.2, p 
=  0.013).  There  was  no  difference  between  these  groups  for  reports  of  other 
symptoms. 
5.3.11.3  Symptoms reported by aware respondents with abnormal vs. normal 
concurrent screen results 
A concurrent screen result was available for 407 of the 413 women who were 
aware  of  a potential  abnormality. There  was no  association between  report of 
symptoms overall (92.9% vs. 88.4%, ns), symptoms at level 2-3 severity (68.3% 
vs. 64.5%, ns) or symptoms at level 2-3 severity, ≥12 days frequency and <12 
months duration (33.7% vs. 32.9%, ns) and abnormal concurrent screen results. 
However, women who reported any symptoms at ≥12 days frequency and <12 
months  duration  were  more  likely  (OR  1.60,  95%  CI  1.07-2.40)  to  have  an 
abnormal concurrent screen result. There was no difference in the median number 
of symptoms at each of the four levels of analysis in women who had abnormal 
concurrent screen results compared to those with normal results. 
The most frequently reported symptom among aware women with an abnormal 
concurrent result was tiredness/fatigue followed by backache or pain, excessive 
flatulence, urinary urgency and leg  ache or pain (Table 5.23). The number of 
women reporting abnormal vaginal bleeding was small (n = 5), but all had an  
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abnormal result. Similarly, 10 of the 14 women who reported an abdominal mass 
or lump had an abnormal screen result. 
Table 5.23.  Most frequently reported symptoms in aware women who had a 
concurrent screen result 
Symptom at any level  n=407  % 
Tiredness, fatigue or lack of energy  231  56.8 
Back ache or pain  186  45.7 
Excessive flatulence  184  45.2 
Urinary urgency  180  44.2 
Leg ache or pain  179  44.0 
Urinary frequency  173  42.5 
Indigestion or heartburn  170  41.8 
Weight gain  134  32.9 
Pelvic discomfort or pain  131  32.2 
Increased abdominal size  129  31.7 
 
Table 5.24 shows the proportion of aware women who reported symptoms who 
went on to have either a normal or abnormal concurrent screen result. Increased 
abdominal  size  and  change  in  appetite  or  feeling  full  was  associated  with 
abnormal concurrent  screen results on two of the four levels of  analysis. The 
largest odds ratio was for feeling full at a frequency of ≥12 days and <12 months 
duration. Women who reported this were 3.55 (95% CI 1.02-12.37) times more 
likely  to  have  an  abnormal  concurrent  screen  result.  However,  the  lower 
confidence  limit  was  close  to  zero.  There  was  a  trend  for  women  who  were 
positive on the Goff or the Lurie symptom indices to have abnormal concurrent 
screen results, although this was not significant.  
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Table 5.24.  Symptom reporting in aware respondents who had a concurrent result (n=407) 
Symptom at any level  n  Abnormal concurrent 
result (%) 
Normal concurrent 
result (%)  OR (95% CI)  p-value 
Change in appetite  370  41 (17.6)  12 (8.8)  2.22 (1.13-4.40)  0.019 
Increased abdominal size  368  90 (39.0)  39 (28.5)  1.60 (1.02-2.53)  0.041 
Leg ache or pain  372  120 (52.4)  59 (41.3)  1.57 (1.03-2.39)  0.036 
Level 2-3 severity 
Increased abdominal size  364  37 (16.1)  9 (6.7)  2.66 (1.24-5.71)  0.009 
≥12 days & <12 months 
Feeling full quickly  347  17 (7.8)  3 (2.3)  3.55 (1.02-12.37)  0.035 
Symptom indices 
Positive on Goff symptom index*  381  55 (23.3)  25 (17.2)  ns  ns 
Positive on Lurie symptom index**  388  117 (48.5)  60 (40.8)  ns  ns 
 
* Pelvic discomfort/pain, abdominal discomfort/pain, feeling full quickly, abdominal bloating or increased abdominal size at ≥12 days and <12 months 
** Abdominal pain, increased abdominal size, abdominal mass or lumps or abnormal vaginal bleeding 
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5.3.12  Symptoms reported to GPs 
A total of 350 (42%) women consulted their GP about at least one of the 32 
symptoms during the past three months, with a median of two symptoms being 
discussed  with  GPs  (range  1-21,  IQR  1-5).  The  symptoms  most  commonly 
reported to GPs were backache or pain, leg ache or pain and tiredness or fatigue 
(Table 5.25). 
Table 5.25.  Symptoms most commonly reported to GPs 
Symptom at any level  n=829  % 
Back ache or pain  109  13.1 
Leg ache or pain  104  12.5 
Tiredness, fatigue or lack of energy  99  11.9 
Indigestion or heartburn  84  10.1 
Leg swelling  69  8.3 
Excessive flatulence  56  6.8 
Pelvic discomfort or pain  52  6.3 
Urinary frequency  51  6.2 
Shortness of breath  49  5.9 
Urinary urgency  48  5.8 
 
Table 5.26 lists the number of women who reported symptoms and the proportion 
who consulted a GP about the symptom during the past three months. Shaded 
boxes indicate the largest proportion of women who consulted their GP about 
symptoms  across  the  four  approaches.  The  top  ten  symptoms  based  on  any 
severity, and with no specified frequency or duration, for which a GP consultation 
had  been  undertaken  were:  leg  swelling  (53.5%),  abnormal  vaginal  bleeding 
(50.0%), abdominal mass or lump (46.2%), nausea or vomiting (45.2%), shortness 
of  breath  (42.3%),  abdominal  discomfort  or  pain  (40.3%),  abnormal  vaginal  
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discharge (40.0%), leg ache or pain (35.0%), pain when passing urine (33.3%) 
and back ache or pain (33.1%). 
Level 2-3 severity was the most important factor determining a GP visit, with 22 
of the 32 symptoms more likely to be reported to GPs when experienced at level 
2-3  severity.  Eleven  symptoms  were  more  likely  to  be  reported  to  GPs  when 
experienced at a frequency of ≥12 days, <12 months duration & level 2-3 severity.  
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Table 5.26.  Symptoms reported to GPs during the past three months 
Symptom reported 
At any level  Level 2-3 severity  ≥12 days & <12 months  ≥12 days, <12 months & 
level 2-3 severity 
n  Consulted 
GPn (%)  n  Consulted 
GPn (%)  n  Consulted 
GPn (%)  n  Consulted 
GPn (%) 
Pelvic discomfort or pain  123  26 (21.1)  39  14 (35.9)  28  7 (25.0)  17  6 (35.3) 
Abdominal discomfort or pain  72  29 (40.3)  30  20 (66.7)  14  6 (42.9)  11  5 (45.5) 
Indigestion or heartburn  150  46 (30.7)  48  22 (45.8)  20  5 (25.0)  11  5 (45.5) 
Nausea or vomiting  42  19 (45.2)  8  5 (83.3)  11  5 (45.5)  8  3 (35.7) 
Feeling full quickly  74  18 (24.3)  26  10 (38.5)  20  5 (25.0)  8  3 (35.7) 
Change in appetite  44  13 (29.5)  11  6 (54.5)  23  9 (39.1)  9  5 (55.6) 
Abdominal bloating or fullness  104  23 (23.1)  33  11 (33.3)  27  9 (33.3)  14  6 (42.9) 
Abdominal pressure  43  13 (30.2)  17  7 (41.2)  13  4 (30.8)  5  3 (60.0) 
Increased abdominal size  107  16 (15.0)  41  6 (14.6)  36  5 (13.9)  22  4 (18.2) 
Abdominal mass or lump  13  6 (46.2)  3  2 (66.7)  7*  2 (28.6)*  2*  1 (50.0)* 
Pelvic bloating or fullness  96  16 (16.7)  39  11 (28.2)  21  1 (4.8)  12  1 (8.3)  
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Symptom reported  At any level  Level 2-3 severity  ≥12 days & <12 months  ≥12 days, <12 months & 
level 2-3 severity 
Pelvic pressure  68  10 (14.7)  25  7 (28.0)  19  3 (15.8)  9  3 (33.3) 
Pelvic heaviness  59  11 (18.6)  20  6 (30.0)  20  3 (15.0)  9  3 (33.3) 
Pain before, during or after opening bowels  81  21 (25.9)  24  8 (33.3)  14  3 (21.4)  10  2 (20.0) 
Difficulty emptying bowels  100  24 (24.0)  39  16 (41.0)  65  19 (29.2)  35  15 (42.9) 
Change in bowel habit  68  18 (26.5)  28  13 (46.4)  24  8 (33.3)  18  8 (44.4) 
Excessive flatulence  165  28 (17.0)  82  18 (22.0)  37  8 (21.6)  30  6 (20.0) 
Urinary frequency  149  26 (17.4)  78  18 (23.1)  39  6 (15.4)  20  2 (10.0) 
Urinary urgency  160  26 (16.3)  79  18 (22.8)  35  7 (20.0)  23  5 (21.7) 
Pressure on the bladder  66  15 (22.7)  24  8 (33.3)  21  5 (23.8)  6  2 (33.3) 
Difficulty emptying bladder  31  7 (22.6)  7  3 (42.9)  8  2 (25.0)  3  1 (33.3) 
Pain when passing urine  9  3 (33.3)  2  2 (100.0)  5  2 (40.0)  1  1 (100.0) 
Shortness of breath  71  30 (42.3)  26  21 (80.8)  13  6 (46.2)  7  6 (85.7) 
Back ache or pain  163  54 (33.1)  73  43 (58.9)  32  12 (37.5)  17  9 (52.9)  
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Symptom reported  At any level  Level 2-3 severity  ≥12 days & <12 months  ≥12 days, <12 months & 
level 2-3 severity 
Leg ache or pain  157  55 (35.0)  73  43 (58.9)  47  12 (25.5)  27  10 (37.0) 
Leg swelling  71  38 (53.5)  29  19 (65.5)  29  12 (41.4)  16  9 (56.3) 
Tiredness, fatigue or lack of energy  200  52 (26.0)  95  31 (32.6)  65  16 (24.6)  41  12 (29.3) 
Weight gain  109  20 (18.3)  43  13 (30.2)  64*  8 (12.5)*  22*  6 (27.3)* 
Weight loss  25  8 (32.0)  7  3 (42.9)  22*  7 (31.8)*  5*  2 (40.0)* 
Abnormal vaginal bleeding  4  2 (50.0)  0  0  0  0  0  0 
Abnormal vaginal discharge  20  8 (40.0)  4  3 (75.0)  4  4 (100.0)  3  3 (100.0) 
Pain during or after sexual intercourse  28  4 (14.3)  9  2 (22.2)  1  0  1  0 
 
Note: Shaded cells indicate the largest proportion of women who reported the symptom to a GP across the four approaches to analysis. *Reported at <12 months 
duration only as frequency data not collected  
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5.3.13  Symptoms and depression screening status 
There  were  192  (23.2%)  women  who  reported  feeling  down,  depressed  or 
hopeless during the past month and 170 (20.5%) who reported little interest or 
pleasure  doing  things,  with  a  total  of  220  (26.5%)  being  depression  screen 
positive (answering yes to one or both questions). 
Women  who  were  depression  screen  positive  were  more  likely  to  report 
symptoms with odds ratios ranging from 2.84 (95% CI 2.04-3.95) for symptoms 
at  ≥12  days  and  <12  months,  up  to  7.02  (95%  CI  2.81-17.57)  for  report  of 
symptoms at any level (Table 5.27). Depression screen positive women were also 
more likely to have discussed symptoms with a GP during the past three months 
(OR 2.63, 95% CI 1.91-3.61) and to be positive on the Goff (OR 2.80, 95% CI 
1.89-4.15) and Lurie symptom indices (OR 2.65, 95% CI 1.91-3.68). 
Depression screen positive women reported a greater number of symptoms overall 
(Mdn 9.0 vs. Mdn 4.0, U = 34791.0, p < 0.0001, r = -0.43) and a greater number 
of symptoms at ≥12 days frequency and <12 months duration (Mdn 1.0 vs. Mdn 0, 
U = 43693.0, p < 0.0001, r = -0.30) (Table 5.27). Effect sizes indicate a moderate 
increase in the number of symptoms with depression screen positive status. 
A  larger  proportion  of  screening  group  women  responded  yes  to  one  or  both 
depression questions compared to controls (29.2% vs. 20.5%, χ
2(1) = 5.0, p = 
0.026). However, there was no difference in the proportion of unaware women in 
the  screen  group  compared  to  controls  who  were  depression  screen  positive 
(25.9%  vs.  20.5%,  ns).  Among  those  who  had  prior  awareness  of  a  possible 
ovarian  lesion,  31.1%  screened  positive  for  depression  compared  to  23.7% 
unaware or control women (χ
2(1) = 5.6, p = 0.018). Most importantly, there was 
no  association  between  concurrent  screen  result  and  depression  status  in  all 
women,  or  in the subgroup  of those who  were aware of the possibility  of an 
ovarian lesion.  
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Table 5.27.  Symptoms in depression screen positive vs. depression screen negative women 
Symptom reported  n 
Depression screen 
positive (% or 
IQR) 
Depression screen 
negative (% or 
IQR) 
Odds ratio (95% 
CI)  p-value 
At any level 
Reported 
804 
215 (97.7)  502 (86.0)  7.02 (2.81-17.57)  <0.0001 
Median  9.0 (5.0-15.0)  4.0 (2.0-8.0)  -  <0.0001 
Range  0-26  0-24  - 
Level 2-3 severity 
Reported 
789 
176 (80.0)  301 (51.5)  4.09 (2.79-6.00)  <0.0001 
Median  0 (0-2.0)  0 (0-0)  -  - 
Range  0-17  0-17  - 
≥12 days & <12 months 
Reported 
789 
146 (66.4)  245 (42.0)  2.84 (2.04-3.95)  <0.0001 
Median  1.0 (0-2.0)  0 (0-1.0)  -  <0.0001 
Range  0-20  0-19  -  
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Symptom reported  n 
Depression screen 
positive (% or 
IQR) 
Depression screen 
negative (% or 
IQR) 
Odds ratio (95% 
CI)  p-value 
≥12 days, <12 months & level 2-3 severity 
Reported 
790 
99 (46.0)  129 (22.4)  2.95 (2.12-4.11)  <0.0001 
Median  0 (0-4.0)  0 (0-1.0)  -  - 
Range  0-17  0-17  - 
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Depression screen positive women were more likely to report all 32 symptoms at 
any level and at level 2-3 severity they were more likely to report 27 symptoms. 
However,  there  was  no  association  between  depression  status  and  report  of 
abdominal  mass  or  lump,  pain  passing  urine,  weight  loss,  abnormal  vaginal 
bleeding and abnormal vaginal discharge at level 2-3 severity. 
Table 5.28 lists the proportion of depression screen positive and negative women 
who reported symptoms at ≥12 days frequency and <12 months duration and ≥12 
days, <12 months and level 2-3 severity. In the interest of brevity, symptoms more 
likely to be reported at any level and at level 2-3 severity are omitted from the 
table.  Interestingly,  abdominal discomfort/pain had  the highest  odds ratio (OR 
10.12, 95% CI 3.68-27.83) for symptoms at ≥12 days and <12 months, yet the 
odds ratio for pelvic discomfort or pain was much lower (OR 3.12, 95% CI 1.67-
5.81). At level 2-3 severity, ≥12 days and <12 months abdominal discomfort/pain 
also  had  the  highest  odds  ratio  (OR  9.49,  95%  CI  3.05-29.45),  followed  by 
shortness of breath (OR 8.92, 95% CI 2.38-33.30) and pressure on the bladder 
(OR 7.82 (2.05-29.80). 
Feeling  full  was  more  likely  to  be  reported  by  depression  screening  positive 
respondents on three of the four approaches,  with the exception being for the 
symptom at level 2-3 severity, ≥12 days and <12 months. However, as reported 
earlier,  this  symptom  was  not  associated  with  elevated  ROC  score,  abnormal 
ovarian morphology, ovarian volume or overall abnormal screen result.  
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Table 5.28.  Symptoms reported by depression screen positive vs. negative respondents 
Symptom reported  n 
Depression screen 
positive 
n (%) 
Depression screen 
negative 
n (%) 
OR (95% CI)  p-value 
≥12 days & <12 months 
Pelvic discomfort or pain  735  22 (11.2)  21 (3.9)  3.12 (1.67-5.81)  <0.0001 
Abdominal discomfort or pain  738  17 (8.6)  5 (0.9)  10.12 (3.68-27.83)  <0.0001 
Indigestion or heartburn  743  17 (8.5)  13 (2.4)  3.82 (1.81-8.01)  <0.0001 
Nausea or vomiting  739  12 (6.1)  5 (0.9)  6.97 (2.42-20.04)  <0.0001 
Feeling full quickly  717  19 (10.2)  17 (3.2)  3.41 (1.73-6.72)  <0.0001 
Change in appetite  727  19 (10.0)  15 (2.8)  3.87 (1.92-7.78)  <0.0001 
Abdominal bloating or fullness  720  25 (13.2)  20 (3.8)  3.89 (2.11-7.20)  <0.0001 
Abdominal pressure  726  16 (8.4)  7 (1.3)  6.95 (2.81-17.17)  <0.0001 
Increased abdominal size  705  26 (14.2)  35 (6.7)  2.30 (1.35-3.95)  0.002 
Pelvic bloating or fullness  720  15 (8.1)  17 (3.2)  2.69 (1.31-5.50)  0.005 
Pelvic pressure  720  11 (5.9)  12 (2.3)  2.71 (1.18-6.26)  0.015  
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Symptom reported  n 
Depression screen 
positive 
n (%) 
Depression screen 
negative 
n (%) 
OR (95% CI)  p-value 
≥12 days & <12 months 
Pelvic heaviness  717  14 (7.8)  11 (2.0)  4.03 (1.80-9.05)  <0.0001 
Pain before, during or after opening bowels  736  13 (6.8)  8 (1.5)  4.90 (2.00-12.02)  <0.0001 
Difficulty emptying bowels  728  46 (24.1)  69 (12.8)  2.15 (1.42-3.27)  <0.0001 
Change in bowel habit  718  18 (9.6)  15 (2.8)  3.64 (1.79-7.37)  <0.0001 
Excessive flatulence  700  28 (15.3)  39 (7.5)  2.21 (1.32-3.72)  0.002 
Urinary frequency  689  27 (14.8)  39 (7.7)  2.09 (1.24-3.53)  0.005 
Urinary urgency  690  26 (14.5)  33 (6.5)  2.46 (1.43-4.25)  0.001 
Pressure on the bladder  714  16 (8.6)  16 (3.0)  2.99 (1.46-6.10)  0.002 
Pain when passing urine  728  6 (3.2)  0  ∞  <0.0001 
Shortness of breath  719  15 (8.0)  5 (0.9)  9.19 (3.29-25.66)  <0.0001 
Back ache or pain  713  27 (14.4)  27 (5.1)  3.12 (1.78-5.47)  <0.0001  
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Symptom reported  n 
Depression screen 
positive 
n (%) 
Depression screen 
negative 
n (%) 
OR (95% CI)  p-value 
≥12 days & <12 months 
Leg ache or pain  696  28 (15.0)  46 (9.0)  1.77 (1.07-2.93)  0.024 
Leg swelling  721  19 (10.1)  23 (4.3)  2.49 (1.33-4.69)  0.004 
Tiredness, fatigue or lack of energy  658  64 (36.8)  49 (10.1)  5.17 (3.37-7.91)  <0.0001 
Weight gain*  716  49 (25.9)  65 (12.3)  2.49 (1.64-3.77)  <0.0001 
≥12 days, <12 months & level 2-3 severity 
Pelvic discomfort or pain  758  16 (7.8)  10 (1.8)  4.56 (2.04-10.23)  <0.0001 
Abdominal discomfort or pain  738  13 (6.6)  4 (0.7)  9.49 (3.05-29.45)  <0.0001 
Indigestion or heartburn  743  11 (5.5)  5 (0.9)  6.31 (2.16-18.39)  <0.0001 
Nausea or vomiting  738  9 (4.6)  4 (0.7)  6.47 (1.97-21.27)  0.001 
Change in appetite  727  9 (4.7)  6 (1.1)  4.40 (1.55-12.53)  0.005 
Abdominal bloating or fullness  720  14 (7.4)  10 (1.9)  4.17 (1.82-9.55)  <0.0001  
 
286
 
Symptom reported  n 
Depression screen 
positive 
n (%) 
Depression screen 
negative 
n (%) 
OR (95% CI)  p-value 
≥12 days, <12 months & level 2-3 severity 
Increased abdominal size  703  16 (8.7)  18 (3.5)  2.67 (1.33-5.36)  0.004 
Pelvic bloating or fullness  720  8 (4.3)  8 (1.5)  2.98 (1.10-8.05)  0.038 
Pelvic pressure  720  7 (3.7)  5 (0.9)  4.11 (1.29-13.10)  0.017 
Pelvic heaviness  718  8 (4.4)  5 (0.9)  4.92 (1.59-15.24)  0.006 
Pain before, during or after opening bowels  736  9 (4.7)  5 (0.9)  5.34 (1.77-16.14)  0.003 
Difficulty emptying bowels  728  24 (12.6)  30 (5.6)  2.43 (1.38-4.27)  0.002 
Change in bowel habit  718  10 (5.3)  10 (1.9)  2.92 (1.20-7.13)  0.014 
Excessive flatulence  700  25 (13.7)  21 (4.1)  3.74 (2.04-6.86)  <0.0001 
Pressure on the bladder  715  8 (4.3)  3 (0.6)  7.82 (2.05-29.80)  0.002 
Shortness of breath  719  9 (4.8)  3 (0.6)  8.92 (2.38-33.30)  <0.0001 
Back ache or pain  713  15 (8.0)  13 (2.5)  3.44 (1.61-7.38)  0.001  
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Symptom reported  n 
Depression screen 
positive 
n (%) 
Depression screen 
negative 
n (%) 
OR (95% CI)  p-value 
≥12 days, <12 months & level 2-3 severity 
Leg ache or pain  696  21 (11.2)  26 (5.1)  2.35 (1.29-4.29)  0.004 
Tiredness, fatigue or lack of energy  658  43 (24.7)  27 (5.6)  5.60 (3.33-9.41)  <0.0001 
Weight gain*  717  17 (9.0)  21 (4.0)  2.39 (1.23-4.63)  0.008 
 
*Reported at <12 months duration only as frequency data not collected  
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5.4  Discussion 
The findings of this pilot suggest that ovarian cancer symptom reporting is very 
complex.  It  is  influenced  by  a  number  of  factors  including  participation  in 
screening,  age,  awareness of a possible ovarian lesion and positive depression 
screening  status,  in  addition  to  the  presence  of  a  screen-detected  abnormality. 
Results  indicate  that  awareness  of  the  possibility  of  an  ovarian  lesion  is  an 
overriding  factor  which  influences  both  symptom  reporting  and  depression 
screening status. We were unable to test this hypothesis in multivariate logistic 
regression models as awareness was not an independent variable (i.e. it was based 
upon  previous screen  result  which was strongly correlated with  the dependent 
outcome variable - concurrent screen result). Awareness of the possibility of an 
ovarian lesion is likely to be a proxy for anxiety. Unfortunately, the study design 
did not permit assessment of anxiety generated by the need for further testing. 
Symptom prevalence 
The proportion of women who reported any symptoms was considerably higher 
than previous studies. For example, 86% of women in the control group were 
symptomatic  compared  to  42%  and  52%  reported  by  two  US  studies  which 
recruited  community  dwelling  women  as  controls.
16-17  When  the  analysis  was 
restricted  to  approximately  similar  symptoms,  40%  of  OCSq  control  group 
women  reported  bloating/fullness  or  pressure  in  the  abdomen  or  pelvis,  while 
Olson et al.
17 found 9% of controls reported this for the 6-12 months prior to 
interview. Differences were more dramatic for the combination of abdominal or 
pelvic  discomfort/pain,  pressure  or  heaviness,  which  was  reported  by  32%  of 
OCSq controls during the past week compared to 10% of controls who reported 
this during the two weeks prior to interview in Vine et al.
16 Similarly, increased 
abdominal  size  was reported by 25% of OCSq  controls compared to 3%  in a 
recent US study.
25  
The higher prevalence  of symptoms in our research is likely to be due to the 
inclusion of a comprehensive list of 32 symptoms in the OCSq. Women in the 
Olson et al.
17 and Vine et al.
16 studies were asked about similar types of pelvic  
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and abdominal symptoms grouped together into a single item, while, for example, 
the OCSq listed five separate items to elicit information on abdominal or pelvic 
discomfort/pain, pressure or heaviness. Asking women about specific symptoms 
in separate items is likely to increase reporting due to either an acquiescent or 
memory cueing effect.
129 141 The high prevalence of symptoms among women in 
our  research  may  also  be  due  to  older  age,  as  ≥50%  of  controls  in  the  two 
comparative  studies  were  aged  under  50  years.  It  is  unlikely  that  symptom 
reporting  was  related  to  increased  prevalence  of  underlying  disease,  as 
UKCTOCS volunteers have lower overall and disease-specific mortality rates.
220 
The large proportion of symptomatic women among those with normal concurrent 
screen results (88%) highlights the need to increase specificity by restricting the 
number of symptoms, adding severity or  frequency  and duration  criteria, or a 
combination of these, to investigate symptoms associated with ovarian cancer in 
follow-up analyses of the 100,000 women study. Restricting analyses to the key 
symptoms  of  abdominal  or  pelvic  discomfort/pain,  increased  abdominal  size, 
abdominal  or  pelvic  bloating/fullness  and  change  in  appetite  or  feeling  full 
reduced  the  proportion  of  symptomatic  women  to  55%,  although  this  still 
identified nearly half (46%) of those who had a normal screen result. 
Symptoms associated with abnormal screening results 
The  most  frequently  reported  symptoms  among  the  postmenopausal  women 
surveyed  were  tiredness/fatigue,  backache/pain,  leg  ache/pain,  excessive 
flatulence, weight gain, indigestion/heartburn and urinary frequency/urgency. In 
comparison,  women  with  abnormal  screen  results  were  more  likely  to  report 
increased abdominal size, abdominal or pelvic pressure, pelvic bloating/fullness, 
pelvic heaviness and shortness of breath. 
Many studies have described abdominal or pelvic pain as among the three most 
common  symptoms  of  ovarian  cancer,  with  research  indicating  that  these 
symptoms often have the largest odds ratios between ovarian cancer cases and 
controls.
9 12 16 19-21 23 46-47 50-51 72-73 121 124 Although one of the two women diagnosed 
with cancer reported both abdominal and pelvic discomfort/pain, these symptoms 
were  not  associated  with  abnormal  concurrent  screen  result,  elevated  CA125,  
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elevated ROC, complex ovarian morphology or increased ovarian volume at any 
level of analysis. This contrasts with Rufford et al.
221 who reported abdominal 
discomfort/pain in 18 out of 23 women with an ovarian abnormality detected on 
ultrasound and 10 out of 13 women with raised CA125. Unfortunately, the only 
other study to-date which investigated symptoms associated with CA125 results 
did not report the percentage of women with abdominal or pelvic discomfort/pain 
among those with elevated CA125 levels.
24 
Multivariate  analyses  identified  abdominal  or  pelvic  pressure  as  the  only 
symptoms which independently predicted an abnormal screen result on three of 
the four approaches, although shortness of breath was included in the final models 
on two approaches. All four symptom models performed only marginally better 
than chance for identifying abnormal screen results, as the largest area under the 
curve  was  0.62  (for  pelvic  pressure  and  tiredness/fatigue  at  any  severity, 
frequency  and  duration).  Given  the  ubiquity  of  tiredness/fatigue  among 
postmenopausal women it is unsurprising that the model with the highest area 
under the curve for detecting an abnormal result had the lowest specificity for 
detecting ovarian cancer. 
With  the  exception  of  urinary  symptoms  and  shortness  of  breath,  symptoms 
associated with elevated CA125 level differed to those associated with elevated 
ROC scores. This may be due to the higher sensitivity of ROC scores for the 
detection  of  ovarian  cancer  compared  to  CA125  level  alone.  Women  with 
elevated  ROCs  were  more  likely  to  report  symptoms  previously  described  as 
associated  with  ovarian  cancer,  including  increased  abdominal  size,  pelvic 
bloating/fullness and urinary symptoms.
12 14-16 18 20 22-23 46 50 
Pelvic pressure and change in bowel habit were the only two symptoms associated 
with complex ovarian morphology. Ten percent of women with complex masses 
reported  change  in  bowel  habit,  which  is  less  than  the  27%  who  reported 
constipation,  and  18%  who  reported  diarrhoea,  in  another  study  which 
investigated symptoms associated with complex ovarian morphology detected on 
ultrasound.
222 Analysis  of symptoms  associated with ultrasound-estimated total 
ovarian volume in those with complex morphology identified urinary frequency  
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and abdominal bloating as associated with larger volumes, which seems plausible 
on a physiological basis. However, the former was reported by both women with 
screen  detected  cancers,  despite  relatively  small  ultrasound-estimated  ovarian 
volumes.  The  association  between  smaller  volumes  and  leg  swelling  is  more 
difficult to interpret and may be a spurious finding. 
Feeling full was notable in that it was associated with abnormal concurrent screen 
result in the sub-group  of aware women. Several studies have described early 
satiety or difficulty eating as a symptom of ovarian cancer.
8 13 15-16 18 23 46 48 124  Its 
importance as a key symptom is reflected by its inclusion in the Goff symptom 
index and both the US and UK symptoms consensus statements.
30 32 It is to be 
noted  that  neither  of  the  two  women  diagnosed  with  cancer  reported  this 
symptom, although it is possible that this is a reflection of the low volume early 
stage disease detected on screening. 
Performance of symptom models and indices for identifying ovarian cancer 
In  this  pilot  of  829  apparently  healthy  postmenopausal  women,  only  1-2 
ovarian/tubal  cancers  were  expected.  The  four  models  which  independently 
predicted an abnormal result were investigated for their usefulness in detecting 
these cancers, and the results were compared with the Goff and Lurie symptom 
indices. All the models and indices had a sensitivity of 50.0%, with very wide 
confidence  intervals  reflecting  the  small  number  of  cases.  However  it  was 
possible to better estimate specificity, which ranged from 44.4%, for Model 1, up 
to 97.6  for Model  4 (abdominal pressure and  shortness of breath  at level  2-3 
severity,  ≥12  days  frequency and  <12  months  duration). With  a  specificity  of 
84.5%, the Goff symptom index performed similarly in our sample compared to 
the authors’ original study, where a sensitivity of 56.7% was reported for early-
stage ovarian cancer with specificities ranging from 86-90%.
23 The Lurie index 
had  a  lower  specificity  (60.8%)  among  our  sample  than  was  reported  in  the 
authors’ own research, where their four-symptom model had a specificity of 71%. 
These  preliminary  findings  emphasise  the  importance  of  exploring  a  range  of 
different  indices.  They  also  underscore  the  likelihood  that  a  symptoms  index  
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developed  from  prospective  research  may  differ  from  previously  published 
indices. 
Impact  of  screening  and  awareness  of  an  ovarian  lesion  on  symptom 
reporting 
Women who participated in the OCSq pilot were either UKCTOCS controls or 
screening group women scheduled to receive annual or repeat (Level 2) screening 
within  4-6  weeks.  Comparison  of  symptoms  between  the  groups  revealed 
screened women were 1.4-1.6 times more likely to report symptoms at three of the 
four levels of analysis. They were also more likely to report key symptoms of 
ovarian cancer, including pelvic discomfort or pain, abdominal bloating/fullness, 
feeling full and change in bowel habit, although they were not more likely to be 
positive  on  the  Goff  or  Lurie  symptom  indices.  As  severity,  frequency  and 
duration criteria were added to individual symptoms, the number of symptoms 
associated with screening was reduced. Lower symptom reporting among controls 
was not related to lower education levels as educational attainment was equivalent 
across the groups, as were other baseline characteristics, this being a randomised 
controlled trial. The finding could be related to women undergoing ovarian cancer 
screening  being  better  informed  (either  through  contact  with  screening  staff, 
literature  displayed  in  clinics  or  their  own  information  searches  prompted  by 
screening) and paying more attention to symptoms associated with ovarian cancer. 
Alternatively, this finding may reflect subtle symptoms related to the presence of 
abnormalities  as  half  the  screen  group  were  respondents  scheduled  for  repeat 
screening due to the detection of a possible abnormality on annual screening. 
In  order  to  explore  this  difference  in  symptom  reporting  between  women 
undergoing screening and no intervention (controls), symptoms were analysed in 
relation to awareness of a possible ovarian lesion. Women who were aware of a 
possible ovarian lesion were more likely to report symptoms across three of th
9e 
four  levels  of  analysis.  Analysis  of  individual  symptoms  revealed  that  aware 
women were more likely to report key symptoms listed in the literature, such as 
pelvic or abdominal discomfort/pain, increased abdominal size, urinary symptoms 
and  change  in  bowel  habit.  In  contrast,  there  was  no  significant  difference  
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between  the  proportion  of  screened  women  attending  for  annual  screening 
(unaware of an abnormality) and controls who reported symptoms overall across 
the four approaches. Unaware screened women were more likely than controls to 
report  feeling  full and  controls were  more likely to  report, backache/pain and 
nausea/vomiting. It is difficult to ascertain why these differences arose but it must 
be noted that the lower confidence limits in all these cases were close to one. 
To further elucidate the relationship between awareness, symptom reporting and 
the  presence  of  ovarian  lesions,  symptoms  were  investigated  according  to 
concurrent  screen  results  in  aware  women.  This  analysis  revealed  that  aware 
women (ie. those who had a previously abnormal screen result) with change in 
appetite, feeling full, increased abdominal size or leg ache/pain were more likely 
to  have  an  abnormal  concurrent  screen  result.  This  finding  is  similar  to 
retrospective  and  medical  records  research  which  has  reported  increased 
abdominal size, change in appetite or feeling full are among the most common 
symptoms reported by women with ovarian cancer.
13 16 18 23 25 46-47 51 
 Increased 
abdominal size is also commonly reported by women with benign, borderline and 
early stage tumours.
16 18 22 50-51 121 123 Medical and insurance records studies also 
indicate that increased abdominal size is commonly experienced several months 
prior to diagnosis,
20 72 121 123 
 with one study finding an elevated odds ratio for the 
symptom in medical notes up to 30 months before diagnosis.
21  
To control for the effect of awareness on symptom reporting, a useful analysis 
would be investigating symptoms reported by unaware respondents who went on 
to have an abnormal concurrent screen result. Unfortunately, numbers were too 
small (n = 18) to conduct this analysis, although it is expected that there will be 
sufficient numbers for analysis in the larger study described in Chapter Six. 
It  is  highly  plausible  that  anxiety  increased  symptom  reporting  among  screen 
group women who were aware of a possible ovarian lesion. Anxiety may have 
heightened  women’s  attention  to  bodily  sensations  and  knowledge  seeking 
behaviours  such  as  searching  websites  for  information  about  ovarian  cancer 
symptoms. Regrettably, we overlooked inclusion of a question on the OCSq about 
health  information searches related  to ovarian  cancer. Anxiety  associated with  
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awareness could have been measured by asking all respondents to complete a 
Hospital  Anxiety  and  Depression  Scale  (HADS)  or  Speilberger  Trait  Anxiety 
Inventory (STAIT) questionnaire at the same time as OCSq. However, there is a 
parallel study collecting detailed information on anxiety and other psychosocial 
morbidity resulting from screening (described in Chapter One). Women in the 
pilot  who  were  attending  repeat  screening  would  have  been  sent  the  HADS 
questionnaire  as  part  of  this  study.  We  did  not  wish  to  confuse  women  and 
contaminate the existing data collection by asking them to complete two anxiety 
measures. In due course this data should be available in the 51% of respondents 
who were in the aware group. This is not ideal and arrangements could have been 
made to send the questionnaire to the remaining respondents if such a large effect 
had been anticipated. 
Symptoms associated with depression screening status 
The  finding  that  27%  of  respondents  screened  positive  for  depression  is 
considerably  higher  than  the  6%  of  women  65  years  or  older  who  screened 
positive for depression in a large US study,
223 8% of women aged over 60 in an 
Australian study,
224 and 10% of people aged 65 years or over in a UK study.
225 
This  high  prevalence  of  depression  persisted,  even  when  comparisons  were 
limited to respondents from the control group. One explanation is that the two-
question  depression  screening  method  used  in  our  research  may  have  lower 
specificity  compared  to  multi-factorial  depression  screening  tools  such  as  the 
Patient Health Questionnaire (PHQ) used in the other studies, although the two-
questions  have  been  previously  found  to  have  specificities  ranging  from  57-
84%.
212-215 217-218 226 Goff et al.
23 also used a comprehensive depression screening 
measure  consisting  of  20  items  on  a  four-point  Likert  scale  (the  Center  for 
Epidemiologic Studies Depression Scale - CES-D), although the authors do not 
report the percentage of women who screened positive for depression. 
The finding that women who screened positive for depression were more likely to 
report symptoms, and reported a greater number of symptoms, is congruent with 
the findings of the recent Goff study.
23 However, in contrast to the Goff study, 
neither  of  the  two  women  diagnosed  with  malignancy  screened  positive  for  
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depression. These two women, like those in Goff series, were attending for further 
investigations and were aware of an abnormality at the time of completing the 
OCSq . 
There was also no association between depression screening status and abnormal 
concurrent screen results. However, respondents who had prior awareness of a 
possible  abnormality  were  more  likely  to  screen  positive  for  depression.  This 
suggests Goff et al.’s
23 finding that depression was significantly associated with 
cancer is likely to be the product of heightened awareness of the possibility of 
malignancy,  or  anxiety  related to  impending  surgery, rather  than  a  product of 
physiological  changes  associated  with  the  disease.  It  also  adds  weight  to  our 
impression that awareness has a psychological impact in the absence of specific 
data on anxiety. 
In contrast to the Goff group, we did not enter depression screening status into 
multivariate analyses. In their confirmatory logistic regression, Goff et al.
23 found 
depression was independently predictive of ovarian cancer in women under 50 
years of age. This analysis appears methodologically flawed as the authors did not 
take into account the impact of awareness of the possibility of malignancy on 
depression screening results. Moreover, the inclusion of depression status into a 
predictive model for ovarian cancer fails to acknowledge the complex relationship 
between depression and symptom reporting.
227-234 
Symptoms reported to GPs 
The top symptoms out of the list of 32 for which the GP was consulted were 
backache/pain,  leg  ache/pain  and  tiredness/fatigue.  The  pilot  confirmed  our 
intuitive impression that respondents were most likely to consult their GP when 
symptoms  were  experienced  at  level  2-3  severity.  Only  in  the  case  of 
postmenopausal bleeding did women consult their GP, irrespective of severity. 
This has significant implications for our attempts to improve time to diagnosis of 
ovarian  cancer.  Previous  research  has  shown  frequency  and  recent  onset  of 
symptoms as the main issues to be considered in women with ovarian cancer.
17-18 
20  23  46  In  contrast,  only  one  published  study  reported  severity  was  of 
significance,
18 although recent PhD research found both higher level severity and  
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increased  frequency  characterised  key  symptoms  such  as  bloating/increased 
abdominal  size,  pelvic/abdominal  pain,  loss  of appetite  and  fatigue  in  ovarian 
cancer cases compared to controls.
34 
Severity  is  not  a  feature  of  either  the  US  or  the  UK  symptoms  consensus 
statements.
30  32  However,  our  pilot  revealed  that  abdominal  or  pelvic  pain, 
increased abdominal size and feeling full were discussed with the GP only when 
experienced at level 2-3 severity. This suggests that women and GPs need to be 
educated about the importance of frequency and duration criteria alone if current 
initiatives are to make a real impact. 
Study strengths 
A unique strength of the research described in this chapter was the use of a valid 
and  reliable  questionnaire  (as  demonstrated  from  the  analyses  presented  in 
Chapter  Four),  developed  specifically  to  elicit  information  on  ovarian  cancer 
symptoms.  The  robustness  of  the  instrument  is  reflected  by  the  fact  that  no 
respondents were excluded from analysis on the basis of illegible data. 
The study recruited a large number of women (n = 829). The response rate was 
slightly higher than the 60% generally considered acceptable for postal surveys,
235 
although it was equivalent to the median reported in medical journals.
236 Women 
were recruited from 13 centres throughout England, Wales and Northern Ireland, 
ensuring a regionally and socially heterogeneous study population. 
Prospective data collection is a chief strength of the research. While other studies 
have  attempted  to  collect  data  prospectively,  this  is  the  first  study  to  include 
symptom  data  collection  in  women  who  were  aware  of  the  possibility  of  an 
abnormality but who were not yet assessed by a gynaecological oncologist. The 
women in the control group were similar to healthy controls in other studies that 
used community-based populations. 
The conduct of this study within an ovarian cancer screening trial is a foremost 
strength of the study. This facilitates the detection of ovarian cancer at early stage 
when the disease volume is low. The enrichment of ovarian cancer cases with 
early stage disease where prompt diagnosis can make a real impact is crucial. In 
many studies reported in the literature, symptoms one year prior to diagnosis are  
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correlated with the stage of disease at diagnosis. At present, there is insufficient 
evidence  to  prove  disease  progression  over  time,  although  studies  implicitly 
assume that stage of disease was static during the pre-diagnosis period. 
The  OCSq  elicited  symptoms  data  using  a  one-week  reference  period.  This 
timeframe  is  another  advantage  of the study, as  research indicates that asking 
participants about events during the past seven days yields more accurate data 
than one-month or longer time periods.
131 160 205 
Study limitations 
The findings of this chapter are limited by higher response rates among women 
attending screening  compared to controls,  and among women  attending repeat 
screening compared to those attending annual screening. This is likely to have 
biased  the  findings  through  the  recruitment  of  women  who  have  enhanced 
knowledge of the symptoms of ovarian cancer. It is also possible that different 
response rates resulted in the recruitment of women who were anxious about their 
screening and were therefore more attuned to symptoms. This is likely to have 
resulted in over-reporting bias, which is another factor which may explain the 
large percentage of symptomatic women. However, this is likely to have occurred 
in all previous questionnaire studies of ovarian cancer symptoms. 
Unfortunately,  it  was  not  possible  to  measure  anxiety  as  this  was  an  existing 
component of the UKCTOCS trial. Data on anxiety may have led to important 
insights about symptom reporting  associated with different levels  of screening 
investigations. 
As  the  aim  of  the  pilot  was  validation  of  an  ovarian  cancer  symptoms 
questionnaire, we deliberately enriched the population with a large proportion of 
women who had an abnormality detected on their previous screen. We considered 
that these women would be able to provide feedback on the wording of symptoms 
rarely  experienced  by  healthy  women,  such  as  abdominal  mass  or  lumps. 
However, as discussed earlier, this is likely to have led to over-reporting bias. 
While this was unavoidable in the pilot, the final study described in Chapter Six 
should succeed in recruiting sufficient numbers of women who are unaware of an 
abnormality, and thus reduce this source of bias.  
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5.5  Summary 
The analyses presented in this chapter found variation in the types of symptoms 
associated with abnormal ovarian cancer screening results. No symptoms were 
associated  with  abnormality  on  all  screening  modalities,  although  increased 
abdominal size, abdominal or pelvic pressure and urinary frequency or urgency 
were  frequently  associated  with  abnormal  results.  Stronger  associations  were 
observed between awareness of a possible ovarian lesion or depression status and 
symptom  reporting,  than  abnormal  concurrent  screen  result  and  symptom 
reporting. However, symptom reporting in aware women may be a result of early 
physiological changes associated with malignant or benign masses, rather than 
awareness  of  the  possibility  of  an  ovarian  lesion  per  se.  Symptom  indices 
described  by  other  groups  had  lower  sensitivity  and  specificity  among  OCSq 
respondents,  although  sensitivity  analyses  were  greatly  restricted  by  the  small 
number of cancer cases. Lastly, the types of symptoms found to be associated 
with abnormal screen results differed across the four levels of analysis. These 
inconsistencies will be further explored in the larger study described in Chapter 
Six.  
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Chapter Six – Analysis of Baseline Data from the OCSq 
Survey of 100,000 Postmenopausal Women 
6.0  Introduction 
This chapter describes the methods and preliminary findings of the prospective 
symptoms study using the finalised OCSq. Earlier chapters of this thesis described 
the paucity of research utilising validated questionnaires and the urgent need for a 
prospective  study,  designed  to  collect  symptoms  data  prior  to  women  being 
assessed by specialist gynaecological oncologists. Many studies have described 
abdominal or pelvic pain, increased abdominal size, bloating, change in appetite, 
urinary frequency or urgency, change in bowel habit and tiredness or fatigue as 
key symptoms of ovarian cancer.
8-10 13-19 22-23 46-47 50-51 73 121 However, Chapter Five 
demonstrated that women who are aware of the possibility of an ovarian lesion are 
more  likely  to  report  these  symptoms,  even  though  few  were  subsequently 
diagnosed with malignancy during follow-up. Several questions arose from these 
analyses, including whether symptoms are related to pre-malignant pathological 
changes, or whether knowledge of the possibility of malignancy prompts greater 
attention to, and perception of, key symptoms. 
6.1  Aims 
●  To estimate the prevalence of ‘key symptoms’ in apparently healthy 
women participating in the finalised OCSq study 
●  To investigate symptoms reported by women receiving ovarian 
cancer screening compared to controls 
●  To explore symptoms according to awareness of the possibility of an 
ovarian lesion  
300 
●  To describe GP consultations for symptoms and assess consultation 
behaviour associated with symptom severity, frequency and duration 
●  To describe depression screening status and investigate symptoms 
associated with depression screening positive status 
6.2  Methods 
6.2.1  Study power 
A  power  calculation  was  conducted  in  2006,  prior  to  the  original  ethics 
application. At this time, the estimated 75% response rate was based upon the 
response  rate  to  the  first  UKCTOCS  follow-up  questionnaire  (described  in 
Chapter One).  Incidence of ovarian cancer was  estimated at  approximately 50 
cases per year per 100,000 women aged over 50. Therefore 1.5 years of follow-up 
may be expected to result in 75 women diagnosed with ovarian cancer. However, 
a healthy volunteer effect has since been confirmed in the UKCTOCS cohort.
220 
This would reduce the number of cases to 49, given a 75% response rate. As the 
pilot found a response rate of 52%, the number of cases may be further reduced to 
25. 
Power  estimates  based  on  testing  a  difference  in  proportions  (normal 
approximation) between cases and non-cases with alpha = 0.05 and a two-sided 
test were calculated for key symptoms of ovarian cancer. This calculation used the 
difference  in  proportions  from  retrospective  questionnaire  research  which 
recruited community-based healthy women as controls.
16 The power of the test 
was very close to one for bloating, increased abdominal size and abdominal/pelvic 
pain, regardless of the response rate, as the anticipated differences between the 
two proportions for these symptoms was large. However, the pilot data analyses 
confirmed earlier reservations regarding tests using the difference in proportions 
of  symptoms at  any level of severity,  frequency  or duration. This inflates  the 
proportion of healthy women with key symptoms of ovarian cancer. Addition of 
level  2-3  severity  criteria,  or  ≥12  days  frequency  and  <12  months  duration, 
reduces the proportion of healthy women with key symptoms to similar levels 
reported by other research.  
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6.2.2  Sample selection 
A  total  of  100,000  randomly  selected  UKCTOCS  volunteers  were  posted  the 
finalised  OCSq.  This  group  included  55,000  controls,  22,500  multimodal  and 
22,500 ultrasound group women. 
Inclusion criteria 
●  Volunteers in the UKCTOCS control, multimodal and ultrasound 
groups 
Exclusion criteria 
●  Volunteers who had died 
●  Volunteers who had previously undergone UKCTOCS trial surgery 
●  Volunteers who had both ovaries removed outside the trial 
●  Volunteers who had registered a complaint about previous 
questionnaires 
●  Volunteers who had requested no further contact from UKCTOCS for 
any reason 
●  Volunteers who had been lost to follow-up due to moving home 
6.2.3  Data collection 
The finalised OCSq (described in Chapter Four and presented in appendix 22), 
cover  letter  (appendix  26),  information  sheet  (appendix  27),  instruction  page 
(appendix  28)  and  return  stamped  envelope  were  posted  to  randomly  selected 
UKCTOCS volunteers. Walledge Associates, a direct mailing and data capture 
company, organised postage of the OCSq, although the Gynaecological Cancer 
Research Centre address and telephone number was printed on all documents. 
All questionnaires were date stamped on receipt and were manually entered by 
Walledge  Associates  staff.  Questionnaires  incorrectly  returned  to  the  research 
coordinating centre were also manually entered.  
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Demographic  data  were  obtained  from  baseline  questionnaires,  completed  at 
UKCTOCS recruitment. Education data were obtained from UKCTOCS follow-
up questionnaires. Both questionnaires are described in Chapter One. 
6.2.4  Data cleaning 
An estimated completion date was calculated for respondents who did not write 
the date on their questionnaire (as described in Chapter Five). This was based 
upon  the  overall  median  number  of  days  between  the  date  of  questionnaire 
completion and receipt back at Walledge Associates, or the research coordinating 
centre,  for  all  participants.  Where  the  completion  date  was  either  written 
incorrectly  by  the  respondent  or  entered  incorrectly  onto  the  database  (e.g. 
23.03.2004 instead of 23.04.2009), an estimated completion date was calculated 
using the same method. 
The OCSq database was set-up so that symptom prevalence/severity was entered 
as follows: 0 = no, 1 = a little, 2 = quite a bit, 3 = very much, 9 = missing data. 
Frequency: 1 = 1-2 days, 2 = 3-5 days, 3 = 6-7 days, 9 = missing data. Duration: 1 
= less than 3 months, 2 = 3-6 months, 3 = 6-12 months, 4 = more than 12 months, 
9 = missing data. GP consultation: 1 = yes, 0 = no, 9 = missing data. 
The data cleaning protocol was as follows: 
●  Where 4 was incorrectly entered for symptom severity, this was re-
coded as 3 (very much) 
●  Where 4 was incorrectly entered for symptom frequency, this was re-
coded as 3 (6-7 days) 
●  Where 0 was incorrectly entered for frequency or duration, this was 
re-coded as 9 (missing data) 
●  Where GP consultation was incorrectly entered as 2 or 3, this was re-
coded as 1 (yes).  
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●  Where respondents completed the frequency section (ticking either 1-
2 days, 3-5 days or 6-7 days during the past week), the duration 
section (ticking either less than 3 months, 3-6 months, 6-12 months or 
more than 12 months) or ticked yes to the GP reported section but did 
not complete the severity section, the symptom was coded as 
experienced but without a severity rating. 
●  Where respondents did not complete the severity, frequency or 
duration sections but ticked no to GP reported section, the symptom 
was coded as not experienced during the past week. 
6.2.5  Data analysis 
UKCTOCS baseline and follow-up questionnaires, together with OCSq data, were 
exported  from  the  main  UKTOCS  database  on  Monday  3  August  2009  and 
imported  into  SPSS  version  12.0.1  (SPSS  Inc.,  Chicago,  USA)  for  analysis. 
Frequencies  were  run  to  describe  the  data  and  distributions  of  continuous 
variables were explored. Respondents who reported a diagnosis of ovarian cancer 
on the OCSq (q35) were excluded from further analysis. 
The same four approaches that were utilised in Chapter Five to classify ‘positive’ 
symptoms were also utilised for analyses described in this chapter. To reiterate: 1) 
symptoms reported at any level of severity; 2) symptoms reported at level 2-3 
severity; 3) symptoms reported at any level of severity with ≥12 days per month 
frequency and <12 months duration; and 4) symptoms with a frequency ≥12 days 
per month, <12 months duration and level 2-3 severity. 
Women who had either pelvic discomfort/pain (q1), abdominal discomfort/pain 
(q2), feeling full (q5), abdominal bloating (q7) or increased abdominal size (q9) 
for 3-5 or 6-7 days during the past week and where the symptom had a duration of 
<12  months  were  considered  positive  on  the  Goff  et  al.
23  symptom  index 
(described in Chapter Two). 
Women  who  had  either  abdominal  pain  (q2),  increased  abdominal  size  (q9), 
abdominal mass/lumps (q10) or abnormal vaginal bleeding (q30) were considered  
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positive on the Lurie et al.
25 symptom index (described in Chapter Two). Hard 
abdomen was not included as this was not listed in the OCSq. 
Symptom Model 4 described in Chapter Five and identified as having the best 
performance for identifying ovarian cancer in the pilot was also investigated. This 
model included abdominal pressure (q8) or shortness of breath (q18) at level 2-3 
severity, ≥12 days frequency & <12 months duration. 
Symptom reporting according to screening group 
Using  the  four  approaches,  symptoms  were  investigated  in  the  control, 
multimodal and ultrasound groups. Symptoms were also explored in the screening 
group (multimodal plus ultrasound) compared to controls. 
Symptom reporting according to awareness of a possible ovarian lesion 
All controls were classified as unaware of a possible ovarian lesion. Screening 
group women whose last screening ‘action’ prior to completing the OCSq was 
‘return to annual screening’ were also classified as unaware of a possible ovarian 
lesion. Women recalled for repeat screening (repeat blood test or ultrasound or 
Level 2 screening), referred to a gynaecological oncologist for clinical evaluation, 
or referred for surgery, were classified as aware. Symptoms were compared in the 
two groups. 
GP consultations for symptoms 
Symptoms most frequently reported to GPs were explored and GP consultations 
for symptoms were investigated across the four levels of analysis. Only women 
who completed the required sections (e.g. frequency and duration sections plus 
GP consultation section for assessment of GP consultations for symptoms at ≥12 
days frequency and <12 months duration) were included in analyses. 
Symptoms and depression screening status 
Respondents who replied positively to one or both depression screening questions 
were  categorised  as  depression  screen  positive  and  those  who  responded 
negatively to both questions were categorised as depressions screen negative. This 
is  in  accordance  with  the  literature.
213-218  237  Depression  screening  status  was 
investigated according to prior awareness of a possible ovarian lesion. Using the  
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four  approaches  to  classify  positive  symptoms,  symptoms  were  investigated 
according to depression screening status. 
Statistical analysis 
Relationships between variables were investigated using the chi-square statistic 
and Mann-Whitney U tests were used to test differences between two groups for 
non-parametric  continuous  data.  Effect  sizes  were  calculated  and  interpreted 
according to Cohen’s criteria of r = 0.3 for a medium effect and r = 0.5 for a large 
effect. Differences were accepted as significant at p < 0.05 for all tests. 
6.3  Results 
6.3.1  Response rates 
A total of 100,000 UKCTOCS volunteers (55,000 controls, 22,500 multimodal 
and 22,500 ultrasound group women) were posted the pilot OCSq over an eight 
week  period  from  12  March  to  13  May  2009.  There  were  51,019  completed 
questionnaires received between 18 March and 31 July 2009, giving an overall 
response  rate  of  51.0%.  This  included  25,823  controls  (47.0%),  12,646 
multimodal (56.2%) and 12,550 (55.7%) ultrasound group women. Response rates 
being significantly higher among women in the screening groups compared to the 
control group (56.0% vs. 47.0%, χ
2(1) = 809.4, p < 0.0001). 
Response rates varied across the 13 regional centres. As in the pilot, Bristol had 
the highest response rate and Liverpool had the lowest (57.0% vs. 47.0%, χ
2(1) = 
123.1, p < 0.0001) (Table 6.1). Questionnaires were still being received at the 
time of data analysis, therefore final response rates will be higher.  
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Table 6.1.  OCSq response rates by regional centre 
Centre 
Invited 
n 
Responded 
n 
Response rate 
% 
Belfast  6,851  3,396  49.6 
Bristol  8,127  4,635  57.0 
Cardiff  8,271  4,114  49.7 
Derby  7,554  3,980  52.7 
East London (St Bart’s)  9,572  4,509  47.1 
Gateshead  8491  4,302  50.7 
Liverpool  4,904  2,306  47.0 
Manchester  8,155  4,107  50.4 
Middlesbrough  5,004  2,534  50.6 
North London (Royal Free)  8,429  4,124  48.9 
North Wales  7,088  3,662  51.7 
Nottingham  8,202  4,270  52.1 
Portsmouth  9,352  5,080  54.3 
Total  100,000  51,019  51.0 
 
After preliminary data exploration, 12 questionnaires (9 controls, 2 multimodal, 1 
ultrasound) were excluded due to self-reported diagnosis of ovarian cancer on 
question 35. This resulted in a final data set of 51,007 questionnaires. No ovarian 
cancer diagnosis was registered on the UKCTOCS database for the 12 women. 
However, they may have been very recently diagnosed. The information provided 
by  these  women,  and  their  contact  details,  was  passed  on  to  the  appropriate 
UKCTOCS staff member for follow-up. 
There were 10,018 (19.6%) respondents (5,221 controls, 2,407 multimodal and 
2,390 ultrasound) who did not have a completion date for the OCSq and 142 
(0.3%) had an incorrect date (62 controls, 36 multimodal and 44 ultrasound). The  
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median  time  from  OCSq  completion  to  receipt  in  the  remaining  40,847 
respondents was four days (range 1-109, IQR 2-6). An estimated completion date 
was  calculated  by  subtracting  four  days  from  the  stamped  receipt  date  for 
respondents who did not date their questionnaire, or had an incorrect date. 
6.3.2  Demographics and co-morbidities 
Reported on OCSq 
Mean age was 66.1 years (range 53.7-82.3, SD = 6.0) with no difference in age 
between the groups (Table 6.2). A total of 4,995 (9.8%) women were using HRT 
at  the  time  of  the  OCSq,  with  an  equivalent  proportion  of  controls  (9.9%), 
multimodal (9.3%) and ultrasound (10.0%) group respondents reporting HRT use. 
Self-reported history of cancer was equivalent across the groups, with 7.9% of 
controls, 7.3% of multimodal and 7.6% of ultrasound group women reporting that 
they had been diagnosed with cancer in the past (Table 6.2). Approximately 10% 
had been diagnosed with hiatus hernia, 13.3% with IBS, 2.3% with inflammatory 
bowel disease, 33.7% with arthritis and 14.0% with depression. There were no 
differences in the proportion of respondents in each group who self-reported these 
co-morbidities. 
Reported on UKCTOCS baseline questionnaire 
An equal proportion (approximately 98%) of women in each group reported a 
white ethnic background (Table 6.3). 
Approximately 35% in each group were overweight and approximately 17% were 
obese. There was a median of 16.2 years (range 3.5-42.8, IQR 10.4-22.4) since 
respondents’ last menstrual periods. A median of zero miscarriages (range 0-12, 
IQR  0-1)  and  two  pregnancies  (range  0-9,  IQR  2-3)  in  each  group,  and  an 
equivalent  proportion  (approximately  63%)  of  controls,  multimodal  and 
ultrasound group respondents reported a history of OCP use.  
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Reported on UKCTOCS follow-up questionnaire 
Of the total 51,007 women, 40,048 (78.5%) completed the UKCTOCS follow-up 
questionnaire.  Education  levels  were  equivalent  across  the  three  groups,  with 
approximately  3%  of  women  reporting  A  level  qualifications,  25%  clerical 
qualifications,  10%  professional  qualifications  and  23%  degree  level 
qualifications  (Table  6.4).  Small  differences  between  the  groups  were  not 
significant.  
 
309
 
Table 6.2.  Demographic and co-morbidity data reported on OCSq 
OCSq 
Controls 
n=25,814 
n (% or SD) 
Multimodal Group 
n=12,644 
n (% or SD) 
Ultrasound Group 
n=12,549 
n (% or SD) 
Overall 
n=51,007 
n (% or SD) 
Age at questionnaire
†  66.1 (SD=6.0)  66.2 (SD=6.0)  66.0 (SD=5.9)  66.1 (SD=6.0) 
Current HRT use  2,557 (9.9)  1,170 (9.3)  1,268 (10.1)  4,995 (9.8) 
Personal history of cancer*  2,030 (7.9)  924 (7.3)  950 (7.6)  3,917 (7.7) 
Personal history of breast cancer  1,306 (5.1)  566 (4.5)  628 (5.0)  2,500 (4.9) 
Diagnosed with hiatus hernia  2,575 (10.0)  1,293 (10.2)  1,200 (9.6)  5,068 (9.9) 
Diagnosed with IBS  3,384 (13.1)  1,695 (1.4)  1,687 (13.4)  6,766 (13.3) 
Diagnosed with inflammatory bowel disease  584 (2.6)  292 (2.3)  273 (2.2)  1,149 (2.3) 
Diagnosed with arthritis  8,661 (33.6)  4,304 (34.0)  4,209 (33.5)  17,174 (33.7) 
Diagnosed with depression  3,573 (13.8)  1,772 (14.0)  1,771 (14.1)  7,116 (14.0) 
 
* Excluding basal cell carcinoma/skin cancer 
† Mean  
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Table 6.3.  Demographic data reported on UKOCTOCS baseline questionnaire 
UKCTOCS baseline questionnaire 
Controls 
n=25,814 
n (% or IQR) 
Multimodal Group 
n=12,644 
n (% or IQR) 
Ultrasound Group 
n=12,549 
n (% or IQR) 
Overall 
n=51,007 
n (% or IQR) 
Ethnic origin 
Bangladeshi 
Black African 
Black Caribbean 
Black other 
Chinese 
Indian 
Pakistani 
White 
Other 
Missing 
 
5 (0.02) 
52 (0.2) 
124 (0.5) 
12 (0.05) 
41 (0.2) 
90 (0.4) 
9 (0.03) 
25,235 (97.8) 
127 (0.5) 
119 (0.5) 
 
1 (0.007) 
27 (0.2) 
83 (0.7) 
4 (0.03) 
19 (0.2) 
36 (0.3) 
2 (0.02) 
12,346 (97.6) 
65 (0.5) 
61 (0.5) 
 
0 
25 (0.2) 
74 (0.6) 
7 (0.05) 
19 (0.2) 
44 (0.4) 
7 (0.06) 
12,240 (97.5) 
76 (0.6) 
57 (0.5) 
 
 
 
 
 
6 (0.01) 
104 (0.2) 
281 (0.6) 
23 (0.05) 
79 (0.2) 
170 (0.3) 
18 (0.04) 
49,833 (97.7) 
268 (0.5) 
237 (0.5) 
Height at recruitment (cm)  162.6 (157.5-167.6)  162.6 (157.5-167.6)  162.6 (157.5-167.6)  162.6 (157.5-167.6) 
Weight at recruitment (kg)  67.0 (60.3-76.2)  67.0 (60.3-76.2)  66.7 (60.3-76.0)  66.7 (60.3-76.2) 
Median Body Mass Index (BMI) at recruitment  25.5 (23.1-28.7)  25.6 (23.2-28.7)  25.5 (23.1-28.5)  25.5 (23.1-28.7)  
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UKCTOCS baseline questionnaire 
Controls 
n=25,814 
n (% or IQR) 
Multimodal Group 
n=12,644 
n (% or IQR) 
Ultrasound Group 
n=12,549 
n (% or IQR) 
Overall 
n=51,007 
n (% or IQR) 
BMI group 
Under-weight (BMI <18.5) 
Optimal weight (BMI 18.5-25.0) 
Over-weight  (BMI 25.1-30.0) 
Obese (BMI >30.0) 
Missing 
 
 
186 (0.7) 
11,438 (44.3) 
9,081 (35.2) 
4,445 (17.2) 
664 (2.6) 
 
106 (0.8) 
5,516 (43.6) 
4,485 (35.5) 
2,242 (17.7) 
295 (2.3) 
 
99 (0.8) 
5,565 (44.3) 
4,466 (35.6) 
2,155 (17.2) 
264 (2.1) 
 
391 (0.8) 
22,520 (44.1) 
18,032 (35.4) 
8,842 (17.3) 
1,223 (2.4) 
 
  Years since last menstruation  16.2 (10.4-22.6)  16.3 (10.4-23.1)  16.2 (10.3-22.4)  16.2 (10.4-22.5) 
Ever use oral contraceptive pill (OCP)  16,271 (63.0)  7,915 (62.6)  8,019 (63.9)  32,205 (63.1) 
Duration of OCP (years) if applicable  5.0 (2.0-10.0)  5.0 (2.0-10.0)  5.0 (2.0-10.0)  5.0 (2.0-10.0) 
Ever use hormone replacement therapy (HRT) at recruitment  5,055 (19.6)  2,439 (19.3)  2,477 (19.7)  9971 (19.5) 
Miscarriages (pregnancies <6 months)  0 (0-1)  0 (0-1)  0 (0-1)  0 (0-1) 
Number of children (pregnancies ≥6 months)  2 (2-3)  2 (2-3)  2 (2-3)  2 (2-3) 
Hysterectomy  4,461 (17.3)  2,297 (18.2)  2,207 (17.6)  8965 (17.6) 
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Table 6.4.  Demographic data reported on UKCTOCS follow-up questionnaire 
UKCTOCS follow-up questionnaire 
Controls 
n=20,123 
n (%) 
Multimodal Group 
n=10,054 
n (%) 
Ultrasound Group 
n=9,871 
n (%) 
Overall 
n=40,048 
n (%) 
Education level 
  No qualification 
  O level 
  A level 
  Clerical qualification 
  Professional qualification 
  Degree level 
  Missing 
 
4,521 (22.5) 
2,335 (11.6) 
692 (3.4) 
4,951 (24.6) 
2,148 (10.7) 
4,681 (23.3) 
795 (4.0) 
 
2,456 (24.4) 
1,124 (11.7) 
340 (3.4) 
2,502 (24.9) 
1,020 (10.1) 
2,151 (21.4) 
461 (4.6) 
 
2,407 (24.4) 
1047 (10.6) 
306 (3.1) 
2,434 (24.7) 
946 (9.6) 
2,240 (22.7) 
491 (5.0) 
 
9384 (23.4) 
4506 (11.3) 
1338 (3.3) 
9887 (24.7) 
4114 (10.3) 
9072 (22.7) 
1747 (4.4) 
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6.3.3  Symptoms reported by OCSq respondents 
A total of 45,140 (88.5%) women reported symptoms at any level of severity, 
with a median of 5.0 (range 0-32, IQR 2-9) symptoms reported. Tiredness/fatigue 
was the most commonly reported symptom overall (52.6%), followed by back 
ache  or pain (46.5%) and  leg  ache or  pain  (37.9%) (Table  6.5).  Both  urinary 
urgency  and  urinary  frequency  were  among  the  ten  most  commonly  reported 
symptoms at any level but no pelvic or abdominal symptoms were among the top 
ten at any level of severity, frequency or duration. 
Table 6.5.  Most common symptoms at any level of severity 
Symptom at any level  n  % 
Tiredness, fatigue or lack of energy  26,830  52.6 
Back ache or pain  23,726  46.5 
Leg ache or pain  19,334  37.9 
Urinary urgency  18,309  35.9 
Indigestion or heartburn  18,117  35.5 
Excessive flatulence  17,850  35.0 
Weight gain  17,284  33.9 
Urinary frequency  16,064  31.5 
Shortness of breath  12,201  23.9 
Difficulty emptying bowels  11,651  22.8 
 
There  were  28,402  (55.7%)  respondents  who  reported  symptoms  at  level  2-3 
severity, with a median of 1.0 symptom at this level (range 0-28, IQR 0-3). The 
types of symptoms most commonly reported at level 2-3 severity were similar to 
those most  commonly  reported at  any level  of  severity (Table 6.6). However, 
shortness of breath was not among the ten most commonly reported symptoms at 
level 2-3 severity, and abdominal bloating/fullness was the ninth most common 
symptom at this level of severity.  
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Table 6.6.  Most common symptoms at level 2-3 severity 
Symptom at level 2-3 severity  n  % 
Tiredness, fatigue or lack of energy  10,850  21.3 
Back ache or pain  9,535  18.7 
Leg ache or pain  8,581  16.8 
Urinary urgency  8,581  15.5 
Urinary frequency  7,669  15.0 
Weight gain  7,374  14.5 
Excessive flatulence  7,289  14.3 
Indigestion or heartburn  4,706  9.2 
Abdominal bloating or fullness  3,622  7.1 
Difficulty emptying bowels  3,325  6.5 
 
There  were  21,250  (41.7%)  respondents  who  reported  any  symptoms  with  a 
frequency of ≥12 days during the past month and a duration of <12 months (Mdn 
0, range 0-25, IQR 0-1). Seven of the 10 most commonly reported symptoms at 
≥12 days frequency & <12 months duration were also among the most commonly 
reported  symptoms  overall  or  at  level  2-3  severity  (Table  6.7).  Increased 
abdominal size was the ninth most common at ≥12 days frequency & <12 months 
duration but this was not among the ten most common symptoms on the other 
three approaches.  
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Table 6.7.  Most common symptoms at ≥12 days & <12 months 
Symptom ≥12 days & <12 months  n  % 
Weight gain*  7,600  14.9 
Tiredness, fatigue or lack of energy  5,906  11.6 
Leg ache or pain  4,303  8.4 
Back ache or pain  4,222  8.3 
Excessive flatulence  3,101  6.1 
Urinary urgency  2,893  5.7 
Urinary frequency  2,877  5.6 
Pelvic discomfort or pain  2,190  4.3 
Increased abdominal size  2,136  4.2 
Weight loss*  2,083  4.1 
 
*Reported at <12 months duration only as frequency data not collected 
A total of 12,548 (24.6%) women reported any symptoms with a frequency of ≥12 
days, <12 months and level 2-3 severity (Mdn 0, range 0-25, IQR 0-0). The most 
common symptoms reported at this level of frequency, duration and severity were 
similar  to  those  reported  on  the  other  three  approaches,  with  tiredness/fatigue 
(6.6%), weight gain (5.5%) and leg ache/pain (4.8%) being the most commonly 
reported symptoms.  
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Table 6.8.  Most common symptoms at ≥12 days, <12 months and level 2-3 
severity 
Symptom ≥12 days, <12 months & level 2-3 severity  n  % 
Tiredness, fatigue or lack of energy  3,376  6.6 
Weight gain*  2,781  5.5 
Leg ache or pain  2,466  4.8 
Back ache or pain  2,377  4.7 
Excessive flatulence  1,807  3.5 
Urinary frequency  1,708  3.2 
Urinary urgency  1,628  3.2 
Indigestion or heartburn  1,073  2.1 
Pelvic discomfort or pain  1,045  2.0 
Abdominal bloating or fullness  1,036  2.0 
 
*Reported at <12 months duration only as frequency data not collected 
Table 6.9 lists the prevalence of key symptoms of ovarian cancer according to the 
four levels of analysis. Pelvic pain was reported by 22.6% of women at any level 
of severity, frequency and duration, and was more common than abdominal pain 
across  the  four  approaches.  Surprisingly,  feeling  full  at  any  level  of  severity 
(18.1%) was nearly as common as increased abdominal size (19.9%), and was 
twice as common as change in appetite (9.5%).  
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Table 6.9.  Prevalence of key symptoms of ovarian cancer 
Symptom reported 
At any level  Level 2-3 severity  ≥12 days & <12 months  ≥12 days, <12 months & 
level 2-3 severity 
n  (%)  n  (%)  n  (%)  n  (%) 
Pelvic discomfort or pain  11,507  22.6  3,171  6.2  2,190  4.3  1,045  2.0 
Abdominal discomfort or pain  9,804  19.2  2,188  4.3  1,384  2.7  684  1.3 
Feeling full quickly  9,208  18.1  2,876  5.6  1,710  3.4  928  1.8 
Change in appetite  4,867  9.5  900  1.8  909  1.8  357  0.7 
Abdominal bloating or fullness  11,627  22.8  3,622  7.1  1,912  3.7  1,036  2.0 
Increased abdominal size  10,146  19.9  3,238  6.3  2,136  4.2  939  1.8 
Abdominal mass or lump  2,211  4.3  274  0.5  317*  0.6  126*  0.2 
Pelvic bloating or fullness  9,452  18.5  2,853  5.6  1,602  3.1  750  1.5 
Change in bowel habit  8,221  16.1  1,416  2.8  1,078  2.1  447  0.9 
Urinary frequency  16,064  31.5  7,669  15.0  2,877  5.6  1,708  3.3 
Urinary urgency  18,309  35.9  7,928  15.5  2,893  5.7  1,628  3.2  
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Symptom reported  At any level  Level 2-3 severity  ≥12 days & <12 months  ≥12 days, <12 months & 
level 2-3 severity 
Abnormal vaginal bleeding  705  1.4  51  0.1  59  0.1  14  0.03 
 
* Reported at <12 months duration only as frequency data not collected  
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6.3.3.1  Prevalence of symptom indices 
There were 5,728 (11.2%) women who were positive on the Goff symptom index 
and 16,829 (33.0%) who were positive on the Lurie index. A total of 1,131 (2.2%) 
women were positive for symptom Model 4, identified from the pilot analyses in 
Chapter Five and consisting of abdominal pressure or shortness of breath at level 
2-3 severity, ≥12 days and <12 months. 
6.3.3.2  Symptom reporting in controls, multimodal and ultrasound group 
respondents 
There was no difference in the proportion of controls, multimodal or ultrasound 
group women who were positive for symptoms on the four approaches overall 
(Table 6.10). Approximately 89% of each group reported symptoms at any level 
of severity, 61% at level 2-3 severity, 53% at ≥12 days frequency and <12 months 
duration,  and  25%  at  level  2-3  severity,  ≥12  days  frequency  and  <12  months 
duration. There was no difference in the median number of symptoms reported by 
women in each group on the four approaches (Table 6.10). 
There was no association between screening group and the number of women who 
were positive on Goff symptom index (controls 11.9% vs. multimodal 11.4% vs. 
ultrasound  11.2%,  ns)  or  Model  4  (controls  2.4%  vs.  multimodal  2.1%  vs. 
ultrasound 2.5%, ns). However, there was an association between screening group 
and the Lurie index (controls 35.2% vs. multimodal 33.9% vs. ultrasound 32.8%, 
p < 0.0001).  
320 
There  was  an  association  between  UKTOCS  study  group  and  report  of  eight 
individual symptoms at any level of severity, nine at level 2-3 severity, two at ≥12 
days frequency and <12 months duration and one when severity level 2-3 was 
added to this frequency and duration criteria (Table 6.11). Interestingly, and in 
contrast to the findings of the pilot, control group respondents were slightly more 
likely to report symptoms. Change in bowel habit at level 2-3 severity, ≥12 days 
and <12 months was the only symptom which screening group respondents were 
more likely to report. Differences were statistically significant for the symptoms 
in  Table  6.11,  but  fairly  small  in  practical  terms.  For  example,  the  largest 
difference was observed for abdominal discomfort/pain at any level of severity. 
This was reported by 21.1% of controls compared to 19.3% of ultrasound group 
respondents, a difference of 1.8 percentage points.  
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Table 6.10.  Prevalence of symptoms in controls, multimodal and ultrasound group women 
Symptom reported  n 
Controls 
(% or IQR) 
Multimodal 
Group 
(% or IQR) 
Ultrasound 
Group 
(% or IQR) 
Overall 
(% or IQR) 
At any level 
Reported 
50,553 
22,851 (89.3%)  11,170 (89.1%)  11,119 (89.4%)  45,140 (89.3) 
Median  5.0 (2.0-10.0)  5.0 (2-0-9.0)  5.0 (2-0-9.0)  5.0 (2.0-10.0) 
Range  0-32  0-30  0-30  0-32 
Level 2-3 severity 
Reported 
46,204 
14,433 (61.7)  6,974 (61.0)  6,995 (61.4)  28,402 (61.5) 
Median  1.0 (0-3.0)  1.0 (0-3.0)  1.0 (0-3.0)  1.0 (0-3.0) 
Range  0-28  0-25  0-25  0-28 
≥12 days & <12 months 
Reported 
40,372 
10,771 (52.6)  5,257 (52.7)  5,222 (52.7)  21,250 (52.6) 
Median  1.0 (0-2.0)  1.0 (0-2.0)  1.0 (0-2.0)  1.0 (0-2.0) 
Range  0-23  0-25  0-25  0-25  
 
322
 
Symptom reported  n 
Controls 
(% or IQR) 
Multimodal 
Group 
(% or IQR) 
Ultrasound 
Group 
(% or IQR) 
Overall 
(% or IQR) 
≥12 days, <12 months & level 2-3 severity 
Reported 
50,553 
6,399 (25.0)  3,062 (24.4)  3,087 (24.8)  12,548 (24.8) 
Median  0 (0-1.0)  0 (0-0)  0 (0-0)  0 (0-0) 
Range  0-22  0-25  0-18  0-25 
 
Note: Overall column included instead of p-values as there were no associations between screening group and symptom reporting  
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Table 6.11.  Symptoms associated with screening group 
Symptom reported  n  Controls  Multimodal  Ultrasound  p-value 
At any level 
Pelvic discomfort or pain  48,542  6,013 (24.5)  2,760 (22.9)  2,734 (22.9)  <0.0001 
Abdominal discomfort or pain  48,266  5,140 (21.1)  2,367 (19.8)  2,297 (19.3)  <0.0001 
Abdominal bloating or fullness  47,607  6,009 (24.9)  2,832 (24.0)  2,786 (23.8)  0.031 
Increased abdominal size  47,559  5,258 (21.8)  2,502 (21.2)  2,386 (20.4)  0.009 
Abdominal mass or lump  47,032  1,188 (5.0)  513 (4.4)  510 (4.4)  0.01 
Pelvic bloating or fullness  47,595  4,926 (20.5)  2,285 (19.4)  2,241 (19.1)  0.004 
Pelvic pressure  48,069  2,933 (12.1)  1,355 (11.4)  1,302 (11.0)  0.007 
Pelvic heaviness  48,043  3,248 (13.4)  1,463 (12.3)  1,419 (12.0)  <0.0001 
Level 2-3 severity 
Pelvic discomfort or pain  39,385  1,676 (8.4)  793 (8.1)  702 (7.3)  0.003 
Abdominal discomfort or pain  38,509  1,164 (6.0)  525 (5.5)  499 (5.2)  0.023  
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Symptom reported  n  Controls  Multimodal  Ultrasound  p-value 
Level 2-3 severity 
Feeling full quickly  38,867  1,527 (7.8)  653 (6.8)  696 (7.2)  0.006 
Abdominal bloating or fullness  38,715  1,899 (9.7)  876 (9.1)  847 (8.8)  0.04 
Pelvic bloating or fullness  38,248  1,509 (7.8)  693 (7.3)  651 (6.9)  0.02 
Excessive flatulence  40,108  3,791 (18.7)  1,743 (17.6)  1,755 (17.7)  0.024 
Shortness of breath  38,214  1,527 (7.9)  666 (7.0)  677 (7.1)  0.007 
Difficulty emptying the bladder  36,869  388 (2.1)  153 (1.7)  157 (1.7)  0.022 
Leg swelling  38,231  1,420 (7.4%)  641 (6.7)  630 (6.7)  0.044 
≥12 days & <12 months 
Pelvic discomfort or pain  48,542  1,169 (4.8)  509 (4.2)  512 (4.3)  0.028 
Abdominal discomfort or pain  48,266  748 (3.1)  337 (2.8)  299 (2.5)  0.012 
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Symptom reported  n  Controls  Multimodal  Ultrasound  p-value 
≥12 days & <12 months & level 2-3 severity 
Change in bowel habit  48,187  195 (0.8)  114 (1.0)  138 (1.2)  0.003 
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6.3.3.3  Symptoms reported by screening group respondents compared to 
controls 
An equal proportion of screened women and controls reported symptoms overall 
at any level (89.3% vs. 89.3%), at level 2-3 severity (61.2% vs. 61.7%), at ≥12 
days frequency and <12 months duration (52.7% vs. 52.6%) and at ≥12 days, <12 
months and level 2-3 severity (24.6% vs. 25.0%). Screened women and controls 
also reported the same number of symptoms at any level (Mdn 5.0), at level 2-3 
severity (Mdn 1.0), at ≥12 days frequency and <12 months duration (Mdn 0) and 
≥12 days, <12 months and level 2-3 severity (Mdn 0). 
When individual symptoms were investigated, screened women were less likely to 
report  13  symptoms  at  any  level,  11  at  level  2-3  severity,  three  at  ≥12  days 
frequency and <12 months duration, and one symptom when severity level 2-3 
was added to this criteria (Table 6.12). However, differences in the proportion of 
women in each group who reported symptoms were small and upper confidence 
intervals were close to one. Change in bowel habit at level 2-3 severity, ≥12 days 
and  <12 months  was  the only symptom  screened women were more likely  to 
report (OR 1.33 95% CI 1.10-1.60).  
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Table 6.12.  Symptoms reported by screened women vs. controls 
Symptom reported  n 
Screening groups 
n (%) 
Controls 
n (%) 
OR (95% CI)  p-value 
At any level 
Pelvic discomfort or pain  48,542  5,494 (22.9)  6,013 (24.5)  0.91 (0.88-0.96)  <0.0001 
Abdominal discomfort or pain  48,66  4,664 (19.6)  5,140 (21.1)  0.91 (0.87-0.95)  <0.0001 
Abdominal bloating or fullness  47,607  5,618 (23.9)  6,009 (24.9)  0.95 (0.91-0.99)  0.009 
Increased abdominal size  47,559  4,888 (20.8)  5,252 (21.8)  0.94 (0.90-0.98)  0.008 
Abdominal mass or lump  47,032  1,023 (4.4)  1,188 (5.0)  0.88 (0.80-0.96)  0.003 
Pelvic bloating or fullness  47,595  4,526 (19.3)  4,926 (20.5)  0.93 (0.89-0.97)  0.001 
Pelvic pressure  48,069  2,657 (11.2)  2,933 (12.1)  0.92 (0.87-0.97)  0.003 
Pelvic heaviness  48,043  2,882 (12.1)  3,248 (13.4)  0.90 (0.85-0.95)  <0.0001 
Excessive flatulence  48,670  8,681 (36.1)  9,169 (37.2)  0.96 (0.92-0.99)  0.017 
Pressure on the bladder  47,053  3,513 (15.1)  3,776 (15.8)  0.95 (0.90-0.99)  0.031 
Difficulty emptying the bladder  46,834  1,036 (4.5)  1,165 (4.9)  0.91 (0.83-0.99)  0.027  
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Symptom reported  n 
Screening groups 
n (%) 
Controls 
n (%) 
OR (95% CI)  p-value 
At any level 
Pain when passing urine  47,097  2,338 (10.0)  2,555 (10.7)  0.81 (0.70-0.94)  0.017 
Leg swelling  48,230  5,101 (21.4)  5,441 (22.3)  0.95 (0.91-0.99)  0.017 
Level 2-3 severity 
Pelvic discomfort or pain  39,385  1,495 (7.7)  1,676 (8.4)  0.91 (0.84-0.98)  0.008 
Abdominal discomfort or pain  38,509  1,024 (5.4)  1,164 (6.0)  0.89 (0.82-0.97)  0.008 
Feeling full quickly  38,867  1,349 (7.0)  1,527 (7.8)  0.89 (0.83-0.96)  0.003 
Abdominal bloating or fullness  38,715  1,723 (9.0)  1,899 (9.7)  0.92 (0.86-0.98)  0.014 
Increased abdominal size  38,287  1,538 (8.1)  1,700 (8.8)  0.92 (0.85-0.99)  0.018 
Pelvic bloating or fullness  38,248  1,344 (7.1)  1,509 (7.8)  0.90 (0.84-0.98)  0.01 
Excessive flatulence  40,108  3,498 (17.6)  3,791 (18.7)  0.93 (0.89-0.98)  0.007 
Shortness of breath  38,214  1,343 (7.1)  1,527 (7.9)  0.88 (0.82-0.95)  0.002 
Difficulty emptying the bladder  36,869  310 (1.7)  388 (2.1)  0.81 (0.70-0.94)  0.006  
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Symptom reported  n 
Screening groups 
n (%) 
Controls 
n (%) 
OR (95% CI)  p-value 
Level 2-3 severity 
Leg swelling  38,231  1,271 (6.7)  1,420 (7.4)  0.91 (0.84-0.98)  0.013 
Abnormal vaginal discharge  36,757  18 (0.1)  33 (0.2)  0.55 (0.31-0.98)  0.04 
≥12 days & <12 months 
Pelvic discomfort or pain  48,542  1,021 (4.3)  1,169 (4.8)  0.89 (0.82-0.97)  0.008 
Abdominal discomfort or pain  48,266  636 (2.7)  748 (3.1)  0.87 (0.78-0.97)  0.009 
Abdominal bloating or fullness  47,607  894 (3.8)  1,018 (4.2)  0.90 (0.82-0.98)  0.020 
≥12 days, <12 months & level 2-3 severity 
Pelvic discomfort or pain  48,542  477 (2.0)  568 (2.3)  0.86 (0.76-0.97)  0.014 
Change in bowel habit  48,187  252 (1.1)  195 (0.8)  1.33 (1.10-1.60)  0.003 
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6.3.4  Symptom reporting according to prior awareness of a possible 
ovarian lesion 
There were 1,989 (3.9%) women who were aware of a possible ovarian lesion 
based on their screen result prior to completing the OCSq. Unaware women (n = 
49,018) included all controls (n = 25,814) and screening group women who were 
returned to annual screening (n = 23,204) after their previous screen. 
There  was  no  association  between  awareness  and  report  of  symptoms  at  any 
severity,  frequency  and  duration  or  level  2-3  severity  (Table  6.13).  However, 
women who were aware of the possibility of an ovarian lesion were more likely to 
report symptoms at ≥12 days frequency and <12 months duration (OR 1.18, 95% 
CI 1.07-1.31) and at level 2-3 severity, ≥12 days and <12 months (OR 1.17, 95% 
CI 1.06-1.29). 
Aware women reported a greater number of symptoms at any level (Mdn 6.0 vs. 
Mdn 5.0, U = 45,584,146.0, p = 0.003, r = -0.1), although, the effect size indicates 
a rather negligible increase symptom reporting due to awareness of a possible 
ovarian lesion. The median number of symptoms reported by aware and unaware 
women was the same on the other three levels of analysis (Table 6.13). 
Women who were aware of the possibility of an ovarian lesion were also more 
likely to be positive on the Goff (OR 1.31, 95% CI 1.15-1.49) and Lurie indices 
(OR 1.11, 95% CI 1.01-1.23). There was no association between awareness and 
women being positive on symptom Model 4.  
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Table 6.13.  Symptoms reported by aware vs. unaware women 
Symptom reported  n 
Aware 
(% or IQR) 
Unaware 
(% or IQR) 
Odds ratio 
(95% CI) 
p-value 
At any level 
Reported 
50,553 
1,771 (90.6)  43,369 (89.2)  ns  ns 
Median  6.0 (2.0-10.0)  5.0 (2.0-9.0)  -  0.003 
Range  0-32  0-32  - 
Level 2-3 severity 
Reported 
46,204 
1,123 (62.8)  27,279 (61.4)  ns  ns 
Median  1.0 (1.0-2.0)  1.0 (1.0-2.0)  -  - 
Range  0-25  0-28  - 
≥12 days & <12 months 
Reported 
40,372 
894 (56.6)  20,356 (52.5)  1.18 (1.07-1.31)  0.001 
Median  1.0 (0-3.0)  1.0 (0-3.0)  -  - 
Range  0-23  0-25  -  
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Symptom reported  n 
Aware 
(% or IQR) 
Unaware 
(% or IQR) 
Odds ratio 
(95% CI) 
p-value 
≥12 days, <12 months & level 2-3 severity 
Reported   
 
50,553 
542 (27.7)  12,006 (24.7)  1.17 (1.06-1.29)  0.002 
Median  0 (0-1.0)  0 (0-0)  -  - 
Range  0-22  0-25  - 
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Investigation  of  individual  symptoms  according  to  awareness  group  found 
significant differences for seven symptoms at any level, five at level 2-3 severity, 
14 at ≥12 days frequency and <12 months duration and 12 when severity level 2-3 
was added to this frequency and duration criteria (Table 6.14). 
Pain when passing urine at level 2-3 severity, ≥12 days and <12 months had the 
highest odds ratio among aware compared to unaware women (OR 2.18, 95% CI 
1.06-4.50), although the lower confidence limit was close to one and the symptom 
was  not  associated  with  awareness  on  the  other  levels  of  analysis.  Pelvic 
discomfort/pain was significant on all four approaches, with odds ratios ranging 
from 1.22 (95% CI 1.03-1.46) at level 2-3 severity to 1.53 (95% CI 1.27-1.84) at 
≥12 days and <12 months. Pelvic pressure was reported by higher proportions of 
aware women on all four levels, with odds ratios ranging from 1.21 (95% CI 1.06-
1.38) at any level of severity to 1.57 (95% CI 1.22-2.02) at ≥12 days and <12 
months. Interestingly, abdominal mass/lump was also more likely to be reported 
by aware women on all four approaches. The symptom had the second highest 
odds ratio overall at level 2-3 severity, ≥12 days <12 months duration (OR 2.14, 
95% CI 1.12-4.09).  
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Table 6.14.  Report of individual symptoms in aware vs. unaware women 
Symptom reported  n 
Aware 
n (%) 
Unaware 
n (%) 
OR (95% CI)  p-value 
At any level 
Pelvic discomfort or pain  48,542  534 (28.4)  10,973 (23.5)  1.29 (1.17-1.43)  <0.0001 
Abdominal bloating or fullness  47,607  495 (26.8)  11,132 (24.3)  1.14 (1.02-1.26)  0.017 
Abdominal mass or lump  47,032  120 (6.6)  2,091 (4.6)  1.45 (1.20-1.75)  <0.0001 
Pelvic bloating or fullness  47,595  419 (22.6)  9,033 (19.7)  1.19 (1.06-1.33)  0.003 
Pelvic pressure  48,069  253 (13.6)  5,337 (11.5)  1.21 (1.06-1.38)  0.006 
Difficulty emptying the bladder  46,834  104 (5.8)  2,097 (4.7)  1.25 (1.02-1.53)  0.031 
Tiredness, fatigue or lack of energy  49,076  1,090 (57.3)  2,5740 (54.6)  1.12 (1.02-1.22)  0.020 
Level 2-3 severity 
Pelvic discomfort or pain  39,385  148 (9.6)  3,023 (8.0)  1.22 (1.03-1.46)  0.02 
Abdominal pressure  37,439  76 (5.2)  1,399 (3.9)  1.35 (1.07-1.72)  0.012 
Abdominal mass or lump  36,749  21 (1.5)  253 (0.7)  2.06 (1.32-3.23)  0.001  
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Symptom reported  n 
Aware 
n (%) 
Unaware 
n (%) 
OR (95% CI)  p-value 
Level 2-3 severity 
Pelvic pressure  38,231  88 (5.9)  1,596 (4.3)  1.39 (1.12-1.74)  0.003 
Urinary urgency  39,192  341 (22.4)  7,587 (20.1)  1.14 (1.01-1.29)  0.033 
≥12 days & <12 months 
Pelvic discomfort or pain  48,542  124 (6.6)  2,066 (4.4)  1.53 (1.27-1.84)  <0.0001 
Abdominal bloating or fullness  47,607  95 (5.1)  1,817 (4.0)  1.31 (1.06-1.62)  0.012 
Abdominal pressure  47,237  28 (1.5)  395 (0.9)  1.76 (1.20-2.59)  0.004 
Increased abdominal size  47,559  110 (5.9)  2,026 (4.4)  1.36 (1.12-1.66)  0.002 
Abdominal mass or lump*  47,032  21 (1.2)  296 (0.7)  1.76 (1.12-2.74)  0.011 
Pelvic bloating or fullness  47,595  81 (4.4)  1,521 (3.3)  1.33 (1.06-1.67)  0.015 
Pelvic pressure  48,069  66 (3.6)  1,063 (2.3)  1.57 (1.22-2.02)  <0.0001 
Pelvic heaviness  48,043  62 (3.3)  986 (2.1)  1.58 (1.22-2.05)  0.001 
Change in bowel habit  48,187  57 (3.1)  1,021 (2.2)  1.40 (1.07-1.84)  0.014  
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Symptom reported  n 
Aware 
n (%) 
Unaware 
n (%) 
OR (95% CI)  p-value 
≥12 days & <12 months 
Excessive flatulence  48,670  157 (8.4)  2,944 (6.3)  1.36 (1.15-1.61)  <0.0001 
Urinary frequency  47,427  136 (7.4)  2,741 (6.0)  1.25 (1.04-1.49)  0.015 
Back ache or pain  49,033  198 (10.4)  4,024 (8.5)  1.25 (1.07-1.45)  0.004 
Tiredness, fatigue or lack of energy  49,076  271 (14.2)  5,635 (11.9)  1.22 (1.07-1.40)  0.003 
Weight gain*  48,556  328 (17.5)  7,272 (15.6)  1.15 (1.02-1.30)  0.021 
≥12 days, <12 months & level 2-3 severity 
Pelvic discomfort or pain  48,542  55 (2.9)  990 (2.1)  1.39 (1.06-1.83)  0.018 
Abdominal bloating or fullness  47,607  53 (2.9)  983 (2.1)  1.34 (1.01-1.78)  0.038 
Abdominal pressure  47,237  55 (3.0)  802 (1.8)  1.72 (1.30-2.26)  <0.0001 
Abdominal mass or lump*  47,032  10 (0.5)  116 (0.3)  2.14 (1.12-4.09)  0.018 
Pelvic bloating or fullness  47,595  43 (2.3)  707 (1.5)  1.51 (1.11-2.06)  0.009 
Pelvic pressure  48,069  35 (1.9)  484 (1.0)  1.82 (1.28-2.57)  0.001  
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Symptom reported  n 
Aware 
n (%) 
Unaware 
n (%) 
OR (95% CI)  p-value 
≥12 days, <12 months & level 2-3 severity 
Pelvic heaviness  48,043  33 (1.8)  432 (0.9)  1.92 (1.34-2.74)  <0.0001 
Pain before, during or after opening bowels  48,262  33 (1.8)  459 (1.0)  1.81 (1.27-2.58)  0.001 
Urinary frequency  47,427  86 (4.7)  1,622 (3.6)  1.33 (1.06-1.66)  0.012 
Urinary urgency  47,689  88 (4.8)  1,540 (3.4)  1.44 (1.16-1.80)  0.001 
Pressure on the bladder  47,053  39 (2.1)  583 (1.3)  1.68 (1.21-2.33)  0.002 
Pain when passing urine  47,097  8 (0.4)  92 (0.2)  2.18 (1.06-4.50)  0.032 
 
* Reported at <12 months duration only as frequency data not collected  
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6.3.4.1  Symptoms reported by screening group women vs. controls in the 
unaware group 
Symptoms  were  investigated  in  screening  group  women  compared  to  controls 
among the 49,018 unaware women. These analyses found no association between 
screening group and report of symptoms overall (89.1% vs. 89.3%, ns), at level 2-
3 severity (61.1% vs. 61.7%, ns), ≥12 days frequency and <12 months duration 
(52.3% vs. 52.6%, ns), or ≥12 days, <12 months and level 2-3 severity (24.4% vs. 
25.0%, ns). However, a slightly higher proportion of controls were positive on the 
Goff (11.9% vs. 11.0%, χ
2(1) = 8.4, p = 0.004), and Lurie (35.2% vs. 33.1%, χ
2(1) 
= 22.6, p < 0.0001) indices. There was no association between screening group 
and symptom Model 4 (2.3% vs. 2.4%, ns). 
When  individual  symptoms  were  investigated,  odds  ratios  were  significant 
between the groups for 16 symptoms at any level, 13 at level 2-3 severity, seven 
at ≥12 days and <12 months and four at level 2-3 severity, ≥12 days and <12 
months (Table 6.15). However, it must be noted that odds ratios were close to one 
for many symptoms, indicating little practical difference between the groups for 
these symptoms. Screening group women were more likely to report only one 
symptom,  change  in  bowel  habit  (OR  1.31,  95%  CI  1.08-1.58)  at  level  2-3 
severity, ≥12 days and <12 months.  
 
339
 
Table 6.15.  Report of individual symptoms in unaware screened women vs. unaware controls 
Symptom reported  n 
Screening groups 
n (%) 
Controls 
n (%) 
OR (95% CI)  p-value 
At any level 
Pelvic discomfort or pain  46,665  4,960 (22.4)  6,013 (24.5)  0.89 (0.85-0.93)  <0.0001 
Abdominal discomfort or pain  46,398  4,262 (19.4)  5,140 (21.1)  0.90 (0.86-0.94)  <0.0001 
Abdominal bloating or fullness  45,757  5,123 (23.7)  6,009 (24.9)  0.93 (0.89-0.97)  0.002 
Abdominal pressure  45,400  2,638 (12.3)  3,095 (12.9)  0.94 (0.89-0.99)  0.031 
Increased abdominal size  45,709  4,463 (20.6)  5,258 (21.8)  0.93 (0.89-0.97)  0.002 
Abdominal mass or lump  45,206  903 (4.2)  1,188 (5.0)  0.84 (0.77-0.92)  <0.0001 
Pelvic bloating or fullness  45,741  4,107 (19.0)  4,926 (20.5)  0.91 (0.87-0.95)  <0.0001 
Pelvic pressure  46,213  2,404 (11.0)  2,933 (12.1)  0.90 (0.85-0.95)  <0.0001 
Pelvic heaviness  46,185  2,624 (12.0)  3,248 (13.4)  0.88 (0.84-0.93)  <0.0001 
Change in bowel habit  46,324  3,641 (16.6)  4,231 (17.4)  0.95 (0.90-0.99)  0.028 
Excessive flatulence  46,795  7,961 (36.0)  9,169 (37.2)  0.95 (0.91-0.98)  0.006  
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Symptom reported  n 
Screening groups 
n (%) 
Controls 
n (%) 
OR (95% CI)  p-value 
At any level 
Pressure on the bladder  45,232  3,231 (15.1)  3,776 (15.8)  0.74 (0.70-0.78)  0.027 
Difficulty emptying the bladder  45,027  932 (4.4)  1,165 (4.9)  0.89 (0.81-0.97)  0.007 
Pain when passing urine  45,273  2,136 (10.0)  2,555 (10.7)  0.92 (0.87-0.98)  0.008 
Back ache or pain  47,137  10, 658 (47.7)  12,114 (48.8)  0.96 (0.92-0.99)  0.016 
Leg swelling  46,368  4,687 (21.3)  5,441 (22.3)  0.94 (0.90-0.99)  0.012 
Level 2-3 severity 
Pelvic discomfort or pain  37,848  1,347 (7.5)  1,676 (8.4)  0.89 (0.82-0.95)  0.001 
Abdominal discomfort or pain  37,005  935 (5.3)  1,164 (6.0)  0.88 (0.81-0.96)  0.005 
Feeling full quickly  37,364  1,237 (7.0)  1,527 (7.8)  0.89 (0.82-0.96)  0.003 
Abdominal bloating or fullness  37,191  1,576 (8.9)  1,899 (9.7)  0.91 (0.85-0.98)  0.009 
Increased abdominal size  36,807  1,410 (8.1)  1,700 (8.8)  0.72 (0.67-0.78)  0.014 
Pelvic bloating or fullness  36,740  1,217 (7.0)  1,509 (7.8)  0.89 (0.82-0.96)  0.003  
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Symptom reported  n 
Screening groups 
n (%) 
Controls 
n (%) 
OR (95% CI)  p-value 
Level 2-3 severity 
Pelvic heaviness  36,620  671 (3.9)  833 (4.3)  0.89 (0.80-0.99)  0.025 
Excessive flatulence  38,547  3,194 (17.5)  3,791 (18.7)  0.92 (0.88-0.97)  0.002 
Shortness of breath  36,728  1,226 (7.0)  1,527 (7.9)  0.91 (0.84-0.98)  0.001 
Urinary frequency  37,026  3,380 (19.3)  3,968 (20.3)  0.94 (0.89-0.98)  0.01 
Difficulty emptying the bladder  35,441  282 (1.7)  388 (2.1)  0.80 (0.68-0.93)  0.004 
Leg swelling  36,750  1,163 (6.7)  1,420 (7.4)  0.90 (0.83-0.97)  0.009 
Abnormal vaginal discharge  35,331  14 (0.1)  33 (0.2)  0.47 (0.25-0.87)  0.014 
≥12 days & <12 months 
Pelvic discomfort or pain  46,665  897 4.1)  1,169 4.8)  0.85 (0.77-0.92)  <0.0001 
Abdominal discomfort or pain  46,398  748 (3.1)  577 (2.6)  0.76 (0.77-0.95)  0.005 
Abdominal bloating or fullness  45,757  799 (3.7)  1,018 (4.2)  0.87 (0.79-0.96)  0.004 
Abdominal pressure  45,400  341 (1.6)  461 (1.9)  0.82 (0.71-0.94)  0.006  
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Symptom reported  n 
Screening groups 
n (%) 
Controls 
n (%) 
OR (95% CI)  p-value 
≥12 days & <12 months 
Pelvic pressure  46,213  466 (2.1)  597 (2.5)  0.86 (0.76-0.98)  0.019 
Excessive flatulence  46,795  1,332 (6.0)  1,612 (6.5)  0.92 (0.85-0.99)  0.02 
Shortness of breath  45,443  795 (3.7)  981 (4.1)  0.90 (0.82-0.99)  0.027 
≥12 days, <12 months & level 2-3 severity 
Pelvic discomfort or pain  46,665  422 (1.9)  568 (2.3)  0.82 (0.72-0.93)  0.002 
Abdominal bloating or fullness  45,757  426 (2.0)  557 (2.3)  0.85 (0.75-0.96)  0.012 
Increased abdominal size  45,709  390 (1.8)  502 (2.1)  0.86 (0.76-0.99)  0.031 
Change in bowel habit  46,324  229 (1.0)  195 (0.8)  1.31 (1.08-1.58)  0.006 
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6.3.5  Symptoms reported to GPs 
A total of 23,271 (45.6%) women discussed at least one of the 32 symptoms with 
a GP during the past three months, with a median of 3.0 symptoms (range 1-29, 
IQR 1-6) being discussed by these women. The three symptoms most commonly 
reported  to  GPs  were  backache/pain,  tiredness/fatigue  and  leg  swelling  (Table 
6.16). 
Table 6.16.  Symptoms most commonly reported to GPs 
Symptom at any level  n  % 
Back ache or pain  8,198  16.1 
Tiredness, fatigue or lack of energy  7,205  14.1 
Leg swelling  6,544  12.8 
Leg ache or pain  6,247  12.2 
Urinary frequency  5,801  11.4 
Shortness of breath  5,419  10.6 
Abdominal discomfort or pain  4,869  9.5 
Pain when passing urine  4,357  8.5 
Indigestion or heartburn  4,276  8.4 
Urinary urgency  3,941  7.7 
 
A substantially higher proportion of women who were Goff index positive (64.9% 
vs. 44.0%, χ
2(1) = 892.9, p < 0.0001) or Lurie index positive (65.7% vs. 36.4%, 
χ
2(1) = 3803.8, p < 0.0001) visited their GP about symptoms during the past three 
months compared to women who were negative on these indices. 
Table 6.17 lists the number of women who reported symptoms and the proportion 
who consulted a GP about the symptom during the past three months. Shaded 
boxes  denote  the  largest  proportion  of  women  who  consulted  their  GP  about 
symptoms across the four approaches. Women with pain when passing urine at 
any level of severity were most likely to consult their GP (91.7%), followed by  
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women with an abdominal mass/lump (82.6%) and abnormal vaginal bleeding 
(73.7%). 
Women were more likely to consult their GP when symptoms were at level 2-3 
severity (16 of the 32 symptoms), although they were more likely to consult their 
GP for 11 of the 32 symptoms at any level of severity. Women were least likely to 
consult their GP when symptoms were experienced at ≥12 days frequency and 
<12 months duration.  
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Table 6.17.  Symptoms most likely to be reported to GPs 
Symptom reported 
At any level  Level 2-3 severity  ≥12 days & <12 months  ≥12 days, <12 months & 
level 2-3 severity 
n 
Consulted 
GP 
n (%) 
n 
Consulted 
GP 
n (%) 
n 
Consulted 
GP 
n (%) 
n 
Consulted 
GP 
n (%) 
Pelvic discomfort or pain  10,592  3,669 (34.6)  2,963  1,343 (45.3)  2,073  815 (39.3)  998  496 (49.7) 
Abdominal discomfort or pain  8,722  4,869 (55.8)  2,039  1,108 (54.3)  1,304  624 (47.9)  656  372 (56.7) 
Indigestion or heartburn  15,380  4,276 (27.8)  4,265  1,587 (37.2)  1,802  476 (26.4)  1,023  298 (29.1) 
Nausea or vomiting  5,080  2,358 (46.4)  616  317 (51.5)  486  207 (42.6)  211  108 (51.2) 
Feeling full quickly  7,767  1,676 (21.6)  2,584  664 (25.7)  1,579  249 (15.8)  863  161 (18.7) 
Change in appetite  4,326  2,437 (56.3)  3,879  332 (41.4)  864  173 (20.0)  346  104 (30.1) 
Abdominal bloating or fullness  9,847  2,372 (24.1)  3,254  1,045 (32.1)  1,781  400 (22.5)  979  274 (28.0) 
Abdominal pressure  5,093  2,556 (50.2)  1312  565 (43.1)  795  239 (30.1)  397  145 (36.5) 
Increased abdominal size  8,338  1,151 (13.8)  2,839  452 (15.9)  1,967  210 (10.7)  871  133 (15.3) 
Abdominal mass or lump  2,120  1,752 (82.6)  251  117 (46.6)  275*  99 (36.0)  113*  52 (46.0)  
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Symptom reported  At any level  Level 2-3 severity  ≥12 days & <12 months  ≥12 days, <12 months & 
level 2-3 severity 
Pelvic bloating or fullness  8,164  2,202 (27.0)  2,565  824 (32.1)  1,470  346 (23.5)  704  206 (29.3) 
Pelvic pressure  4,877  1,904 (39.0)  1,536  754 (49.1)  1,039  370 (35.6)  487  229 (47.0) 
Pelvic heaviness  5,399  2,192 (40.6)  1,431  559 (39.1)  971  255 (26.3)  435  138 (31.7) 
Pain before, during or after opening 
bowels  7,975  3,185 (39.9)  1,868  755 (40.4)  1,028  323 (31.4)  467  179 (38.3) 
Difficulty emptying bowels  9,709  2,722 (28.0)  2,916  924 (31.7)  1,387  300 (21.6)  690  179 (25.9) 
Change in bowel habit  7,158  3,823 (53.4)  1,255  561 (44.7)  1,015  247 (24.3)  427  137 (32.1) 
Excessive flatulence  1,4890  3,838 (25.8)  6,457  1,479 (22.9)  2,898  411 (14.2)  1,708  285 (16.7) 
Shortness of breath  10,530  5,419 (51.5)  2,602  1,438 (55.3)  1,723  638 (37.0)  737  352 (47.8) 
Urinary frequency  13,222  5,801 (43.9)  6,540  2,550 (39.0)  2,672  789 (29.5)  1,619  572 (35.3) 
Urinary urgency  14,723  3,941 (26.8)  6,831  1,896 (27.8)  2,653  580 (21.9)  1,526  381 25.0% 
Pressure on bladder  5,877  1,607 (27.3)  2,282  674 (29.5)  1,225  275 (22.4)  568  158 (27.8) 
Difficulty emptying bladder  1,846  578 (31.3)  606  181 (29.9)  400  103 (25.8)  146  49 (33.6) 
Pain when passing urine  4,749  4,357 (91.7)  305  209 (68.5)  213  111 (52.1)  95  67 (70.5)  
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Symptom reported  At any level  Level 2-3 severity  ≥12 days & <12 months  ≥12 days, <12 months & 
level 2-3 severity 
Back ache or pain  20,511  8,198 (40.0)  8,667  4,080 (47.1)  3,928  1,355 (34.5)  2,263  945 (41.8) 
Leg ache or pain  16,481  6,247 (37.9)  7,699  3,514 (45.6)  4,008  1,381 (34.5)  2,342  986 (42.1) 
Leg swelling  9,383  6,544 (69.7)  2,410  1,473 (61.1)  1,311  653 (49.8)  626  386 (61.7) 
Tiredness, fatigue or lack of energy  22,224  7,205 (32.4)  9,654  3,443 (35.7)  5,569  1,335 (24.0)  3,243  935 (28.8) 
Weight gain  13,896  2,991 (21.5)  6,326  1,229 (19.4)  6,714*  967 (14.4)  2,480*  452 (18.2) 
Weight loss  2,836  922 (32.5)  942  338 (35.9)  1,831*  557 (30.4)  516*  223 (43.2) 
Abnormal vaginal bleeding  639  471 (73.7)  42  27 (64.3)  56  32 (57.1)  14  10 (71.4) 
Abnormal vaginal discharge  1,148  324 (28.2)  180  75 (41.7)  366  101 (27.6)  78  31 (39.7) 
Pain during or after sexual intercourse  2,033  818 (40.2)  485  138 (28.5)  69  8 (11.6)  23  5 (21.7) 
 
Note: Shaded cells indicate the largest proportion of women who reported the symptom to a GP across the four approaches to analysis. *Reported at <12 months 
duration only as frequency data not collected. 
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6.3.5.1  Symptoms and depression screening status 
There were 12,451 (24.4%) women who responded yes to the question, ‘During 
the  past  month  have  you  often  been  bothered  by  feeling  down,  depressed  or 
hopeless?’ and 8,500 (16.7%) women who responded yes to, ‘During the past 
month have you often been bothered by little interest or pleasure doing things?’ A 
total of 13,733 (26.9%) women responded yes to one or both questions, indicating 
they  were  depression  screen  positive,  28,983  (56.8%)  answered  no  to  both 
questions, indicating they were depression screen negative, while 8,291 (16.3%) 
women did not respond to both questions. 
Women  who  were  depression  screen  positive  were  more  likely  to  report  any 
symptoms overall (OR 7.30, 95% CI 6.49-8.22), symptoms at level 2-3 severity 
(OR 4.39, 95% CI 4.18-4.62), at ≥12 days and <12 months (OR 1.89, 95% CI 
1.81-1.98) and when level 2-3 severity was added to this frequency and duration 
criteria (OR 2.79, 95% CI 2.67-2.92) (Table 6.18). Depression screen positive 
women were also more likely to be positive on the Goff (OR 2.59, 95% CI 2.44-
2.75) and Lurie indices (OR 3.44, 95% CI 3.39-3.59), and Model 4 (described in 
Chapter Five) (OR 4.64, 95% CI 4.03-5.33). There was no association between 
awareness of the possibility of an ovarian lesion and depression screening positive 
status (32.8% vs. 32.1%, ns). 
The median number of symptoms reported by depression screen positive women 
was more than double the number reported by depression screen negative women 
at any level (Mdn 9.0 vs. Mdn 4.0, U = 97495120.5, p <0.0001, r = -0.41), at level 
2-3 severity (Mdn 3.0 vs. Mdn 1.0, U = 98464780.5, p <0.0001, r = -0.38) and at 
≥12  days  frequency  and  <12  months  duration  (Mdn  1.0  vs.  Mdn  0,  U  = 
109514721.5, p <0.0001, r = -0.19). Effect sizes for symptoms at any level and 
level  2-3  severity  indicate  a  moderate  increase  in  the  number  of  symptoms 
associated  with  depression  screen  positive  status,  while  the  effect  size  for 
symptoms at ≥12 days and <12 months indicates a small increase in the number of 
symptoms associated with depression screen positive status.  
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Table 6.18.  Symptoms reported by depression screen positive vs. depression screen negative women 
Symptom reported  n 
Depression 
screen positive 
(% or IQR) 
Depression 
screen negative 
(% or IQR) 
Odds ratio (95% 
CI)  p-value 
At any level 
Reported 
42,624 
13,413 (97.8)  24,752 (85.6)  7.30 (6.49-8.22)  <0.0001 
Median  9.0 (5.0-14.0)  4.0 (1.0-7.0)  - 
<0.0001 
Range  0-32  0-28  - 
Level 2-3 severity 
Reported 
40,475 
10,473 (80.7)  13,410 (48.8)  4.39 (4.18-4.62)  <0.0001 
Median  3.0 (1.0-6.0)  0 (0-2.0)  - 
<0.0001 
Range  0-28  0-25  - 
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Symptom reported  n 
Depression 
screen positive 
(% or IQR) 
Depression 
screen negative 
(% or IQR) 
Odds ratio (95% 
CI)  p-value 
≥12 days & <12 months 
Reported 
34,860 
8,025 (63.8)  10,765 (48.3)  1.89 (1.81-1.98)  <0.0001 
Median  1.0 (0-3.0)  0 (0-1.0)  - 
<0.0001 
Range  0-25  0-21  - 
≥12 days, <12 months & level 2-3 severity 
Reported 
42,624 
5,472 (39.9)  5,555 (19.2)  2.79 (2.67-2.92)  <0.0001 
Median  0 (0-1.0)  0 (0-0)  - 
<0.0001 
Range  0-25  0-16  - 
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Analysis  of  individual  symptoms  found  no  association  between  depression 
screening status and report of abnormal vaginal bleeding at level 2-3 severity and 
at ≥12 days, <12 months and level 2-3 severity (appendix 29). All other symptoms 
were  strongly  associated  with  depression  screening  status,  with  significance 
values  of  all  but  one  symptom  being  <  0.0001.  Pain  during  or  after  sexual 
intercourse at level 2-3 severity, ≥12 days frequency and <12 months duration 
was p = 0.008. 
All symptoms which were associated with depression screening status were more 
likely to be reported by depression screening positive women. The highest odds 
ratio was for pain when passing urine at any level of severity (OR 10.84, 95% CI 
9.67-12.14) and the lowest odds ratio was for weight gain at <12 months duration 
(frequency data not collected), (OR 1.71, 95% CI 1.62-1.80). Depression screen 
positive  women  were  more  likely  to  report  key  symptoms  of  ovarian  cancer 
including pelvic pain (OR 2.56, 95% CI 2.33-2.81), abdominal pain (OR 2.82, 
95% CI 2.51-3.18), abdominal bloating/fullness (OR 2.97, 95% CI 2.69-3.28) and 
increased abdominal size (OR 2.91, 95% CI 2.66-3.19) at ≥12 days frequency and 
<12 months duration.  
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6.4  Discussion 
Findings  relating  to  symptom  prevalence,  symptoms  associated  with  prior 
awareness  of  a  possible  ovarian  lesion,  GP  consultations  for  symptoms  and 
symptoms associated with depression screening status parallel the findings of the 
pilot OCSq, presented in Chapter Five. However, findings on symptom reporting 
in women receiving ovarian cancer screening compared to controls contrast with 
the results of Chapter Five. 
Prevalence of symptoms 
The overall prevalence of symptoms was high (89%) considering the cohort was 
comprised of apparently healthy postmenopausal women. It is striking that this 
proportion is similar to the 90-95% of women with ovarian cancer who report 
symptoms.
120  In  contrast,  42-52%  of  community-based  controls  have  been 
previously  found  to  report  ovarian  cancer  associated  symptoms  during  the  12 
months  prior  to  interview.
16-17  Unfortunately,  Goff  et  al.
23  do  not  provide 
information  on  the  proportion  of  symptomatic  women  among  those  receiving 
screening in the Ovarian Cancer Early Detection Study (OCEDS), although the 
median  of  5.0  symptoms  in  this  group  is  equivalent  to  that  among  OCSq 
respondents. 
The  large  proportion  of  symptomatic  women  may  be  due  to  the  older  age  of 
UKCTOCS volunteers compared to the Vine et al.
16 and Olson et al.
17 studies, 
where  ≥50%  of  controls  were  aged  under  50  years.  However,  a  more  likely 
explanation is enhanced symptom recall over the one-week reference period and 
an acquiescent effect arising from a comprehensive symptoms checklist.
140-141 147 
151 160 238 This is corroborated by research which recruited UKCTOCS volunteers 
as controls in a case-control study of ovarian cancer symptoms, where a shorter 
symptom checklist and 12 month reference period found a considerably reduced 
proportion (62%) of symptomatic controls.
34 
These findings emphasise the need to add severity, frequency and duration criteria 
to symptoms in  order to enhance the power of the study to detect significant 
differences  in  key  symptoms  in  ovarian  cancer  cases  compared  to  controls  in  
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follow-up analyses. Restricting analyses to symptoms at level 2-3 reduced the 
prevalence of key symptoms of ovarian cancer within the cohort. Pelvic pain at 
any level of severity, frequency or duration was reported by 23% of women, while 
6% reported the symptom at level 2-3 severity and 4% at ≥12 days frequency and 
<12 months duration. Similarly, feeling full was reduced from 18% to 6% and 
3%. Adding severity or frequency and duration criteria to symptoms in this way 
may increase the positive predictive value of symptoms in the final analyses by 
reducing their prevalence among women who do not develop ovarian cancer. 
The imperative to include symptom severity or frequency and duration criteria in 
the  final  analyses  is  underscored  by  the  ubiquity  of  some  key  symptoms  of 
ovarian cancer among healthy women. For example, a large postal survey in the 
UK study found 61% of women reported urinary urgency,
239 while US research 
indicates 24% of community-dwelling women report abdominal discomfort/pain 
and 19% report abdominal bloating or distension.
240 
Symptom indices 
Follow-up data on ovarian cancer diagnoses were not available at the time of 
analysis, therefore it was not possible to calculate the sensitivity and specificity of 
symptom  indices.  However,  preliminary  findings  indicate  the  Goff  index  may 
have lower specificity among OCSq respondents as 11% of women were positive 
on the index compared to just 1% of women aged ≥50 years attending primary 
care  in  the  Goff  research.
23  Alternatively,  33%  of  OCSq  respondents  were 
positive  on  the  four-symptom  Lurie  index  compared  to  47%  in  the  original 
study.
25  
Sixty-five percent of women who were positive on the Goff index had attended 
primary care for any OCSq symptoms in the past three months. If, as ovarian 
cancer advocacy groups are urging, all women who were positive on the Goff 
index consulted their doctor, this would represent a 54% increase in consultations 
(from 3,719 to 5,728 women) among this group. This increase may have serious 
time and resource implications when considered at a population level.  
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Impact  of  screening  and  awareness  of  an  ovarian  lesion  on  symptom 
reporting 
Findings  relating  to  symptom  reporting  in  women  receiving  ovarian  cancer 
screening  compared  to  controls  contrast  with  the  findings  of  the  pilot  OCSq. 
While there was no difference between controls and screened women for report of 
symptoms overall, or the number of symptoms reported at each level of analysis, 
controls were more likely to report key symptoms of ovarian cancer. This finding 
may have arisen due to the different methods used. Forty-seven percent of women 
invited to take part in the pilot were attending Level 2 screening and therefore had 
heightened awareness of the possibility of an ovarian lesion. In contrast, women 
in the final study were posted the OCSq independently of screening appointment 
letters. Perhaps the OCSq raised anxiety among controls who were not reassured 
by the results of previous screening investigations, resulting in higher levels of 
some symptoms. 
Controls were more likely than screened women to report abdominal/pelvic pain, 
abdominal  and  pelvic  bloating/fullness,  increased  abdominal  size,  abdominal 
mass/lump and feeling full. While these differences were statistically significant, 
they  were  fairly  meaningless  in  practical  terms  as  there  was  less  then  one 
percentage point between the proportion of controls and screened women for the 
majority of symptoms. 
Women who were aware of the possibility of an ovarian lesion were more likely 
to report any symptoms at ≥12 days frequency and <12 months duration or when 
level 2-3 severity was added to this criteria. They were more likely to be positive 
on the Goff index and to report pelvic pain, pelvic pressure, pelvic heaviness, 
pelvic  and  abdominal  bloating/fullness,  abdominal  mass/lump,  increased 
abdominal size, urinary frequency or urgency and pressure on bladder. However, 
the odds ratios for these symptoms were fairly small. 
Awareness of the possibility of an ovarian lesion will be investigated according to 
study outcome in the final analyses. This should answer the question whether 
symptoms reported by aware women are associated with diagnosis of cancer or 
awareness of the possibility of abnormality.  
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GP consultations 
In contrast to the pilot, several symptoms were more likely to be reported to GPs 
when experienced at any level of severity, rather than level 2-3 severity. These 
included  change  in  appetite,  abdominal  pressure,  pelvic  heaviness,  change  in 
bowel habit and excessive flatulence, which seem less salient than flag symptoms 
such as abnormal vaginal bleeding. The reasons for this are unclear, although the 
majority of respondents in the pilot were scheduled to attend screening within 
approximately six weeks. Perhaps this offered women some reassurance that they 
could discuss minor symptoms with screening staff during their appointment. The 
absence of an impending screening appointment in the finalised OCSq may have 
increased the willingness of women to seek medical advice for certain symptoms, 
even when these were experienced at a low level of severity. 
Symptoms associated with depression screening status 
The proportion of women who screened positive for depression (27%) was equal 
to the pilot. Women who were depression screen positive were 7.30 times more 
likely to report symptoms and 4.39 times more likely to report symptoms at level 
2-3 severity. They were also 2.59 times more likely to be positive on the Goff 
index and 3.44 times more likely to be positive on the Lurie index. Similarly, to 
Goff  et  al.
23,  depression  screen  positive  women  reported  a  greater  number  of 
symptoms overall, and at higher severity. Surprisingly, and in contrast to the pilot, 
there was no association between awareness of the possibility of an ovarian lesion 
and depression screening positive status. However, this may be due to the OCSq 
being sent separately to screening appointments. In contrast, pilot questionnaires 
were posted with appointment letters, including letters requesting the women to 
attend repeat screening due to an abnormality detected on annual screening. 
Women who were depression screen positive were more likely to report all 32 
symptoms at any level of severity and at a frequency of ≥12 days and <12 months 
duration,  although  there  was  no  association  between  depression  status  and 
abnormal vaginal bleeding at level 2-3 severity or when frequency and duration 
was added to this severity criteria. These findings parallel wider research which  
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has  indicated  depression  and  negative  affectivity  is  associated  with  increased 
attention to and reporting of, symptoms.
37 39 241-243 
Study strengths 
The  fundamental  strength  of  the  study  is  collection  of  genuinely  prospective 
symptoms data. This is the first study to attempt this methodology. Symptoms 
reported by apparently healthy women will be correlated with diagnosis of benign 
and  malignant  ovarian/fallopian  tube  tumours  in  the  18  months  following 
completion of the questionnaire. Women will be excluded from the final analyses 
if they completed the OCSq after being clinically assessed by a gynaecological 
oncologist. This will eliminate recall bias from the study. 
A second core strength of the study is its direct access to UKCTOCS screening, 
surgery and histopathology data, and regular updates of cancer diagnoses from 
regional cancer registries. This will reduce misclassification bias when follow-up 
analyses  are  conducted  and  enable  accurate  calculation  of  the  sensitivity  and 
specificity of various symptom complexes. 
Other strengths of the study include the use of a comprehensive, valid and reliable 
questionnaire, and the recruitment of a large sample of women. Demographics 
and co-morbidities were equivalent across the screening groups, indicating that 
differences in symptom reporting were unlikely to be due to differences in age, 
education levels or pre-existing conditions. 
Study limitations 
The response rate at the time of data analysis was 51%, although the final figure 
will be higher as questionnaires were still being received at the time of writing. 
While  the  51%  response  rate  is  lower  than  the  60%  generally  considered 
acceptable  for  questionnaires,  it  is  substantially  higher  than  the  average  45% 
response rate previously described for UK postal health surveys,
235 and the 26% 
response rate for a large prospective study of lifestyle and cancer risk conducted 
in the US.
244 The one other ovarian cancer symptoms study which utilised postal 
questionnaires,  conducted  by  Goff  et  al.
13,  achieved  a  substantially  higher 
response  rate  of  88%.  However,  the  Goff  study  population  was  comprised  of 
women diagnosed with ovarian cancer, a group which is likely to have greater  
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motivation to participate. While reminder telephone calls and letters have been 
found  to  increase  response  rates  to  approximately  70-80%,
245-246  this  was  not 
feasible or affordable due to the large sample size. 
The age of the UKCTOCS study population needs to be taken into account when 
assessing the response rate. The average age of respondents was 66 years with a 
range of 54-82 years. A postal survey of physical activity among a similar age 
group  in  England  found  a  comparatively  lower  response  rate  of  37.9%.
247 
Previous research has indicated that older people are more likely to have difficulty 
comprehending  questionnaires.
248  However,  pilot  of  the  OCSq  proved  its 
acceptability and readability, with small percentages of women reporting that they 
had difficulty responding to items. We anticipated increased prevalence of visual 
problems among the study population and would have liked to compensate for it 
by increasing the font size of the OCSq. However, this was not possible without 
either increasing the number of pages or changing the page format to a less user-
friendly landscape style. 
A second limitation of the research was recruitment of women who were already 
participating in an ovarian cancer screening study. This group are likely to have 
higher levels of knowledge about the symptoms of ovarian cancer compared to the 
general  population  of  postmenopausal  women,  which  may  lead  to  increased 
attention to key symptoms and over-reporting bias. Evidence of this tendency may 
be observed in the finding that 18% reported feeling full, whereas other research 
has found only 3% of community-based controls report the symptom.
17 However, 
knowledge of this symptom may also be due to recent advocacy group awareness 
campaigns and media coverage of the UK consensus statement on ovarian cancer 
symptoms. 
Research  has  indicated  that  approximately  47%  of  women  in  the  general 
population  are  aware  of  increased  abdominal  size/bloating  or  feeling  full  as 
symptoms  of  ovarian  cancer  and  26%  are  aware  of  urinary  frequency  or 
urgency.
249  However, these findings are based upon an internet survey which is 
likely to have recruited younger, well educated women who have the knowledge 
and skills to allow them to readily access health information. Knowledge of the  
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symptoms of ovarian  cancer  among the  general population of postmenopausal 
women in the UK is likely to be substantially lower. 
A third limitation of the research was the higher response rate among women 
receiving screening compared to controls. Findings from the pilot indicated that 
this  may  result  in  over-reporting  bias,  due  to  screened  women  having  greater 
awareness of symptoms. However, this may not be the case as the proportion of 
women  who  reported  symptoms  in  the  two  groups  was  very  similar  in  the 
finalised OCSq. 
6.5  Summary 
This  chapter  presented  baseline  data  from  the  OCSq  survey  of  100,000 
postmenopausal women. The prevalence of key symptoms of ovarian cancer was 
surprisingly  high,  with  approximately  one  in  five  women  reporting  pelvic  or 
abdominal  discomfort/pain,  feeling  full  or  bloating/increased  abdominal  size 
during the past week. Moreover, one in ten women were positive on the Goff 
symptom  index,  which  casts  doubt  upon  the  usefulness  of  symptom  indices 
among  community-based  postmenopausal  women.  Similarly  to  the  pilot, 
depression screening status and symptom reporting were strongly associated, with 
depression  screening  positive  women  more  likely  to  report  symptoms,  and  a 
greater  number  of  symptoms,  compared  to  those  who  screened  negative  for 
depression.  The  relationship  between  awareness  of  a  possibility  of  an  ovarian 
lesion and symptom reporting was weaker than in the pilot, nevertheless, women 
who were aware of the possibility of an abnormality were more likely to report 
key symptoms of ovarian cancer and were more likely to be positive on the Goff 
symptom index.  
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Chapter Seven – Discussion and Future Research Plans 
7.0  Introduction 
The  research  presented  in  this  thesis  set  out  to  prospectively  identify  type, 
severity,  frequency  and  duration  of  symptoms  in  a  large  cohort  of  apparently 
healthy postmenopausal women, then to correlate symptoms with diagnosis of 
ovarian cancer upon follow-up. The research is currently ongoing and while the 
goal of prospectively recording symptoms was achieved, this data has yet to be 
correlated with diagnosis of ovarian cancer, as insufficient time has passed for this 
information to become available. Though answers to fundamental questions about 
the  pattern  of  symptoms  prior  to  diagnosis  of  ovarian  cancer  are  awaited,  a 
number of important findings have resulted from this phase of the work and these 
are discussed in this chapter. 
7.1  Main findings 
7.1.1  The need for a validated ovarian cancer symptoms measure 
Preliminary  searches  of  the  literature  confirmed  the  absence  of  an  existing, 
properly  validated,  questionnaire  specifically  designed  to  collect  data  on 
symptoms  of  ovarian  cancer.  While  two  groups  described  limited  validation 
processes,
7  70  they  did  not  provide  full  details  of  their  findings  or  copies  of 
questionnaires  when  requested.  After  learning  this  information  we  had  two 
options.  We  could  have  expedited  the  research  by  adapting  an  existing 
questionnaire which had been supplied by another group, or we could follow a 
robust  though  lengthy  process  of  developing  and  validating  our  own 
questionnaire. We chose the latter as a review of the literature generated a list of 
349 symptoms described as associated with ovarian cancer, yet a maximum of 23 
symptoms  were  listed  in  questionnaires  used  by  other  groups.  The  strong 
correlation  between  the  number  of  symptoms  listed  in  questionnaires  and  the 
median  number  of  symptoms  reported  by  women  (described  in  Chapter  Two) 
underscored the importance of ensuring questionnaire comprehensiveness whilst  
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avoiding inclusion of symptoms with low specificity to the disease. To achieve 
this goal we utilised rigorous questionnaire development methods described by 
the EORTC. 
Development of the OCSq started with the very first literature search in October 
2006 and concluded with final formatting in February 2009. The process involved 
experts in the fields of gynaecological oncology and questionnaire design, as well 
as  women  living  with  ovarian  cancer.  Validation  of  the  OCSq  confirmed  the 
questionnaire’s face and content validity and its reliability among postmenopausal 
women. This affords some degree of assurance that the symptoms data collected 
in the finalised study will be sufficiently robust to accurately identify prospective 
symptoms of ovarian cancer. 
7.1.2  Symptoms reported retrospectively 
The retrospective component of the research included symptoms data from a total 
of  213  women:  188  Ovacome  survey  respondents  and  25  former  UKCTOCS 
volunteers who were diagnosed with ovarian cancer. 
The four symptoms most commonly reported by Ovacome survey respondents 
were: 
●  Abdominal or pelvic discomfort/pain 
●  Increased abdominal size/bloating 
●  Tiredness/fatigue 
●  Urinary frequency/urgency 
However,  tiredness  or  fatigue  was  not  included  in  the  four-symptom  complex 
which identified the largest proportion of respondents: 
●  Abdominal or pelvic discomfort/pain 
●  Increased abdominal size/bloating 
●  Abnormal vaginal bleeding 
●  Urinary frequency/urgency  
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Analysis  of  data  from  telephone  interviews  with  25  UKCTOCS  volunteers 
diagnosed  with  ovarian  cancer  revealed  the  most  common  symptoms  were 
equivalent  to  the  Ovacome  data.  The  symptoms  women  identified  as  most 
relevant during the period leading up to their diagnosis were: 
●  Tiredness/fatigue 
●  Pelvic discomfort/pain/pressure 
●  Increased abdominal size/bloating 
●  Urinary frequency 
Two principal conclusions may be drawn from the retrospective data. Firstly, the 
types  of  symptoms  most  commonly  reported  by  women  were  equivalent  to 
previous research. Secondly, and most importantly, the retrospective data suggest 
that existing symptom indices may not be as useful for identifying ovarian cancer 
compared  to  symptom  complexes  which  include  abnormal  vaginal  bleeding, 
change in bowel habit or urinary symptoms. 
Given the prominence afforded to feeling full in the Goff index,
23 and both the US 
and the UK ovarian cancer consensus statements,
30 32 findings from the Ovacome 
data are somewhat controversial. Only one woman reported feeling full quickly 
and the prevalence of change in appetite or feeling full quickly combined was less 
than  1%.  This  finding  contrasts  with  other  UK  research,
46-47  although,  as 
discussed in Chapter Three, this may be due to the symptom lacking salience 
among  women,  and  therefore  being  more  likely  to  be  forgotten  over  time. 
However, it is surprising that the symptom was so rare given that the majority of 
respondents were diagnosed with stage III or IV ovarian cancer and the symptom 
is often associated with advanced disease.
17-18  47 These findings emphasise the 
need to further explore the utility of early satiety for identifying ovarian cancer in 
the prospective research. It also raises important questions about the inclusion of a 
symptom  associated  with  advanced  disease  in  indices  which  aim  to  ‘lead  to 
detection at the earliest possible stage of the disease’.
30  
Within the literature, abnormal vaginal bleeding is usually described  as a less 
common  symptom  of  ovarian  cancer,  with  two  studies  not  mentioning  the  
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symptom  at  all.
17  124  However,  abnormal  bleeding  was  included  in  the  Lurie 
index,
25  and  recent  UK  research  indicates  that  the  symptom  may  be  more 
important  than  previously  thought.
46-47  Findings  from  the  Ovacome  data  are 
congruent with this research, as the symptom was included in the most prevalent 
three and four-symptom complexes. Crucially, the symptom was associated with 
early  stage  disease  and  prompt  diagnosis.  While  women  with  unexplained 
postmenopausal bleeding meet Department of Health and NICE criteria for an 
urgent  referral  to  specialist  gynaecological  oncology  centres,
43-44  awareness  of 
postmenopausal  bleeding  as  a  ‘flag’  symptom  for  gynaecological  malignancy 
among women cannot be taken for granted.
250-252 Indeed, one-third of the women 
with the symptom did not report it as a symptom which prompted them to seek 
medical advice and one of the women with abnormal bleeding waited more than 
two  years before  consulting  her doctor.  As  current advocacy  group awareness 
campaigns do  not include postmenopausal bleeding, this may  result in  missed 
opportunities to diagnose women at an early stage of the disease. 
Change in bowel habit was identified as a key symptom of ovarian cancer among 
Ovacome  survey  respondents.  While  this  symptom  is  mentioned  in  the 
Department  of  Health  Ovarian  Cancer:  key  messages  for  health  professionals 
guidance, it is not listed as one of the three symptoms which can ‘suggest’ ovarian 
cancer.
33 However, the research also indicated that change in bowel habit was 
associated  with  late  stage  disease,  which  suggests  that  it  may  have  limited 
relevance for early detection efforts. 
Urinary  frequency  and  urgency  were  commonly  reported  by  both  Ovacome 
survey  respondents  and  UKCTOCS  volunteers  diagnosed  with  ovarian  cancer. 
Additionally,  urinary  frequency/urgency  were  among  the  top  three  symptoms 
described as ‘causing the most trouble’. While these symptoms are not included as 
key  symptoms  in  the  UK  consensus  statement  or  Department  of  Health  key 
messages  guidance,
32-33  they  are  mentioned  in  these  documents  and  they  are 
included  in  the  four-symptom  GCF  consensus  statement.
30  However,  the 
specificity of urinary symptoms for detecting ovarian cancer is likely to be low 
given  the  28-87%  prevalence  of  these  symptoms  among  community-based 
women.
239 253-257 Addition of severity criteria to these symptoms in the prospective  
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study may not improve the positive predictive value of urinary frequency/urgency 
as 18-29% of women aged over 50 years report severe urinary symptoms.
258 
7.1.3  Symptoms reported prospectively 
Symptoms  which  were  most  commonly  associated  with  abnormal  screening 
results  (overall  abnormal  result,  elevated  CA125,  elevated  ROC  or  complex 
ovarian morphology) were: 
●  Increased abdominal size 
●  Abdominal or pelvic pressure 
●  Abdominal or pelvic bloating/fullness 
●  Shortness of breath 
●  Urinary frequency 
With the exception of shortness of breath and abnormal vaginal bleeding, these 
symptoms  were  equivalent  to  the  retrospective  data.  They  are  also  similar  to 
symptoms  reported  in  the  literature,  although  shortness  of  breath  is  usually 
described  as  a  symptom  of  advanced  disease,  not  a  symptom  of  early  stage 
ovarian cancer or benign tumours.
9 16 20 51 The association between shortness of 
breath  and  abnormal  screening  results  will  be  further  explored  in  follow-up 
analyses.  
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An unexpected finding  was the ubiquity of symptoms. Approximately 89% of 
women reported a median of 5-6 symptoms during the past week and 42-48% 
reported any symptoms onset within the past year which occurred ≥12 days during 
the past month. Surprisingly large proportions of women reported key symptoms 
such as abdominal (19%) or pelvic (23%) discomfort/pain, increased abdominal 
size (29%), bloating (23%) and feeling full (18%). Frequency and duration criteria 
reduced  the  prevalence  of  symptoms,  nevertheless  11-16%  of  women  were 
positive on the Goff symptom index. In contrast, only 2.6% of women attending 
primary care in Goff study were positive on the index.
23 This difference may stem 
from  enhanced  recall  of  symptoms  over  the  one-week  OCSq  reference  period 
compared to the one-month Goff index. Alternatively, a tendency for patients to 
focus  upon  the  need  to  present  their  doctor  with  a  single  concern  may  have 
interfered  with  recall  of  symptoms  in  the  index.
142  Moreover,  this  finding 
highlights  the  importance  of  further  research  into  the  usefulness  of  symptom 
indices among community-based women and women attending primary care. 
If 11-16% of postmenopausal women sought urgent advice relating to Goff index 
symptoms, GPs would be swamped with ‘worried well’ women. This would have 
serious implications for primary care funding and GP workloads. It would also 
increase psychological morbidity among women (demonstrated in the pilot OCSq 
by  the  finding  of  an  association  between  awareness  and  depression  screening 
positive  status),  as  well  as  anxiety  for  women’s  families.  There  is  also  the 
consideration that this may result in substantial increases in the number of women 
referred for potentially painful, expensive screening interventions and an increase 
in unnecessary surgery with the concomitant risk of complications. This increase 
in  psychological  morbidity,  investigations,  service  costs,  and  surgery  may  not 
necessarily lead to reduced ovarian cancer mortality. Indeed, at the present time 
there  is  currently  no  evidence  that  the  integration  of  ovarian  cancer  symptom 
indices into primary care would reduce the stage of disease at diagnosis for the 
6,500 women diagnosed with ovarian cancer each year in the UK.  
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This  was  the  first  study  to  investigate  symptoms  according  to  ultrasound-
estimated  ovary  volumes.  While  the  numbers  included  in  these  analyses  were 
small, women with complex ovarian morphology who reported urinary frequency 
and abdominal bloating/fullness were found to have substantially larger ovarian 
volumes.  Urinary  frequency  was  also  associated  with  elevated  CA125  levels 
while bloating/fullness and increased abdominal size was associated with elevated 
ROCs. These findings will be further explored in future analyses as research by 
Andersen et al.
24 indicated that combining a symptom index with CA125 may 
improve its sensitivity from approximately 50% to 81% for the detection of early 
stage ovarian cancer. This suggests that combining symptoms with CA125 may 
achieve the elusive goal of stage shift towards earlier diagnosis, which is the most 
important  determinant  of  survival.  However,  at  the  present  time,  there  is 
insufficient evidence to warrant introduction of symptoms assessment alongside 
CA125 testing. It must also be remembered that CA125 level has previously been 
described as poorly correlated with symptoms.
259 
The PPV of the Goff index for detecting an abnormal screen result was 52% and 
the NPV was 61%. However, the study population was enriched with women who 
had  a  previous  abnormal  screen  result,  therefore  the  PPV  is  likely  to  be 
considerably lower among the cohort of women followed-up over the next 12-18 
months. Results of these future analyses should provide sufficient information to 
assess whether symptom indices yield sufficiently large PPVs to balance the risks 
of awareness campaigns. 
An  enlightening  finding  from  the  research  was  the  discrepant  symptoms 
associated with abnormal screen results when severity, frequency and duration 
criteria were added to analyses. No symptoms were consistently associated with 
abnormal  results  across  the  four  approaches.  This  will  be  further  explored  in 
future analyses to determine whether a similar effect is observable in relation to 
symptoms  associated  with  ovarian  cancer,  although  the  finding  suggests  that 
symptoms many previous studies described as associated with ovarian cancer may 
have been different if these criteria were added to analyses. This finding also 
indicates  that  the  current  focus  upon  frequency  and  duration  in  symptom 
awareness campaigns and indices may need to be revised.  
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Findings  from  the  pilot  suggest  that  symptom  models  including  abdominal 
pressure  or  abdominal  bloating/fullness  with  severity,  frequency  and  duration 
criteria included may have superior performance for detecting early stage ovarian 
cancer  compared to  the  Goff  or  Lurie indices.  However, the  number of  cases 
detected during the pilot was too small to draw definite conclusions. 
As  discussed  in  the  literature  review,  previous  questionnaire  research  on  the 
symptoms of ovarian cancer is limited by recall bias and reporting bias arising 
from  knowledge  of  malignancy.  Evidence  of  the  tendency  for  research 
participants to selectively search illness relevant memory following confirmation 
of diagnosis,
144 or even information about the possibility of an abnormality, is 
observable in the increased symptom reporting among women who had previous 
awareness of the possibility of an ovarian lesion.  In the pilot study, only two 
‘aware’ women were diagnosed with ovarian or fallopian tube cancer during the 
follow-up period, yet as a group, aware women were significantly more likely to 
report symptoms, including key symptoms of ovarian cancer such as increased 
abdominal size, abdominal/pelvic bloating, pressure and heaviness. Importantly, 
women who were aware of the possibility of an ovarian lesion in the pilot study, 
and 100,000 women study, were more likely to be positive on the Goff and Lurie 
symptom indices. While previous studies have attempted to control for reporting 
and recall bias by interviewing women prior to surgery for a pelvic mass, none 
have explored the impact of awareness on symptom reporting. 
The methodology of the research was not appropriate for a thorough assessment 
of  psycho-social  influences  symptom  perception,  interpretation  and 
communication. However, the findings suggested that reporting of symptoms of 
ovarian cancer is associated with depression screening positive status, and that 
this is strongly correlated with knowledge of a possible abnormality. 
According to current Department of Health guidelines, one of the two women 
diagnosed with ovarian/fallopian tube cancer in the OCSq pilot would not have 
been urgently referred. The woman was not positive on the Goff or Lurie indices, 
or the UK consensus statement, although she was positive on the GCF consensus 
statement. This  one case exemplifies  the need  to compare the  performance  of  
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symptom indices with the results of the UKCTOCS screening trial. This will be 
possible in 2014 when trial follow-up concludes. 
The lengthy follow-up period required for sufficient ovarian cancer diagnoses to 
be confirmed is a limitation of the research. Unfortunately, due to the relatively 
low  incidence  of  ovarian  cancer,  the  considerable  time  interval  required  for 
follow-up analyses is unavoidable in a prospective study. Another shortcoming of 
the research is the possibility that women later diagnosed with malignancy may be 
asymptomatic at the time of OCSq completion but develop symptoms soon after. 
Unfortunately, the only way to avoid misclassification of symptoms in these cases 
would be to conduct a second OCSq study in approximately six months. However, 
this would not be possible due to the considerable financial resources required for 
a second mailing of the OCSq. 
The research presented in this thesis presented many challenges. With the benefit 
of hindsight, some aspects of the study would have been approached differently. 
For  example,  it would  have been ideal  to  alter the one-week OCSq  reference 
period to one-month for a sub-study in the pilot. This would have facilitated direct 
comparison with the Goff symptom index and would have ruled-out the different 
time periods as a possible reason for increased symptom prevalence among OCSq 
respondents. 
7.2  Future research plans 
The  aims  of  this  project  were:  1)  to  prospectively  identify  type,  severity, 
frequency and duration of symptoms that precede ovarian cancer diagnosis in a 
pilot study using a cohort of apparently healthy postmenopausal women, and 2) to 
set up a prospective study to assess the performance characteristics of symptoms 
and symptom complexes for the diagnosis of ovarian cancer upon follow-up. This 
thesis reported on the important incremental steps made in achieving these aims 
within the timeframe of the three-year PhD. Preliminary analyses of the 100,000 
women  symptoms  study  were  presented  in  Chapter  Six,  although  analyses 
fundamental to the research will not be possible until 12-18 months has elapsed 
from the date on which the last questionnaires were posted out (13 May 2009).  
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May 2010 is the earliest date when follow-up surgery and diagnostic data can be 
matched to OCSq symptoms data. By this time it is anticipated approximately 19 
women will have developed ovarian cancer. Waiting until mid November 2010 
will result in approximately 25 cases. Future analyses will include: 
●  Analysis of symptoms in women diagnosed with benign masses 
●  Analysis of symptoms in women diagnosed with malignant ovarian or 
fallopian tube lesions 
●  Exploration of symptom complexes in women diagnosed with 
malignant ovarian/fallopian tube cancer 
●  Assessment of the performance characteristics (sensitivity, 
specificity, positive and negative predictive values) of symptom 
complexes derived from the data for detecting both an abnormal 
result upon follow-up and ovarian or fallopian tube cancer 
●  Assessment of the performance characteristics of symptom indices 
described by other research groups for detecting an abnormal result 
upon follow-up and for detecting ovarian or fallopian tube cancer 
●  Assessment of whether symptom indices can be combined with 
CA125, ultrasound or both screening methodologies to improve 
sensitivity and specificity 
●  Analysis of the predictive validity of the OCSq  
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7.3  Conclusion 
The  findings  of  this  research  suggest  symptom  reporting  is  influenced 
considerably by awareness of the possibility of an ovarian lesion and depression 
status. The research also shows that symptom severity, in addition to frequency 
and duration, may be an important discriminatory factor in identifying ovarian 
abnormalities. The results indicate that it may be premature to implement the use 
of  symptom  indices  developed  from  retrospective  studies.  Further  research  is 
required  to  assess  the  performance  of  symptom  complexes  which  include 
abnormal vaginal bleeding,  abdominal or pelvic pressure or heaviness, urinary 
frequency/urgency  and  increased  abdominal  size/bloating,  for  detecting  early 
stage  ovarian  cancer.  The  utility  of  including  symptom  assessments  alongside 
CA125 testing also requires further exploration.  
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Appendix I  Ovarian Cancer Symptom Terms 
Generated from the Literature 
Symptom term  Source reference 
1  Abdominal bloating  6,14,14,15,17,21 
2  Abdominal bloating or pressure  6 
3  Bloated  3,4 
4  Bloatedness  7 
5  Bloating  2,8,10,14,20,36 
6  Bloating/abdominal swelling  9 
7  Bloating or feeling of fullness  33 
8  Abdominal bloating or increased 
abdominal size  28 
9  Unusual bloating, fullness and 
pressure in the abdomen or pelvis  24 
10  Abdominal bloating, fullness, 
pressure  12 
11 
Abdominal 
distension/bloating/increased 
size/weight 
8 
12  Ascites  7,22,26 
13  Abdominal fullness  20 
14  Abdominal fullness or pressure  4 
15  Pregnant feeling  4 
16  Abdominal swelling  11,17,19,21,29,31,35 
17  Abdominal swelling or tightening  34 
18  Swollen abdomen  3,8  
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Symptom term  Source reference 
19  Swelling  4 
20  General abdominal swelling 
without a detectable mass  34 
21  Increased abdominal 
circumference  35,36 
22  Increased abdominal girth  4,7,16,23,36 
23  Increased abdominal girdle  11 
24  Increased abdomen size  15 
25  Increased abdominal size  13,14 
26  Persistent abdominal enlargement  2 
27  Weight gain around middle  10 
28  Abdominal distension  5,9,18 
29  Distended or hard abdomen  33 
30  Distended or tense abdomen  25 
31  Distension  4 
32  Abdominal mass  18,26,34 
33  Mass in abdomen  28 
34  Able to feel abdominal mass  14,15 
35  Abdominal or pelvic mass  7 
36  Palpable abdominal mass  5 
37  Any mass the woman herself felt  35,36 
38  Self-detected abdominal mass  23 
39  Lumps in abdomen  20 
40  Lump or mass  32,33 
41  Lump  3  
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Symptom term  Source reference 
42  Mass noted by woman  36 
43  Patient-noticed abdominal mass  4 
44  Mass  8 
45  Palpable mass  1,2,13,17 
46  Palpable tumour  9,11,31 
47  Pelvic mass  37 
48  Growth/movement in pelvis  9 
49  Abdominal discomfort  21 
50  Abdominal discomfort other than 
pain or bloating  12 
51  Abdominal pain and distension  2 
52  Pain  1,8,10,11,13,31,35,36 
53  Pain (abdominal or pelvic)  4 
54  Abdominal pain  3,8,10,11,12,13,14,15,17,18,19,21,29,30,31,34,36 
55  Abdominal-back pains  23 
56  Unusual abdominal or lower back 
pain  23 
57  Pain in abdomen  20 
58  Abdominal or pelvic pain  7,14,17 
59  Abdominal/pelvic pain  9 
60  Abdominal pain or discomfort  5,25,28 
61  Right abdominal pain  8 
62  Pain in abdomen or pelvis  27 
63  Pain related to abdominal function  35 
64  Ache and pain under right rib cage  8  
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Symptom term  Source reference 
65  Abdominal pain or pressure  34 
66  Abdominal pain (cramping pain)  36 
67  Painful spots in abdomen  20 
68  Abdominal pain not related to 
bowel dysfunction  36 
69  Vague abdominal pain  20,21,37 
70  Severe abdominal pain  33 
71  Stomach/pelvic cramping  9 
72  Stomach cramps  10 
73  Sense of abdominal pressure  7 
74  Abdominal pressure  21 
75 
Pelvic or abdominal discomfort 
such as heaviness, fullness, 
pressure or pain 
32,33 
76  Pelvic discomfort  6,32 
77  Pelvic and or/abdominal pain not 
related to bowel function  35 
78  Pelvic pain  12,13,22,28 
79  Transient acute lower abdominal 
pain  4 
80  Severe lower abdominal pain  4 
81  Pain in lower abdomen  20 
82  Period-type pain  8 
83  Pelvic (lower abdomen) pain  15 
84  Pelvic pressure  1,37 
85  Lower abdominal pressure  16 
86  Pelvic/rectal pressure  9  
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Symptom term  Source reference 
87  Lower abdominal (pelvic) pressure 
or heaviness  17 
88  Pelvic fullness  37 
89  Pelvic symptoms  13,23 
90  ‘Popping’ in abdomen  8 
91  Digestive difficulties  8 
92  Indigestion  8,9,10,13,14,15,17,29 
93  Indigestion problems  20 
94  Indigestion or heartburn  28 
95  Indigestion, dyspepsia, heartburn, 
GERD  12 
96  Heartburn  11,17 
97  Nausea  3,9,12,13,14,17,15,21,24,26,35,36 
98  Nausea or vomiting  14,15,28 
99  Vomiting  8,12,17,18,26,35,36 
100  Reflux  21 
101  Eructation  11 
102  Hiccups  17 
103  Gas  9 
104  Gas or bloating  32 
105  Intestinal gas  12 
106  Flatulence  3 
107  Gas, nausea, indigestion  33 
108  Gastrointestinal symptoms  1,8,10,11,13,17,18,20,21,28,34,35,36 
109  Non-specific gastrointestinal 
complaints  16  
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Symptom term  Source reference 
110  Gastrointestinal tract problems  20 
111  Gastroenteritis  12 
112  Epigastric distress  6 
113  Fluid in abdomen  20 
114  Stomach problems  10 
115  Abdominal symptoms  13,34 
116  Meteorismus  11 
117  Bowel symptoms  5 
118  Other bowel symptoms  28 
119  Altered bowel habit  18 
120  Altered bowel habits  8 
121  Bowel changes  36 
122  Bowel changes/difficulty  9 
123  Change in bowel habit  3,7,19 
124  Defecation at night/early morning  2 
125  Constipation/diarrhoea  29 
126  Bowel muscles not working 
properly  8 
127  Difficulty voiding  17 
128  Pressure during voiding  17 
129  Bowel irregularity  25,32 
130 
Bowel irregularity such as 
diarrhoea, constipation, gas or 
bloating 
32 
131  Bowel irregularity such as 
diarrhoea or constipation  33  
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Symptom term  Source reference 
132  Constipation  1,9,10,12,13,14,15,17,20,21,26,28,32,33,35,36 
133  Unusual constipation  24 
134  Persistent constipation  8 
135  Diarrhoea  9,10,12,13,14,15,28,32,33,35,36,37 
136  Unusual diarrhoea  24 
137  Diarrhoea with bloating  8 
138  Bowel pain  32 
139  Painful defecation  35,36 
140  Rectal pain  12,27 
141  Symptoms of bowel obstruction  6 
142  Compression on the bladder or 
bowel  31 
143  Rectal bleeding  9,25 
144  Gynaecologic symptoms  1,36 
145  Gynaecological symptoms  31,34,35 
146  Gynaecological/hormonal 
symptoms  8 
147  Gynecological–urological 
symptoms  23 
148  Abnormal discharge  35,36 
149  Excessive vaginal discharge  4 
150  Increased vaginal discharge  23 
151  Vaginal discharge  8,17 
152  Bleeding  30 
153  Bleeding or spotting (vaginal)  20 
154  Vaginal bleeding  3,7,9,13,17,19,36  
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Symptom term  Source reference 
155  Vaginal bleeding or discharge  11,32 
156  Irregular bleeding  3 
157  Irregular vaginal bleeding  29,35,36 
158  Irregular premenopausal bleeding  21 
159  Postmenopausal vaginal bleeding  4 
160  Abnormal vaginal bleeding  2,21,23,28 
161  Abnormal menstrual or vaginal 
bleeding or discharge  25,33 
162  Heavy, painful periods  10 
163  Menstrual irregularities  14,15,32 
164  Menstrual irregularities/changes  8 
165  Menstrual symptoms  5 
166  Dysmenorrhoea  17,30 
167  Menorrhagia  4,21 
168  Metrorrhagia  22,29 
169  Absent or very light menses  17 
170  Missed periods  9 
171  Bleeding after menopause  14,15 
172  Postmenopausal bleeding  14,18,21 
173  Bleeding during intercourse  20 
174  Bleeding with intercourse  13,14,15 
175  Bleeding after intercourse  8 
176  Pain with intercourse  13 
177  Dyspareunia or abdominal pain 
with sexual intercourse  4  
380 
Symptom term  Source reference 
178  Pain during intercourse  3,14,15,28,32,33 
179  Painful intercourse  8 
180  Sexual problems  10 
181  Genital pain  27 
182  Dyspareunia  17 
183  Vaginal pain  4 
184  Secondary dyspareunia  35,36 
185  Vaginal/rectal pain  9 
186  Rapid vaginal delivery  17 
187  Technical difficulty and pain with 
speculum exam  17 
188  Bladder symptoms  35,36 
189  Urinary/bladder symptoms  34 
190  Change in urinating habit  3 
191  Urinary problems  20 
192  Urination problems  29 
193  Urinary symptoms  5,7,17,18,21,34,35,36 
194  Urinary tract symptoms  14 
195  Lower urinary tract symptoms  16 
196  Other urinary problems  32 
197  Urinary problems (retention and 
pain)  2 
198  Problem passing urine  10 
199  Retention of urine  18 
200  Urinary tract infection  3  
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Symptom term  Source reference 
201  Urinary tract infection, cystitis  12 
202  Urinary urgency  10,14,15 
203  Frequent urination or urgency  25 
204  Frequent urination, urgency, or 
burning  24 
205  Frequent urination  8,14,15,17 
206  Increased urinary frequency  21 
207  Frequency or urgency of urination  33 
208  Urinary frequency  1,9,10,12,13,14,15,16,28 
209  Urinary frequency or dysuria  7 
210  Urinary frequency or urgency  8 
211  Urinary frequency/urgency  32 
212  Urinary frequency, urgency or 
incontinence  37 
213  Need to urinate more often than 
usual  32 
214  Frequency of micturition  18 
215  Frequent micturition  35,36 
216  Urinary burning, dysuria  12 
217  Dysuria  11,17,23 
218  Irritative voiding  16 
219  Painful urination  8,17 
220  Bladder pressure or urinary 
frequency  4 
221  Pressure on the bladder  20,35,36 
222  Nocturia  16,17  
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Symptom term  Source reference 
223  Incontinence  35,36 
224  Urge incontinence  16 
225  Urinary stress incontinence  21 
226  Urinary incontinence  8,12,13,17,28 
227  Breathlessness  3 
228  Difficulty breathing  15 
229  Breathing difficulties  8,20 
230  Breathing problems  8 
231  Respiratory difficulties  25,32 
232  Respiratory symptoms  8,31 
233  Short of breath  10 
234  Shortness of breath  12,19,20,29,37 
235  Shortness of breath with activity  17 
236  Shortness of breath at rest  17 
237  Pain in chest  20 
238  Chest pain or respiratory 
difficulties  33 
239  Coughing  20 
240  Dyspnoea  11,17,23,35,36 
241  Pleurisy  37 
242  Pleural effusion   26,37 
243  Fluid in chest  20 
244  Local symptoms  35,36 
245  General symptoms  23,35,36 
246  Headache  12  
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Symptom term  Source reference 
247  Headaches  17 
248  Backache  19 
249  Pain in back  20 
250  Back pain  9,11,13,14,15,17,20,28,32,33,34 
251  Back pain, upper back  12 
252  Back pain, lower back  12 
253  Back pain, both lower and upper  12 
254  Lower back pain  27 
255  Back pressure or pain  4 
256  Pain in shoulder or shoulder blade 
pain  17 
257  Pain outside the abdominal cavity  25 
258  Pain, side of trunk, flank  12 
259  Pain under ribs  8 
260  Pain in the side or ribs  24 
261  Pain - thoracic  17 
262  Pain inside  8 
263  Pain - other sites  17 
264  Pain - site unspecified  17 
265  Sense of raised body temperature  2 
266  Elevated temperature  20 
267  Fever  4,9,10,11,17,32 
268  Flu-like virus  20 
269  Aching joints or muscles  17 
270  Leg cramps  20  
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Symptom term  Source reference 
271  Leg pain  8 
272  Thigh pain  14 
273  Pain or swelling in legs  32 
274  Leg swelling  14,15 
275  Deep venous thrombosis  13,18 
276  Ankle swelling  18 
277  Swelling in ankles/legs  9 
278  Swelling of the legs or feet  17 
279  Oedema, diffuse swelling, fluid 
retention  12 
280  Swollen lymph nodes  9 
281  Malaise  17 
282  General malaise  34 
283  Extreme fatigue  35,36 
284  Fatigue  3,4,6,9,10,11,13,14,15,17,20,29,31,32,36 
285  Fatigue, lack of energy, general 
weakness  12 
286  Fatigue/lethargy/tiredness  28 
287  Ongoing fatigue  33 
288  Persisting fatigue or weight loss  25 
289  Exhaustion  8 
290  Feeling weak  10 
291  Unusual lack of energy  24 
292  Tiredness  8 
293  Dizziness  23  
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Symptom term  Source reference 
294  Anorexia  12,21 
295  Appetite loss  8,29 
296  Change in appetite  3 
297  Changed appetite  8 
298  Decreased appetite  7,9,33 
299  Lack of appetite/feeling full  8 
300  Loss of appetite  12,17,32,35 
301  Loss of appetite or difficulty eating  28 
302  Loss of appetite and weight  36 
303  Unusual lack of appetite  24 
304  Early satiety  17 
305  Difficulty eating  14 
306  Feeling full quickly  15 
307  Feeling full after a few bites of 
food  17 
308  Unable to eat normally  13,14,15 
309  Taste changes  17 
310  Food intolerance  12 
311  Food aversions  2 
312  Weight loss  4,7,8,9,13,14,15,18,19,22,28,31,36 
313  Nondeliberate weight loss  6 
314  Unintentional weight loss  12 
315  Unplanned weight loss  17 
316  Loss of weight  35 
317  Unplanned weight gain  17  
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Symptom term  Source reference 
318  Getting fat  4 
319  Weight gain  7,8,20 
320  Gained weight  10 
321  Obesity  12 
322  Unexplained weight gain or loss  33 
323  Change in weight  3 
324  Weight loss or gain  32 
325  Anaemia  36 
326  Severe anaemia  35 
327  Fluid in lungs  20 
328  Non-menopausal hot flushes  2 
329  Menopausal symptoms, hot flushes  12 
330  Hot flashes  17,32 
331  Insomnia  20 
332  Night sweats  8,32 
333  Anxiety, panic attacks  12 
334  Panic attacks  9 
335  Umbilical hernia  8 
336  Breast swelling  17 
337  Mammary swelling  11 
338  Breast tenderness  17 
339  Tenesmus  11 
340  Difficulty moving legs  17 
341  Paresthesia, numbness, burning, 
tingling  12  
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Symptom term  Source reference 
342  Irritable bowel syndrome  12,13 
343  Constitutional symptoms  1,13,17,28 
344  Metastatic symptoms  6 
345  Symptoms of mass effect  1 
346  Systemic symptoms  6,31 
347  Regional symptoms  6 
348  Depression  9,13,15,17 
349  Stress  13 
  
388 
Source reference  Symptoms questionnaire used? 
1  Attanucci et al. (2004)    
2  Bankhead et al. (2005)*    
3  Bayne & Gilbert (2007)*  Yes 
4  Beck et al. (2001)  Yes 
5  Chan et al. (2003)    
6  DiSilvestro et al. (1998)    
7  Eltabbakh et al. (1999)    
8  Evans et al. (2006)    
9  Ferrell et al. (2003)    
10  Fitch et al. (2002)    
11  Flam et al. (1988)    
12  Friedman et al. (2005)    
13  Goff et al. (2000)  Yes 
14  Goff et al. (2004)  Yes 
15  Goff et al. (2007)  Yes 
16  Goldberg et al. (2001)    
17  Igoe (1997)  Yes 
18  Kennedy & Gordon (1981)    
19  Kirwan et al. (2002)    
20  Koldjeski et al. (2003)  Yes 
21  Lataifeh et al. (2005)    
22  Mantzavinos et al. (1988)    
23  Nelson et al. (1999)    
24  Olson et al. (2001)  Yes  
389 
Source reference  Symptoms questionnaire used? 
25  Paulsen et al. (2005)    
26  Piura et al. (1998)    
27  Portenoy et al. (1994)  Yes 
28  Rufford et al. (2007)    
29  Smith & Anderson (1985)  Yes 
30  Takeuchi et al. (2002)    
31  Thulesius et al. (2004)    
32  Vine et al. (2001)  Yes 
33  Vine et al. (2003)  Yes 
34  Webb et al. (2004)  Yes 
35  Wikborn et al. (1993)    
36  Wikborn et al. (1996)    
37  Yawn et al. (2004)    
 
* Conference abstract  
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Appendix II  Symptom Questionnaire for Health 
Professional Interviews 
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Appendix III  Letter of Invitation for Telephone 
Interviews with Women Diagnosed with Ovarian Cancer 
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Appendix IV  Study Information Sheet for Women 
Invited to Participate in Telephone Interviews 
 
Ovarian cancer symptoms study 
 
As a previous participant in the United Kingdom Collaborative Trial of Ovarian Cancer Screening 
(UKCTOCS) you are being asked to take part in research to develop a questionnaire which will ask 
women about ovarian cancer symptoms. Before you decide to take part it is important for you to 
understand why the research is being done and what it will involve. Please read the following 
information carefully and discuss it with friends, relatives and your GP if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to decide whether or not 
you wish to take part. 
 
Thank you for reading this. 
 
What is the purpose of the study? 
 
Previous research has reported that the early symptoms of ovarian cancer are subtle or non-specific. 
Due to this the majority of women are diagnosed with ovarian cancer after it has spread from the 
ovaries. The purpose of this study is to develop a questionnaire which will be used in a larger study 
of symptoms that precede a diagnosis of ovarian cancer. 
 
Why have I been chosen? 
 
This study is a sub-study of the United Kingdom Collaborative Trial of Ovarian Cancer Screening 
and you participated in UKCTOCS. We are inviting women who have received a diagnosis of 
ovarian cancer to participate in an interview about a symptoms questionnaire. 
 
Do I have to fulfil any other criteria to take part? 
 
No. The only criteria you need to fulfil are: 
1.  Participated in the United Kingdom Collaborative Trial of Ovarian Cancer Screening and 
have been diagnosed with ovarian cancer. 
 
Do I have to take part? 
 
No. It is up to you to decide whether or not to take part. If you do decide to take part you will be 
asked to sign a consent form. This form is different to the original consent form that you signed to 
enrol in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. If you decide to take 
part you are free to withdraw at any time and without giving a reason. This will not affect any 
medical care you receive. 
 
What will happen to me if I take part? 
 
Structured questionnaire telephone interview 
 
If you would like to take part in this study please sign the enclosed consent form then send to the 
researcher, Penny Allen, in the enclosed pre-paid envelope. The consent form also asks for your 
permission to audio tape record the interview. The researcher will telephone you to discuss the study 
in greater detail, give you the opportunity to ask any questions and arrange a convenient time for you 
to participate in a telephone interview. If you decide to take part in an interview you can decline to     
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answer any questions that you are not comfortable answering and you are free to end the interview at 
any time without giving a reason. 
 
What are the possible disadvantages of taking part? 
 
1.  Participation in the telephone interview will take 30-45 minutes of your time.  
2.  Discussing symptoms during interview may create anxiety or may make some women 
upset 
 
What are the possible benefits of taking part? 
 
  We cannot promise the study will help you directly but the information collected may, in the 
future, help to identify symptoms of ovarian cancer.   
 
What if I become worried or anxious about any of the issues raised during the interview? 
 
The researcher cannot give you any information or advice about your symptoms. If you are worried 
about any symptoms please discuss them with your GP or gynaecologist. If you would like the 
details of an ovarian cancer patient support group please ask the interviewer. 
 
What if something goes wrong? 
 
We consider there to be little risk associated with taking part in this study and it is not anticipated 
that anything will go wrong in the study as it only involves you discussing symptoms. It does not 
involve any tests.  
 
You will always be able to contact the researcher to discuss your concerns about the study. Every 
care will be taken to ensure your safety during the course of the study. University College London 
(UCL), the Research Governance Sponsor, ha s indemnity (insurance) arrangements in place for 
non-negligent harm, in the event that something does go wrong and you are harmed as a result of 
taking part in this study. If you are harmed and this is due to someone’s negligence then you may 
have grounds for legal action for compensation but you may have to pay your legal costs. 
 
Will taking part in this study be kept confidential? 
 
All information which is collected about you during the course of the research will be kept strictly 
confidential. You will be asked not to use your name, address or personal details during the tape-
recorded interview. We will not write your name or any personal details on any interview notes. 
Occasionally the research documentation and results will be looked at by the people funding the 
research programme to check that the study is being carried out properly. Any information which is 
viewed by people not directly related to the research team will not have your name and address on it. 
 
What will happen to the results of the research study? 
 
The results of the research will be used in a PhD study of the symptoms of ovarian cancer. 
Additionally, the results will be reviewed by medical professionals and published in the medical 
press. Individuals will not be identified in any publications.    
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Who is organising and funding the research? 
The research is part of a PhD study that is linked to the United Kingdom Collaborative Trial of 
Ovarian Cancer Screening. The Medical Research Council is funding the study. 
 
Complaints 
 
If you have a concern about any aspect of this study you should ask to speak with Penny Allen or Dr 
Usha Menon (tel. 0207 380 6907) who will do their best to assist. If you remain unhappy, and wish 
to complain formally, you can do this by contacting the Research Governance Sponsor of this study, 
University College London. Please write to: 
 
UCLH/UCL Joint Biomedical Research Unit 
R&D Directorate 
Rosenheim Wing, Ground Floor 
25 Grafton Way 
London WC1E 5DB 
 
 
Contact for further information 
 
For further information please telephone Penny Allen in the Department of Gynaecological 
Oncology on tel. 0789 733 7573 or 0207 380 6919. Alternatively, you can write to: 
 
Penny Allen 
Department of Gynaecological Oncology 
UCL Institute for Women’s Health 
Level 1, Maple House 
149 Tottenham Court Road 
London 
W1T 7DN 
 
 
Thank you for taking the time to read this information.    
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Appendix V  Consent Form Sent to Women Invited 
to Participate in Telephone Interviews 
 
Department of Gynaecological Oncology 
Maple House, 1
st Floor 
149 Tottenham Court Road 
London 
W1T 7NF 
Centre Number:     ______________ 
Volunteer reference number:  ______________ 
 
 
 
CONSENT FORM 
 
Title of Project: Prospective study of ovarian cancer symptoms. 
 
Name of researcher: Penny Allen 
                      Please initial box 
 
1.  I confirm that I have read and understand the information sheet dated 
............................ (version ...........................) for the above study and 
have had the opportunity to ask questions. 
 
2.  I understand that my participation is voluntary and that I am free to  
withdraw at any time, without giving reason, without my medical care  
or legal rights being affected. 
 
3.   I understand that information collected by the UKCTOCS study 
may be looked at by the researcher where it is relevant to my taking  
part in the research. I give permission for the researcher to have  
access to my UKCTOCS records. 
 
4.   I give permission for my interview to be audio-taped.  
 
5.  I agree to take part in the above study. 
 
 
 
 
______________________    ____________  ______________________ 
Name of study volunteer    Date      Signature 
 
 
______________________    ____________  ______________________ 
Researcher        Date      Signature 
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Appendix VI  Symptoms Questionnaire for Telephone 
Interviews with Women Diagnosed with Ovarian Cancer 
 
 
Symptoms Questionnaire for Telephone Interviews with Women Diagnosed with 
Ovarian Cancer 
 
Interview no: _______    Site: _____________________   Months since diagnosis: ______ 
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Please identify 5 to 10 symptoms that caused the greatest trouble leading up to diagnosis (tick 
boxes). 
 
Were any additional symptoms experienced during the time leading up to diagnosis that are 
not included in this list?  
___________________________________________________________________________   
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Appendix VII  Interview Guide for Telephone 
Interviews with Women Diagnosed with Ovarian Cancer 
Prior to commencing interview check that the participant has the symptom list in 
front of them. Inform participant that their name will not be used once the tape 
starts  recording,  that  they  can  refuse  to  answer  any  questions  they  are  not 
comfortable answering and that they can end the interview at any time. 
Identify the 18 month period prior to diagnosis before commencing the interview. 
Clarify date at the start of the 18 month period and the date of diagnosis. Use 
significant  dates  (e.g.  Christmas,  Easter,  birthdays,  holidays,  etc.)  to  help 
participant remember the exact time period. 
For each item: 
●  Did you experience the symptom in the 18 months leading up to your 
diagnosis? 
●  If yes, did you experience it a little, quite a bit or very much? (Circle) 
●  Can you tell me about the symptom? 
●  In your own words how would you describe it? 
●  When did you first notice it? 
●  What did it feel like? 
●  Where exactly in your body did you feel/see it? 
●  How often did it happen? 
●  Did you take anything for it? 
●  Did you go to the doctor about it? 
●  Did it change at all or stop altogether? If so, how and when? 
●  What do you think caused that symptom?  
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Can you think of any additional symptoms which you experienced during the 18 
months leading up to your diagnosis that are not included in the list? 
Which of these symptoms in the list, and any that you have mentioned yourself, 
troubled  you  the  most  during  that  time?  Please  identify  up  to  10  issues  (tick 
boxes) 
Do you have any other comments about these symptoms? 
Thank interviewee for their time  
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Appendix VIII  Results of Preliminary Revision of the 
Symptoms List 
Symptom term  Revised to 
1  Abdominal bloating 
Abdominal bloating 
2  Abdominal bloating or pressure 
3  Bloated 
4  Bloatedness 
5  Bloating 
6  Bloating/abdominal swelling 
7  Bloating or feeling of fullness 
8  Abdominal bloating or increased abdominal size 
9  Unusual bloating, fullness and pressure in the 
abdomen or pelvis 
10  Abdominal bloating, fullness, pressure 
11  Abdominal distension/bloating/increased 
size/weight 
12  Ascites  Deleted - medical terminology 
13  Abdominal fullness 
Abdominal fullness  14  Abdominal fullness or pressure 
15  Pregnant feeling 
16  Abdominal swelling 
Abdominal swelling 
Swollen abdomen  
Abdominal tightening 
17  Abdominal swelling or tightening 
18  Swollen abdomen 
19  Swelling 
20  General abdominal swelling without a 
detectable mass    
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Symptom term  Revised to 
21  Increased abdominal circumference 
Increased abdominal size 
22  Increased abdominal girth 
23  Increased abdominal girdle 
24  Increased abdomen size 
25  Increased abdominal size 
26  Persistent abdominal enlargement 
27  Weight gain around middle 
28  Abdominal distension 
Abdominal distension  
Hard abdomen  
Tense abdomen 
29  Distended or hard abdomen 
30  Distended or tense abdomen 
31  Distension 
32  Abdominal mass 
 
 
 
 
Able to feel abdominal mass/lumps 
Lump 
33  Mass in abdomen 
34  Able to feel abdominal mass 
35  Abdominal or pelvic mass 
36  Palpable abdominal mass 
37  Any mass the woman herself felt 
38  Self-detected abdominal mass 
39  Lumps in abdomen 
40  Lump or mass 
41  Lump 
42  Mass noted by woman 
43  Patient-noticed abdominal mass 
44  Mass  
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Symptom term  Revised to 
45  Palpable mass 
 
46  Palpable tumour 
47  Pelvic mass 
48  Growth/movement in pelvis 
49  Abdominal discomfort 
Abdominal discomfort 
50  Abdominal discomfort other than pain or 
bloating 
51  Abdominal pain and distension 
Abdominal pain 
52  Pain 
53  Pain (abdominal or pelvic) 
54  Abdominal pain 
55  Abdominal-back pains 
56  Unusual abdominal or lower back pain 
57  Pain in abdomen 
58  Abdominal or pelvic pain 
59  Abdominal/pelvic pain 
60  Abdominal pain or discomfort 
61  Right abdominal pain 
62  Pain in abdomen or pelvis 
63  Pain related to abdominal function 
64  Ache and pain under right rib cage 
65  Abdominal pain or pressure 
66  Abdominal pain (cramping pain) 
67  Painful spots in abdomen  
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Symptom term  Revised to 
68  Abdominal pain not related to bowel 
dysfunction 
69  Vague abdominal pain 
70  Severe abdominal pain 
71  Stomach/pelvic cramping 
Stomach cramping  
Pelvic cramping 
72  Stomach cramps 
73  Sense of abdominal pressure 
Abdominal pressure 
74  Abdominal pressure 
75  Pelvic or abdominal discomfort such as 
heaviness, fullness, pressure or pain 
Pelvic discomfort 
76  Pelvic discomfort 
77  Pelvic and or/abdominal pain not related to 
bowel function 
Pelvic pain 
78  Pelvic pain 
79  Transient acute lower abdominal pain 
80  Severe lower abdominal pain 
81  Pain in lower abdomen 
82  Period-type pain 
83  Pelvic (lower abdomen) pain 
84  Pelvic pressure 
Pelvic pressure  85  Lower abdominal pressure 
86  Pelvic/rectal pressure 
87  Lower abdominal (pelvic) pressure or heaviness  Pelvic heaviness 
88  Pelvic fullness  Pelvic fullness 
89  Pelvic symptoms  Deleted - non-specific 
90  ‘Popping’ in abdomen  Deleted - non-specific  
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Symptom term  Revised to 
91  Digestive difficulties 
Indigestion or heartburn 
92  Indigestion 
93  Indigestion problems 
94  Indigestion or heartburn 
95  Indigestion, dyspepsia, heartburn, GERD 
96  Heartburn 
97  Nausea 
Nausea 
98  Nausea or vomiting 
99  Vomiting  Vomiting 
100  Reflux  Reflux 
101  Eructation  Deleted - medical terminology 
102  Hiccups  Deleted - non-specific 
103  Gas 
Belching, gas 
Passing wind/gas/flatulence  
104  Gas or bloating 
105  Intestinal gas 
106  Flatulence 
107  Gas, nausea, indigestion 
108  Gastrointestinal symptoms 
Deleted - non-specific  109  Non-specific gastrointestinal complaints 
110  Gastrointestinal tract problems 
111  Gastroenteritis  Deleted - medical terminology 
112  Epigastric distress  Deleted - medical terminology 
113  Fluid in abdomen 
Deleted - non-specific 
114  Stomach problems  
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Symptom term  Revised to 
115  Abdominal symptoms 
116  Meteorismus  Deleted - medical terminology 
117  Bowel symptoms  Deleted - non-specific 
118  Other bowel symptoms  Deleted - non-specific 
119  Altered bowel habit 
Change in bowel habit 
120  Altered bowel habits 
121  Bowel changes 
122  Bowel changes/difficulty 
123  Change in bowel habit 
124  Defecation at night/early morning 
125  Constipation/diarrhoea 
126  Bowel muscles not working properly 
Difficulty opening bowels  127  Difficulty voiding 
128  Pressure during voiding 
129  Bowel irregularity 
Bowel irregularity  130  Bowel irregularity such as diarrhoea, 
constipation, gas or bloating 
131  Bowel irregularity such as diarrhoea or 
constipation 
132  Constipation 
Constipation  133  Unusual constipation 
134  Persistent constipation 
135  Diarrhoea 
Diarrhoea  136  Unusual diarrhoea 
137  Diarrhoea with bloating  
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Symptom term  Revised to 
138  Bowel pain 
Pain when opening bowels 
139  Painful defecation 
140  Rectal pain  Rectal pain 
141  Symptoms of bowel obstruction  Deleted - non-specific 
142  Compression on the bladder or bowel  Deleted - medical terminology 
143  Rectal bleeding  Rectal bleeding 
144  Gynaecologic symptoms 
Deleted - non-specific 
145  Gynaecological symptoms 
146  Gynaecological/hormonal symptoms 
147  Gynecological–urological symptoms 
148  Abnormal discharge 
Abnormal vaginal discharge 
149  Excessive vaginal discharge 
150  Increased vaginal discharge 
151  Vaginal discharge 
152  Bleeding 
 
 
 
Abnormal vaginal bleeding 
153  Bleeding or spotting (vaginal) 
154  Vaginal bleeding 
155  Vaginal bleeding or discharge 
156  Irregular bleeding 
157  Irregular vaginal bleeding 
158  Irregular premenopausal bleeding 
159  Postmenopausal vaginal bleeding 
160  Abnormal vaginal bleeding  
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Symptom term  Revised to 
161  Abnormal menstrual or vaginal bleeding or 
discharge 
162  Heavy, painful periods 
163  Menstrual irregularities 
164  Menstrual irregularities/changes 
165  Menstrual symptoms 
166  Dysmenorrhoea 
167  Menorrhagia 
168  Metrorrhagia 
169  Absent or very light menses 
170  Missed periods 
171  Bleeding after menopause 
172  Postmenopausal bleeding 
173  Bleeding during intercourse 
Bleeding during/after intercourse  174  Bleeding with intercourse 
175  Bleeding after intercourse 
176  Pain with intercourse 
Painful intercourse 
177  Dyspareunia or abdominal pain with sexual 
intercourse 
178  Pain during intercourse 
179  Painful intercourse 
180  Sexual problems  Deleted - non-specific 
181  Genital pain 
Vaginal pain  182  Dyspareunia 
183  Vaginal pain  
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Symptom term  Revised to 
184  Secondary dyspareunia 
185  Vaginal/rectal pain 
186  Rapid vaginal delivery  Deleted - not relevant in 
postmenopausal women 
187  Technical difficulty and pain with speculum 
exam 
Deleted - not relevant for 
symptoms questionnaire 
188  Bladder symptoms 
Deleted - non-specific 
189  Urinary/bladder symptoms 
190  Change in urinating habit 
191  Urinary problems 
192  Urination problems 
193  Urinary symptoms 
194  Urinary tract symptoms 
195  Lower urinary tract symptoms 
196  Other urinary problems 
197  Urinary problems (retention and pain) 
Difficulty emptying bladder  198  Problem passing urine 
199  Retention of urine 
200  Urinary tract infection 
Urinary tract infection 
201  Urinary tract infection, cystitis 
202  Urinary urgency 
 
 
Urinary urgency 
Urgent need to pass urine 
Urinary frequency 
Passing urine more often 
203  Frequent urination or urgency 
204  Frequent urination, urgency, or burning 
205  Frequent urination 
206  Increased urinary frequency  
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Symptom term  Revised to 
207  Frequency or urgency of urination 
208  Urinary frequency 
209  Urinary frequency or dysuria 
210  Urinary frequency or urgency 
211  Urinary frequency/urgency 
212  Urinary frequency, urgency or incontinence 
213  Need to urinate more often than usual 
214  Frequency of micturition 
215  Frequent micturition 
216  Urinary burning, dysuria  Urinary burning 
217  Dysuria 
Pain or soreness on passing urine  218  Irritative voiding 
219  Painful urination 
220  Bladder pressure or urinary frequency 
Pressure on the bladder 
221  Pressure on the bladder 
222  Nocturia  Deleted - medical terminology 
223  Incontinence 
Urinary incontinence 
224  Urge incontinence 
225  Urinary stress incontinence 
226  Urinary incontinence 
227  Breathlessness  Breathlessness 
228  Difficulty breathing 
Difficulty breathing  229  Breathing difficulties 
230  Breathing problems  
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Symptom term  Revised to 
231  Respiratory difficulties 
Deleted - non-specific 
232  Respiratory symptoms 
233  Short of breath 
Shortness of breath 
234  Shortness of breath 
235  Shortness of breath with activity 
236  Shortness of breath at rest 
237  Pain in chest 
Chest pain 
238  Chest pain or respiratory difficulties 
239  Coughing  Coughing 
240  Dyspnoea 
Deleted - medical terminology 
241  Pleurisy 
242  Pleural effusion  
243  Fluid in chest 
244  Local symptoms 
Deleted - non-specific 
245  General symptoms 
246  Headache 
Deleted - non-specific 
247  Headaches 
248  Backache  Backache 
249  Pain in back 
Back pain 
250  Back pain 
251  Back pain, upper back 
252  Back pain, lower back 
253  Back pain, both lower and upper 
254  Lower back pain  
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Symptom term  Revised to 
255  Back pressure or pain 
256  Pain in shoulder or shoulder blade pain  Shoulder pain 
257  Pain outside the abdominal cavity  Deleted - non-specific 
258  Pain, side of trunk, flank 
Pain in side of trunk, flank  259  Pain under ribs 
260  Pain in the side or ribs 
261  Pain - thoracic  Deleted - medical terminology 
262  Pain inside 
Deleted - non-specific  263  Pain - other sites 
264  Pain - site unspecified 
265  Sense of raised body temperature 
Fever  266  Elevated temperature 
267  Fever 
268  Flu-like virus  Flu-like symptoms 
269  Aching joints or muscles  Aching limbs 
270  Leg cramps  Leg cramps 
271  Leg pain 
Leg pain  272  Thigh pain 
273  Pain or swelling in legs 
274  Leg swelling 
Leg swelling 
275  Deep venous thrombosis 
276  Ankle swelling 
Ankle swelling  277  Swelling in ankles/legs 
278  Swelling of the legs or feet  
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Symptom term  Revised to 
279  Oedema, diffuse swelling, fluid retention  Deleted - medical terminology 
280  Swollen lymph nodes  Swollen lymph nodes 
281  Malaise 
Malaise 
282  General malaise 
283  Extreme fatigue 
Fatigue 
284  Fatigue 
285  Fatigue, lack of energy, general weakness 
286  Fatigue/lethargy/tiredness 
287  Ongoing fatigue 
288  Persisting fatigue or weight loss 
289  Exhaustion 
290  Feeling weak 
Lack of energy 
291  Unusual lack of energy 
292  Tiredness  Tiredness 
293  Dizziness  Deleted - non-specific 
294  Anorexia 
Loss of appetite 
295  Appetite loss 
296  Change in appetite 
297  Changed appetite 
298  Decreased appetite 
299  Lack of appetite/feeling full 
300  Loss of appetite 
301  Loss of appetite or difficulty eating 
302  Loss of appetite and weight  
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Symptom term  Revised to 
303  Unusual lack of appetite 
304  Early satiety 
Feeling full quickly after beginning 
to eat 
305  Difficulty eating 
306  Feeling full quickly 
307  Feeling full after a few bites of food 
308  Unable to eat normally 
309  Taste changes  Taste changes 
310  Food intolerance  Deleted - non-specific 
311  Food aversions  Deleted - non-specific 
312  Weight loss 
Weight loss Weight gain 
313  Nondeliberate weight loss 
314  Unintentional weight loss 
315  Unplanned weight loss 
316  Loss of weight 
317  Unplanned weight gain 
318  Getting fat 
319  Weight gain 
320  Gained weight 
321  Obesity 
322  Unexplained weight gain or loss 
323  Change in weight 
324  Weight loss or gain 
325  Anaemia  Deleted - medical terminology 
326  Severe anaemia  Deleted - medical terminology  
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Symptom term  Revised to 
327  Fluid in lungs  Deleted - medical terminology 
328  Non-menopausal hot flushes 
Hot flushes  329  Menopausal symptoms, hot flushes 
330  Hot flashes 
331  Insomnia  Deleted - non-specific 
332  Night sweats  Night sweats 
333  Anxiety, panic attacks 
Panic attacks 
334  Panic attacks 
335  Umbilical hernia  Deleted - medical terminology 
336  Breast swelling 
Breast swelling 
337  Mammary swelling 
338  Breast tenderness  Breast pain 
339  Tenesmus  Deleted - medical terminology 
340  Difficulty moving legs  Deleted - non-specific 
341  Paresthesia, numbness, burning, tingling  Deleted - medical terminology 
342  Irritable bowel syndrome 
Deleted - non-specific 
343  Constitutional symptoms 
344  Metastatic symptoms 
345  Symptoms of mass effect 
346  Systemic symptoms 
347  Regional symptoms 
348  Depression  Depression 
349  Stress  Deleted - non-specific  
418 
Appendix IX  Results of Health Professionals 
Interviews 
Symptom  Relevance 
Mean  Prioritised (%) 
Abdominal bloating  3.57  91 
Abdominal fullness  3.29  57 
Increased abdominal size  3.57  91 
Abdominal tightening  2.38  19 
Hard abdomen  2.14  14 
Able to feel abdominal mass/lumps (abdomen)  2.33  52 
Abdominal discomfort  3.10  81 
Abdominal pain  2.57  48 
Abdominal pressure  2.57  24 
Abdominal cramping  1.62  0 
Indigestion  2.76  71 
Heartburn  2.19  24 
Nausea/feeling sick  2.43  67 
Vomiting/being sick  2.10  24 
Reflux of food  2.05  5 
Burping  1.43  5 
Taste changes  1.33  0 
Feeling full quickly after beginning to eat  2.10  33 
Loss of appetite  2.81  67 
Change in bowel habit  2.95  81 
Constipation  2.52  38  
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Symptom  Relevance 
Mean  Prioritised (%) 
Diarrhoea  2.19  24 
Excessive passing of wind/flatulence  1.71  5 
Difficulty opening bowels  2.38  14 
Pain before, during or after opening bowels  1.81  10 
Rectal pain  1.76  5 
Rectal bleeding  1.43  10 
Urgent need to open bowel  2.10  5 
Bowel incontinence  1.38  0 
Able to feel mass or lump (pelvis)  2.14  29 
Pelvic discomfort  2.71  57 
Pelvic pain  2.48  33 
Pelvic cramping  1.76  5 
Pelvic pressure  2.38  29 
Pelvic fullness  2.48  33 
Pelvic heaviness  2.24  24 
Vaginal discharge  1.71  14 
Vaginal bleeding  2.14  43 
Vaginal pain  1.52  5 
Pain during/after sexual intercourse  1.76  19 
Bleeding during/after intercourse  1.38  10 
Prolapse  1.71  0 
Urgent need to pass urine  2.57  33 
Passing urine frequently  3.10  76  
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Symptom  Relevance 
Mean  Prioritised (%) 
Feeling of pressure on the bladder  2.76  71 
Leakage of urine  2.00  5 
Difficulty emptying bladder  2.19  14 
Burning on passing urine  1.62  0 
Pain on passing urine  1.57  0 
Chest pain  1.14  0 
Cough  1.38  5 
Difficulty breathing  1.71  14 
Shortness of breath  1.95  52 
Backache  2.43  52 
Back pain  2.05  33 
Shoulder pain  1.38  5 
Pain in side of trunk, flank  2.05  14 
Pain in the hip/buttock/outside leg  1.43  5 
Aching limbs  1.48  0 
Pain in legs  1.33  0 
Leg cramps  1.29  5 
Leg swelling  2.29  33 
Ankle swelling  2.05  19 
Lump in neck  1.43  10 
Fever/raised temperature  1.38  0 
Tiredness  3.00  57 
Fatigue  3.05  71  
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Symptom  Relevance 
Mean  Prioritised (%) 
Lack of energy  2.95  48 
Generally feeling unwell  3.14  86 
Weight loss without trying  2.62  48 
Weight gain without trying  2.67  67 
Hot flushes  1.38  0 
Night sweats  1.48  0 
Breast swelling  1.14  0 
Breast pain  1.10  0 
Lump in breast  1.14  0 
Difficulty sleeping  2.00  10 
Feeling tense or anxious  1.76  14 
Feeling down, depressed or hopeless?  1.67  0 
Little interest or pleasure doing things?  1.76  10 
  
422 
Appendix X  Example of Coded Qualitative Data 
from Health Professional Interviews 
Symptom: Breast pain 
Coded data for breast pain 
Lead Nurse, Site 1 
I haven‟t heard of that. 
Research Nurse, Site 1 
Sometimes …I‟m trying to remember now, the women who talked about breast pain had breast 
cancer in the past, but I couldn‟t say that for sure. But um, it tends to be on the ward rounds, 
that‟s the only location you hear about symptoms being in the breast. 
Consultant 1, Site 1 
I‟m not aware of a patient ever having breast pain. 
Nurse Specialist, Site 1 
I can‟t remember anyone talking about breast pain to me. 
Registrar, Site 1 
Breast pain, never seen it. 
Consultant 2, Site 1 
Breast pain is totally irrelevant. 
Nurse Specialist, Site 2 
I haven‟t come across that. 
Consultant 1, Site 2 
I‟ve not come across that really. 
Consultant 2, Site 2 
I don‟t see the relevance of that in the context of ovarian tumours, unless you‟re looking for 
metastases from the breast. 
Research Nurse, Site 2 
Breast pain, never. 
Consultant, Site 3 
An hormonally active tumour could produce mastalgia, or breast discomfort but they are 
relatively rare tumours. All I can say if that I‟ve not had any patients complain of that. 
Research Nurse, Site 3 
I haven‟t heard anybody say it‟s led them to the doctor and the diagnosis … Not at all, no, 
nobody has said that they‟ve had breast pain. 
Consultant, Site 4 
It‟s connected with other problems but not ovarian cancer. 
Research Nurse, Site 4 
I haven‟t seen that.  
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 Consultant, Site 5 
It‟s not something that I‟ve seen women complaining of. 
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Appendix XI  Results of Telephone Interviews with 
Women with Ovarian Cancer 
Symptom  Relevance 
Mean 
Symptom 
caused most 
trouble (%) 
Pelvic fullness  1.00  0 
Pain during/after sexual intercourse  1.06  0 
Pain when passing urine  1.08  0 
Pelvic heaviness  1.08  0 
Able to feel abdominal mass or lumps  1.12  0 
Abnormal vaginal discharge  1.12  4 
Abdominal discomfort, pain or pressure  1.16  0 
Pain in side of trunk, flank  1.16  0 
Abnormal vaginal bleeding  1.16  4 
Aching limbs  1.20  0 
Difficulty emptying bladder  1.20  0 
Leg swelling  1.20  0 
Nausea/feeling sick or vomiting/being sick  1.20  0 
Shortness of breath  1.20  0 
Weight loss without trying  1.28  0 
Feeling of pressure on the bladder  1.32  8 
Leg pain  1.36  0 
Feeling full quickly after beginning to eat  1.36  8 
Change in bowel habit  1.40  0 
Change in appetite  1.40  4  
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Symptom  Relevance 
Mean 
Symptom 
caused most 
trouble (%) 
Back ache/pain  1.44  0 
Difficulty emptying bowels  1.44  0 
Generally feeling unwell  1.44  4 
Heartburn  1.44  4 
Pain before, during or after opening bowels  1.44  4 
Excessive passing of wind/flatulence  1.48  0 
Urgent need to pass urine  1.48  12 
Indigestion  1.56  4 
Abdominal bloating or fullness  1.68  8 
Weight gain without trying  1.72  0 
Passing urine frequently  1.80  8 
Increased abdominal size/waistband feels tighter  1.88  4 
Lower abdominal/pelvic discomfort, pain or pressure  1.96  24 
Tiredness, fatigue or lack of energy  2.04  4 
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Appendix XII  Pilot Ovarian Cancer Symptoms 
Questionnaire (OCSq) 
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Number of 
days present 
during past 
week
How many 
months have you 
had this?
Discussed 
with GP in 
past 3 
months?
E.g. Have you had hot flushes?
1
2
3
4
How to complete this questionnaire:
Please feel free to leave out any question if you feel uncomfortable replying to it, or for any other reason.
The questionnaire has 7 pages and takes approximately 15 minutes to complete.
During the past week:
Please read the enclosed information sheet and sign the consent section before starting the 
questionnaire.
For each item please tick the extent to which you have experienced it during the past week (either not at all, a 
little, quite a bit or very much), tick the number of days in the past week it has been experienced, tick how many 
months since it first started and tick whether or not you have discussed it with a GP in the past three months. 
If you have not had the symptom in the past week tick 'not at all' and move onto the next question.  
Below is an example of how to fill in the questionnaire. This shows that the woman had hot flushes 'a little' for 
three to five days during the past week, has been having hot flushes for more than a year and has not 
discussed her hot flushes with the GP during the past three months.
I understand that information collected by the UKCTOCS study may be looked at by the                                                     
researcher where it is relevant to my taking part in the research. I give permission for the                                                                                     
researcher to have access to my UKCTOCS records.
Please fill-in the consent section below before turning over the page to start the questionnaire
Please initial each box
I have read the understand the information sheet dated 3 April 2008, version 3.
I understand that my participation is voluntary and that I am free to withdraw at any time,                                                    
without giving reason, without my medical care or legal rights being affected.
I agree to take part in the study.
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12
Name Date Signature
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Number of 
days present 
during past 
week
How many 
months have 
you had this?
Discussed 
with GP in 
past 3 
months?
Q1 Have you had lower abdominal                      
or pelvic discomfort or pain?
shaded area indicates site of symptom
Q2 Have you had upper abdominal                              
discomfort or pain?
shaded area indicates site of symptom
Q3 Have you had indigestion or heartburn?
Q4 Have you had nausea or vomiting?
Q5 Have you felt full quickly when eating?
During the past week:
For each item please tick the extent to which you have experienced it during the past week, tick the number of 
days in the past week it has been experienced, tick how many months since it first started and tick whether or 
not you have discussed it with a GP in the past three months.
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
Date Volunteer Ref
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Number of 
days present 
during past 
week
How many 
months have you 
had this?
Discussed 
with GP in 
past 3 
months?
Q6 Have you had a change in appetite?
Q7 Have you had a feeling of upper                          
abdominal bloating or fullness?
shaded area indicates site of symptom
Q8 Have you had a feeling of upper                          
abdominal pressure?
shaded area indicates site of symptom
Q9
Have you had increased abdominal                           
size or waistbands of clothes feeling                     
too tight?
Q10 Were you able to feel an abdominal                   
mass or lump?
N/A
Q11
Have you had a feeling of lower                             
abdominal or pelvic bloating                      
or fullness?
shaded area indicates site of symptom
During the past week:
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
Volunteer Ref
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
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days present 
during past 
week
How many 
months have 
you had this?
Discussed 
with GP in 
past 3 
months?
Q12 Have you had a feeling of lower                             
abdominal or pelvic pressure?
shaded area indicates site of symptom
Q13 Have you had a feeling of lower                             
abdominal or pelvic heaviness?
shaded area indicates site of symptom
Q14 Have you had pain before, during or                     
after opening your bowels?
Q15 Have you had difficulty emptying                             
your bowels?
Q16 Have you had a change in bowel habit?
Q17 Have you had excessive passing of wind                               
or flatulence?
During the past week:
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
Volunteer Ref
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
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Number of 
days present 
during past 
week
How many 
months have 
you had this?
Discussed 
with GP in 
past 3 
months?
Q18 Have you passed urine frequently?
Q19 When you felt the urge to pass urine                  
did you have to hurry to get to the toilet?
Q20 Have you had a feeling of pressure on                
the bladder?
Q21 Have you had difficulty emptying                           
the bladder?
Q22 Have you had pain when passing urine?
Q23 Were you short of breath?
During the past week:
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
Volunteer Ref
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
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days present 
during past 
week
How many 
months have 
you had this?
Discussed 
with GP in 
past 3 
months?
Q24 Have you had ache or pain in your back?
Q25 Have you had an ache or pain in one or              
both legs?
Q26 Have you had swelling in one or                   
both legs?
Q27 Have you had a feeling of tiredness,                
fatigue or lack of energy?
Q28 Have you gained weight without trying? N/A
Q29 Have you lost weight without trying? N/A
During the past week:
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
Volunteer Ref
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days present 
during past 
week
How many 
months have 
you had this?
Discussed 
with GP in 
past 3 
months?
Q30 Have you had abnormal vaginal bleeding?
Q31 Have you had abnormal vaginal discharge?
Q32 Have you had pain during or after sexual          
intercourse?
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Number of 
days present 
during past 
week
How many 
months have 
you had this?
Discussed 
with GP in 
past 3 
months?
33a
During the past week have you experienced any other symptoms? If so, please make a note of the symptom(s) 
in the space(s) below and on the next page.
For each symptom(s) please tick the extent to which you have experienced it during the past week, tick the number of 
days in the past week it has been experienced, tick how many months since it first started and tick whether or not you 
have discussed it with a GP in the past three months
During the past week:
Please answer this question only if you have been sexually active during the past week:
During the past week:
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
1-2 days
3-5 days
6-7 days
Yes
No
3 2 1
less than 3 
3-6 months
7-12 months
more than 12
No
1 2 3 0
1-2 days
3-5 days
6-7 days
Yes less than 3 
3-6 months
7-12 months
more than 12 if not at all 
move to next 
question
Volunteer Ref
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33b
33c
Q34
Please tick all that apply:
Heart failure
Irritable Bowel Disease (IBS)
Cancer
Please specify type of cancer:
Q35.
Q36.
Q37.
Have you ever been diagnosed by a doctor with any of the following conditions?
Chronic bronchitis Hiatus hernia
Emphysema Arthritis
Inflammatory bowel disease                                           
(e.g. Crohn's disease or                                         
ulcerative colitis)
Endometriosis Depression
During the past month have you often been bothered by feeling down,                              
depressed or hopeless?
Please tick yes or no
Are you currently taking hormone replacement therapy (HRT)?
Please tick yes or no
Thank you for taking the time to complete this questionnaire
Please remember this is only a survey, if you have any symptoms that are worrying or persistent please discuss them 
with your GP.
During the past month have you often been bothered by little interest or pleasure             
doing things?
Please tick yes or no
1-2 days
3-5 days
6-7 days
Yes
No
1-2 days
3-5 days
6-7 days
Yes
No
Yes
No
Yes
No
Yes
No
3 2 1
3 2 1
less than 3 
3-6 months
7-12 months
more than 12
less than 3 
3-6 months
7-12 months
more than 12
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Appendix XIII  GP Letter and Fact Sheet 
UKCTOCS Coordinating Centre 
Gynaecological Cancer Research Centre 
Institute of Women’s Health, UCL 
Maple House, 1
st Floor 
149 Tottenham Court Road 
London W1T 7DN 
 
 
{GP Name} 
{GP Address 1} 
{GP Address 2}, {GP County} 
{GP Postcode} 
 
Date 
 
MREC Reference No: 06/Q0505/103 
 
Dear Dr {GP name}, 
 
Re: United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOC) sub-study: 
Prospective study of ovarian cancer symptoms 
 
I am writing to let you know about a sub-study of UKCTOCS that is investigating symptoms 
that precede a diagnosis of ovarian cancer. This study has two objectives: 1) to develop a 
valid and reliable ovarian cancer symptoms questionnaire and; 2) to identify type, severity, 
frequency and duration of symptoms that precede a diagnosis of ovarian cancer in post-
menopausal women using the UKCTOCS cohort. The study is funded by the MRC and will 
be co-ordinated by the Ovarian Cancer Screening Unit at University College London. 
 
Healthy women, aged 50-74 years, who are already enrolled in the UKCTOCS study will be 
invited to participate in the ovarian cancer symptoms study. Women who wish to participate 
will be asked about symptoms found to be associated with ovarian cancer in previous studies. 
The participant information sheet states, ‘Many of the symptoms listed in the questionnaire 
are common in healthy people or may be related to other conditions. However, if you are 
worried about any symptoms please contact your GP.’ Participants in the sub-study will 
continue being followed-up as usual in the UKCTOCS study. 
 
A fact sheet about the symptoms sub-study is attached. If you would like further information 
or have any questions about the study please do not hesitate to contact either Usha Menon or 
Ms Penny Allen on 0207 380 2125. 
 
Yours sincerely 
 
 
 
Usha Menon, MD, MRCOG 
Director of Clinical Research    
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Prospective Study of Symptoms Preceding Ovarian Cancer Diagnosis Using 
the UKCTOCS Cohort – Fact Sheet 
 
 
Funding bodies  MRC, Eve Appeal 
Design    Questionnaire development according to European Organisation for 
Research and Treatment of Cancer (EORTC) guidelines 
  Prospective study of  symptoms that precede a diagnosis of ovarian 
cancer using a postal questionnaire sent to all three UKCTOCS 
groups (controls, multimodal group and ultrasound group) 
Objectives  Objective 1 
  To develop a valid and reliable ovarian cancer symptoms 
questionnaire according to EORTC guidelines 
Objective 2 
  To identify type, severity, frequency, and duration of symptoms that 
precede a diagnosis of ovarian cancer in postmenopausal women 
Endpoints/primary 
outcomes 
Diagnosis of ovarian cancer and identification of symptom type, severity, 
frequency and duration prior to diagnosis 
Inclusion/exclusion 
criteria 
Inclusion criteria 
  Participation in UKCTOCS  
Exclusion criteria 
  Those who have been withdrawn from UKCTOCS 
Recruitment    Women will be posted invitations to participate in interviews to assist 
in the development of the symptoms questionnaire. 
  Women will be posted the finalised symptoms questionnaire. If they 
wish to participate they will be advised to sign the consent section and 
complete the questionnaire. 
Planned sample size    Interviews to assist in the development of the symptoms 
questionnaire: 15 interviews with clinicians, 15 interviews with 
women enrolled in UKCTOCS, 15 interviews with women who 
participated in UKCTOCS and had a confirmed diagnosis of ovarian 
cancer. 
  1,000 women participating in UKCTOCS to field-test the draft 
symptoms questionnaire and provide feedback. 
  100,000 women in the finalised prospective symptoms questionnaire 
study.  
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Follow-up    Via UKCTOCS postal follow-up and ONS flagging 
Study duration  February 2007 to March 2010 
Contact details  Penny Allen or Dr Usha Menon 
Gynaecological Cancer Research Centre 
Institute of Women’s Health 
University College London 
Maple House, 1
st Floor 149 Tottenham Court Road 
London, W1T 7DN 
Telephone: 0207 380 2125, Email: p.allen@ucl.ac.uk  
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Appendix XIV  Pilot OCSq Invitation Letter 
 
Department of Gynaecological Oncology 
Level 1, Maple House 
149 Tottenham Court Road 
London 
W1T 7DN 
(Name) 
(Address line 1) 
(Address line 2) 
(Address line 3) 
 
 
Date                    Volunteer Ref: 
 
Dear (name), 
 
We are writing to you about a new study that is being conducted as part of the United Kingdom 
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The study is inviting a group of 
randomly selected women who are participating in UKCTOCS to complete a draft symptoms 
questionnaire and provide feedback on its content. 
 
If you wish to take part please read the enclosed study information sheet, sign the consent section 
and complete the questionnaire. Please return the completed questionnaire in the freepost envelope 
provided. 
 
Please take care to complete both sides of the questionnaires as it is printed double-sided. 
 
If you would like more information about the study please contact Penny Allen on 0207 380 6919 or 
0789 733 7573. 
 
Thank you for taking the time to read this information. 
 
Yours sincerely 
Penny Allen 
 
 
 
 
 
 
 
 
 
    
438 
Appendix XV  Pilot OCSq Study Information Sheet 
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Appendix XVI  Pilot OCSq Consent Form 
 
Prospective Study of Ovarian Cancer Symptoms 
 
Consent Section for Questionnaire 
 
                      Please initial box 
 
1.  I confirm that I have read and understand the information sheet dated 
............................ (version ...........................) for the above study. 
 
2.  I understand that my participation is voluntary and that I am free to  
withdraw at any time, without giving reason, without my medical care  
or legal rights being affected. 
 
3.   I understand that information collected by the UKCTOCS study 
may be looked at by the researcher where it is relevant to my taking  
part in the research. I give permission for the researcher to have  
access to my UKCTOCS records. 
 
5.  I agree to take part in the study. 
 
 
 
______________________    ____________  ______________________ 
Name of study volunteer    Date      Signature 
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Appendix XVII  Pilot OCSq Retest Validation Invitation 
Letter 
 
Department of Gynaecological Oncology 
Level 1, Maple House 
149 Tottenham Court Road 
London 
W1T 7DN 
(Name) 
(Address line 1) 
(Address line 2) 
(Address line 3) 
 
 
Date                      Volunteer Ref: 
 
Dear (name), 
 
We are writing to you about a new study that is being conducted as part of the United Kingdom 
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The study is inviting a group of 
randomly selected women who are participating in UKCTOCS to complete a draft symptoms 
questionnaire and provide feedback on its content. 
 
If you wish to take part please read the enclosed study information sheet, sign the consent section 
and complete questionnaire A. Two days later please complete questionnaire B. Please do not copy 
information from questionnaire A to questionnaire B as we wish to know about your symptoms on 
the two different dates. If you have any difficulties completing the questionnaire, or have any 
comments, please write these on the feedback sheet. Please return the completed questionnaires in 
the freepost envelope provided. 
 
Please take care to complete both sides of the questionnaires as they are printed double-sided. 
 
If you would like more information about the study please contact Penny Allen on 0207 380 6919 or 
0789 733 7573. 
 
Thank you for taking the time to read this information. 
 
Yours sincerely 
Penny Allen 
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Appendix XVIII  Pilot OCSq Retest Validation Study 
Information Sheet 
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Appendix XIX  Pilot OCSq Feedback Form 
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Appendix XX  Pilot OCSq Spearman Correlations Table 
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Appendix XXI  Draft OCSq Shading Formats 
Shading Option A 
 
Shading Option B 
 
Shading Option C 
 
Shading Option D 
 
Shading Option D  
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Appendix XXII  Final OCSq 
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Appendix XXIII  Symptoms Associated with CA125 Level 
Level 2-3 severity  n 
CA125≥30 U/mL 
n (%) 
CA125 < 30 U/mL 
n (%) 
OR (95% CI)  p-value 
Difficulty emptying the bladder  276  2 (6.5)  1 (0.4)  16.83 (1.48-191.36)  0.03 
≥12 days & <12 months 
Urinary frequency  254  7 (25.9)  21 (9.3)  3.43 (1.30-9.06)  0.02 
Shortness of breath  268  4 (13.8)  8 (3.3)  4.62 (1.30-16.44)  0.03 
≥12 days, <12 months & level 2-3 severity 
Change in appetite  271  3 (9.1)  4 (1.7)  5.85 (1.25-27.41)  0.04 
Urinary frequency  254  5 (18.5)  11 (4.8)  4.46 (1.42-14.02)  0.02 
Shortness of breath  268  3 (10.3)  4 (1.7)  6.78 (1.44-31.96)  0.03 
Back ache or pain  278  4 (13.8)  8 (3.2)  4.68 (1.32-16.65)  0.03 
 
Note: There were no associations between symptoms reported at any level of severity and CA125 level  
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Appendix XXIV  Symptoms Associated with ROC Score 
Symptom reported  n 
Elevated ROC 
n (%) 
Normal ROC 
n (%) 
OR (95% CI)  p-value 
At any level 
Indigestion or heartburn  303  39 (54.2)  91 (39.4)  1.82 (1.07-3.10)  0.03 
Increased abdominal size  291  28 (41.8)  59 (26.3)  2.01 (1.14-3.55)  0.02 
Weight gain  290  31 (45.6)  64 (28.8)  2.07 (1.18-3.61)  0.01 
Level 2-3 severity 
Increased abdominal size  289  15 (22.4)  18 (8.1)  3.27 (1.54-6.92)  <0.0001 
Pelvic bloating or fullness  286  11 (16.9)  13 (5.9)  3.26 (1.38-7.68)  0.005 
Tiredness, fatigue or lack of energy  294  27 (40.3)  60 (26.4)  1.88 (1.06-3.32)  0.03 
Weight gain  288  17 (25.4)  27 (12.2)  2.44 (1.24-4.83)  0.009 
≥12 days & <12 months 
Indigestion or heartburn  295  7 (10.0)  6 (2.7)  4.06 (1.32-12.50)  0.02  
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Symptom reported  n 
Elevated ROC 
n (%) 
Normal ROC 
n (%) 
OR (95% CI)  p-value 
≥12 days & <12 months 
Urinary frequency  259  13 (20.6)  15 (7.7)  3.14 (1.40-7.02)  0.004 
Urinary urgency  261  11 (18.0)  13 (6.5)  3.16 (1.34-7.49)  0.006 
Shortness of breath  273  6 (9.5%)  6 (2.9%)  3.58 (1.11-11.52)  0.04 
Weight gain  279  17 (26.6%)  33 (15.3%)  1.99 (1.02-3.89)  0.04 
≥12 days, <12 months & level 2-3 severity 
Increased abdominal size  272  9 (14.1)  7 (3.4)  4.70 (1.67-13.18)  0.004 
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Appendix XXV  Symptoms Associated with Complex Ovarian Morphology 
At any level  n 
Complex 
Morphology 
n (%) 
Normal 
Morphology 
n (%)* 
OR (95% CI)  p-value 
Pelvic pressure  455  36 (23.4)  42 (14.0)  1.88 (1.15-3.09)  0.012 
Level 2-3 severity 
Change in bowel habit  451  16 (10.4)  14 (4.7)  2.34 (1.11-4.94)  0.022 
 
Note: there were no associations between complex ovarian morphology and symptoms reported at ≥12 days frequency and <12 months duration or level 2-3 severity, 
≥12 days frequency and <12 months duration 
*Includes normal ovaries as well as simple cysts below <60cc and non-visualised ovaries  
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Appendix XXVI  100,000 Women Study Invitation Letter 
Department of Gynaecological Oncology 
Level 1, Maple House 
149 Tottenham Court Road 
London 
W1T 7DN 
(Name) 
(Address line 1) 
(Address line 2) 
(Address line 3) 
 
Date                  Volunteer Ref: 
 
Dear (name), 
 
We are writing to you about a new study that is being conducted as part of the United Kingdom 
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The study is inviting a group of 
randomly selected women who are participating in UKCTOCS to complete a symptoms questionnaire. 
 
Participation in the research is voluntary and only includes a questionnaire. If you wish to take part 
please read the enclosed study information sheet first, then complete the questionnaire. We are 
interested to find out the symptoms post-menopausal women commonly experience. Even if you think 
your symptoms may be related to another condition we are still interested to know about them. 
 
Please take care to complete both sides of the questionnaire as it is printed double-sided. A freepost 
envelope is enclosed for you to send your questionnaire back to us. 
 
If you would like more information about the study please contact Penny Allen on 0207 380 6919 or 
0207 380 6925. 
 
Thank you for taking the time to read this information. 
 
Yours sincerely 
The UKCTOCS Team 
 
Frequently asked questions 
 
1.  I am already in UKCTOCS, is this the same study? 
2.  This study is part of UKCTOCS but is a sub-study of the main screening trial. 
 
Q) Has this questionnaire been sent to me before? 
A) Approximately 1,000 UKCTOCS volunteers were sent a pilot version of this questionnaire so 
you may be one of these women who are asked to complete the questionnaire again. This 
questionnaire is, however, different to the UKCTOCS follow-up questionnaire and menopausal 
symptoms study. 
 
Q) Can you give me my results on the above telephone number? 
A) Sorry, no. We do not have direct access to your results. If you have any questions regarding 
results please telephone your local UKCTOCS centre on the telephone number given on your 
appointment letter. 
 
Q) Do I have to do the questionnaire? 
A) No, it is entirely up to you whether to take part or not.    
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Appendix XXVII  100,000 Women Study Invitation Letter 
 
Ovarian Cancer Symptoms Study Information Sheet 
As a participant in the United Kingdom Collaborative Trial of Ovarian Cancer Screening 
(UKCTOCS) you are being asked to take part in research about symptoms. Before you decide to take 
part it is important for you to understand why the research is being done and what it will involve. 
Please read the following information carefully and discuss it with friends, relatives and your GP if 
you wish. Ask us if there is anything that is not clear, or if you would like more information. Take 
time to decide whether or not you wish to take part. Thank you for reading this. 
 
What is the purpose of the study? 
Previous research has reported that the early symptoms of ovarian cancer are subtle or non-specific. 
Due to this the majority of women are diagnosed with ovarian cancer after it has spread from the 
ovaries. By then it is much more difficult to treat and as a consequence many women will die of the 
cancer. By contrast, treatment is more successful and the outlook can be good for women diagnosed 
before the cancer has spread. The purpose of this study is to identify symptoms that precede a 
diagnosis of ovarian cancer in post-menopausal women. 
 
Why have I been chosen? 
This study is a sub-study of the United Kingdom Collaborative Trial of Ovarian Cancer Screening 
and you are already participating in UKCTOCS. We are inviting a randomly selected group of 
women to take part in a symptoms questionnaire. 
 
Do I have to fulfil any other criteria to take part? 
The only criteria you need to fulfil are: 
1.  Already enrolled in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do decide to take part please fill in the 
questionnaire. If you decide not to take part you do not have to give a reason. Deciding to participate 
or not will not affect any medical care you receive. 
 
What will happen to me if I take part? 
 
Symptoms Questionnaire 
If you would like to take part in this study please complete the questionnaire then return it in the 
freepost envelope provided. If you have any questions please contact Penny Allen (telephone number 
at the end of this form), who will discuss the study in greater detail and will give you the opportunity 
to ask any questions.  
 
What are the possible disadvantages of taking part? 
2.  Participation in the questionnaires will take approximately 10-15 minutes of your time.  
3.  Thinking about symptoms may create anxiety in some women. 
 
What are the possible benefits of taking part? 
  There are no direct benefits of taking part, although being asked about symptoms may help some 
women to remember symptoms that should be discussed with their doctor.    
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What if I have experienced any of the symptoms in the questionnaire or am worried about 
symptoms? 
Please keep in mind that you have been randomly selected to participate in the survey, not for any 
other reason. Many of the symptoms listed in the questionnaire are common in healthy people, or 
may be related to other conditions. If you are worried about any symptoms please contact your GP or 
gynaecologist. 
 
What if something goes wrong? 
It is not anticipated that anything will go wrong in this study as it only involves you filling in the 
enclosed questionnaire. It does not involve any tests or other questions.  
 
You will always be able to contact the researcher to discuss your concerns about the study. Every 
care will be taken to ensure your safety during the course of the study. University College London 
(UCL), the Research Governance Sponsor, has indemnity (insurance) arrangements in place for non-
negligent harm, in the event that something does go wrong and you are harmed as a result of taking 
part in this study. If you are harmed and this is due to someone’s negligence then you may have 
grounds for legal action for compensation but you may have to pay your legal costs. 
 
Will taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly 
confidential. Only your UKCTOCS volunteer reference number is on the questionnaire, not your 
name or any other personal details.  
 
Occasionally the research documentation and results will be looked at by the people funding the 
research programme to check that the study is being carried out properly. Any information which is 
viewed by people not directly related to the research team will not have your name and address on it. 
 
What will happen to the results of the research study? 
The results of the research will be used in a PhD study of the symptoms of ovarian cancer. 
Additionally, the results will be reviewed by medical professionals and published in the medical 
press. Individuals will not be identified in any publications. 
 
Who is organising and funding the research? 
The research is part of a PhD study that is linked to the United Kingdom Collaborative Trial of 
Ovarian Cancer Screening. The Medical Research Council is funding the study. 
 
Contact for further information 
 
For further information please telephone Penny Allen in the Department of Gynaecological 
Oncology on 0207 380 6919 or 0207 380 6925. Alternatively, you can write to: 
 
Penny Allen 
Department of Gynaecological Oncology 
UCL Institute for Women’s Health 
Level 1, Maple House 
149 Tottenham Court Road 
London 
W1T 7DN 
 
Thank you for taking the time to read this information.    
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Appendix XXVIII 100,000 Women Study OCSq 
Instruction Page 
no
a 
little
quite 
a bit
very 
much
How many 
days during 
past week?
How many 
months have 
you had this?
Discussed 
with GP in 
past 3 
months?
E.g.
Have you had hot flushes during the past 
week?
Please feel free to leave out any question if you feel uncomfortable replying to it, or for any other reason.
The questionnaire has 7 pages and takes approximately 10-15 minutes to complete.
1. Please read the enclosed information sheet.
3. For each question please tick the extent to which it has been experienced during the past week. If you have
not experienced it, please tick the 'no' box and move onto the next question. If you have experienced it, please
tick either the 'a little', 'quite a bit' or 'very much' box, tick the number of days in the past week it has been
experienced, tick how many months since it first started and tick whether or not you have discussed it with a
GP in the past three months.
Below is an example of how to fill in the questionnaire. This shows that the woman had hot flushes 'a little' for six to
seven days during the past week, has been having hot flushes for six to 12 months and has not discussed her hot
flushes with a GP during the past three months.
2. We are interested to find out the symptoms post-menopausal women commonly experience. Even if you think
your symptoms may be related to another condition we are still interested to know about them.
How to complete the questionnaire
If you have any questions or need help completing the questionnaire please telephone Penny Allen                                                                         
on 0207 380 6919 or 0207 380 6925.
Thank you for taking the time to complete this questionnaire
No
1-2 days Yes
more than 12
less than 3
3-6 months
6-12 months
3-5 days
6-7 days
if no move to next 
question
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Appendix XXIX  Symptoms Associated with Depression Screening Status in 100,000 Women 
Study 
At any level  n 
Depression 
screen positive 
n (%) 
Depression 
screen negative 
n (%) 
OR (95% CI)  p-value 
Pelvic discomfort or pain  41,682  47,88 (36.4)  4,872 (17.1)  4.63 (4.03-5.33)  <0.0001 
Abdominal discomfort or pain  41,484  3,916 (30.0)  3,346 (11.8)  3.23 (3.06-3.40)  <0.0001 
Indigestion or heartburn  41,854  6,431 (48.5)  9,149 (32.0)  2.00 (1.92-2.09)  <0.0001 
Nausea or vomiting  41,729  5,032 (38.1)  4, 479 (15.7)  3.31 (3.16-3.47)  <0.0001 
Feeling full quickly  41,782  4,264 (32.2)  3,754 (13.2)  3.14 (2.99-3.30)  <0.0001 
Change in appetite  40,687  2,426 (19.0)  985 (3.5)  3.28 (2.86-3.77)  <0.0001 
Abdominal bloating or fullness  40,861  5,077 (39.4)  5,034 (18.0)  2.96 (2.83-3.10)  <0.0001 
Abdominal pressure  40,574  2,776 (21.9)  1,815 (6.5)  4.02 (3.77-4.28)  <0.0001 
Increased abdominal size  40,805  4,666 (36.3)  4,282 (5.3)  3.15 (3.00-3.30)  <0.0001 
Abdominal mass or lump  40,441  970 (7.7)  288 (1.0)  8.00 (7.00-9.14)  <0.0001  
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At any level  n 
Depression 
screen positive 
n (%) 
Depression 
screen negative 
n (%) 
OR (95% CI)  p-value 
Pelvic bloating or fullness  40,795  4,177 (32.5)  3,980 (14.2)  2.90 (2.76-3.04)  <0.0001 
Pelvic pressure  41,323  2,720 (21.0)  2,049 (7.2)  3.42 (3.22-3.64)  <0.0001 
Pelvic heaviness  41,302  2,943 (22.7)  1,969 (6.9)  3.94 (3.70-4.19)  <0.0001 
Pain before, during or after opening bowels  41,454  3,920 (30.1)  3,536 (12.4)  3.02 (2.87-3.18)  <0.0001 
Difficulty emptying bowels  41,564  4,619 (35.2)  5,327 (18.7)  2.36 (2.26-2.48)  <0.0001 
Change in bowel habit  41,388  3,288 (25.3)  2,584 (9.1)  3.38 (3.19-3.58)  <0.0001 
Excessive flatulence  41,764  6,761 (51.0)  8,200 (28.8)  2.58 (2.47-2.69)  <0.0001 
Shortness of breath  40,540  5,133 (40.1)  4,437 (16.0)  3.52 (3.36-3.70)  <0.0001 
Urinary frequency  40,505  6,028 (47.0)  6,966 (25.2)  2.63 (2.52-2.75)  <0.0001 
Urinary urgency  40,767  6,617 (51.3)  9,098 (32.7)  2.17 (2.08-2.26)  <0.0001 
Pressure on the bladder  40,364  3,228 (25.5)  3,104 (11.2)  2.72 (2.57-2.87)  <0.0001 
Difficulty emptying the bladder  40,270  1,015 (8.1)  855 (3.1)  2.77 (2.52-3.04)  <0.0001  
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At any level  n 
Depression 
screen positive 
n (%) 
Depression 
screen negative 
n (%) 
OR (95% CI)  p-value 
Pain when passing urine  40,304  1,650 (13.1)  379 (1.4)  10.84 (9.67-12.14)  <0.0001 
Back ache or pain  41,863  8,522 (63.8)  11,182 (39.2)  2.74 (2.62-2.86)  <0.0001 
Leg ache or pain  41,728  7,317 (55.1)  9,222 (32.4)  2.71 (2.48-2.97)  <0.0001 
Leg swelling  41,373  4,058 (31.1)  3,113 (11.0)  3.66 (3.48-3.86)  <0.0001 
Tiredness, fatigue or lack of energy  41,918  11,171 (82.9)  11,668 (41.0)  6.95 (6.61-7.31)  <0.0001 
Weight gain  41,600  6,462 (49.1)  8,635 (30.4)  2.21 (2.12-2.31)  <0.0001 
Weight loss  41,078  1,602 (12.5)  1,519 (5.4)  2.52 (2.34-2.71)  <0.0001 
Abnormal vaginal bleeding  40,340  311 (2.5)  161 (0.6)  4.36 (3.60-5.28)  <0.0001 
Abnormal vaginal discharge  38,649  790 (7.3)  672 (2.4)  3.16 (2.85-3.51)  <0.0001 
Pain during or after sexual intercourse  18,735  853 (13.2)  942 (7.7)  1.82 (1.65-2.01)  <0.0001 
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Level 2-3 severity  n 
Depression 
screen positive 
n (%) 
Depression 
screen negative 
n (%) 
OR (95% CI)  p-value 
Pelvic discomfort or pain  37,852  1,556 (13.9)  1,070 (4.0)  3.88 (3.57-4.20)  <0.0001 
Abdominal discomfort or pain  37,414  1,135 (10.5)  710 (2.7)  4.26 (3.87-4.69)  <0.0001 
Indigestion or heartburn  37,903  2,064 (18.3)  1,962 (7.4)  2.81 (2.63-3.00)  <0.0001 
Nausea or vomiting  37,209  386 (3.6)  198 (0.7)  3.31 (3.16-3.47)  <0.0001 
Feeling full quickly  37,664  1,547 (14.0)  926 (3.5)  4.54 (4.17-4.94)  <0.0001 
Change in appetite  36,742  566 (5.4)  184 (0.7)  3.28 (2.86-3.77)  <0.0001 
Abdominal bloating or fullness  37,244  1,935 (17.6)  1,179 (4.5)  4.56 (4.22-4.92)  <0.0001 
Abdominal pressure  36,656  805 (7.7)  420 (1.6)  5.10 (4.52-5.75)  <0.0001 
Increased abdominal size  37,072  1,798 (16.6)  981 (3.7)  5.12 (4.72-5.55)  <0.0001 
Abdominal mass or lump  36,353  144 (1.4)  101 (0.4)  3.71 (2.87-4.79)  <0.0001 
Pelvic bloating or fullness  37,065  1,489 (13.8)  940 (3.6)  4.30 (3.95-4.68)  <0.0001 
Pelvic pressure  37,396  924 (8.6)  492 (1.8)  4.99 (4.46-5.58)  <0.0001  
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Level 2-3 severity  n 
Depression 
screen positive 
n (%) 
Depression 
screen negative 
n (%) 
OR (95% CI)  p-value 
Pelvic heaviness  37,308  913 (8.5)  431 (1.6)  5.65 (5.03-6.35)  <0.0001 
Pain before, during or after opening bowels  37,486  1,047 (9.6)  693 (2.6)  4.00 (3.62-4.41)  <0.0001 
Difficulty emptying bowels  37,731  1,556 (14.1)  1,255 (4.7)  3.31 (3.06-3.58)  <0.0001 
Change in bowel habit  37,340  724 (6.7)  458 (1.7)  4.12 (3.66-4.65)  <0.0001 
Excessive flatulence  38,088  3,208 (28.2)  2,985 (11.2)  3.12 (2.95-3.30)  <0.0001 
Shortness of breath  36,944  1,513 (14.0)  857 (3.3)  4.80 (4.40-5.23)  <0.0001 
Urinary frequency  36,905  3,258 (29.9)  3,282 (12.6)  2.96 (2.80-3.12)  <0.0001 
Urinary urgency  37,220  3,329 (30.2)  3,394 (13.0)  2.91 (2.76-3.07)  <0.0001 
Pressure on the bladder  36,617  1,340 (12.7)  883 (3.4)  4.15 (3.80-4.54)  <0.0001 
Difficulty emptying the bladder  36,350  354 (3.5)  215 (0.8)  4.30 (3.63-5.11)  <0.0001 
Pain when passing urine  36,233  159 (1.6)  114 (0.4)  3.61 (2.84-4.60)  <0.0001 
Back ache or pain  38,434  4,083 (35.1)  3,953 (14.8)  3.13 (2.97-3.29)  <0.0001  
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Level 2-3 severity  n 
Depression 
screen positive 
n (%) 
Depression 
screen negative 
n (%) 
OR (95% CI)  p-value 
Leg ache or pain  38,112  3,734 (32.7)  3,552 (13.3)  3.17 (3.00-3.34)  <0.0001 
Leg swelling  37,283  1,203 (11.2)  998 (3.8)  3.24 (2.97-3.54)  <0.0001 
Tiredness, fatigue or lack of energy  38,610  6,172 (51.7)  3,186 (11.9)  7.90 (7.51-8.32)  <0.0001 
Weight gain  38,055  3,240 (28.6)  2,676 (10.0)  3.60 (3.40-3.81)  <0.0001 
Weight loss  37,099  550 (5.2)  319 (1.2)  4.52 (3.93-5.20)  <0.0001 
Abnormal vaginal bleeding  36,363  28 (0.3)  11 (0.04)  6.55 (3.26-13.16)  ns 
Abnormal vaginal discharge  36,461  178 (1.7)  81 (0.3)  5.67 (4.36-7.38)  <0.0001 
Pain during or after sexual intercourse  15,331  257 (6.3)  262 (2.3)  2.81 (2.36-3.35)  <0.0001 
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≥12 days & <12 months  n 
Depression 
screen positive 
n (%) 
Depression 
screen negative 
n (%) 
OR (95% CI)  p-value 
Pelvic discomfort or pain  41,682  1,001 (7.6)  889 (3.1)  2.56 (2.33-2.81)  <0.0001 
Abdominal discomfort or pain  41,484  638 (0.9)  509 (1.8)  2.82 (2.51-3.18)  <0.0001 
Indigestion or heartburn  41,854  816 (6.2)  694 (2.4)  2.64 (2.38-2.92)  <0.0001 
Nausea or vomiting  41,729  300 (2.3)  146 (0.5)  4.52 (3.71-5.52)  <0.0001 
Feeling full quickly  41,782  885 (6.7)  696 (2.4)  4.54 (4.17-4.94)  <0.0001 
Change in appetite  40,687  560 (4.4)  312 (1.1)  3.28 (2.86-3.77)  <0.0001 
Abdominal bloating or fullness  40,861  976 (7.6)  751 (2.7)  2.97 (2.69-3.28)  <0.0001 
Abdominal pressure  40,574  473 (3.7)  287 (1.0)  3.72 (3.21-4.31)  <0.0001 
Increased abdominal size  40,805  1,128 (8.8)  892 (3.2)  2.91 (2.66-3.19)  <0.0001 
Abdominal mass or lump*  40,441  152 (1.2)  124 (0.4)  2.73 (2.16-3.47)  <0.0001 
Pelvic bloating or fullness  40,795  832 (6.5)  635 (2.3)  2.97 (2.68-3.31)  <0.0001 
Pelvic pressure  41,323  624 (4.8)  395 (1.4)  3.59 (3.16-4.08)  <0.0001  
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≥12 days & <12 months  n 
Depression 
screen positive 
n (%) 
Depression 
screen negative 
n (%) 
OR (95% CI)  p-value 
Pelvic heaviness  41,302  577 (4.5)  373 (1.3)  3.54 (3.06-3.99)  <0.0001 
Pain before, during or after opening bowels  41,454  567 (4.3)  390 (1.4)  3.27 (3.87-3.72)  <0.0001 
Difficulty emptying bowels  41,564  706 (5.4)  584 (2.1)  2.72 (2.43-3.04)  <0.0001 
Change in bowel habit  41,388  559 (4.3)  443 (1.6)  2.83 (2.50-3.21)  <0.0001 
Excessive flatulence  41,764  1,357 (10.2)  1,499 5.3%  2.06 (1.91-2.22)  <0.0001 
Shortness of breath  40,540  920 (7.2)  586 (2.1)  3.59 (3.23-3.99)  <0.0001 
Urinary frequency  40,505  1,243 (9.7)  1,296 (4.7)  2.18 (2.01-2.37)  <0.0001 
Urinary urgency  40,767  1,223 (9.5)  1,336 (4.8)  2.08 (1.92-2.25)  <0.0001 
Pressure on the bladder  40,364  676 (5.3)  534 (1.9)  2.87 (2.56-3.22)  <0.0001 
Difficulty emptying the bladder  40,270  212 (1.7)  181 (0.7)  2.62 (2.14-3.19)  <0.0001 
Pain when passing urine  40,304  110 (0.9)  99 (0.4)  2.45 (1.87-3.22)  <0.0001 
Back ache or pain  41,863  1,712 (12.8)  1,867 (6.5)  2.10 (1.96-2.25)  <0.0001  
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≥12 days & <12 months  n 
Depression 
screen positive 
n (%) 
Depression 
screen negative 
n (%) 
OR (95% CI)  p-value 
Leg ache or pain  41,728  1,760 (13.3)  1,915 (6.7)  2.12 (1.98-2.27)  <0.0001 
Leg swelling  41,373  643 (4.9)  518 (1.8)  2.79 (2.48-3.13)  <0.0001 
Tiredness, fatigue or lack of energy  41,918  3,038 (22.5)  2,460 (8.7)  3.07 (2.90-3.26)  <0.0001 
Weight gain*  41,600  2,961 (22.5)  4,125 (14.5)  1.71 (1.62-1.80)  <0.0001 
Weight loss*  41,078  990 (7.7)  926 (3.3)  2.48 (2.26-2.72)  <0.0001 
Abnormal vaginal bleeding  40,340  34 (0.3)  18 (0.1)  4.19 (2.36-7.42)  <0.0001 
Abnormal vaginal discharge  38,649  230 (2.1)  167 (0.6)  3.57 (2.92-4.37)  <0.0001 
Pain during or after sexual intercourse  18,735  28 (0.4)  16 (0.1)  3.33 (1.80-6.15)  <0.0001 
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≥12 days, <12 months & level 2-3 severity  n 
Depression 
screen positive 
n (%) 
Depression 
screen negative 
n (%) 
OR (95% CI)  p-value 
Pelvic discomfort or pain  41,682  529 (4.0)  377 (1.3)  2.56 (2.33-2.81)  <0.0001 
Abdominal discomfort or pain  41,484  353 (2.7)  220 (0.8)  3.57 (3.01-4.23)  <0.0001 
Indigestion or heartburn  41,854  486 (3.7)  400 (1.4)  2.68 (3.35-3.07)  <0.0001 
Nausea or vomiting  41,729  134 (1.0)  58 (0.2)  5.04 (3.70-6.86)  <0.0001 
Feeling full quickly  41,782  514 (3.9)  347 (1.2)  3.28 (2.86-3.77)  <0.0001 
Change in appetite  40,687  239 (1.9)  103 (0.4)  5.15 (4.09-6.50)  <0.0001 
Abdominal bloating or fullness  40,861  581 (4.5)  365 (1.3)  3.57 (3.13-4.08)  <0.0001 
Abdominal pressure  40,574  243 (1.9)  127 (0.5)  3.72 (3.21-4.31)  <0.0001 
Increased abdominal size  40,805  574 (4.5)  319 (1.1)  4.04 (3.52-4.65)  <0.0001 
Abdominal mass or lump*  40,441  65 (0.5)  32 (0.1)  4.52 (2.96-6.90)  <0.0001 
Pelvic bloating or fullness  40,795  428 (3.3)  266 (1.0)  3.58 (3.06-4.18)  <0.0001 
Pelvic pressure  41,323  306 (2.4)  161 (0.6)  4.25 (3.51-5.15)  <0.0001  
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≥12 days, <12 months & level 2-3 severity  n 
Depression 
screen positive 
n (%) 
Depression 
screen negative 
n (%) 
OR (95% CI)  p-value 
Pelvic heaviness  41,302  274 (2.1)  146 (0.5)  4.17 (3.41-5.11)  <0.0001 
Pain before, during or after opening bowels  41,454  264 (2.0)  163 (0.6)  3.58 (2.94-4.36)  <0.0001 
Difficulty emptying bowels  41,564  369 (2.8)  272 (1.0)  3.00 (2.56-3.52)  <0.0001 
Change in bowel habit  41,388  241 (1.9)  175 (0.6)  3.04 (2.50-3.70)  <0.0001 
Excessive flatulence  41,764  825 (6.2)  846 (3.0)  2.17 (1.97-2.40)  <0.0001 
Shortness of breath  40,540  427 (3.3)  186 (0.7)  5.12 (4.30-6.09)  <0.0001 
Urinary frequency  40,505  794 (6.2)  705 (2.5)  2.52 (2.28-2.80)  <0.0001 
Urinary urgency  40,767  762 (5.9)  688 (2.5)  2.48 (2.23-2.75)  <0.0001 
Pressure on the bladder  40,364  348 (2.8)  200 (0.7)  3.89 (3.27-4.64)  <0.0001 
Difficulty emptying the bladder  40,270  89 (0.7)  47 (0.2)  4.21 (2.95-6.00)  <0.0001 
Pain when passing urine  40,304  48 (0.4)  41 (0.1)  2.57 (1.70-3.91)  <0.0001 
Back ache or pain  41,863  1,090 (8.2)  906 (3.2)  2.71 (2.48-2.97)  <0.0001  
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≥12 days, <12 months & level 2-3 severity  n 
Depression 
screen positive 
n (%) 
Depression 
screen negative 
n (%) 
OR (95% CI)  p-value 
Leg ache or pain  41,728  1,064 (8.0)  1,039 (3.7)  2.30 (2.10-2.51)  <0.0001 
Leg swelling  41,373  312 (2.4)  199 (0.7)  3.47 (2.90-4.15)  <0.0001 
Tiredness, fatigue or lack of energy  41,918  2,046 (15.2)  1,110 (3.9)  4.41 (4.08-4.75)  <0.0001 
Weight gain*  41,600  1,304 (9.9)  1,178 (4.1)  2.54 (2.35-2.76)  <0.0001 
Weight loss*  41,078  308 (2.4)  192 (0.7)  3.61 (3.01-4.32)  <0.0001 
Abnormal vaginal bleeding  40,340  6 (0.5)  7 (0.03)  ns  ns 
Abnormal vaginal discharge  38,649  56 (0.5)  28 (0.1)  5.13 (3.26-8.08)  <0.0001 
Pain during or after sexual intercourse  18,735  13 (0.2)  8 (0.1)  3.08 (1.28-7.44)  0.008 
 
* Reported at <12 months duration only as frequency data not collected  
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